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͞Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so 
that we may fear less͘͟͸ Marie CƵrie 
 
͞The art and science of asking questions is the source of all knowledge͘͟ ʹ Thomas Berger 
 
͞Scientists have become the bearers of the torch of discovery in our quest for knowledge͘͟ ʹ Stephen 
Hawking 
 
͞Success is a science; if you have the conditions, you get the result͘͟ ʹ  Oscar Wilde  
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Abstract 
Mycobacterium tuberculosis (Mtb), the bacteria causing tuberculosis (TB), and the human 
immunodeficiency virus type 1 (HIV-1), the etiological agent of acquired immunodeficiency syndrome 
(AIDS), act in synergy to exacerbate the progression of each other in co-infected patients. While clinical 
evidence reveals a frequent increase of the viral load at co-infected anatomical sites, the mechanisms 
explaining how Mtb favours HIV-1 progression remain insufficiently understood.  
Macrophages are the main target for Mtb. Their infection by the bacilli likely shapes the 
microenvironment that favours HIV-1 infection and replication at sites of co-infection. To address this 
issue, I took advantage of an in vitro model mimicking the TB-associated microenvironment (cmMTB, 
͞condiƚioned media of Mƚb-infecƚed macrophages͟Ϳ previously established in the laboratory; a model 
that renders macrophages susceptible to intracellular pathogens like Mtb. Upon joining the team, I 
participated in the study on how Mtb exacerbates HIV-1 replication in macrophages, using this model. 
We found that cmMTB-treated macrophages (M(cmMTB)) have an enhanced ability to form 
intercellular membrane bridges called tunneling nanotubes (TNT), which increase the capacity of the 
virus to transfer from one macrophage to another, leading to the exacerbation of HIV-1 production 
and spread.  
The principal objective of my PhD thesis was to identify novel factors that are involved in the 
exacerbation of HIV-1 replication in macrophages in the context of tuberculosis. To this end, a 
transcriptomic analysis of M(cmMTB) was conducted, and revealed two key factors: the Siglec-1 
receptor and type I interferon (IFN-I)/STAT1 signaling. 
The first part of my PhD thesis dealt with the characterization of Siglec-1 as a novel factor 
involved in the synergy between Mtb and HIV-1 in macrophages. First, I demonstrated that its 
increased expression in M(cmMTB) was dependent on IFN-I. Second, in Mtb and simian 
immunodeficiency virus co-infected non-human primates, I established a positive correlation between 
the abundance of Siglec-1+ alveolar macrophages and the pathology, associated with the activation of 
the IFN-I/STAT-1 pathway. Third, I revealed that Siglec-1 is localized on a specific subset of thick TNT. 
These thick Siglec-1+ TNT were longer and contained high HIV-1 cargos compared to Siglec-1- TNT, 
suggesting that the virus might preferentially use these TNT. Finally, I showed that Siglec-1 was 
responsible for the enhanced HIV-1 replication by increasing viral capture and cell-to-cell transfer, at 
least in part through TNT. These findings argue that Siglec-1 has a physiological significance to 
macrophage and TNT biology. It may also be a potential target for designing new therapies aimed at 
reducing viral dissemination in a co-infection context. 
 In the second part of my PhD project, I determined that TB dysregulates the IFN-I/STAT-1 
signaling pathway to diminish the antiviral response. Indeed, upon exogenous IFN-I stimulation, I 
noticed a reduced STAT1 activation and lower expression of the interferon-stimulated genes (ISG) in 
M(cmMTB) compared to control cells, indicating a potential desensitization to the IFN-I/STAT-1 
pathway. By blocking IFNAR2 or inhibiting STAT-1 gene expression during cmMTB-treatment, I 
prevented this desensitization to exogenous IFN-I and restored control of HIV-1 infection in 
macrophages. Altogether, these results point to a deleterious role of IFN-I in the co-infection setting. 
My thesis work unveils the capacity of Mtb to dysregulate host-antiviral responses against HIV-
1. Modulation of the macrophage response by TB-induced IFN-I, including upregulation of Siglec-1 
expression, explains how these cells become vessels for viral spread that contributes to co-infection 
severity. In addition, the identified factors in this project may be used as new diagnostic tools or 
therapeutic targets to ameliorate the diagnosis and treatment of co-infected individuals.  
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Résumé 
Mycobacterium tuberculosis (Mtb), la bactérie responsable de la tuberculose (TB), et le virus 
de l͛immƵnodéficience hƵmaine ;VIH-ϭͿ͕ l͛agenƚ dƵ sǇndrome de l͛immƵnodéficience acqƵise ;SIDAͿ͕ 
accélèrent leurs progressions mutuelles chez les patients co-infectés. Alors que de nombreuses 
données cliniques rapportent une augmentation de la charge virale dans les sites anatomiques co-
infectés, les mécanismes qui en sont responsables restent insuffisamment décrits.  
Mƚb cible principalemenƚ les macrophages͘ NoƵs émeƚƚons l͛hǇpoƚhèse qƵe l͛infecƚion des 
macrophages par Mtb créé un microenvironnement propice à la réplication du VIH-1 au niveau des 
sites co-infecƚés͘ PoƵr le monƚrer͕ j͛ai Ƶƚilisé Ƶn modèle in vitro précédemment établi par mes équipes 
(le cmMTB ʹ pour « conditioned media of Mtb-infected macrophages »). Celui-ci permet de mimer un 
enǀironnemenƚ ƚƵbercƵleƵǆ͕ par la différenciaƚion eƚ l͛acƚiǀaƚion des macrophages vers un profil 
« M(cmMTB) ͕ͩ largemenƚ reƚroƵǀé dans les poƵmons lors d͛Ƶne ƚƵbercƵlose acƚiǀe͘ En rejoignanƚ le 
laboraƚoire͕ j͛ai parƚicipé à l͛éƚƵde des mécanismes responsables de l͛aƵgmenƚaƚion de la réplicaƚion 
virale dans le contexte de co-infection, en utilisant ce modèle. Nous avons trouvé que les M(cmMTB) 
forment de nombreux nanotubes (ponts intercellulaires), leur permettant de transférer plus de virus 
d͛Ƶn macrophage à l͛aƵƚre͕ eƚ condƵiƚ à Ƶne forƚe aƵgmenƚaƚion de la prodƵcƚion virale. 
L͛objecƚif principal de ma ƚhèse a donc éƚé d͛idenƚifier͕ dans Ƶn conƚeǆƚe ƚƵbercƵleƵǆ͕ de 
noƵǀeaƵǆ facƚeƵrs impliqƵés dans l͛aƵgmenƚaƚion de la réplicaƚion dƵ VIH-1 dans les macrophages. 
Pour cela, une analyse transcriptomique des M(cmMTB) a été réalisée, révélant deux facteurs 
essentiels : le récepteur Siglec-1 et les interférons de type I (IFN-I) via STAT1.  
Dans Ƶn premier ƚemps͕ j͛ai éƚƵdié le rôle de Siglec-1 dans la synergie entre Mtb et le VIH-1 
dans les macrophages͘ D͛abord͕ j͛ai monƚré que son expression de surface était augmentée par le 
cmMTB, de façon dépendante des IFN-I͘ EnsƵiƚe͕ j͛ai éƚabli qƵe l͛abondance des macrophages 
alvéolaires exprimant Siglec-1 chez les primates non-humains co-infectés avec Mtb et le virus de 
l͛immƵnodéficience simienne corrélait avec la sévérité de la pathologie, et était associée à la 
signalisation des IFN-I, via l͛acƚiǀaƚion de STATϭ͘ De plƵs͕ j͛ai idenƚifié Ƶne noƵǀelle localisaƚion de 
Siglec-ϭ le long d͛Ƶn soƵs-type de nanotubes. Ceux-ci, plus larges et plus longs, contenaient plus de 
VIH-ϭ qƵe les aƵƚres͕ sƵggéranƚ qƵe le ǀirƵs pƵisse les emprƵnƚer en majoriƚé͘ Enfin͕ j͛ai monƚré qƵe 
Siglec-ϭ éƚaiƚ responsable de l͛aƵgmenƚaƚion de la réplicaƚion dƵ VIH-1, grâce à une meilleure capture 
du virus et de son transfert intercellulaire, potentiellement grâce aux nanotubes. Ces résultats 
permettent de proposer que Siglec-1 a un rôle physiologique dans la biologie des nanotubes et des 
macrophages. 
Dans Ƶn second ƚemps͕ j͛ai déƚerminé qƵe la TB dérégƵle la signalisation IFN-I/STAT1 dans les 
macrophages eƚ diminƵe leƵr réponse anƚiǀirale͘ Après sƚimƵlaƚion des M;cmMTBͿ par de l͛IFN-I 
eǆogène͕ j͛ai démonƚré Ƶne diminƵƚion de l͛acƚiǀaƚion de STATϭ eƚ de l͛eǆpression des gènes de 
réponse à l͛IFN͕ indiqƵanƚ Ƶne poƚenƚielle désensibilisaƚion de ces cellƵles à l͛IFN-I. Ces observations, 
ainsi que la perte de contrôle de la réplication du VIH-ϭ͕ onƚ éƚé reǀersées par l͛inhibiƚion dƵ récepƚeƵr 
aux IFN-I (IFNAR2) ou du facteur de transcription STAT1. Ensemble, ces résultats indiquent que les IFN-
I onƚ Ƶn rôle déléƚère poƵr l͛hôƚe dans le conƚeǆƚe de la co-infection. 
Mon projet de thèse a permis de révéler la capacité de Mtb à déréguler les réponses antivirales 
de l͛hôƚe conƚre le VIH-1, participant ainsi à la gravité de la co-infection. Les facteurs identifiés au cours 
de ma thèse pourraient à plus long terme être utilisés à des fins diagnostiques ou thérapeutiques, dans 
le bƵƚ d͛améliorer la prise en charge des paƚienƚs co-infectés.
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Scientific contributions 
 
The work presented in this manuscript aims at understanding the mechanisms by which 
Mycobacterium tubecrulosis (Mtb) infection exacerbates the replication of the human 
immunodeficiency virus (HIV-1) in macrophages, in the context of co-infection. More precisely, my PhD 
project involved the identification of novel factors involved in this phenomenon, which in the future 
could be used as a diagnostic tool or therapeutic target to improve the diagnosis of co-infected 
patients, as well as monitoring disease progression. The studies performed during my time at IPBS in 
the laboratories of Drs O. Neyrolles and I. Maridonneau-Parini, under the supervision of Drs G. Lugo-
Villarino and C. Vérollet led to articles that have been published in various peer-review international 
scientific journals while others remain in the preparation process. 
 
The first paper presented in the current manuscript, in the introduction section is: 
1. Tunneling Nanotubes: Intimate Communication between Myeloid Cells. Dupont M, Souriant S, 
Lugo-Villarino G, Maridonneau-Parini I, Vérollet C. 
Front Immunol. 2018 Jan 25;9:43. doi: 10.3389/fimmu.2018.00043. eCollection 2018. Review. 
PMID: 29422895 
 
I participated to the bibliographical research and to the writing of the review, in collaboration with Drs 
C. Vérollet and G. Lugo-Villarino. Dr. S. Souriant was responsible for the figure presented in the review 
and, together with Dr. I. Maridonneau-Parini, she helped with the manuscript corrections. 
 
The second article presented in this document is an original research article:   
2. Tuberculosis Exacerbates HIV-1 Infection through IL-10/STAT3-Dependent Tunneling Nanotube 
Formation in Macrophages. Souriant S, Balboa L, Dupont M, Pingris K, Kviatcovsky D, Cougoule C, 
Lastrucci C, Bah A, Gasser R, Poincloux R, Raynaud-Messina B, Al Saati T, Inwentarz S, Poggi S, 
Moraña EJ, González-Montaner P, Corti M, Lagane B, Vergne I, Allers C, Kaushal D, Kuroda MJ, 
Sasiain MDC, Neyrolles O, Maridonneau-Parini I, Lugo-Villarino G*, Vérollet C*. 
Cell Rep. 2019 Mar 26;26(13):3586-3599.e7. doi: 10.1016/j.celrep.2019.02.091. 
PMID: 30917314 
* : equivalent contribution of the authors to the work 
 
Upon arrival to the laboratory, I reproduced the phenotype obtained after monocyte exposure to a 
tuberculous-associated microenvironment, i.e. the upregulation of the following markers: CD16, 
CD163 and MerTK. I also reproduced the exacerbation of HIV-1 replication in macrophages in the co-
infection context. I also performed, analyzed and interpreted the experiments requested during the 
revision process of the manuscript (detailed further in the Result Section ʹ chapter I) and helped with 
the manuscript corrections.  
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The third paper presented here has been submitted to Cell Reports journal: 
3. Tuberculosis-associated IFN-I induces Siglec-1 on microtubule-containing tunneling nanotubes 
and favours HIV-1 spread in macrophages. Dupont M, Souriant S*, Balboa L*, Vu Manh TP, 
Pingris K, Rousset S, Cougoule C, Rombouts Y, Poincloux P, Ben Neji M, Allers C, Kaushal D, 
Kuroda MJ, Benet S, Martinez-Picado J, Izquierdo-Useros N, Sasiain MC, Maridonneau-Parini 
I#, Neyrolles O#, Vérollet C#¶ and Lugo-Villarino G#¶ 
* and # : equivalent contribution of the junior (*) and senior (#) authors to the work 
¶: corresponding authors 
 
In this article, I performed the majority of the experiments, except those involving macaqƵes͛ infection, 
follow-up and sacrifice, along with the histological staining that were performed by our collaborators 
(Drs. MJ Kuroda and D. Kaushal) and the histology platform of Toulouse-Purpan. However, I quantified 
all histological staining of the alveolar macrophages. I also analysed (except the raw transcriptomic 
data which were processed by TP Vu Manh), quantified and interpreted all data obtained in this study 
and constructed the majority of the figures, including movies. Finally, I participated in the writing and 
correction of the manuscript. 
 
The last paper presented in this document is a paper manuscript under preparation concerning the 
second objective of my PhD thesis:  
4. Unpublished data: Dysregulation of the type-I Interferon signaling pathway by Mycobacterium 
tuberculosis leads to HIV-1 exacerbation in human macrophages 
For this part, I performed the vast majority of the experiments, analyzed all the data, and I created the 
figures. I received help from my master student, Stella Rousset, who I trained for her master degree to 
do flow cytometry, qPCR and western blots, but also from our team engineer, Karine Pingris, for WB 
and qPCR experimentations, which allowed us to confirm the upregulation of several ISG at both mRNA 
and protein levels in cmMTB-treated cells. 
Before my thesis, I had the chance to do my master internship at IPBS, under the supervision of Drs. C. 
Vérollet and B. Raynaud-Messina in the team of Dr I. Maridonneau-Parini. During my 6-month 
internship, I spend a month in the laboratory of Dr S. Bénichou, Institut Cochin, Paris, where I learned 
how to work in a BSL-3 facility and to efficiently perform HIV-1 transfer experiments. This expertise 
was used to produce data for our research project on the mechanisms of infection of osteoclasts and 
how their functions are modified upon infection. The results I obtained were part of an original 
research article that was published in PNAS in 2018: 
5. Bone degradation machinery of osteoclasts: An HIV-1 target that contributes to bone loss. 
Raynaud-Messina B, Bracq L*, Dupont M*, Souriant S, Usmani SM, Proag A, Pingris K, Soldan 
V, Thibault C, Capilla F, Al Saati T, Gennero I, Jurdic P, Jolicoeur P, Davignon JL, Mempel TR, 
Benichou S, Maridonneau-Parini I, Vérollet C. 
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2556-E2565. doi: 10.1073/pnas.1713370115. 
Epub 2018 Feb 20. 
PMID: 29463701 
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*  : equivalent contribution of the authors to the work 
My contributions for this paper were mainly experimental, as I acquired the viral cell-to-cell transfer 
system used by our collaborators in Paris. I performed, analysed and quantified all data presented in 
Figure 3 and participated in manuscript corrections. 
Finally, during my thesis, I also participated in a study conducted by our Argentinian collaborators on 
the mechanisms involved in the formation of foamy macrophages upon Mycobacterium tuberculosis 
infection of macrophages: 
6. Formation of Foamy Macrophages by Tuberculous Pleural Effusions Is Triggered by the 
Interleukin-10/Signal Transducer and Activator of Transcription 3 Axis through ACAT 
Upregulation. Genoula M, Marín Franco JL*, Dupont M*, Kviatcovsky D, Milillo A, Schierloh P, 
Moraña EJ, Poggi S, Palmero D, Mata-Espinosa D, González-Domínguez E, León Contreras JC, 
Barrionuevo P, Rearte B, Córdoba Moreno MO, Fontanals A, Crotta Asis A, Gago G, Cougoule 
C, Neyrolles O, Maridonneau-Parini I, Sánchez-Torres C, Hernández-Pando R, Vérollet C, Lugo-
Villarino G, Sasiain MDC, Balboa L. 
Front Immunol. 2018 Mar 9;9:459. doi: 10.3389/fimmu.2018.00459. eCollection 2018. 
PMID: 29593722 
*  : equivalent contribution of the authors to the work 
For this work, I was involved in the experimental procedures and analysis (Figure 6 and 7) s well as the 
training of the first author of the paper when she came for several internship at IPBS to learn new 
techniques. I also participated in the revision process and the manuscript corrections.  
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Preamble 
 
The presented work has been conducted under the direction and collaboration of two teams 
at the Institute of Pharmacology and Structural Biology (IPBS) in Toulouse: the team of Dr O. Neyrolles, 
specialized in host-pathogen interactions in the context of tuberculosis (TB); and the team of Dr I. 
Maridonneau-Parini, specialized in phagocyte differentiation and functions under physiological and 
pathological conditions, including infection with the human immunodeficiency virus type 1 (HIV-1). A 
strong participation of Argentinian collaborators from the IMEX-CONICET Institute in Buenos Aires 
allowed us to get access to samples from TB patients, and sometimes from TB-HIV co-infected patients. 
Moreover, the laboratory of Dr M.C. Sasiain and Dr L. Balboa has a strong expertize in TB research, 
especially in the development of drug resistant TB. The long collaboration arrangement between these 
three laboratories has been granƚed ƚhe sƚaƚƵs of ͞Laboraƚoire Inƚernaƚional Associé͟ ;LIA #1167), by 
the government scientific agencies in France (CNRS) and Argentina (Conicet), which also funded my 
PhD scholarship from the University of Toulouse.  
The research program of the LIA is centered on the understanding of how Mycobacterium 
tuberculosis (Mtb), the etiological agent of TB, exacerbates HIV-1 infection and replication in 
macrophages. Indeed, TB-HIV-1 co-infection is a serious clinical issue at a global scale for several 
reasons. There are about 14 million co-infected individuals around the world, among which about 
300 000 die every year [1]). A major problem in co-infection is that its diagnosis is quite complicated 
and difficult to detect since there are no biomarkers available to follow the progression of the disease. 
Moreover, co-infection diagnosis requires a large amount of resources that are not readily available 
everywhere, especially in low-income countries where co-infection prevalence is high. In addition, 
treatment of co-infected patients is challenging due to drug interactions. On top of that, it is well 
known that Mtb and HIV-1 act in synergy to potentiate one another within the host, notably by 
accelerating the deterioration of the immune system through mechanisms that are not fully 
understood yet. While it is widely accepted that HIV-1 induces susceptibility to TB due to CD4+ T cell 
depletion (important cell for the control of TB) [2], the mechanisms by which Mtb favours HIV-1 
replication remain insufficiently understood. In the context of the LIA project and my PhD project, we 
focused on the role of macrophages in TB-HIV-1 co-infection, as these cells are the main target of Mtb 
and important target for HIV-1, as they mediate viral dissemination throughout the host and act as 
viral reservoirs (for more details, see introduction, chapter II section III.A.d.) [3], [4]. Two main tasks 
have been determined for our collaborative project: (i) mapping and characterizing the pathways 
established in macrophages during Mtb-driven exacerbation of HIV-1 infection, and (ii) identification 
of the changes in factors involved in macrophage activation and metabolic processes during Mtb-
driven exacerbation of HIV-1 infection. During my PhD, I focused on the identification of novel factors 
induced by Mtb-associated environment that could participate to the exacerbation of HIV-1 replication 
in macrophages, by using a genome-wide transcriptomic analysis, and I identified the lectin receptor 
Siglec-1 and IFN-I/STAT1 signaling as important factors. 
For all reasons stated above, I will focus my introduction on the macrophage responses in both 
Mtb and HIV-1 infection, with a specific emphasis on type I interferon (IFN-I) responses involved in 
both pathologies. The reason for this is that we found that IFN-I signaling pathway is the main pathway  
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Table 1: Monocytes subsets and their functions (from [5]) 
 
 
 
 
Table 2: Macrophages activation profiles and nomenclature (adapted from [6]) 
  
Monocyte subset Marker Chemokine Receptor Main functions 
Classical CD14highCD16- CCR2highCX3CR1low Immune responses, phagocytosis 
Intermediate CD14highCD16+ CCR2lowCX3CR1high Pro-inflammatory response, tissue repair 
Non-classical CD14lowCD16high CCR2lowCX3CR1high Patrolling, fibrosis 
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modified in the TB context, and we thought it might have a role in the exacerbation of HIV-1 infection 
of macrophages (see Results, chapter III).  
 
I. Monocytes-macrophages at a glance 
Both monocytes and macrophages belong to the mononuclear phagocyte system and are 
involved in tissue homeostasis, host defense mechanisms against pathogens, auto-immune disease, 
and tissue repair [7].  These cells have an important role in the immune response, as they sequentially 
participate to danger signal recognition, leukocyte recruitment and migration to the site of 
inflammation, elimination of the inflammatory element and finally to the resolution of inflammation, 
which comprises tissue damage repair and subsequent return to homeostasis. When these 
mechanisms fail to clear the inflammatory element (e.g. bacteria, viruses), a constant danger signal 
persists in the host and leads to chronic inflammatory diseases [8]. Here, I will briefly discuss the origin, 
phenotype and function of monocytes and macrophages, as my PhD work is centered on the role of 
macrophages in Mtb and HIV-1 co-infection settings. 
 
A. Monocytes 
Monocytes are derived from the bone marrow, and more precisely from hematopoietic stem cells 
(HSC). They represent about 10% of blood circulating leukocytes in humans. Monocytes are 
categorized into three different subsets, according to their expression of two specific markers: CD14, 
the receptor for lipopolysaccharide (LPS), and CD16, a receptor belonging to the FcJRIII family [9]. The 
so-called ͞classical͟ monocǇƚes are characƚeriǌed bǇ ƚhe high eǆpression of CDϭϰ and ƚhe absence of 
CD16 (CD14highCD16-) and represent about 85-90% of the monocyte population under physiological 
conditions͘ The ͞inƚermediaƚe͟ CDϭϰhighCD16+ monocytes are less abundant and display pro-
inflammatory properties. Upon inflammation, this population of monocytes expands [10], and is often 
correlated with disease severity, as in Mtb infection [251] (see Introduction, chapter I section II.D.b.i.), 
HIV-1 infection [11] (see Introduction, chapter II section II.A.a.iii.) or sepsis [12]. Finally, 
CD14lowCD16high constitute the last subset of monocyƚes͕ also knoǁn as ͞non-classical͟ monocǇƚes 
[13](see Table 1 for a summary of the different subset functions).  
Functionally, monocytes establish the link between the induction of inflammatory responses by 
the innate immune system and the establishment of the adaptive immune response. As circulating 
innate immune cells, they can migrate from the blood into tissues, they are capable of phagocytosis, 
antigen presentation to T cells, cytokine production and present a strong phenotypical plasticity [9]. 
Indeed, the destiny of monocyte is to differentiate into innate immune cells, specialized in specific 
functions depending on the tissue where they migrate, their microenvironment and the physiological 
or pathogenic context. Depending on the signals they receive, monocytes differentiate into dendritic 
cells (DC) or macrophages, which then adopt the appropriate phenotype to fulfil the specific functions 
associated to tissue specificity. 
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Figure 1: Distribution and functions of tissular macrophages (adapted from [14]) 
Mononuclear phagocytes can be generated from the yolk sac during embryogenesis, from fetal liver, or from 
committed haematopoietic stem cells (HSC) located in the bone marrow. Macrophage precursors of 
hematopoietic origin are released into the blood circulation as monocytes. They quickly migrate into any tissues 
of the body, where they differentiate into mature macrophages to replenish the tissular macrophage pool. 
Certain tissue macrophages, which originate from the yolk sac, are capable of self-renewal and are particularly 
long-lived. Various populations of mature tissue macrophages are strategically located throughout the body and 
perform important immune surveillance activities, including phagocytosis (e.g. alveolar macrophages, splenic 
macrophages), antigen presentation (e.g. Kuppfer cells, subcapsular macrophages) and immune suppression 
(e.g. intestinal macrophages). 
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B. Macrophages 
Like monocytes, macrophages are involved in tissue homeostasis, defense against invaders 
and tissue repair. In addition, macrophages are important for embryogenic development [9]. Several 
types of macrophages have been described, according to their origin, functions and the developmental 
stage of the organism. Primitive macrophages originate from the yolk sac and appear during the first 
stages of embryonic development. They are long-lived tissue resident macrophages (e.g. microglia in 
the brain, Kupffer cells in the liver or macrophages in the pancreas) and are capable of in situ self-
renewal during adult life. Fetal liver macrophages are closer to macrophages found in adults. They are 
present in the majority of organs (e.g. splenic macrophages, Langerhans cells in the derma), and are 
renewed, at least in part, by macrophages deriving from HSC of the bone marrow (e.g. macrophages 
in the heart or the gastro-intestinal (GI) tract) [15]. In certain tissues, macrophages display mixed 
origins and fulfil different functions (Figure 1). For example in the lung, alveolar macrophages come 
from embryogenic origins (i.e. from the yolk sac and replenish independently of blood monocyte 
differentiation), while interstitial macrophages derive from hematopoietic origin and are renewed by 
circulating monocytes [15].  
Macrophages are highly plastic cells, able to adapt their phenotype and function to their 
microenvironment. In the bone for instance, the main myeloid cells are osteoclasts, cell specialized in 
bone degradation while in the GI tract, monocyte-derived macrophages are specialized in phagocytosis 
[14]. According to their environment, and particularly during inflammation, macrophages acquire an 
activation or polarization program. By definition, macrophage activation/polarization (both terms are 
used interchangeably in this manuscript) correspond to the cell perturbation in response to an 
exogenous agent (e.g. cytokines, growth factors, pathogens), which results in a distinct pattern of gene 
and protein expression within and at the surface of macrophages [6]. Historically, macrophage 
activation was separated into ƚǁo caƚegories͗ classical ͞Mϭ͟ pro-inflammatory macrophages and non-
classical ͞MϮ͟ anƚi-inflammatory macrophages, based on the type-1 and type-2 (Th1 and Th2) 
immunity possessed by T cells [16]. However, this nomenclature poorly reflects the spectrum of 
macrophage polarization profiles. Therefore, a scientific consensus was implemented and proposed 
that the nomenclature to the specific signals induced upon macrophage activation, also taking into 
account the factors expressed by these macrophages (refer to table 2)[6]. Typically͕ ͞Mϭ͟ 
macrophages are polarized in response to IFNJ, TNFD, and LPS (M(IFNJ), M(TNFD), and M(LPS) 
respectively). Generally, ƚhe ͞Mϭ͟ macrophage family is highly microbicidal and anti-tumoral, produce 
pro-inflammatory cytokines and are resistant to intracellular pathogens. Their antimicrobial function 
mainly derives from their capacity to produce reactive oxygen (ROS) and nitrogen species by inducing 
NADPH oxidase (nicotinamide adenine dinucleotide phosphate oxidase) and inducible nitric oxide 
synthase (iNOSͿ͘ ConǀerselǇ͕ ͞MϮ͟ macrophages are mainlǇ anƚi-inflammatory and immuno-
regulatory. They usually balance the host response to avoid tissue damage. The ͞MϮ͟ caƚegorǇ 
comprises several types of macrophages, including: 
x M(IL-4) or M(IL-13), responsible for tissue repair and control of allergy and parasite 
infection [17];  
x M(Immune complex), strong antigen presenting cells, particularly important in anti-
tumoral responses; 
 
29 
 
 
 
 
Figure 2: Type I interferon induction and signaling pathway (adapted from [18], [19]) 
Upon pathogen attack, microbial products are recognized through different cell-surface and intracellular pattern 
recognition receptors (PRR), including Toll-like receptors (TLR), RNA and DNA sensors and NOD-like receptor 
(NLR), which engage different signaling pathway to lead to the induction of a first wave of IFNE. This is followed 
by a second wave of IFN-I production, including all subtypes. IFN-I will activate the infected cell and bystander 
cells by binding to its receptor, IFNAR. Consequently, multiple downstream signaling pathways can be induced, 
leading to a diverse range of biological effects, the main consequence being the induction of IFN-inducible gene 
(ISG) induction. Both MAPK and ISGF3 complex, composed of STAT1-STAT2 heterodimers and IRF9, activate the 
IFN-stimulated response elements (ISRE) in gene promoters, leading to induction of a large number of ISG. IFN-I 
can also signal through STAT1 homodimers, which are more commonly associated with the IFNɶ-mediated 
signalling pathway. Other signaling pathways like PI3K activate a response to IFN-I, leading to diverse effects on 
the cell. 
cGAS: cytosolic GAMP synthase; cGAMP: cyclic di-GMP-AMP; DAI: DNA-dependent activator of IRF; ER: 
endoplasmic reticulum; GAS E: cGAS-activated sequence; IKKε: IκB kinase-ε; MAVS: mitochondrial antiviral 
signalling protein; MDA5: melanoma differentiation-associated gene 5; MyD88: myeloid differentiation primary 
response protein 88; NFκB: nuclear factor-κB; NOD2: NOD-containing protein 2; STING: stimulator of IFN genes; 
TBK1: TANK-binding kinase 1; TRAF: TNF receptor-associated factor; TRAM: TLR adaptor molecule; TRIF: TIR 
domain-containing adaptor protein inducing IFNβ; TYK2: tyrosine kinase 2; JAK1: Janus kinase 1; IRF: interferon 
regulatory factor. 
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x M(IL-6), which are more pro-inflammatory than the others and associated with a poor 
prognostis in patients with cancer [20]; and  
x M(IL-10), involved in the clearance of apoptotic bodies and inhibition of Th1 responses, 
while they induce tolerance in the tissue by activating regulatory T cells [21]. 
During the course of inflammation, a dynamic modification of macrophage polarization occurs, 
resulting in either beneficial or detrimental outcomes for the host, according to the nature and stage 
of the inflammation. For example, as discussed in ƚhe resƚ of ƚhis manƵscripƚ͕ ƚhe ƚransiƚion from ͞Mϭ͟ 
polarization towards an ͞MϮ͟ ;general ƚerm Ƶsed here ƚo inclƵde ƚhe differenƚ pro-inflammatory ʹ 
M(IFNJ), M(TNFD) - and anti-inflammatory macrophages ʹ M(IL-4), M(IL-10), respectively) profile 
during a pathological infection, with either Mtb or HIV-1, is associated with the establishment of 
disease chronicity and aggravation. 
 
II. Type I interferon responses in macrophages 
Among the different weapons the immune system can wage against pathogen invasion, 
interferons (IFN) are key. They are able to trigger many different signaling pathways and genes that 
play an important role in the host defense against both viruses and bacteria. There are three families 
of IFN. In this manuscript, I will particularly focus on the multi-gene type I IFN (IFN-I) family, and how 
they are modulated by Mtb and HIV-1. Several subtypes are encoded by IFN-I, including 13 homologous 
IFND in humans, 1 IFNE and several other single genes, which have been poorly studied so far: IFNH, 
IFNW, IFNN, IFNZ, IFNG and IFN[[18], [19]. Here, only IFND and IFNE will be discussed, as they have 
been studied in more depth than the other subtypes.  
In the body, almost all cells are able to produce and respond to IFN-I, usually after the 
stimulation of pathogen recognition receptors (PRR) by microbial products. Microbial nucleic acids 
count for one of the best IFN-I inducers. For example, foreign messenger RNA is recognized by RIG-I1, 
MDA52 [22], or even cytosolic molecular sensors NOD13 and NOD2, the latter being involved in 
cytosolic Mtb recognition [23]. These different sensors rely on the adaptor mitochondrial antiviral 
signaling protein MAVS to activate the TANK-binding kinase 1 (TBK1). Phosphorylated TBK1 then 
recruits and activates the IFN regulatory factor 3 (IRF3) [19], which subsequently translocates to the 
nucleus, binds to the IFN-I promoter sequence and induces the expression of IFND4 and IFNE subtypes. 
After this first wave of IFN-I synthesis, secreted IFN-I act both in an autocrine and paracrine manner to 
trigger IRF7 transcription, which then mediates a positive feedback loop, leading to the transcription 
of all IFN-I gene subtypes [24]ʹ[26]. Besides foreign RNA, exogenous DNA can also provoke IFN-I 
production. In the cytosol, DNA motifs can be recognized by DNA-dependent activator of IFN (DAI) 
                                                          
1 RIG-I: retinoic acid-inducible gene I is an RNA helicase. It is a PRR involved in viral sensing that recognizes short double or 
single stranded uncapped RNA molecules. 
2 MDA5: melanoma differentiation-associated gene 5 belongs to RIG-I PRR family and recognizes shorter RNA molecules, 
including viral RNA. 
3 NOD: Nucleotide-binding oligomerization domain-containing protein is involved in bacterial molecule and immune reaction. 
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Figure 3: Immuno-suppression induced by IFN-I (from [18]) 
A | Virus-infected cells produce type I interferons (IFN-I) in response to the infection. The released IFN-I then act 
in an autocrine and paracrine manner to protect the bystander cells from becoming infected and to block the 
viral replication cycle in the infected cells. Interferon stimulated genes (ISG) are responsible for these functions. 
IFN-I also act on innate immune cells, including professional antigen-presenting cells (APC), natural killer (NK) 
cells, T cells and B cells to enhance their immune functions.  
B | During chronic viral infection, IFN-I are produced for a longer period of time, compared to acute infection. 
Consequently, to avoid immuno-pathology, sustained IFN-I expression induce the secretion of immunoregulatory 
cytokines such as interleukin-10 (IL-10), and the expression of immunosuppressive ligands (such as programmed 
cell death 1 ligand 1 (PD-L1)) for T cell-inhibitory receptors (such as PD1, the PD-L1 receptor). These factors lead 
to the suppression of T cell function and, often, failure to clear infection. 
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regulatory factors, by DEAD and DEAH boxes and by cGAS4. Recognition of foreign DNA leads to the 
activation of INB kinase H (IKKH), which then recruits and activates IRF7, whose subsequent nuclear 
translocation induces further IFN-I synthesis [18]. Notably, recognition of foreign DNA molecules by 
cGAS leads to the production of the second messenger cGAMP5 that recruits and activates the 
stimulator of IFN genes, STING, which then signals through the TBK1/IRF3 pathway to induce IFN-I 
transcription [18], [27]. Other PRR, such as TLR, are also able to mediate IFN-I synthesis and involve 
signal transduction through the MyD88/NFNB axis, as recapitulated in figure 2 [18]. 
Secreted IFN-I bind and signal through their receptor IFNAR, composed of two subunits, 
IFNAR1 and IFNAR2. Globally, ligand-receptor binding activates the receptor-associated kinases JAK1 
and TYK2, which phosphorylate both the signal transducer and activator of transcription 1 (STAT1) and 
STAT2. Upon activation, STAT1 and STAT2 heterodimerize and recruit IRF9 to form the ISG factor 3 
(ISGF3) complex. Subsequently, ISGF3 translocates into the nucleus and binds to IFN-stimulated 
response element (ISRE) in the interferon stimulated genes (ISG) promoter [18], [19]. Consequently, 
ISG are expressed and mediate the adequate response to control the pathogen invader. IFN-I can also 
induce signaling through homodimerization of STAT1, more commonly associated to IFNJ-signaling, 
and through other STAT (STAT3, 4 and 5) despite their typical role in other cytokine signaling (see 
Figure 2) [18]. Altogether, this diversity in possible signaling pathways engaged by IFN-I could explain, 
in part, the broad effects of IFN-I signaling and different outcomes observed in several infectious 
settings. 
ISG are expressed constitutively in response to the low levels of IFN-I present in the 
microenvironment. More commonly, ISG are induced at higher levels in response to IFN-I production 
occurring in response to viral infection. Most of these genes display antiviral properties, which act both 
in the infected cells to restrict the viral replication cycle and in bystander cells to prevent the spread 
of infection [18], [28]. Moreover, IFN-I are able to activate immune cells to enhance the immune 
response to the infection, for example by recruiting T cells and NK cells to kill the infected cells, often 
through the induction of apoptosis. It also stimulates B cell humoral responses. When prolonged, IFN-
I can also induce immunosuppression, in order to halt inflammation and T cell mediated-killing (Figure 
3). 
 
Now that macrophages and IFN-I responses in immune cells have been briefly described, I will 
introduce and discuss the current literature on HIV-1 and TB pathologies. For the entire manuscript, a 
particular focus will be brought on IFN-I responses and on the role of macrophages in the control or 
the exacerbation of each disease, but also in the co-infection context. 
                                                          
4 cGAS: Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates IFN-I responses by binding to self and microbial 
DNA present in cell cytoplasm, and is responsible for cGAMP synthesis. 
5 cGAMP: Cyclic guanosine monophosphateʹadenosine monophosphate is synthetized from ATP and GTP (adenosine or 
guanosine triphosphate) by cGAS and function as second messenger in IFN-I induction. 
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Chapter I: Mycobacterium tuberculosis infection 
and the macrophage response 
  
Although the main cause of morbidity and mortality in developed countries have progressively 
shifted towards non-transmissible pathologies grouped under the designation ͞ chronic diseases͟ (e.g., 
cancers, cardio-vascular diseases, obesity, diabetes), infectious diseases remain the principal cause of 
death in children and young adults worldwide, and in adulthood in developing countries [1]. In 2016, 
lower respiratory infections including tuberculosis, killed 3 million people, reaching the 4th ranked 
leading cause of death worldwide. Nowadays, and despite a reduction in the epidemic burden, 
tuberculosis remains the deadliest disease caused by a single infectious agent on the world scale [1]. 
 
I. Mycobacterium tuberculosis: the etiological agent of tuberculosis 
A. Koch's tubercle bacillus 
a. Historical perspective 
Tuberculosis (TB) is an old and highly contagious disease, infecting humans for thousands of 
years [29]. The oldest record of the disease dates back to 1550-1080 B.C. [30], and phylogenetic studies 
reported that the Mycobacterium tuberculosis complex (MTBC), composed of Mycobacterium 
tuberculosis and other closely related species (africanum, canettii and bovis), had a common African 
ancestor about 35 000 to 15 000 years ago [30]. It appears that ancient Egyptian society already 
suffered from TB 5 000 years ago, as typical skeletal abnormalities of TB, inclƵding Poƚƚ͛s deformiƚies6, 
were found in Egyptian mummies [31]. Throughout history, the disease was referred to under several 
names (schachepheth in the Old Testament, phthisis by Hippocrates in the Greek literature, cunsunptio 
in Roman era or consumption in occidental countries during the XIXth century). However, it was only in 
1834 that J. L. Schönlein unified the nosologǇ and proposed ƚhe name ͞ƚƵbercƵlosis͟ dƵe ƚo ƚhe 
presence of tubercles in all forms of the disease [32]. The contagious nature of TB was first suggested 
by Benjamin Marten, but it was the French military surgeon J-A. Villemin who convincingly proved the 
contagious nature of the disease in ϭϴϲϱ͕ bǇ inocƵlaƚing a rabbiƚ ǁiƚh ͚͞a small amoƵnƚ of pƵrƵlenƚ 
liqƵid from a ƚƵbercƵloƵs caǀiƚǇ͟ obƚained from ƚhe aƵƚopsǇ of a TB paƚienƚ [30]. 
The history of TB changed dramatically when its etiological agent, Mycobacterium tuberculosis 
(Mtb) or Koch bacillus, was identified for the first time in 1882 by the German Dr. R. Koch; a discovery 
that was awarded the Nobel Prize in 1905. Following this crucial finding, tuberculin, an extract of Mtb 
proteins, was first used as a therapy, which failed, and then in animals and humans to identify TB 
infection by intra-dermal skin testing [32]. Between 1908 and 1921, A. Calmette and C. Guérin sub- 
                                                          
6 Pott deformity: clinical manifestation of spine infection attributed to Mtb. One of the most common forms of 
extra-pulmonary TB, characterized by back pain, tenderness, paraplegia or paraparesis, and kyphotic or scoliotic 
deformities. 
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Figure 4: New Mtb infections worlwide in 2017 (from [1]) 
The severity of national TB epidemics in terms of the annual number of new TB cases relative to population size 
(the incidence rate) varied widely among countries in 2017. There were less than 10 incident cases per 100 000 
persons in most high-income countries (North America, Western Europe, Oceania), 150ʹ400 in most of the 30 
highest TB burden countries (e.g. India, Mongolia), and above 500 in a few countries including the Democratic 
People͛s RepƵblic of Korea͕ Lesoƚho͕ MoǌambiqƵe͕ ƚhe Philippines and SoƵƚh Africa ;WHO TB reporƚ͕ ϮϬϭϴͿ͘ 
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cultured the close Mtb relative Mycobacterium bovis more than 200 times, and showed that the 
resulting bacterium had lost its virulence in a large number of animal models. This final bacterial strain, 
today referred to as BCG (for Bacillus Calmette-Guérin) was used as a vaccine to prevent TB, and 
proved to be efficient at protecting infants from TB meningitis and other infectious diseases in infants 
(described later in this chapter ʹ section I.A.c.).  
In the late 1880s, TB prevalence was equated to about 500 cases per 100 000 inhabitants in 
Europe and one of the leading causes of death, according to the National Vital Registration system. At 
the turn of the 20th century, the improvement of incomes, hygiene and nutrition, as well as the socio-
economic development, brought about a slow decline in the number of TB cases and deaths in Western 
Europe and Northern America [33], [34]. From the 1940s, the discovery, development and use of 
effective antibiotherapy (i.e. discovery of streptomycin in 1943 by A. Schatz [30], [32]) accelerated this 
trend, reducing the disease incidence nowadays to less than 10 cases per 100 000 inhabitants and less 
than 1 death per 100 000 inhabitants per year in European and North American countries [1]. 
 This progression in the control of the epidemic in developed countries has given the false 
impression that TB is now a disease of the past. However, for manǇ coƵnƚries͕ ƚhe ͞end͟ of the TB 
pandemic is still a distant reality, despite the possibility to be cured with timely diagnosis and proper 
treatment. Even with the call to consider TB as a global health emergency by the World Health 
Organization (WHO) in 1993, the progress made to fight the epidemic remains insufficient, calling for 
more efforts to step up the political commitments that have intensified in 2017 and 2018 [1].  
 
b. Epidemiology 
Since 1997, the WHO publishes a yearly report to follow the evolution of the epidemic. 
Worldwide, TB remains the leading cause of death due to a single infectious agent, with millions of 
people becoming sick with the disease each year and 10 million newly infected people in 2017. The 
same year, TB caused 1.3 million deaths among the HIV negative population. Today, we estimate that 
one quarter of the global population is latently infected with Mtb, meaning that these infected people 
do not present any symptoms of the disease [1]. Despite a continuous decline in TB prevalence, the 
importance to continue the fight against TB resides in the fact that multi-drug resistant (MDR) and 
extensively drug resistant (XDR) Mtb strains, which cannot be eradicated by conventional 
antibiotherapy, are flourishing every year, representing almost a half of new TB cases in low-income 
countries (India, China and the Russian Federation in particular). For example, in India, TB incidence 
was of 204/100 000 in 2017, among which 92% of Mtb infections were MDR [1]. 
Several factors are involved in TB susceptibility. First, TB is officially considered as a disease of 
the poor and is tightly linked with the social and economic stability of the country. Other important 
factors related to TB susceptibility are hygiene, overcrowding and malnutrition, which all related to 
poverty status. In 2017, two-third of the cases were reported to occur in 8 countries (see Figure 4): 
India (27%), China (9%), Indonesia (8%), the Philippines (6%), Pakistan (5%), Nigeria (4%), Bangladesh 
(4%) and South Africa (3%). It was estimated that among the 10 million new infections annually, 1.9 
million are due to malnutrition. Other factors that increase susceptibility to TB are: alcoholism, 
smoking, diabetes and co-infection with HIV-1 (described in Chapter III of the present manuscript) [1]. 
37 
 
In addition, intrinsic factors also have an impact on TB incidence repartition worldwide. Indeed, age, 
sex and genetic factors also play a role in the disease development. The WHO reported that in the new 
cases identified in 2017, 90% were adults over 15 years old, among which 64% were males, indicating 
an incidence of about 2 males infected for 1 female [1].  
 
c. Pulmonary and extra-pulmonary disease 
Mtb is a facultative slow growing (generation time around 20h) intracellular pathogen whose 
reservoir is exclusively human, and that is particularly well-adapted to its main cell target: the 
macrophage. In conditions where the immune system is unable to control the bacterial growth 
(between 5 to 10% of the time [35], [36]), the disease symptoms (e.g. fever, cough, weight loss) appear. 
This form of TB is referred to as ͞acƚiǀe TB͟ and results in patients transmitting the infection to new 
hosts by aerosol release. In the absence of treatment or in drug inefficiency settings, 50% of patients 
die of TB due to destruction of the lungs caused by exacerbated inflammation [35], [37]. Fortunately, 
in 90% of the cases, the immune system is able to contain the infection in an asymptomatic latent 
stage, during which Mtb is dormant and does not proliferate [36]. This form of the disease, which is 
non-transmittable, is the most common form of TB worldwide. 
In certain cases, active TB can develop into an extra-pulmonary manifestation of the disease. 
These manifestations involve bacterial dissemination through the bloodstream to reach several 
organs, including the pleural cavity, lymph node, spleen, liver, bone, urogenital and peritoneal tracts, 
and brain (for review, see [38]). The prevalence of extra-pulmonary TB varies with geographical 
location and is more frequent in low-income countries. The most common form of extra-pulmonary 
TB is the pleural manifestation of the disease. It is characterized by the abnormal presence of fluids in 
the pleural cavity surrounding the lungs. This fluid contains leukocytes, of which 50% are lymphocytes. 
This type of extra-pulmonary TB is highly prevalent in African countries like Burundi, where more than 
25% of TB patients have pleural effusions [39]. The incidence of this type of TB manifestation is strongly 
increased in immuno-compromised patients, such as those co-infected with HIV-1 [40]. The deadliest 
form of TB is TB meningitis, for which more than 100 000 new cases are estimated to occur each year, 
a majority of which affect children. This form of TB is difficult to diagnose due to the long time needed 
to culture the bacteria. Moreover, it is likely that antibiotherapy is poorly effective against this form of 
the disease since drug access to the brain is quite limited [41]. 
 
d. Mycobacteria taxonomy and characteristics 
Mtb is an acid-fast resistant Gram-positive bacterium that belongs to the Mycobacteriaceae 
family. The genus Mycobacterium comprises more than 170 species, most of which are environmental 
organisms [42]. Generally, pathogenic or opportunistic Mycobacteria can be divided into three major 
groups for the purpose of diagnosis and treatment: first, the MTBC which causes TB and includes Mtb, 
M. bovis, M. africanum, M. microti, M. canetti and other species; second, M. leprae that causes leprosy; 
and third, the non-tuberculous mycobacteria or NTMs (M. avium, M. kansasii, M. abscessus, M. 
chelonae, M. fortuitum, M. pregrinum and M. marinum) that can cause pathology in immuno-
compromised individuals. The MTBC group is unique as it is an obligate human pathogen, with no  
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known animal or environmental reservoir. Moreover, its virulence is also unique as it mainly relies on 
its transmission between individuals [42]. From now on, I will particularly focus on Mtb, which is 
responsible for the human pandemic of TB. 
Under optimal conditions, Mtb grows at 37°C with a generation time of about 18 to 24h. It can 
also be cultured on solid culture media, where colonies appear within two to three weeks [43]. 
However, the host environment is not optimal for bacterial growth. To circumvent this issue, Mtb is 
able to enter a dormant, non-replicative state that is characterized by low metabolic activity and 
phenotypic drug resistance [43]. The genome of Mtb H37Rv strain, the most commonly used in 
laboratory research, was sequenced in 1998 by Cole and colleagues [44]. The genome is 4 million base 
pairs, encoding for almost 4 000 genes, among which many are highly conserved in the 
Mycobacteriaceae family, and more specifically genes involved in lipid metabolism [45]. Another 
conserved region of the Mtb genome, the RD17 locus, is involved in Mtb virulence and encodes a 
secretory apparatus, the ESX-18 secretion system responsible for exporting virulence factors such as 
cell filtrate protein 10 (CFP-10) and early secretory antigen 6 (ESAT-6); both of which play a key role in 
Mtb pathogenesis (for more detail, refer to section II.) [46]. 
 
e. The mycobacterial cell envelope  
The Mycobacteriaceae family is characterized by the peculiar structure of its cell wall that 
comprises complex lipids and sugars, and contains high levels of glycosylation, which allow it to be 
recognized by the host immune system [47], [48]. The mycobacterial cell wall (Figure 5) is divided into 
two sections: the inner and the outer layers. The inner layer is composed of (i) peptidoglycan, (ii) 
arabinogalactan and (iii) mycolic acids [48]ʹ[50]. These three components form an insoluble core that 
is essential for viability of mycobacteria, and it is the main target for drug development to combat Mtb 
[51]. The outer layer, called capsule, has only minor amounts of lipids and consist of a loosely-bound 
structure of polysaccharides, proteins and non-covalently linked glycoconjugates, such as 
phosphatidyl-myo-inositol (PI) mannosides (PIMs), lipomannan (LM) and lipoarabinomannan (LAM). 
These mannosylated molecules are thought to play important roles in the integrity of the cell wall and 
pathogenesis of Mtb [52].  
The nature and quantity of the different cell envelope layer components vary between Mtb 
isolates and impact their interaction with the host cells. Such is the case with the lipid composition of 
the cell wall, which represents 60% of this structure and is responsible for Mtb resistance to antibiotics. 
Mtb dedicates 6% of its genome to lipid metabolism [53], a phenomenon that favours the lipid 
repertoire expressed at the bacterial cell wall. The genomes of different Mtb clinical isolates are well 
conserved and show no sign of exogenous genetic material acquisition despite the high variability in 
the mycomembrane components [45]. Therefore, the resistance of the bacteria to antibiotics targeting 
Mtb lipids is conferred by punctual mutations in the Mtb genome. 
                                                          
7 RD1: region of difference 1 expressed by all virulent strains of Mtb, encodes 9 genes involved in Mtb virulence, 
including CFP-10 and ESAT-6. 
8 ESX-1: early secretory antigenic target 6 system-1 is required for Mtb virulence and secretion of the bacterial 
protein CFP-10 and ESAT-6. 
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Figure 5: Structure of the mycobacterial cell wall (adapted from [54]) 
Mtb cell envelope is composed of a plasma membrane containing glycolipids, lipoglycans and lipoproteins. The 
peptidoglycane (PG) is covalently linked to arabinogalactane (AG) and form a complex that is bound to mycolic 
acid (shown in dark green). Those are covered with lipids, and together form the mycomembrane, on which the 
capsule, containing proteins and polysaccharides (lipomannan [LM], phosphatidyl-myo-inositol mannosides 
[PIM] and lipoarabinomannan [ManLAM]), is lying. 
 
Blue symbols: arabinose residues; red symbols: galactose residues; brown symbols: mannose residues; black 
circles: glucose residues. 
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Its genome encodes for many factors responsible for its virulence (e.g. RD1 region encodes for 
ESAT-6, one of the most important virulence factors of Mtb) and for its resistance to antibiotics. In the 
following section, I will discuss the methods of prevention, diagnosis and treatment for Mtb infections.  
 
B. Therapeutic tools to detect and treat tuberculosis 
a. Prevention 
To date, the only available vaccine to prevent Mtb infection and the development of TB is the 
BCG vaccine, based on the living BCG attenuated strain. In 1902, the first isolate of BCG was obtained 
from TB-infected cattle, and since then, cultured for decades, reducing this strain virulence by inducing 
a loss of the RD1 region in its genome [55]. It was used for human vaccination for the first time in 1921, 
and since then, a number of laboratories continue to culture BCG, which explains the high diversity of 
genetic variance used for vaccination.  
Over time, history and clinical data revealed that the BCG vaccine efficiency is quite variable. 
Indeed, it effectively protects children (90%) against pulmonary TB, but also against extra-pulmonary 
forms of the disease such as TB meningitis (see section I.A.c.) [55], [56]. However, BCG vaccine 
protection in adults is only relatively efficient (50% of the cases [1], [35], [57]) and depends on the (i) 
patient age at the moment of vaccination, (ii) contact with environmental mycobacteria, (iii) host 
genetics, (iv) strain of BCG used for the vaccine formulation and (v) Mtb strain virulence [58]. 
Consequently, new strategies to prevent Mtb infection are crucial to halt the pandemics, especially 
with regards to co-infections settings like HIV-1, since HIV-infected people present higher risk of 
developing TB and MDR-TB (up to 24% more MDR-TB occur in HIV-1+ patients [59]) [60]. 
Several strategies have been developed to create new vaccines to protect the population 
against TB infection (Figure 6). Indeed, the vaccine strategy seems appropriate considering that our 
immune system is able, in the majority of the cases, to control the bacteria and to maintain it in a 
dormant status. However, vaccine development is more difficult than expected since the immune 
memory induced by a primary Mtb infection is not entirely efficient: patients who have been infected 
once with Mtb are still highly susceptible to be re-infected [61], even though a recent study in 
macaques reported an efficient protection against secondary infection with different Mtb strains after 
primary Mtb infection [62]. Therefore, new strategies will aim at preventing new infections (pre-
exposition vaccines), but also at targeting both replicative and dormant bacteria to aid in its eradication 
(post-exposition vaccines) [63]ʹ[65]. Any strategy should take into consideration (i) the improvement 
of immune memory induction by a rapid stimulation and recruitment of Mtb-specific T cells, (ii) the 
prevention of Mtb transmission and (iii) to protect lung tissue against Mtb-mediated inflammation 
[66]ʹ[68]. As of today, there are two main strategies being carried out to develop new vaccine 
candidates [69]. The first strategy aims at replacing BCG with safer, more immunogenic vaccine that 
induces long-lasting protection against highly virulent clinical isolates (e.g., Mtb Beijing strains, MDR 
strains). This includes the improvement of BCG by introducing immunodominant Mtb antigens (e.g., 
ESAT-6), overexpressing mycobacterial antigens (e.g., Ag85), or genetically engineering new strains for 
superior immune efficacy. Alternatively, this first strategy also includes the manipulation of Mtb  
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Figure 6: BCG vaccination efficiency. 
Hypothetical curve showing the immune response to vaccination with BCG vaccine (solid green line) and the 
proposed action of improved priming (a) and boosting (b) vaccines (red dashed line). When immunity drops 
under an arbitrary threshold (black line), the vaccine no longer protects the individual to become latently infected 
with Mtb. Improved priming vaccines aim to keep the immune response above this threshold for longer, whereas 
intervention in the form of a booster vaccine (more immunogenic Mtb component, stronger adjuvant) is 
hypothesized to induce a long-lasting protective immunity to levels remaining above the threshold 
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attenuated strains by deleting of essential metabolic (e.g., panCD) or virulence (e.g., phoP) genes [69]. 
The second strategy aims to boost BCG with sub-unit vaccines either in the form of protein-lipid 
mycobacterial antigens (e.g., ESAT-6, Ag85) with different adjuvants (e.g., liposome/TLR4 agonist), or 
recombinant viral vectors (e.g., modified vaccinia Ankara virus) [69].  
Collectively, despite its limitations, the BCG vaccine is not easily replaced because it is safe and 
offers multiple advantages. Its improvement remains the best alternative for the rational design of a 
tuberculosis vaccine. Major efforts should be rallied towards the identification of new mycobacterial 
epitopes and antigens, and for the improvement of the immune stimulatory capacity, to make a multi-
valent BCG vaccine. 
 
b. Diagnostic 
TB is a highly contagious airborne infection. In the respiratory tract, Mtb can be eliminated 
before the establishment of a successful infection by mucocilliary clearance, or it can be efficiently 
controlled and eradicated by the immune system. Sometimes, the bacillus succeeds to establish a niche 
in the lung where it either stays latent or replicates to progress towards the disease (Figure 7) [70]. To 
avoid this progression and the transmission of the infection, an early and accurate diagnosis is 
necessary [71]. 
Tuberculin Skin Test (TST) is usually used to detect asymptomatic latent TB [72], [73]. A 
commercial extract of mycobacteria antigens (common antigens between several mycobacteria 
species, including Mtb and BCG species) is injected under the patient skin. After 3 days, the induration 
(local inflammation) is measured to determine if the patient is infected. A limiting factor of that 
method is that it is not specific for Mtb and the quantification of the inflammation is not precise. 
Therefore, false positives occur, frequently due to a reaction to BCG vaccination [72], [74]. This TST 
can be complemented by a blood test, measuring interferon gamma (IFNJ) (IFNJRelease Assay ʹ IGRA) 
[72]. This test measures ex vivo T-cell release of IFNJafter stimulation with Mtb-specific antigens, and 
allows physicians to discriminate TST false-positive results [72], [74].  
Diagnosis of active TB is more time-consuming and expensive since it requires the detection of 
the pathogen from a patient sputum or lung tissue. These samples are then observed by microscopy 
to detect Mtb, a method which is poorly sensitive [75]. In addition, a bacterial culture from these 
samples is conducted (Figure 7), as well as bacterial DNA amplification, in order to identify the 
pathogen. The limit of this culture method is the Mtb generation time, which delays the results [75], 
[76]. Finally, lung X-ray, and more recently, PET-SCAN exams, allow physicians to visualize 
characteristic structures of the disease in infected patients and the bacterial activity and load [77].  
Despite TB diagnostic tools improvement these last five years, specifically with the 
implementation of the Xpert MTB/RIF molecular test that simultaneously detects Mtb resistance to 
rifampicin, strong efforts still remain to be done to improve TB infection identification, especially in 
patients also infected with HIV-1. Indeed, TB diagnosis is particularly difficult in HIV-1 co-infected 
individuals who often display atypical, non-specific clinical presentation and smear-negative disease 
(from 21 to 61% of cases) with less cavitary lesions, along with increased propensity to develop extra-
pulmonary TB [59]. In addition, and particularly in low-income countries, greater advancements are  
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Figure 7: Spectrum of tuberculosis disease and associated diagnosis (adapted from [35]). 
Upon inhalation of Mtb-aerosol, the bacteria will be eliminated in the upper airways either by mechanisms 
independent of the immune system (mucocilliary clearance), or by an efficient intervention of immune cells 
(infection clearance). If the pathogen is not cleared, the immune system will establish a cellular response to 
contain the bacteria. When successful, this response maintains the bacteria in a dormant, non-replicative stage. 
The disease is then latent and asymptomatic, and can remain so for decades. Under certain conditions, e.g. an 
immune-deficiency, Mtb can re-enter a replicative state and escape immune surveillance, leading to the disease 
reactivation. This form of the disease is called active TB and allows the transmission of the bacilli to other 
individuals. Both tuberculin skin test (TST) and interferon gamma release assay (IGRA) are used to diagnose latent 
TB, while active TB can be detected by bacterial culture from the patient sputum or broncho-alveolar lavages. 
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needed to improve TB diagnostic in children, which is challenging, notably because of the low 
sensitivity of traditional diagnostic tools. Clinical diagnosis lacks standardized methods and there is 
lack of laboratory and clinical centers able to process samples from TB patient for Mtb growth in low-
income countries [78], [79]. 
 
c. Treatment 
Upon active TB diagnosis, the patient receives a standard first line treatment: an oral 
antibiotherapy combining four different antibiotics for two months (isoniazid, rifampicin, 
pyrazinamide and ethambutol). This step is then followed by four months of oral ingestion of isoniazid 
and rifampicin [80]. This treatment is both long and constraining due to the daily basis of drug 
ingestion. However, if taken seriously and accurately supported by a physician, this antibiotherapy has 
a curative efficiency of 95% [81]. A limitation of this treatment is the absence of a rapid method to 
verify its efficiency. Indeed, two months are necessary to validate Mtb elimination from the patient 
sputum using the in vitro bacterial culture method. Moreover, Mtb clearance efficiency relies on the 
patient strict compliance to the treatment, which is not always respected. This leads to the 
development of drug-resistant bacteria (MDR, XDR and TDR: total drug resistant), which decreases the 
treatment effectiveness and renders control of the pandemic difficult [82].  
Emergence of antibiotic resistance (especially to rifampicin and isoniazid) required the 
establishment of a second-line of treatment: an antibiotherapy combining oral and injectable 
antibiotics (fluoroquinolones, acid para-amino-salicylic, aminoglycoside, ethionamid and cycloserine). 
The use of this line of drugs extends the treatment duration up to two years, induces severe secondary 
effects and reduces Mtb clearance efficiency to 50% [35], [82], [83]. Unfortunately, the number of MDR 
cases is increasing every year [1] and allows the emergence of highly resistant strains called XDR and 
TDR [84], [85], which are not sensitive to any line of antibiotics. For example, in an MDR-TB patient 
cohort in 2015, treatment success of MDR-TB was lower than 50% in China and India. In fact, India, the 
Russian federation and Ukraine accounted for 75% of XDR-TB cohort recruited by the WHO, and 
mortality rates reached 42% in the Indian study [1]. In addition, known cohorts of MDR and XDR-TB 
infected patients (2015, WHO) treated with second-line of treatment controlled the infection in only 
20% of cases [1]. Early in 2019, the FDA approved the use of a novel antibiotic, Pretomanid, in 
combination with two other antibiotics for six months, to treat XDR-TB and intolerant or non-
responsive MDR-TB.  
TB remains a burden at the world scale, with the possibility of a rebound of epidemic within 
the coming years, even in countries where it is not highly prevalent (Northern and Western Europe, 
North America) due to the increasing population and wealth inequalities. On top of that, there is the 
rapid emergence of MDR, XDR and TDR-Mtb strains, of which diagnosis is not always obvious, 
especially in co-infection settings with other pathogens such as HIV-1. All things considered, finding 
new treatments and preventive alternatives to eradicate Mtb infection remains an urgent global health 
priority.  
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Figure 8: Epithelial secretion of MMP9 and innate cells recruitment to the site of infection (from [86]) 
Mtb takes advantage of macrophage infection to secrete virulence factors (e.g. ESAT-6) through its ESX-1 
secretion system encoded by the RD1 locus. The release of ESAT-6 through secretion or macrophage apoptosis 
caused by the infection alarms surrounding cells, in particular epithelial cells that will produce and secrete MMP-
9. As a result, uninfected macrophages are recruited to the site of infection and accumulate there, forming a 
mass: the immature granuloma.  
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II. Macrophages at the heart of host-pathogen interactions with 
Mycobacterium tuberculosis  
A. Physiopathology of the Mycobacterium tuberculosis infection 
a. Establishment of the cellular response 
The host defense against Mtb requires the intervention of both the innate and adaptive 
immune system. When an infected individual with active tuberculosis sneezes or coughs, he/she 
exhales Mtb-rich droplets that can be inhaled by uninfected surrounding individuals. After inhalation, 
the droplets can either get stuck in the upper airways, or reach the lower lung, depending on their size 
(from 0.65 to < 0.7 µm [87], [88]). In the former case, airway epithelial cells detect Mtb through PAMP 
recognition by Pathogen Recognition Receptors (PRR), and present Mtb antigens to MAIT T cells that 
rapidly produce IFNJ and TNFD, and activate innate macrophages towards a microbicidal profile that 
then perform an efficient bacterial clearance [88], [89]. However, in the latter case, small droplets ;у 
0.65 µm [87]) can reach the lower airways, where Mtb is able to efficiently invade the host [88], [90], 
[91]. 
 Once in the alveoli, inhaled Mtb bacilli are recognized through several PRR such as TLR and C-
type lectin receptors (CLR), among others (see section II.B.a of this chapter), and are subsequently 
ingested by alveolar macrophages. Engagement of these PRR drive the macrophages to secrete several 
cytokines, including TNFD, IL-1D/E, IL-12 and IL-6 [71], [92]. By using a mouse model of Mtb infection, 
Cohen and colleagues found in vivo that early Mtb productive infection occurs exclusively in the airway 
resident alveolar macrophages, which are leukocytes derived from embryonic origin [93]. Following 
their infection, alveolar macrophages translocate to the lung interstitium through the epithelial 
barrier, involving mechanisms dependent on Mtb ESX-1 secretion system and MyD88/IL-1R9 
inflammasome signaling [93]. Mtb also takes advantage of macrophages infection by secreting 
virulence factors encoded by the RD1 genomic region via its ESX-1 secretion system. Among these 
factors, ESAT-6 alarms surrounding epithelial cells, which start to secrete metalloproteinase 9 (MMP-
9) (Figure 8). Consequently, new innate immune cells including neutrophils, DC and 
monocytes/macrophages are actively recruited to the site of infection, at a high rate and speed [90], 
[86], and eventually participate in Mtb uptake. Of note, recruited monocytes undergo differentiation 
into macrophages with different activation profiles (see preamble and figure 9). According to the 
signals received upon recruitment, monocytes may become ͞Mϭ͟ macrophages͕ ǁhich are pro-
inflammatory effector cells, like interstitial macrophages deriving from a hematopoietic lineage, and 
are responsible for Mtb clearance. Likewise, monocytes also polariǌe inƚo ͞MϮ͟ macrophages͕ ǁhich 
regƵlaƚe inflammaƚion ƚo proƚecƚ ƚhe hosƚ againsƚ immƵnopaƚhologǇ͘ Hoǁeǀer͕ ƚhese ͞MϮ͟ 
macrophages are permissive to Mtb infection and display characteristics of alveolar macrophages. 
Indeed, the group of D.G. Russell reported that the alveolar macrophages lineage exhibits higher 
bacterial burden than interstitial macrophages lineage, due to different metabolic state; alveolar 
macrophages are committed to fatty acid oxidation, whereas interstitial macrophages are glycolytically 
active, allowing for control of bacterial growth [94]. Infected alveolar macrophages also contribute to  
                                                          
9 MyD88: Myeloid differentiation primary response 88; IL-1R: interleukin-1 receptor 
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Figure 9 : Macrophages activation profile during Mtb infection (adapted from [95]) 
A ͮ ClassicallǇ acƚiǀaƚed ͞Mϭ͟ macrophages are differenƚiaƚed bǇ IFNɶ͕ LPS and TNFɲ͘ TheǇ are characƚeriǌed bǇ 
the expression of pro-inflammatory cytokines (e.g. TNFɲ͕ IL-ϭɴ͕ IL-12 and IL-6), and receptors (e.g. MHC-II, TLR, 
and FcɶRͿ͘  
B | Alternatively acƚiǀaƚed ͞MϮ͟ macrophages are differenƚiaƚed bǇ IL-4, IL-13, IL-10, immune complexes, etc. 
MosƚlǇ͕ ͞MϮ͟ macrophages displaǇ an anƚi-inflammatory signature with increased expression of the MRC1, 
PPARɶ͕ IL-10, CD200R, CD163, CD36, and MARCO. 
C | Alveolar macrophages are unique immunoregulatory cells which express both M1 and M2 markers. Their 
acƚiǀaƚion is ƚighƚlǇ regƵlaƚed bǇ molecƵles sƵch as PPARɶ͕ IRAK-M, IL-10 and SOCS proteins. Alveolar 
macrophages are susceptible to Mtb, however, they are able to contain the bacteria to certain extent. Usually, 
Mƚb is killed bǇ inƚersƚiƚial macrophages͕ ǁhich displaǇ ͞Mϭ͟ acƚiǀaƚion profile and are highlǇ microbicidal͘ 
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the recruitment of natural killer (NK) cells and NKT cells to the infected tissue. These cells produce IFNJ 
in response to Mtb and favour monocytes differentiation towards an ͞ Mϭ͟ phenoƚǇpe͕ resƚraining Mƚb 
growth. However, this control is temporary and lasts for about 14 to 21 days. The secretion of 
exosomes enriched in Mtb lipids by infected macrophages is a mechanism by which the bacillus 
manipulates the immune system. Mtb exosomes increase pro-inflammatory signals and cytokines 
production (e.g. TNFD, IL-1D, IL-10, CCL2, CXCL10) that in turn, accelerate the recruitment of 
neutrophils, DC and macrophages to the site of infection, therefore providing the pathogen with new 
target cells. In addition, exosomes containing Mtb lipids not only trigger macrophage activation, but 
also prevent IFNJ secretion by activated T cells [96]. The agglomeration of all these innate cells around 
the translocated infected macrophages represent the first step of granuloma formation: an amorphous 
mass exists initially as a preliminary form of the classical tuberculous granuloma, which is a much more 
complex, highly organized and stratified structure [86], [97]. During the recruitment of new cells to the 
site of infection, a proportion of newly infected macrophages leave the primary granuloma and migrate 
through the tissue to establish a secondary granuloma [71], [98].  
In parallel, tissue-recruited monocytes also differentiate towards DC, which mature upon Mtb 
exposure and/or infection. Within 10 to 14 day post-infection, infected DC migrate to the draining 
lymph node while secreting interleukin 12 (IL-12), CCL1910 and CCL2111 (Figure 10). This is a major 
characteristic of Mtb infection which is heavily investigated; indeed, two weeks is quite a long time to 
observe DC recruitment to the draining lymph node as compared to other pulmonary infections that 
require a few hours to maximum 3 days ([86], [99]ʹ[102]). Once in the lymph node, DC present Mtb 
antigens to naive T cells. They are able to cross-prime CD4+ T cells through MHC-II12 molecules, and 
CD8+ T cells through MHC-I. CD4+ T cells acquire a T-helper 1 (Th1) profile, and quickly migrate to the 
lungs and aggregate around the amorphous granuloma (Figure 10) [90]. Th1 cells are the main 
producer of a key cytokine that helps to contain the infection: IFNJ, which triggers the macrophage 
microbicidal functions and is secreted by NK and NKT cells at the site of infection, prior to Th1 cell 
recruitment.  
Finally, B cells and fibroblasts are recruited to close the granuloma that finally harbors the 
distinctive mature TB granuloma phenotype (Figure 11). Classically, mature granulomas are structured 
aroƵnd a necroƚic cenƚer͕ sƵrroƵnded bǇ an inner ring composed of epiƚhelioid ͞Mϭ͟-like 
macrophages, multi-nucleated giant macrophages and foamy macrophages, which are mainly 
microbicidal. A second ring surrounds the inner ring with IFNJ+-TNFD+ T cells and ͞MϮ͟ macrophages 
that prevent lung inflammation and damages, while also replenishing the pool of Mtb-killer 
macrophages in the inner ring. Finally, close to the granuloma, lymphoid structures composed of 
antibody-secreting B cells form to provide the host with humoral responses to Mtb [86], [97]. The 
formation and maintenance of this structure deeply relies on the macrophage production of TNFD, but 
is also mediated by Mtb virulence factors. Indeed, Volkman and colleagues showed that Mtb virulence 
plays a role in granuloma formation in the zebrafish model. Using a 'RD1 mutant strain of M. marinum, 
the authors found that despite its capacity to grow in macrophages, 'RD1 bacteria failed to elicit  
                                                          
10 CCL19: chemokine C-C motif ligand 19, also known as macrophage inflammatory protein 3b (MIP-3b), is 
involved in lymphocytes recirculation and homing, through ligation to C-C chemokine receptor 7 (CCR7). 
11 CCL21: chemokine C-C motif ligand 21 is a chemoattractant to CCR7-expressing cells.  
12 MHC: major histocompatibility complex, receptor found on antigen presenting cells (MHC-II) or ubiquitous 
(MHC-I) involved in antigen presentation to T cells that initiate adaptive immune responses. 
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Figure 10: The cellular response to Mtb infection (from [71]) 
Following aerosol infection of the lower lungs with Mtb, resident lung alveolar macrophages (1a), and neutrophils 
(1b) can be infected, leading to the subsequent production and secretion of host defense molecules (e.g. 
antimicrobial peptides, cytokines, and chemokines). Depending on the balance between prostaglandin E2 (PGE2) 
and lipoxin A4 (LXA4), infected macrophages will undergo either apoptosis or necrosis, leading to the recruitment 
of new cells. Lung DCs (1c) close to the infection site can then phagocytize Mtb antigens and apoptotic debris. 
Subsequently, and with a strong delay in the case of Mtb infection (8-12 days instead of 72h in influenza infection 
for example), DCs secrete IL-12 (2) and migrate into the draining lymph node to activate naïve CD4+ T cell towards 
a Th1 activation program (3). Protective antigen-specific Th1 cells migrate back to the lungs in a chemokine-
dependent manner 14ʹϭϳ daǇs afƚer ƚhe poinƚ of iniƚial infecƚionͬeǆposƵre ;ϰͿ and prodƵce IFNɶ͕ leading ƚo 
macrophage activation, cytokine production, the induction of microbicidal factors including iNOS (5). This usually 
contains efficiently the bacteria, but in some cases, Mtb escapes this response and spreads within the host, 
potentially by manipulating neutrophils. 
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granuloma formation, leading to a reduced bacterial burden compared to wild type (WT) Mycobacteria 
[103]. In the adult zebrafish model, the same observation was made, showing that it was a default in 
the macrophage mobility that decreased granuloma formation and that limited M. marinum growth in 
infected animals [104]. These studies contribute to the growing evidence for how Mtb virulence 
modulates granuloma formation to establish a proliferative niche for infection by manipulating 
macrophages functioning. 
Once formed, the granuloma is encapsulated in a fibrous capsule and remains well 
vascularized. The center of the structure slowly becomes hypoxic, leading to Mtb containment. While 
Mtb growth during granuloma formation is exponential, once hypoxic environment is established in 
the necrotic caseous center, Mtb metabolism switches to a non-replicative persistent state [71], [90], 
[86]. Progressive granulomas develop with time, and several granulomas at different stages of 
development are present in a single individual. Upon reactivation of the disease in 
immunocompromised situations (e.g. HIV-1 co-infection, diabetes, malnutrition), the natural evolution 
of the granuloma moves towards caseation liquefaction, finally leading to the disruption of the 
structure. As a consequence, thousands of viable infectious bacteria are released in the lung, upgrading 
the disease to a transmissible status [97]. 
 
b.  Importance of cytokines in the immune response 
Cytokines are key players of the immune system, and their involvement in Mtb immune 
responses tightly intertwine innate and adaptive immunity. Some of them, like TNFD and IL-12/IFNJ 
cannot be circumvented. Several studies reported a critical role in Mtb burden control by TNFD. 
Indeed, patients receiving anti-TNF therapy to treat rheumatoid arthritis or Crohn͛s disease shoǁed a 
more than 5-fold increase in their susceptibility to TB reactivation [105]. These patients exhibited 
disseminated bacteria and extra-pulmonary disease, despite the presence of normal granuloma [106], 
[107]. The same observations were made in non-human primate (NHP) animal models receiving anti-
TNFD treatment [108], as well as the mouse model [109], [110]. Strikingly, TNFD-/- mice showed an 
increased susceptibility to Mtb infection, and a delayed granuloma formation [111], [112], supporting 
the key role of TNFD in the formation and maintenance of this structure. In the mouse model of TB 
reactivation using anti-TNFD antibodies, treated infected mice showed an increased bacterial load, 
increased necrosis in granuloma and in all cases, a lethal reactivation of the disease [110], [113]. 
Further supporting the key role of both macrophages and TNFD in the formation of granuloma, Egen 
and colleagues found that efficient recruitment of T cells and myeloid cells to mature granuloma in 
mice was highly dependent on TNFD signals [114]. In addition, anti-TNF treatment led to a decrease in 
granuloma size, due to few numbers of recruited macrophages [114]. Altogether, these studies show 
the importance of TNFDwhich is mainly secreted by macrophagesin the control of the pathology, by 
boosting the intracellular killing of Mtb, as reported by other publications [115]. 
The IL-12/IFNJaxisis crucial to fight against Mtb, as it activates macrophages microbicidal 
function, allowing for ƚhe conƚrol and eliminaƚion of ƚhe bacƚeria bǇ ͞Mϭ͟ macrophages. As previously 
discussed, IFNJ is secreted by CD4+ T cells, NKT, CD8+ T cells and NK cells, in response to IL-12 signaling. 
When migrating to the draining lymph node, Mtb-activated DC secrete IL-12 that primes naive T cells 
and engages their Th1 activation program [99], [116]. In IFNJ mice [117], as well as in IL-12-/- mice,  
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Figure 11: The mature tuberculous granuloma structure (from [86]) 
The tuberculous granuloma is composed of a macrophage necrotic center and free bacilli, surrounded by an inner 
ring with innate cells (neutrophils, macrophages infected or not, foamy cells, multinucleated Langhans giant cells 
and epithelioid macrophages that cannot become infected). The second ring is composed of DC, neutrophils and 
Ƶninfecƚed macrophages displaǇing eiƚher an ͞Mϭ͟ acƚiǀaƚion program͕ ƚo replenish the inner ring with 
bacƚericidal macrophages͕ or a ͞MϮ͟ polariǌaƚion ƚhaƚ proƚecƚs ƚhe sƵrroƵnding ƚissƵe of immƵne damages͘ 
Finally, T cells and B cells surrounds the structure to maintain an adaptive immune response to the infection: T 
cells produce IFNJ, a crucial cytokine to polarize macrophages towards a microbicidal profile, and to maintain 
TNFD secretion, which is necessary for granuloma formation and maintenance. 
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researchers reported a lack of reactive oxygen and nitrogen species (ROS, NS) in macrophages, a 
progressive destruction of the lung integrity and, importantly, a lack of control of bacterial growth [99], 
[116], [118]. IL-12 mutations in human, especially in children from consanguineous marriages, 
predispose these individuals to severe TB infections [119].  In NHP models of co-infection with the 
simian immunodeficiency virus (SIV), latently TB-infected macaques presented with an increased 
frequency of Mtb-specific IFNJIL-2T cell responses between 2-5 weeks post-SIV infection. After this 
spike, the IFNJTcells decreased to low levels, corresponding to a fall in CD4+ T cell counts. This led to 
rapid reactivation of TB in certain animals, who showed greater bacteria burden and high pathology 
scores at the necrotic granuloma. Therefore, in co-infection settings, increased proportion of IFNJ+IL-
2+ CD4+ T cells specific for Mtb during acute SIV infection suggests an increased level of Mtb antigen, 
leading to TB-reactivation [120]. These results were corroborated with the observation that in TB-HIV-
1 co-infected patients, the level of IFNJIL-2CD4+ T cells was inversely proportional to viral load [121]. 
Considering all these studies, an efficient establishment of IFNJalong with other cytokine responses is 
essential to control the bacterial growth and to create an environment in which Mtb can be contained 
and consequently eliminated. 
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B. Macrophages and Mycobacterium tuberculosis: an ongoing 
evolutionary arms-race 
a. Mtb recognition through PRR and initiation of the host response 
As previously mentioned, macrophages are the main effector cell against Mtb. To fulfill this 
function, these cells must first come in contact with Mtb, internalize and destroy it, and engage in an 
appropriate immune response to activate both the innate and adaptive arms of the immune system. 
To accomplish this, several PRR have been involved in Mtb recognition by the host, including TLR, CLR, 
nucleotide-binding oligomerization domain-like receptors, or NOD-Like Receptors (NLR), scavenger 
receptors and complement and Fc-J receptors. The engagement of the different PRR drives 
macrophage activation through different signaling pathways, leading to combinatory signals that result 
in the establishment of the host innate immune response. However, macrophages play a dual role in 
tuberculosis because they are also the primary host cell reservoir for Mtb. In fact, the bacillus has 
evolved different strategies to hijack the function of PRR. Here, I will give some examples that illustrate 
these principles. 
 
i. Toll Like Receptors (TLR) 
TLR belong to a highly-conserved family of transmembrane receptors of which the extracellular 
domain recognizes PAMP, while their intracytoplasmic domain induces a signaling cascade in the cell 
upon ligand recognition [122]. They are expressed by almost all immune cells, including alveolar 
macrophages, neutrophils, lymphocytes and DC. Upon ligand binding, most of the signaling cascades 
involve the activation of MyD88 and NFNB13, which translocate to the cell nucleus and stimulate 
inflammatory responses, including the up-regulation of their various negative regulators. Once the 
pro-inflammatory response is initiated, microbicidal functions of the activated innate cell become 
effective and control the growth of the bacteria. The innate immune cells then engage a long-lasting 
adaptive immune response led by Th1 immunity [122]. As TLR are numerous and activate many 
different signaling pathways, they can also lead to alternate signaling cascades, resulting in anti-
inflammatory responses [71], [95]. Mtb is recognized through the plasma membrane TLR2 and 4, and 
by the phagosomal TLR9. Of note, TLR2 expression is lower in alveolar macrophages compared to other 
cell types, whereas TLR4 and TLR9 are expressed at similar or higher levels, respectively [95].  
TLR are important PRR in Mtb pathogenesis. Indeed, several studies reported that individuals 
with genetic variants of TLR2, which binds to Mtb lipomannan (LM) and phosphatidylinositol-
mannosides (PIMs) [95], are more susceptible to Mtb infection [123]. Moreover, TLR2 can form 
heterodimers with TLR1 and TLR6. These heterodimers have been implicated in the recognition of 
mycobacterial cell wall components, such as LAM, LM, and PIM and mediate a Th1-driven immune 
response to Mtb [122]. In addition, MyD88-deficient mice lose resistance to Mtb infection and display 
an impaired production of Th1 cytokines (e.g. IL-12, and TNFD) and of inducible nitric oxide synthase 
                                                          
13 NFNB: nuclear factor kappa-light-chain-enhancer of activated B cells is a protein complex expressed by almost 
all cell types that controls transcription of DNA, cytokine production and cell survival upon stimulation. 
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(iNOS)14 [124]. Moreover, TLR are responsible for the activation of the IFN-I responses in the cell, a 
subject that will be discussed in this chapter, section C. 
ii. C-type lectin receptors (CLR) 
Many CLR have been described to bind glycosylated molecules expressed by host cells and/or 
pathogens. Most of them contain a carbohydrate recognition domain that acts in a calcium-dependent 
manner. Here, I will particularly focus on two CLR described in both Mtb and HIV-1 pathogenesis: the 
mannose receptor (MRC1) and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN). 
 
(1) MRC1 (CD206) 
This is a predominant CLR expressed by non-activated macrophages, including alveolar 
macrophages. It contains a carbohydrate recognition domain that binds with high affinity to mannans 
present on host cells, but also on several pathogens, and maintains host homeostasis [95], [125].  
Pathogens like Mtb and HIV-1 express mannosylated structures in their wall/envelope. MRC1 
specifically recognizes glycosylated ligands in the Mtb envelope, including LAM, ManLAM and PIMs 
(see chapter I section I.A.e.) [126]. Importantly, MRC1 is involved in the modulation of the immune 
responses against Mtb, and is usually associated with an anti-inflammatory program in macrophages 
that is protective against immunopathology [127].  
It is thought that the development of these highly mannosylated PAMP play a role as molecular 
mimics, by which Mtb evades the immune system through cloaking itself in molecules similar to those 
from the host [128]. Upon Mtb recognition through MRC1, the bacteria are internalized into 
phagosomes, which are deficient for fusion abilities with the lysosomal compartment. In addition, 
infected cells display anti-inflammatory cytokines secretion that inhibit IL-12 [129] and ROS secretion 
[130]. These immunosuppressive properties are regulated by the peroxisome proliferator-activated 
receptor J (PPARJ), which inhibits NFNB activation, and in an indirect manner, IFNJ production. Indeed, 
this molecule is key in Mtb evasion mechanisms since its deletion in mice leads to growth reduction of 
virulent Mtb and lower granuloma infiltration, along with enhanced pro-inflammatory cytokines 
secretion [131]. By contrast, MRC1-deficient mice did not show any particular phenotypic changes 
after Mtb infection, suggesting that its expression is not essential in Mtb pathology, probably due to 
the functional redundancy of PRR [126]. 
 
(2) DC-SIGN (CD209) 
DC-SIGN is expressed by a small proportion of macrophages, including alveolar macrophages 
as well as DC, and recognizes mannosylated glycol-conjugates such as N-linked high mannose 
structures [126]. Initially, DC-SIGN was highlighted for its capacity to bind HIV-1 particles through 
                                                          
14 iNOS: one of the three isoforms of the nitric oxide synthase that produces azote monoxide and that is 
synthesized by phagocytes as a microbicidal molecule. Other forms of NOS are constitutively expressed in 
neuronal and epithelial cells and are controlled by intracellular calcium concentrations. 
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recognition of the viral glycoprotein gp120, and to mediate trans-infection of CD4+ T cells (see chapter 
II section III.D.a.i) [132], [133]. Since then, it was shown that this lectin is able to recognize several 
other pathogens, including viruses, bacteria and parasites [134]. Along with others, my group, led by 
O. Neyrolles, has published important breakthroughs on the role of DC-SIGN in Mtb pathology, and 
was one of the first to show that DC-SIGN binds to Mtb [135], [136]. Human DC-SIGN assembles in 
tetramers for optimal ligand binding and recognizes the same molecules as MRC1 (i.e., PIM and 
ManLAM) that are expressed by Mtb, leading to clathrin-dependent endocytosis of the complex [126].  
Interestingly, while DC-SIGN is not usually expressed in non-activated macrophages, Mtb has the 
capacity to up-regulate its expression on these cells. Indeed, my group found that in TB patients, up to 
70% of alveolar macrophages from broncho-alveolar lavages (BAL) express DC-SIGN (against 1.7% in 
healthy individuals), and the bacilli are concentrated in DC-SIGN enriched pulmonary regions [137]. Ex 
vivo, Tailleux and colleagues showed that this Mtb-induced expression of the lectin is dependent on 
TLR4, IL-4 and IL-13 signaling. My group also showed that DC-SIGN+ alveolar macrophages constitute a 
preferential target for Mtb since blocking of DC-SIGN lead to decreased bacterial uptake [137].  
 
Additional studies performed in the lab showed an increased expression of DC-SIGN both in 
CD68+ lung macrophages from Mtb-infected NHP and in pleural effusion cells from TB patients. In vitro, 
DC-SIGN expression is particularly high on IL-4 induced monocyte-derived macrophages (MDM). After 
DC-SIGN depletion in these cells, a genome-wide transcriptomic analysis revealed the up-regulation of 
pro-inflammatory signals in response to Mtb challenge and a reduced permissiveness to infection 
despite equivalent levels of bacterial uptake. Altogether, these results indicate that DC-SIGN plays a 
dual role in Mtb infection, by inducing anti-inflammatory responses that protect the host from 
immunopathology, resulting in reduced inflammatory responses against Mtb, therefore promoting 
bacterial proliferation [138].   
Other C-type lectins are also involved in Mtb binding. For example, the transmembrane PRR 
Dectin-1 binds to Mtb E-glucan and induces phagocytosis of the bacteria, initiating signaling cascades 
that interact with TLR activated pathways, leading to macrophage activation and IL-12 production in 
DC. The C-type lectin Mincle is mainly expressed by myeloid cells after exposure to various 
inflammatory stimuli, such as cytokines and TLR activation, and can recognize Mtb trehalose 
dimycolate (TDM), but is not essential in Mtb control in mice despite its involvement in the regulation 
of anti-mycobacterial immune responses [126].  
 
iii. Other receptors 
Other receptors families have been shown to recognize Mtb antigens. Among them, we can 
find scavenger receptors, NLR, integrins, FC-J and complement receptors. 
Among scavenger receptors, which participate in homeostatic functions and bind to oxidized low 
density lipoproteins, MARCO has been well described [95]. Indeed, MARCO binds to Mtb TDM and acts 
in combination with TLR2 signaling to induce pro-inflammatory responses [139], therefore 
participating in the establishment of anti-Mtb responses in the host.  
 
56 
 
Complement Receptor 3 (CR3 or integrin DE2) is a heterodimeric receptor that belongs to the 
integrin family expressed on neutrophils, monocytes, natural killer cells and macrophages. CR3 
recognizes C3b opsonized Mtb in vitro, however, it is unlikely that this interaction happens in vivo due 
to low concentrations of complement molecules in the lung [126].  
 
Finally, the intracellular NLR family comprises molecules such as NOD1 and NOD2, able to 
detect gram-positive and gram-negative bacterial peptidoglycans. Their expression is abundant in 
human macrophages. Upon ligation to its target, NOD2 activates MAPK, the mitogen-activated protein 
kinase, that indirectly allows NFNB activation [126]. NOD2 is also able to directly bind and activate 
caspase-1 and interacts with the inflammasome [140]. This particular NLR is therefore important for 
Mtb-induced immune responses since it induces IL-1E, IL-6 and TNFD secretion, allowing for the 
establishment of a strong pro-inflammatory response against Mtb. In addition, NOD2 deficiency in 
mice and in human macrophages leads to enhanced Mtb growth [141], further supporting the role of 
NLR in the activation of microbicidal pathways in innate immune cells. 
Macrophages express numerous PRR able to recognize different components of the bacteria, 
including cell wall components, proteins, lipids, and nucleic acid. Binding of these different ligands lead 
to macrophage activation by stimulation of relevant pathways, leading to bacterial internalization and 
engagement of bactericidal functions. However, some of these PRR are involved in maintaining the 
balance between pro- and anti-inflammatory cytokine responses, and protect the host from 
immunopathology (e.g. MRC1). As PRR are numerous and can have different consequences for the 
host immune response, particularly in an Mtb infection context, a better understanding of the PRR 
homeostatic and inflammatory roles is key to develop host-targeted therapies to cure TB, based on 
the modulation of PRR activity.  
 
b. Macrophages and Mtb immunity: a complex interplay between 
bacterial control and escape mechanisms 
i. The Mtb phagosome 
Now that we have seen how Mtb is recognized by PRR, I will focus on how the bacterium is 
processed by macrophages. These cells specialize in the ingestion of cell debris and microbes; they are 
professional cleaners of the body. As such, macrophages exhibit different processes, including 
phagocytosis. During normal phagocytosis, actin-mediated movements of the phagocyte cell 
membrane engulf cell debris or microbes into a specific intracellular compartment: the phagosome 
[87]. Once inside the macrophage, a sequence of events leads to phagosome maturation. First, Rab 
GTPases15 are recruited to the phagosomal membrane, which then attract the vacuolar v-ATPases to 
acidify the phagosome content. At this stage, the pH decreases from 6.5 to 6. Finally, the phagosome 
fuses with a pre-formed lysosome to merge their contents, including lysosomal acid hydrolases. This 
                                                          
15 Rab GTPases: member of the Ras superfamily of small G-proteins possessing a GTPase fold. They regulate many 
steps of membrane trafficking, including vesicle formation, transport and endo/exocytosis. Of note, these 
proteins switch between inactive conformation, linked to guanosine diphosphate and active conformation that 
is linked to guanosine triphosphate. 
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process is known as phagosome maturation. After degradation, microbial debris is either recycled or 
destroyed. In TB, this process is impaired through many mechanisms. Actually, Mtb is able to inhibit 
phagosome maturation and fusion with lysosomes. Often, the bacilli are contained in phagosomes with 
an abnormally high pH of у ϲ͘Ϯ [142]. This is best exemplified by the study of Mwandumba and 
colleagues where large non-acidified vacuoles, containing a large number of bacilli, are observed in 
alveolar macrophages isolated from active TB patients due to inhibition of phagosome-lysosome fusion 
[143].  
Mtb possesses many mechanisms to stop phagosome maturation, most of which involve cell 
wall lipids and virulence factors. First, maturation is arrested by the alteration of the Rab GTPases, 
which in physiological conditions, regulate the intracellular trafficking of organelles [144], [145]. 
Previous studies have shown that this blockage occurred between the maturation stage controlled by 
Rab5, an early endosomal marker that is accumulated normally to the phagosomal membrane, and 
Rab7, whose recruitment to the phagosome was inhibited (late lysosomal marker) [146]. Tightly 
intertwined with this mechanism, the implication of the Rab5 effector EEA1 (early endosomal 
autoantigen 1) has also been reported. Mtb ManLAM was shown to interfere with EEA1 recruitment 
to the phagosome, therefore preventing the complexation of EEA1 with Rab5 and leading to inhibition 
of phago-lysosome membrane fusion [144], [145]. ManLAM also inhibits the formation of PI3K-
calmodulin complex, inducing PI3P exclusion from the phagosomal membrane. This blocks phagosome 
maturation since PI3P is a critical lipid for the attraction of v-GTPases and v-ATPases16 to this cellular 
compartment, preventing its acidification [146]ʹ[148]. Finally, Hartlova and colleagues reported the 
implication of the negative regulator of phagosomal maturation LRRK2 in the recruitment of PI3K and 
its negative regulation of phagosomes in human macrophages, leading to uncontrolled bacterial 
growth [149]. In addition, Mtb is able to resist phagosome acidification, which is the last step of 
phagosome maturation. Indeed, the mycobacterial envelope is poorly permissive to proton entry and 
thus acidification, and additionally possesses proteases like MarP17 and RipA18 that allows for the 
secretion of basic component such as ammoniac, leading to phagolysosome pH neutralization [150], 
[151].  
One way for the host to circumvent Mtb escape from these organelles is to induce spacious 
phagosomes. This event was observed thanks to electron microscopy studies, notably in monocytes 
from active TB patients [152]. These structures were induced in an IFNJ-dependent manner, up-
regulating the endosomal protein Rab20 machinery. Indeed, the overexpression of Rab20 in a 
macrophage cell line induced the formation of large phagosomes, which contained several bacilli that 
showed decreased growth capacities compared to controls, and displayed late endosomal markers 
such as LAMP-2, demonstrating their maturation. By contrast, Rab20-/- bone marrow-derived murine 
macrophages were unable to form spacious organelles and were unable to maintain membrane 
integrity, leading to subsequent bacterial growth enhancement. Finally, the capacity of macrophages 
to form spacious phagosomes was dependent on Mtb virulence factors, especially those encoded in 
the RD1 genome region [153]. However, Mtb is also a ͞HoƵdini͟ master at escaping phagosomes by 
disrupting their membrane integrity through ESAT-6, leading to subsequent colonization of the 
                                                          
16 v-ATPase or v-GTPase: vacuolar ATPase or GTPase 
17 MarP: Mycobacterium acid resistance protease 
18 RipA: peptidoglycan endopeptidase that cleaves the bond between D-glutamate and meso-diaminopimelate, 
binds and degrades high-molecular weight peptidoglycan expressed by bacteria. 
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macrophage cytosol [89], [154]. In particular, the Mtb lipid phthiocerol dimycocerosates (DIM) was 
shown to facilitate Mtb colonization of the host cytoplasm [155]. 
Upon damage induced by Mtb, permeable phagosomes are rapidly recognized by the 
autophagosome machinery. Autophagy is a process similar to phagocytosis, except that instead of 
ingesting extracellular components, macrophages either recycle or degrade internal components, 
including organelles into a structure called the autophagosome [87]. As for phagosomes, Mtb is able 
to inhibit autophagosome fusion with lysosomes through the ESX-1 system [156]. Autophagy is 
initiated through Mtb ubiquitination, but also induced by IFNJ activation. In addition, the active form 
of vitamin D3 induces autophagy in human macrophages in a cathelicidin-dependent manner. Of note, 
cathelicidin is an anti-microbial peptide involved in the transcription of autophagy-related genes. In 
fact, vitamin D deficiency is linked with an increased risk of developing active TB [157]. Historically, 
sunlight exposure and vitamin D administration were used to treat TB; however, subsequent clinical 
trials reported only a moderate efficacy of this treatment [158].  
 
ii. Oxidative and hypoxic stresses in response to Mtb internalization  
Phagosome maturation works in tandem with the activities of toxic components such as 
reactive oxygen and nitrogen species (ROS and NS respectively), which kill ingested bacteria. ROS and 
NS are toxic derivatives of oxygen and nitrogen metabolism within macrophages, and notably include 
nitric oxide (NO), hydrogen peroxide (H2O2) and peroxide ion (02-). Their production is mediated by 
iNOS and NOX219 proteins, which act synergistically to provide macrophage phagosomes with high 
bactericidal potential, particularly by triggering bacterial lipid, nucleic acid and protein oxidation [159]. 
In addition to killing the bacteria, these two pathways are also involved in the regulation of the 
inflammation caused by Mtb. Indeed, high inflammation, often caused by exacerbated cell death as a 
consequence of Mtb infection, is detrimental to the host. This cell death is usually driven by high 
inflammasome activation, which was reported to induce high inflammation, responsible for the more 
severe forms of tuberculosis, such as TB-IRIS and TB meningitis (see section I.A.c of the present 
chapter) [160]͘ In macrophages͛ NO pathway, NOS2, a nitric oxide synthase involved in (i) 
neurotransmission, (ii) anti-tumoral and (iii) antimicrobial activities, takes part in the regulation of 
Mtb-driven inflammation by inhibiting the activation of the NLRP320/Caspase 1 inflammasome in 
macrophages, reducing IL-1 secretion, and therefore, cell death. A molecule of the ROS pathway, Phox, 
is also involved in the inhibition of inflammasome activation [160].  
As for other killing strategies, Mtb possesses several enzymes allowing it to escape these 
oxidative stresses. For example, the superoxide dismutase (SodAC) and the peroxidase KatG secreted 
by Mtb act sequentially to transform 02- ions into H2O2, and then water. The bacillus can also prevent 
                                                          
19 NOX2: nicotinamide adenine dinucleotide phosphate oxidase 2 is a cofactor involved in anabolic reactions and 
requires NADPH as a reducing agent. 
20 NLRP3 inflammasome: nucleotide-binding and oligomerization domain-like receptors 3 inflammasome is 
primarily found in immune and inflammatory cells following activation by inflammatory stimuli. NLRP3 activates 
caspase 1 cascade, leading to the production of pro-inflammatory cytokines (i.e. IL-1E and IL-18), and induces 
cell pyroptosis, a form of programmed cell death. 
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iNOS fixation to the phagosome membrane to avoid NO importation into this compartment [161], 
thereby promoting a more favourable environment for survival. 
In the TB granuloma, the necrotic center becomes hypoxic. Because of a reduction in oxygen 
availability, nitrite and nitrate pathways are of even higher importance for both Mtb control by the 
host and Mtb survival. In hypoxic environments, Mtb enters a dormant state, where its replication is 
almost arrested [162]. Despite the low oxygen concentration, Mtb is still able to survive, due to nitrate 
reductases that transform nitrates into oxygen [163]. In a study conducted in my team, the horizontal 
acquisition of moaA1-D1 genes by Mtb allowed the bacteria to better use nitrate respiration. In vitro, 
under hypoxia, moaA1-D1 genes were upregulated and allowed the bacteria to survive, while Mtb 
moaA1-D1-null mutants were unable to survive oxygen depletion via nitrate respiration. In vivo, the 
mutant strain presented an impaired survival in hypoxic granulomas of C3HeB/FeJ mice [164], further 
supporting the role of moaA1-D1 genes in nitrate respiration and Mtb survival in hypoxic environments 
such as the granuloma. 
 
iii. Nutrients deprivation 
Although Mtb has multiple mechanisms to avoid phagosome maturation, macrophages 
employ other means to kill the bacteria, including nutrients deprivation in the Mtb phagosome [165]. 
An example of nutrient access restriction set by the host is iron deprivation. Like human cells, Mtb 
needs iron to survive, grow and spread. The host keeps key nutrients, like iron and manganese, away 
from the bacteria by complexing them into proteins such as transferrin and ferritin, or by pumping 
them out of the phagosome using cation transporters [166]. In the case of iron, the expression of 
Nramp121 at the phagosome membrane allows iron exportation out of the vacuole, thereby limiting its 
access to the bacteria [165]. Unfortunately for the host, Mtb has also evolved to capture host-
sequestered iron cations through siderophores and heme utilization [167], [168]. For example, the 
carboxymycobactins siderophores are specialized in iron removal from transferrin and ferritin [169]. 
This mechanism is an important tool for Mtb, since increased loads of iron within the host have been 
shown to be an exacerbating factor for TB disease [170]. 
Lipids are also important nutrients for Mtb metabolism and represent the main source of 
carbon available during the infection, and more specifically cholesterol and triacylglycerol (TAG). Mtb 
infection of macrophages leads to the accumulation of TAG droplets in the cell, which in turn can 
become foamy macrophages. The bacteria are able to import the fatty acid that derives from TAG 
processing, a process that indicates that the bacteria is entering a dormant state [171], [172]. In 
addition, Mtb strains depleted of the mce4 operon coding for cholesterol transporters display 
attenuated growth in infected mice, indicating that cholesterol is required in the later phases of Mtb 
infection [173].  
As a last example, my team has identified aspartate and asparagine as the major source of 
nitrogen for the bacteria. Access to aspartate is possible within the phagosome, through its import by 
the bacterial nitrogen transporter protein Ansp1. Indeed, Mtb Ansp1 null mutants have a reduced 
                                                          
21 Nramp1: Natural resistance-associated macrophage protein 1, involved in iron metabolism and resistance to 
certain pathogens 
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capacity to proliferate in mice [174]. The other nitrogen source for Mtb is asparagine, the favoured 
source of nitrogen for the bacteria in vitro. In fact, my team showed that Mtb employs the asparagine 
transporter AnsP2 and the secreted asparaginase AnsA to assimilate nitrogen in phagosomes. It also 
uses these proteins to resist acid stress by hydrolyzing asparagine and releasing it in the cell cytosol 
[175]. 
 
iv. Bacterial intoxication with metals 
In addition to nutrient deprivation, limited oxygen access, and acidic and oxidative 
environments, Mtb must face the risk of metal intoxication inside the phagosome. For example, copper 
is an essential redox-active metal used as an enzyme cofactor at steady state. Under pathological 
conditions, copper intoxication represents an efficient way to intoxicate the microbe. In fact, copper 
deficiency in animal models proved to be detrimental for the ability of macrophages and neutrophils 
to induce the respiratory burst, leading to impaired elimination of the phagocytosed bacilli [176], [177]. 
In the lungs of Mtb-infected guinea pigs, primary granuloma exhibited elevated copper levels 
compared to unaffected tissue [178]. In the Mtb phagosome, copper ions imported in this 
compartment after macrophage activation encounter hydrogen peroxide and react to generate 
superoxide radical anions. This process exposes the surrounding bacteria to an oxidative stress that 
inflicts damage to its lipids and cell wall. This attack may not kill the bacteria; however, it could prime 
it for subsequent destruction mediated by other phagosomal functions such as acidification [179], 
[180].  
Metal intoxication is also mediated by zinc flux inside macrophages. Indeed, zincosomes 
(vacuoles containing free zinc) span the entire endocytic pathway, including within Rab5 early 
endosome where Mtb is often sequestered [181], [182]. Zinc toxicity occurs due to the replacement of 
other cations in essential enzymes, consequently inhibiting their activity [182]. Copper and zinc both 
accumulate in Mtb phagosomes in order to kill the bacteria. However, as for many other host-defense 
mechanisms, Mtb has evolved to circumvent both copper and zinc intoxication by expressing efflux 
pumps such as CtpV [183] and CtpC [184], respectively. Indeed, Mtb is particularly sensitive to copper 
since concentrations lower than that found in the phagosome of macrophages are able to kill the 
bacteria in vitro [178]. For this reason, copper resistance, conferred by CtpV, is essential for Mtb 
virulence. The same is true for Mtb resistance to zinc poisoning. My team previously showed that in in 
vitro Mtb-infected macrophages, the zinc efflux pump CtpC is upregulated while free zinc 
concentration in the cytosol of macrophages was increased within few hours post-infection [184]. 
To conclude, Mtb has evolved for millenia with its natural host, and has acquired numerous 
escape mechanisms to counteract the immune response, more specifically to elude the microbicidal 
functions of macrophages. The major focal point of this hide-and-seek game between the host and the 
pathogen seem to be the phagosome, whose functions have been met equally by Mtb throughout 
evolution. 
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c. Role of specific macrophages subsets induced by Mtb infection 
Primary Mtb infection occurs in lung alveolar macrophages and triggers the recruitment of 
innate immune cells to the site of infection. Consequently, and with the establishment of the adaptive 
immune response, a granuloma forms around Mtb-infected cells, mainly macrophages, to contain the 
bacilli. The infection of macrophages leads to their differentiation into particular subtypes, including 
epithelioid macrophages, multinucleated giant macrophages (MGC, also called Langhans cells) and 
foamy macrophages. The implication and specific functions of these different subtypes are poorly 
described to date, especially for epithelioid macrophages, which were mainly used as a marker of 
granulomatous lesions within TB infected lung biopsies, allowing for disease identification. However, 
few studies have investigated the function of MGC and foamy macrophages during TB disease and are 
hereafter discussed. 
 
i. Macrophages polarization in Mtb-infection 
As mentioned in the preamble, macrophage polarization is mainly driven by type-1 and type-
2 inflammatory signals. In TB, defense against the pathogen strongly requires type-1 immunity, since 
expression of inflammatory cytokines of this type are associated with efficient anti-Mtb immune 
responses [185]. During infection, T cells produce large amount of IFNJ, which drive macrophage 
differentiation within the granuloma towards an M1 or M(IFNJ) profile. These cells are professional 
killers of Mtb and are the first to intervene in the early phase of infection [186]. However, the bacillus 
has eǀolǀed and deǀeloped sƚraƚegies ƚo circƵmǀenƚ ͞Mϭ͟ polariǌaƚion bǇ shifƚing macrophages 
towards ͞MϮ͟ anƚi-inflammatory programs, which are immunomodulatory and poorly microbicidal 
[187]. It is frequently observed that during pathogen infection, a shift from M1 to M2 program of 
macrophage polarization occurs at the sites of inflammation. This shift is associated with the adaptive 
immune transition from acute to chronic phases, and is probably necessary for the resolution of 
inflammation and for tissue repair [188].  
To induce the shift towards an M2 profile in macrophages, Mtb express virulence factors, such 
as ManLAM or ESAT-6 that prevent IFNJ-mediated differentiation of macrophages, by inhibiting the 
activation of NFNB and IFNJ regulatory factors [186]. In addition to IFNJ signaling inactivation, Mtb can 
also influence TLR signaling by targeting DC-SIGN and MRC1 to induce IL-10 production. M(IL-10) 
macrophages counteract pro-inflammatory responses and protect the host from immunopathology 
and as such, they are poorly microbicidal and highly permissive to intracellular pathogens like Mtb 
[189]. The bacterium also modifies the metabolism of macrophages to control their polarization. 
Indeed, in mice models of Mtb infection, NO production is reduced, while iron availability is increased, 
therefore providing the mycobacteria with a permissive intracellular environment to grow [190]. In 
another study, it was shown that Mtb infection induces the expression of arginase 1 through the 
MyD88 pathway, resulting in the inhibition of NO production [191], thus rendering cells permissive to 
the infection. In addition to iNOS metabolism, Mtb is also able to trigger the accumulation of lipids as 
carbon sources in infected macrophages, leading to their differentiation into foamy cells (described 
later in section II.B.c.iii.). 
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ii. Multinucleated Giant Langhans Cells 
Macrophage fusion is a hallmark of several inflammatory pathologies, such as HIV-1 [192] and 
Mtb infection [86], [98], [191]. Multinucleated giant Langhans cells (MGLC) are usually present in 
granulomas, and are considered as a host defense mechanism. When caused by a pathogen infection, 
MGLC formation can be induced to phagocytize large and indigestible microorganisms. Few studies 
have reported the specific role of MGLC during Mtb infection. However, few studies suggest a role for 
MRC1 in the fusion process between macrophages during TB [95]. Despite a possible role of MRC1 in 
fusion induction, fully differentiated MGLC did not express CD11b or MRC1 [193]. Another molecule 
related to fusion processes in monocytes, called dendritic cell-specific transmembrane protein (DC-
STAMP), was shown to be upregulated during the formation of MGLC. Indeed, when DC-STAMP was 
inhibited by small RNA interference (siRNA), MGLC formation was dampened by 2-fold. The authors 
showed that entryentr expression was induced by IFNJ secreted by T cells. In fact, in this study, T cell-
macrophages interactions through CD40/CD40L interactions proved to be essential for Langhans cells 
formation [194]. Another study conducted at IPBS reported the involvement of TLR2/ADAM922/E1 
integrin axis in MGCL formation. This cascade of events starts with the recognition of bacterial 
lipomannans by macrophages. Fusion into MGLC required the E1-integrin/ADAM9 cell fusion 
machinery. Indeed, in an in vitro model where granuloma-like structures are induced using virulent 
Mtb glycolipids-coated beads, anti-E1 integrin or anti-ADAM9 utilization prevented MGLC formation 
[195].  
Despite these breakthroughs in possible macrophage fusion mechanisms, these studies did not 
report any specific functions for MGLC in TB disease. In fact, the only reported function of MGLC was 
to present Mtb antigen, when other macrophage bactericidal functions like phagocytosis were lost 
[196]. 
 
iii. Foamy macrophages: an energy reservoir for the bacteria 
Foamy macrophages are characterized by the abundance of lipid bodies, rich in TAG and 
neutral lipids that accumulate within lipid droplets in the cytosol. They play a central role in several 
inflammatory diseases such as artherosclerosis or chronic infectious diseases, including co-infection 
between HIV-1 and M. avium [197], [198]. In the context of Mtb infection, foamy macrophages mainly 
localize at the interface between the immune cells ring and the necrotic center of the granuloma [172]. 
The presence of foamy macrophages within granulomas has been described both in infected animals  
 
 
 
 
                                                          
22 ADAM9: Disintegrin and metalloproteinase domain-containing protein 9 is a membrane-anchored protein 
involved in cell-cell and cell-matrix interactions 
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Figure 12: Lipid bodies structure (adapted from [198]) 
Lipid bodies are composed of a core of triacylglycerol (TAG) and sterol esters surrounded by a phospholipid 
monolayer. Several proteins are inserted in the monolayer, along with cholesterol molecules and associated 
proteins.  
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and patients [199], [200]. Because of the many changes occurring upon progression to TB, Mtb has to 
adapt to the host in order to survive. Among these adaptations, the accumulation of neutral lipids 
within the bacterial cytosol in compartments called ILI (intracytosolic lipid inclusions), serve as carbon 
and energy reservoirs and are thus of main importance to bacterial survival [201]. ILI induction in Mtb 
was proposed to be a hallmark of persistent and non-dividing bacteria, especially when considering 
the abundance of Mtb genes encoding for proteins involved in lipid metabolism [44].   
Lipid bodies in most eukaryote and prokaryote cells display a similar structure (Figure 12). They 
are composed of a core of neutral lipids, mainly sterol esters and TAG, surrounded by a monolayer of 
phospholipids in which cholesterol esters and proteins are inserted. In eukaryotes, these lipid bodies 
are thought to originate from the endoplasmic reticulum, where fatty acids are used to re-synthetize 
TAG and sterol esters [198]. The high cell density and hypoxic environment within the TB granuloma 
are the basis for foamy macrophage formation [202]. In addition, the close proximity of foamy 
macrophages to the necrotic center of the granuloma may provide these cells with neutral lipids and 
phospholipids from dying cells [203]. However, the question remains to unveil the factors triggering 
foamy macrophage formation and to understand how Mtb gains access to host lipids and transports 
them into their own cytosol. Previous work showed that Mtb cell wall mycolic acid is a key component 
for foamy macrophage induction, as peritoneal injection of these lipids in mice leads to the foamy 
phenotype in the peritoneal cavity and airways [204]. However, work conducted at IPBS showed that 
only virulent Mtb were able to induce foam cell formation through mycolic acid [172]. In this study, 
Peyron and colleagues showed that Mtb present in foamy macrophages were internalized prior to 
foamy differentiation. At the functional level, in addition to their inability to phagocytize new bacilli, 
foamy macrophage cells displayed a decreased microbicidal activity and capacity to induce a 
respiratory burst. Finally, upon the differentiation of foamy macrophages, Mtb entered a dormant 
state by up-regulating dormant genes [172]. More recently, in a study published by the Argentinian 
laboratory, where I had the opportunity to perform part of my PhD research, led by Drs. Saisian and 
Balboa, they showed that foamy macrophage formation was induced by Mtb lipids and whole bacteria, 
as well as with monocytes treated with acellular fractions of TB patient pleural effusion. These cells 
contained high levels of TAG and cholesterol, along with an increased expression of IL-10 and CD36, a 
receptor involved in free lipid capture, and a decreased secretion of TNFD. This phenotype was 
acquired in an IL-10/STAT3-dependent manner, through activation of the enzyme acyl CoA:cholesterol 
acyl transferase (ACAT). Functionally, foamy macrophages were able to activate CD4+ T cells. Yet, the 
number of IFNJ producing clones was lower compared to control macrophages (Annex 1 [205]). Finally, 
a genome-wide analysis of TB granulomas performed by Kim and colleagues allowed the identification 
of genes involved in lipid sequestration and metabolism. They found an enrichment of cells expressing 
adipophilin, acyl-coA-synthase and saposin C around the necrotic center and identified the lipid species 
that were overexpressed in the caseum, namely cholesterol, cholesterol esters, TAG and 
lactosylceramide [203]. These findings suggest a similar structure for eukaryotic lipid droplets and 
bacterial ILI. In Mtb, ILI are not only carbon and energy sources, but also help the bacilli fight against 
oxidative and metabolic stresses [198].  
To conclude, foamy macrophages induced by Mtb mycolic acid form a secure reservoir of 
carbon and energy for dormant Mtb, allowing it to persist in the host, hidden from immune responses.  
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C. Induction of the innate immune type I interferon response 
IFND and IFNE are well known for their ability to induce antiviral responses upon viral infection, 
both in infected and bystander cells, mainly by interfering with different stages of the viral replication 
pathway [19], [18], [24], [27]. Nonetheless, both cytokines have numerous other functions that 
influence the immune response to not only viruses, but other microbes, including parasites, fungi and 
bacteria. With the increasing number of studies deciphering the role of IFN-I in different pathological 
settings, it has become obvious that the outcome of the IFN-I response upon infection is highly 
dependent on the context. In fact, IFN-I modulated responses can be either beneficial or detrimental 
to the host, all depending on when, where and how abundant IFN-I are.  
 
a. Role of IFN-I in bacterial infection 
During bacterial infections, IFN-I can either be detrimental or protective to the host, depending 
on the bacterial challenge [18]. On the one hand, intracellular pathogens usually induce a type-1 
immunity (characterized by Th1 cells), including the activation of M1 microbicidal macrophages. On 
the other hand, extracellular bacteria require a combination of antibody-mediated responses, 
activation of phagocytes (neutrophils and macrophages), and Th17-dependent immune responses 
[18]. To coordinate the responses to either intra- or extracellular pathogens, many cytokines, 
chemokines and antibacterial effector molecules, usually IFN inducible (mainly through IFNJ signaling) 
are necessary. However, under various conditions, host antibacterial effector molecules together with 
pro-inflammatory cytokines can be inhibited by IFN-I [18], [206]. Yet, the mechanisms by which IFN-I 
promote host protection or susceptibility to bacterial infection are far from fully understood [18]. 
In Chlamydia trachomatis infection, IFN-I are beneficial for the host since mice treated with 
exogenous IFN-I are protected against the pathogen. The mechanism underlying this protection 
involves the IDO23-mediated depletion of L-tryptophan, an essential amino acid for several cellular 
functions. The reduction of L-tryptophan levels reduces its availability to the intracellular pathogen, 
which leads to a lethal outcome [207], [208]. Protection against Chlamydia pneumonia infection, 
through a cooperation between IFN-I and IFNJ that induces antibacterial effectors, was also reported 
and shown to be mainly dependent on IFNJ-induced responses [209]. Finally, IFN-I receptor IFNAR 
knocked-out (IFNAR-/-) macrophages are more sensitive to Legionella pneumophila infection compared 
to their WT counterpart, an effect mediated by macrophage polarization towards pro-inflammatory 
activation and iNOS expression [210]. 
While IFN-I can help the host against bacterial assault, it is also true that some bacteria are 
able to use it to their advantage. The best examples are bacterial pathogens such as Listeria 
monocytogenes, Tropheryma whipplei and Mtb (see the following section for IFN-I responses to Mtb). 
Indeed, IFNAR-/- mice are resistant to L. monocytogenes infection, a phenotype characterized by a 
longer survival and by lower spleen and liver bacterial load compared to their wild type littermates 
[211]ʹ[213]. This reduced susceptibility to the infection in IFNAR-/- mice is due to lower levels of IFN-
                                                          
23 IDO: Indoleamine-pyrrole 2,3-dioxygenase is a heme-containing enzyme that catalyzes the O2-dependent 
oxidation of L-tryptophan. 
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inducible apoptosis associated genes, leading to reduced cell death by apoptosis [213]. IFN-I are also 
detrimental in Tropheryma whipplei infection, by the diversion of macrophage polarization towards an 
alternate activation profile, which are more permissive to infection and with higher apoptosis rates 
[214]. Finally, IFN-I has been studied in Mtb infection context by several groups, whose observations 
are discussed further here-after. 
 
b. Accentuated IFN-I responses during active tuberculosis 
Multiple studies conducted both in patients and mouse models collectively point towards a 
detrimental role of IFN-I in TB, as evidenced by a decrease in bacterial load and/or improved survival 
of the host either in the absence of IFN-I signaling through different approaches [214]ʹ[217], including 
IFNAR-/- deficient mice [27], [218]ʹ[220]. Whole blood transcriptional profiling of patients with active 
TB were dominated by IFN-I inducible gene signatures, particularly overexpressed in neutrophils and 
monocytes, correlating with the disease severity assessed by X-ray scans. This signature diminished 
along with successful treatment [221]. Overexpression of several ISG, such as STAT1, Myxovirus 
resistance 1 (MX1), Interferon-induced protein with tetratricopeptide repeats (IFITs), oligoadenylate 
synthetase (OAS1), guanylate-binding protein (GBPs) and IRF1, among others, was detected early on 
in the blood of individuals who were in contact with TB patients and who progressed towards active 
disease [222], [223], further suggesting that peripheral blood activation of IFN-I signaling precedes the 
evolution and apparition of clinical manifestations of active TB.  
Other evidence supporting the notion that IFN-I activation is deleterious for the host in the 
context of TB infection come from different clinical and experimental settings. For instance, there is a 
well-documented reactivation of TB disease in patients receiving IFND based therapy for chronic 
hepatitis C infection [224], [225]. In addition, IFN-I production during the chronic phase of Mtb 
infection leads towards the establishment of immunosuppressive effects; for example, the induction 
of IL-10 production in macrophages [226] and in CD4+ T cells [227] limits immune-mediated tissue 
destruction, but also favours bacterial persistence [27], [228]. Likewise, treatment of human 
macrophages with exogenous IFN-I impaired their antimicrobial activity [229] and favoured the 
establishment of type-2 immunity (characterized by Th2 cell activation and humoral responses), 
thereby facilitating bacterial growth and reducing host survival [230]. Corroborating these 
observations, experiments using hypervirulent strains of Mtb showed that increased levels of IFN-I 
correlated with increased Mtb virulence [215]ʹ[217], [230]. Moreover, exogenous IFN-I instillation in 
the mouse model of TB infection induced pulmonary injuries to the host, further supporting the 
detrimental role of IFN-I in the TB setting [230]. Finally, IFN-I have been shown to promote early cell 
death of alveolar macrophages and to boost the local accumulation of permissive myeloid cells, further 
contributing to the spread of the infection and pulmonary inflammation [219], [231]. 
The above evidence is in line with studies using knock-out mice for various IFN-related 
molecules, which are used to evaluate the role of IFN-I during the course of the disease. One of them, 
for example, is a mouse model carrying a loss-of-function mutation within the ISG, ubiquitin-specific 
peptidase 18 (USP18), one of the negative regulator of IFN-I signaling. These mice showed that such 
deficiency led to hyperactivation of IFN-I signaling during bacterial infection, resulting in a higher 
susceptibility to Mtb infection, increased bacterial burden and a decreased survival [27], [232].  
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Figure 13: Dichotomy of IFN-I responses during Mtb infection (adapted from [233]) 
In Mtb infection, type I IFN (IFN-I) have been reported to display both detrimental and beneficial functions to the 
host.  
A | Initial secretion of type I IFN (IFN-I), which acts both in autocrine and paracrine manner, induces the 
expression of protective cytokines, such as IL-ϭϮ and TNFɲ͘  
B | However, later in the infection stage, high and sustained levels of IFN-I promote the production of immuno-
regulatory factors like IL-10, and inhibit the production of protective cytokines (e.g. IL-ϭϮ͕ TNFɲ͕ IL-ϭɲ͕ and IL-
ϭɴͿ͘ Doǁnsƚream of IFN-I, IL-10 exerts a negative feedback loop on IFN-I signaling, further decreasing the 
production of IL-ϭϮ and TNFɲ͘ SƵsƚained IFN-I secreƚion also inhibiƚs mǇeloid cell responsiǀeness ƚo IFNɶ͕ sƚriping 
the host of its protection. In addition, IFN-I can promote alveolar macrophage cell death and recruitment of 
permissive myeloid cells at the site of infection.  
IFNAR: IFN-I receptor; IFNJR: IFNJ receptor; IL-10R: IL-10 receptor. 
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Other studies have focused on the different ways that Mtb sustains IFN-I responses that would 
benefit its survival and spread. These studies point to bacterial genes like ESAT-6 and CFP-10 that 
induce IFN-I mainly through the TBK1/IRF3 axis. Indeed, IRF3-/- mice are resistant to Mtb and Listeria 
monocytogenes infections, even more than IFNAR-/- mice [24], [216]. There are also mycobacterial 
components that contribute to the activation of IFN-I in the host. For example, our team has shown 
that the sensing of Mtb lipids such as TDM (in this particular study, a synthetic mimic was used) by CLR 
(in this case, Mincle) in macrophages can induce IFN-I responses in B cells [234]. Other groups 
demonstrated that recognition of Mtb peptidoglycans in the infected macrophage cytosol by NOD2 
activates TBK1 that recruits IRF5, leading to the production of IFN-I [27]. Mtb-mediated activation of 
TLR is also a way for the bacilli to increase target cell susceptibility to the infection. For instance, 
deletion of MAPK8, a negative regulator of IFN-I downstream of TLR signaling, leads to increased levels 
of IFN-I and bacterial burden [235]. These two effects were abrogated in MAPK8-/-IFNAR-/-, translating 
in better bacterial control, which correlated with decreased levels of IL-10 and increased 
concentrations of IL-12 in the mouse sera. Collectively, these studies indicate that Mtb possesses a 
wide range of effectors able to trigger IFN-I responses in the host, that act in favour of bacterial 
proliferation and to the detriment of the host. 
Despite the large amount of evidence pointing at the deleterious role of IFN-I to the host in TB, 
this cytokine can also have a protective effect to a certain extent and under specific conditions, 
described in figure 13. Several clinical studies reported improved clinical symptoms and decreased 
bacterial burden after a co-administration of IFND and anti-mycobacterial chemotherapy to patients 
with active TB who did not respond to conventional antibiotherapy [236], [237]. Other evidence of a 
possible beneficial effect of IFN-I in TB was reported in the specific context of knock-out mice models. 
The IFNAR and ,)1*R (the receptor for IFNJ) double knock-out mouse model exhibits higher mortality 
rates after Mtb infection than in the single ,)1*R-/- knock-out mice, arguing that IFN-I could protect 
the host in the absence of IFNJ [238], [239].  
c. Balance between IL-1E and IFN-I in TB-disease 
IFN-I has been reported to inhibit the production of the key inflammatory cytokines IL-1D and 
IL-1E, crucial for host defense against Mtb [18], [240]. Their production is inhibited by IFN-I both in 
mice and human leukocytes. One of the mechanisms involves the inhibition of NOD sensors and 
consequent activation of both NOD-like receptor family, pyrin domain containing 1 and 3 (NLRP1 and 
NLRP3) inflammasomes. Nonetheless, NLRP3 inflammasome is necessary for IL-1E maturation and 
secretion [27], [241]. Other mechanisms are dependent on host lipids mediators such as eicosanoids, 
which are critical determinants of the death modality in alveolar macrophages [24], [27]. Among 
eicosanoids, prostaglandin E2 (PGE2) has been shown to be a critical mediator of IL-1-dependent host 
resistance to Mtb infection. As for IL-1 production, IFN-I can also limit PGE2 levels both in human and 
mouse cells [242]. During TB disease, PGE2 has been described to prevent macrophages necrosis upon 
Mtb infection by promoting apoptosis [27]. Moreover, PGE2 is known to be a critical determinant of 
alveolar macrophage death modality. This specific function is mediated by the balance of modulation 
between the levels of PGE2 and the lipoxin LXA4, a non-classic eicosanoid, in the cells. This balance is 
what determines whether alveolar macrophages undergo apoptosis or necrosis, which can be 
beneficial for the host or pathogen, thus influencing the infection outcome [24], [243]ʹ[245]. Indeed, 
virulent Mtb strains induce LXA4 production in alveolar macrophages, causing PGE2 synthesis to shut  
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Figure 14: Necrosis of Mtb-infected macrophages (from [86]) 
A | When Mtb-infected macrophages undergo apoptosis, the cellular debris, which can still contain bacteria, are 
phagocytized by surrounding uninfected macrophages, resulting in the repartition of the bacilli between multiple 
cells. 
B | Necrotic infected macrophages lose their membrane integrity, leading to bacterial release in the extracellular 
milieu, which is highly permissive for mycobacterial growth. When the number of bacteria in the extracellular 
milieu reaches exuberant levels, the necrotic center of the granuloma liquefies and cause the structure 
disruption, together with the liberation of thousands of infectious bacilli into the lungs. 
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down and pushing cell death towards necrosis, ultimately helping Mtb to evade the immune system. 
[24].  
Reciprocally, IL-1E signaling is involved in the negative regulation of STING-dependent IFN-I 
production in macrophages and DC through inhibition of TBK1-STING association [246], consequently 
suppressing the advantages given for mycobacteria survival in the host [18]. In these settings, shifting 
the balance from LXA4 towards higher PGE2 levels proved to be responsible for IFN-I synthesis 
inhibition, which resulted in a decrease in the production of IL-10 and IL-1 receptor antagonist, 
resulting in an increase of IL-1 production and enhanced protection against Mtb in macrophages [24], 
[242], [247]. 
Collectively, elevated levels of IFN-I are associated with Mtb virulence and increased host 
susceptibility to bacterial growth, underlying the pathological role of this cytokine in TB. Several 
mechanisms, including down-regulation of the IL-12/IFNJ and IL-1/PGE2 host-protective pathways, are 
responsible for this phenomenon. Yet, IFN-I can also play a protective role against the bacilli under 
certain conditions, including time of exposure and cytokine abundance, highlighting the complex role 
of IFN-I in TB. Of note, IFN-I cytokines are involved in the disease chronicity, a feature discussed in the 
following section. 
 
D. Establishment of a chronic inflammation to promote Mycobacterium 
tuberculosis transmission. 
a. Obligate pathogen 
We have seen that the immune response to Mtb infection is complex and involves many 
different factors. The formation of the granuloma, in 90 to 95% of cases allows the host to control the 
bacterial burden and to induce dormancy of the bacteria. Latency is not an inert state, neither to the 
host, nor to the pathogen. Indeed, the Mtb dormancy state needs continuous local immunity to 
support bacterial growth control. The constant recruitment of CD4+ T cells is necessary to maintain the 
integrity of the granuloma. Any impairment in these dynamics can lead to TB reactivation, due to 
several factors, including environmental factors, malnutrition, co-infections with HIV-1 (this setting will 
be discussed in chapter III) and immunocompromised patients. For example, patients who receive anti-
TNFD for rheumatoid polyarthritis or Crohn͛s disease have a higher risk of developing active TB [107], 
[248].  
Macrophage necrosis in the granuloma center is also a factor influencing the granuloma fate. 
When necrosis takes over apoptosis, the granuloma undergoes a caseation process and liquefies, 
causing the granuloma explosion and liberation of thousands of viable infectious bacteria into the lungs 
[86]. Data obtained from human lung biopsies of TB patients showed a correlation between enhanced 
bacterial growth and caseum presence, particularly in regions rich in macrophages and in bacterial 
exudate harboring cellular debris, evidence of cell necrosis [86] (Figure 14). Necrosis is not induced 
similarly in differentially activated macrophages. Lerner and colleagues reported that despite 
equivalent susceptibility to Mtb intracellular growth, GM-CSF- and M-CSF-activated macrophages are 
not equally susceptible to necrotic cell death. Propidium Iodine-positive cells were enriched in M-CSF 
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macrophage populations, indicating higher levels of macrophages undergoing necrosis. Consequently, 
Mtb growth rate was increased in these cells, even after IFNJ stimulation [249]. 
The constant immune system renewal during latent TB in order to keep disease reactivation in 
check categorizes TB within the family of chronic inflammatory diseases. In the next section, I will 
discuss how this chronicity impacts the monocyte/macrophage compartment. 
 
b. Effect on the monocyte/macrophage compartment 
i. Impact on monocytes 
In mammals, CD14+ monocytes subsets are distinguished by the expression of the FcJRIII ʹ 
CD16 receptor. In healthy individuals, CD14+CD16+ are in the minority and only represent 5 to 10% of 
the total monocyte population (see preamble) [13]. In inflammatory conditions like lupus, rheumatoid 
arthritis, cancer or HIV-1 infection, the proportion of CD16+ monocytes is significantly increased [12]. 
Similarly, circulating CD14highCD16+ monocytes are enriched in TB patients and express relatively low 
levels of phagocyte maturation, differentiation and function [250]. Moreover, these sub-population 
can be infected by Mtb, and produce more TNFD and less IL-10 after 6h of infection than CD16- subsets. 
Mtb-infected CD16+ monocytes are also more susceptible to apoptosis during their differentiation 
towards macrophages [250]. In addition to their increased levels in the bloodstream in Mtb infection 
context, CD16+ monocytes can represent 80% of pleural effusion cells and up to 50% of all circulating 
monocytes. Additionally, their abundance correlates with both TNFD levels in the blood and the 
disease severity, as assessed by chest X-rays in TB infected patients [251]. In the same study, our 
Argentinian collaborators showed that TB-induced CD16+ populations displayed a phenotype different 
from that of healthy donors. In TB patients, monocytes up-regulated CD14, CD16, CD11b, TLR2, TLR4 
and the chemokines receptors CCR1, CCR2 and CCR5, indicating that these cells could be efficiently 
recruited to the site of infection. Using in vitro and in vivo models, the same team showed that CD16+ 
subsets are more permissive to Mtb infection and have reduced migratory capacities. In fact, in the 
lungs and BAL of SCID mice adoptively transferred with either CD16- or CD16+ monocytes from Mtb-
infected WT mice, CD16- cells had higher inflammatory responses than CD16+ monocytes, along with 
decreased necrotic cell death [252]. 
Monocytes physiologically differentiate towards the macrophage (including osteoclasts) or DC 
fate, according to the homeostatic and inflammatory signals encountered in the blood and in tissues 
[9]. In their study, Balboa and colleagues studied the capacity of both monocyte subsets to 
differentiate into DC in the context of TB. As expected, healthy human monocytes differentiated 
normally into DC (under GM-CSF/IL-4 treatment), characterized by a cell-surface CD16-
CD1a+CD86highDC-SIGNhigh phenotype, ability to trigger high activation and proliferation of T cells (upon 
irradiated Mtb stimulation) and to secrete significant levels of IL-12 and IL-1E[253]. By contrast, 
monocytes isolated from active TB patients yielded a CD16+CD1a-CD86highDC-SIGN+ phenotype that 
poorly activated T cells due to intrinsically high levels of activated p38 MAP kinase [253], which is 
known to affect monocyte differentiation towards DC [254]. Altogether, this study showed that CD16+ 
monocytes from TB patients are deficient in the induction of DC differentiation. 
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ii. Impact on macrophages 
The presently described studies have shown the importance of CD16+ monocyte 
subpopulations in TB disease. However, only their ability to differentiate in DC has been studied. In 
this section, I will focus on how TB chronicity impacts the macrophage population.  
Macrophages polarization is an important feature in the immune response to Mtb infection. A 
range of macrophages activation profiles, modulated by the bacilli, are involved during the evolution 
of the disease. Actually, early stage of TB seems to be marked by the enrichment of M1 pro-
inflammatory macrophages (please refer to preamble and chapter I section II.B.c.i.), in favour of 
pathogen clearance through high microbicidal mechanisms. Later stages of the infection are 
characterized by an inversion in the balance between pro and anti-inflammatory cells; where M2 
macrophages are enriched and serve to reduce inflammation and protect the host from tissue 
damages [187], [255].  
Early after infection, Mtb-infected macrophages display an activation profile close to IFNJ-
activated M1 phenotype [256], [257]. Six days post Mtb infection, macrophages collected from mice 
BAL are polariǌed in a ͞Mϭ͟ programs and are highlǇ microbicidal͕ especially efficient at producing NS 
and IFNJ͘ Laƚer dƵring ƚhe infecƚion͕ beƚǁeen daǇ Ϯϭ and ϲϬ͕ an eǆƚended presence of ͞MϮ͟ polariǌed 
macrophages is detected in lung biopsies in mice [258]. Importantly, TB severity is positively correlated 
with the abundance of the anti-inflammatory cytokines IL-4, IL-13 and IL-10 [259], suggesting that the 
shift in macrophages population towards inflammation resolution activities is beneficial for the 
pathogen. In fact, this phenomenon is largely triggered by Mtb. The bacterial virulence factor ESAT-6 
is able ƚo inƚerfere ǁiƚh ƚhe ͞ Mϭ͟ acƚiǀaƚion profile͕ bǇ inhibiting MyD88-dependent activation of NFNB 
[260]. Using an in vitro model mimicking the Mtb-associated microenvironment, my team previously 
identified a mechanism that triggers the transition of macrophages towards an ͞MϮ͟ profile͘ This 
model consists of the utilization of bacteria-free supernatants from Mtb-infected human macrophages 
(conditioned media MTB, or cmMTB) to differentiate primary human monocytes. Monocyte treatment 
with cmMTB induced the up-regulation of CD16, CD163 and MerTK at the cell surface. The acquisition 
of ƚhis ͞MϮ͟ profile ǁas dƵe ƚo ƚhe high concenƚraƚion of ƚhe anƚi-inflammatory cytokine IL-10, which 
activated the STAT3 signaling pathway. These cells showed high motility and 3D migration capacities 
in dense matrices, immunosuppressive properties, illustrated by a poor capacity to secrete 
inflammatory cytokines and to activate T cells, and a decreased control of bacterial intracellular 
growth. Presence of these CD16+CD163+ macrophages was also observed in lung biopsies of Mtb-
infected macaques and correlated with high bacterial burden. Finally, thanks to our close collaboration 
with the Argentinian group, my team found that TB patient monocytes expressing CD16 were enriched 
in the blood. While CD163 and MerTK expression was not detected at the cell-surface in CD16pos cells, 
the plasma of active TB patients was enriched with their soluble forms. Indeed, sMerTK and sCD163 
abundance correlated with the disease severity in these patients. Altogether, this study showed that 
the TB-associaƚed microenǀironmenƚ indƵces an ͞MϮ͟ acƚiǀaƚion profile in macrophages ƚhroƵgh ƚhe 
IL-10/STAT3 axis, which is more sensitive to Mtb-infection than other polarizations (Annex 2) [261].  
In conclusion, the immune response to Mtb infection is quite complex and involves many 
cellular and molecular factors of both the innate and adaptive immune system to contain the bacteria. 
The main characteristics of a controlled infection is the formation of granulomas, which encapsulate 
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Mtb and prevent it from disseminating systematically in the host. Macrophages are the center of this 
response, and they play a dual role in Mtb infection as the main effector and target cell. As an ancient 
human pathogen, Mtb has evolved with its host for centuries and has developed ways to circumvent 
aggressive host responses. This pathogen is highly adapted to macrophages, as it is able to survive 
many imposed stresses, such as low pH, oxidation, nutrient depravation, and heavy metal poisoning. 
To do so, Mtb is able to orient macrophages towards more permissive profiles, allowing the bacilli to 
survive and maintain its cellular niche for years. 
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Chapter II: Aspects of the immune response to 
HIV-1 infection 
 
Acquired ImmunoDeficiency Syndrome (AIDS) is caused by the infection by Human 
Immunodeficiency Virus (HIV). In 2000, HIV-1/AIDS used to be the 7th highest cause of death 
worldwide, but as of 2016 has declined to 770 000 - 1 000 000 deaths per year. However, despite the 
global progress made to prevent the spread of the infection and to reduce AIDS-related co-morbidities, 
we are still far from controlling and eliminating the HIV pandemic [262], [263].  
 
I. HIV-1 infection: an overview 
A. History of AIDS and epidemiology 
a. History and origins of HIV 
AIDS was first recognized as a new sexually transmissible disease in 1981, when increasing 
numbers of young homosexual men were found to die from unusual opportunistic infections like 
Pneumocystis carinii pneƵmonia and rare malignancies sƵch as Kaposi͛s sarcoma in ƚhe USA [264]. In 
1983, the French researcher Dr. F. Barré-Sinoussi and colleagues were the first to identify the causative 
agent of AIDS, a retrovirus belonging to the lentivirus genus [265], which specifically targets CD4+ T 
cells [266]. This discovery was awarded the Nobel Prize in medicine in 2008, shared between herself 
and Dr. L. Montagnier. One year later, the teams of Drs. R. Gallo and L.S. Oshiro both described the 
virus using different names than the one coined by the French team [267], [268], and unveiled a more 
widespread epidemic than originally thought. It was only in 1985 that the virus responsible for AIDS 
was officially designated HIV-1. The same year, the first clinical test to detect the virus was approved 
by the FDA [269]. Additionally, Ratner et al., Sanchez-Pescador et al., and Wain-Hobson et al., 
described the first complete viral DNA sequence, revealing the complexity of the viral genome and 
providing insights into the replication modalities of the virus [270]ʹ[272]. The first antiviral drug, 
azidothymidine (AZT), was approved in 1987 [273]. The discovery of HIV-1 proteins, in particular the 
protease and reverse transcriptase in 1989 [274], aided in the development of both antiretroviral drugs 
and therapy (ART) and vaccine design. In fact, the first HIV-1 vaccine using the viral envelope 
glycoprotein gp120 was shown to protect chimpanzees from infection [275]. During the following 
years, many discoveries helped to better understand HIV-1 pathogenesis (e.g. continuous viral 
replication even in the chronic phase of infection [276]; role for CD8+ T cells in controlling the viral load 
[277]; identification of entry receptors and co-receptors [278], [279]; establishment of viral reservoirs 
[280]) and the development of additional drugs to fight infection, along with clues for vaccine design. 
Ever since HIV-1 was discovered, intensive research was conducted to understand its origin, 
how it emerged and the reasons behind its unique pathogenicity. The first clue arose in 1986 when a  
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Table 3: Summary of the global HIV epidemic (from [262]) 
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morphologically similar but antigenically distinct retrovirus was found to cause AIDS in patients in 
Western Africa [281]. Interestingly, this new virus, called HIV-2, was only distantly related to HIV-1 but 
quite similar to simian immunodeficiency virus (SIV) that infects macaques [282]. Soon after this 
discovery, several other SIV viruses were reported in different monkey species, such as African Green 
Monkeys (AGM), Sootey Mangabeys, Mandrills, and Chimpanzees (CPZ). Strikingly, these viruses were 
inoffensive in their natural host, but infection in non-natural hosts was highly pathogenic [282].  In 
addition, close SIV relatives of HIV-1 and HIV-2 were found to infect Chimpanzees  and Sootey 
Mangabeys, respectively [283], [284]. Together, these results led to the hypothesis that HIV viruses 
infecting humans resulted from multiple cross-species transmission of the parental SIV naturally 
infecting AGM (SIVAGM) [285], which led to the effective infection of Humans, due to the HIV-1 high 
mutation rate (1 million time faster than mammalian DNA).  
SIV infection has only been found in AGM and Apes, suggesting that primate lentiviruses 
originated in Africa [282]. Moreover, studies undertaken to date the age of SIV infection in 
geographically isolated subspecies of monkeys, indicate that this virus has existed for at least 30 000 
years [286]. These findings support the idea that Africa was the birthplace of HIV-1 emergence. Several 
reports confirmed this idea, and more particularly identified Leopold city (actual Kinshasa in Congo) as 
the cradle of the HIV-1 epidemic. Most probably, human contamination by SIV occurred from the 
traditional hunting of monkeys amongst the African population, where hunters were in direct contact 
with the animals blood and mucus. Consumption of raw meat from infected animals could also aid the 
contamination process [287]. If human acquisition of SIVAGM mostly resulted in limited spread in 
human, contamination with SIVCPZ, originally in Cameroon, gave birth to HIV-ϭ͕ responsible for ƚodaǇ͛s 
pandemic [282]. Phylogenetic and statistical analyses indicated that after the first emergence of HIV-
1 epidemic in West Central Africa between 1910 and 1930, the virus spread for some 50 to 70 years 
before being recognized as a pandemic infection [288]. 
To summarize, HIV-1/AIDS is quite a young infectious disease that was born in Africa from the 
cross-species transmission of a primate lentivirus. HIV-1 was able to adapt quickly from its original host 
to a new one, as well as being qƵiƚe efficienƚ aƚ spreading among indiǀidƵals ͞silenƚlǇ͟ for ƚhe pasƚ ϳϬ 
years before it was considered a top priority in health research. From now on, I will focus on HIV-1, 
since HIV-2 infection does not lead to AIDS, except in very rare cases [282]. 
 
b. Epidemiology 
Since the beginning of the pandemic, HIV-1 infection has claimed more than 35 million lives. 
Currently, it is estimated that approximately 37.9 million people live with HIV-1. In 2018, 1.7 million 
people became newly infected with the virus while it caused the death of 770 000 individuals 
(summary of the global epidemic is presented in Table 3) [262], [263]. HIV-1, like TB, can be considered 
a disease of poverty. Indeed, its repartition on the globe is quite unequal. Africa is the most affected 
region and represent 54% of the world population living with HIV-1, representing 25.7 million people 
in 2018 and 61% of AIDS-related deaths. Moreover, even if access to treatment has increased, only 
64% of HIV-1 infected people in Africa receive ART [262], [263]. 
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Figure 15: Increased risk incidence of acquiring HIV among key populations, global (from [262]) 
 
 
 
 
 
 
 
Figure 16: Number of HIV new infections from 1990 to 2018 with 2020 milestone, global (from [262]) 
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Certain popƵlaƚions͕ considered as ͞ at risk͟ popƵlaƚions͕ are more sƵscepƚible ƚo the infection. 
These populations include homosexual men and men having sex with men (MSM), transgender people, 
sex workers and people injecting drugs (see Figure 15). In fact, MSM and people injecting drugs have 
a 22 times higher chance of becoming infected with the virus compared to the general population 
(Figure 15), thus increasing the risk of developing AIDS [262]. An important issue when dealing with 
the pandemic is to consider all population and to ignore prejudices. Many efforts are being conducted 
in order to reach the point where all populations will get access to adequate diagnosis and treatment. 
These efforts have already led to improvements, notably by slowly decreasing the number of new 
infections per year, as well as in drug distribution (e.g. people receiving ART in Africa represented 24% 
of HIV-1 infected people in this region in 2010, against 64% today) [262]. Since 2010, AIDS-related 
mortality has declined by 33%, with this mainly occurring in Eastern and Southern Africa. However, 
this is not sufficient to stop the epidemic by 2030, an objective set by the WHO. Indeed, at the global 
scale, reaching the 2020 milestone of fewer than 500 000 deaths will require further declines of about 
135 000 per year (Figure 16), a goal which is unattainable today [260].  
In conclusion, many efforts remain to be made to stop the pandemic and to increase the 
population with access to ART. To reach the 2030 milestone, more funding and government initiatives 
in the fight will be needed, if we want to, one day, succeed in the eradication of HIV-1 infection. 
 
B. Therapeutic tools to fight the epidemic 
a. Transmission and prevention 
The main axis for HIV-1 to pass from one individual to another is horizontal transmission, occurring 
through contaminated body fluids. These fluids include blood, mucosal fluids such as sperm, vaginal 
and rectal mucus, and can be exchanged via needle exchange between drug users, blood transfusion 
or transplantation (which happened before 1991) and sexual relations. In addition, vertical 
transmission occurs when the virus is able to pass from a mother to her baby either during pregnancy 
through the placental barrier, labor and delivery, or breast-feeding via contaminated milk. Globally, 
80% of adults infected with the virus were contaminated after exposure to contaminated mucus while 
the remaining 20% were infected through intravenous inoculation [289]. To prevent infection, several 
solutions exist: use of condoms, use of sterile needle, voluntary medical male circumcision, which 
reduces the risk of heterosexually acquired HIV-1 by 60%, and proper education concerning HIV-1 
infection and how it is transmitted. While this can prevent horizontal transmission, it is not an effective 
mean to prevent vertical transmission.   
ART can also be used to avoid HIV-1 transmission between partners or from mother to child during 
pregnancy. Indeed, multiple clinical trials have reported ART regimens as efficient ways to avoid HIV-1 
transmission when followed with good compliance, and reduced the risk of acquiring HIV-1 to 
uninfected partner by 96%. Moreover, antiretrovirals can be used daily as pre-exposure prophylaxis 
(PrEP) treatment by HIV-1 negative partners to prevent viral infection. More than 10 randomized 
studies have demonstrated PrEP efficiency in different populations, including MSM, transgender, and 
heterosexual couples [290]. In addition, antiretroviral drugs can also be taken as a post-exposure 
prophylaxis (PEP) for HIV-1, for 28 day post-exposure, and were shown to protect the exposed 
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individual from becoming infected if started within 72h post-HIV-1 exposure. Finally, ART is also very 
efficient to avoid mother-to-child viral transmission. 
 
b. Diagnosis and treatment 
i. Diagnosis 
HIV-1 infection does not cause any uniquely specific symptoms, and typically includes fever, 
headache, rash or sore throat, and can vary during the course of the infection. As the infection slowly 
progresses, symptoms evolve into swollen lymph nodes, weight loss, and lymphopenia. It is during the 
first few months that infected people are the most contagious, and one of the major issues with HIV-
1 is that a large part of the human reservoir is constituted with people who ignore their infection, and 
therefore contribute to feeding the pandemic. That is why early diagnosis is key if we are to control 
the infection both at an individual and a global scale. Several diagnostic tools are available to diagnose 
HIV-1. The most common is the serological blood test, which assesses if the individual has developed 
a humoral response to the virus by measuring the anti-HIV-1 antibody titers in the patient plasma. This 
test is often confirmed by western blot on blood samples, where the viral proteins (p24, Gag) are tested 
for. The limit of this technique is that the humoral response takes several weeks to occur, delaying the 
diagnosis. Using the same samples, the viral protein p24 can also be quantified by ELISA. A more precise 
and sensitive method of detection is possible by measuring the viral DNA and RNA levels in the patient 
blood cells, a technique mostly used in babies born from infected mothers. These tests must be 
accomplished in health care centers, which unfortunately are not always accessible to all populations. 
That is why automated tests that work on the basis of an ELISA, have been developed [262], [263], 
[291]. 
 
ii. Treatment 
Improvements in diagnosis have led to an increase in the global coverage of people receiving 
ART, which reached 62% in 2018.  However, more efforts are needed to scale up treatment, particularly 
for children and adolescents, as only 54% were reported to receive ART at the end of 2018 [259]. Since 
the discovery of the epidemic, the development of ART has helped transform HIV-1 infection from a 
fatal disease to a chronic inflammatory disease, with hope of a cure still not on the horizon. Indeed, a 
rapid decrease in HIV-1-related morbidities and mortality was observed upon ART in the USA in the 
1990s [292]. Nonetheless, the virus rapidly evolved and developed resistance to certain antiretroviral 
drugs like AZT [293]. To avoid this, ART are now used in combination (cART) to target different steps 
of the viral replication cycle (see section II.C.b). There are seven classes of drugs that can be used in 
combination: non-nucleoside reverse transcriptase inhibitors (NNRTI), nucleotide reverse 
transcriptase inhibitors (NRTI), proteases inhibitors, fusion inhibitors, CCR5 antagonists (which 
compete with the entry co-receptor CCR5), integrase strand transfer inhibitors (INSTI) and post-
attachment inhibitors [263]. Within these classes, a combination of three drugs is proposed to HIV-1 
infected patients, according to their infection susceptibility to the drugs, but also on the side-effects 
and to possible drug interactions. The main effect of cART is to control the viral replication and plasma 
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viral load in infected patients. Yet, the treatment is unable to eliminate latent viral cellular reservoirs 
that become established during the early stages of infection, and these reservoirs can be reactivated 
upon treatment cessation. Even though these therapies enable patients to live a long and almost 
͞normal͟ life͕ cART is a life-long treatment that needs to be taken daily, carries a number of side effects 
and is costly. In addition, increased life expectancy revealed that HIV-1-infected patients have higher 
chances of developing other pathologies, including neuropathologies whose prevalence are increasing 
despite cART, and bone disorders, with up to a 6.4-fold increased risk of developing osteoporosis [294]. 
Since its discovery in 1983, huge efforts have been made to control and eliminate HIV-1 
infection, responsible for an important epidemic at the global scale. However, the capacity of HIV-1 to 
establish persistent reservoirs within its host makes treatment mandatory for a lifetime but prevents 
complete elimination of the pathogen. In addition to that, HIV-1 diagnosis, even if improved, remains 
an issue since a large proportion of infected people ignore their infection, and feed the invisible 
epidemic. As the infection continues to spread and cannot be cured, more efforts are still necessary to 
develop effective prevention measures, as well as to find a curative treatment. Within the last few 
years, several programs and world consortium have intensively focused their research on creating a 
vaccine against the virus, yet, designing an efficient vaccine against HIV-1 is more difficult than 
expected (for review, see [295]ʹ[297]). Most of the vaccine approaches are based on the utilization of 
soluble Env soluble trimers (HIV-1 receptors that allow the virus to infect a target cell), with the 
ultimate goal to create immune memory against the HIV-1 entry receptor by inducing broadly 
neutralizing antibodies. However, Env trimers are relatively stable in solution and harbor different 
conformations, including some that are irrelevant to induce efficient neutralizing antibody production. 
A second issue with these trimers is that they expose unwanted immuno-dominant surfaces (i.e. 
glycan) that can distract the immune system from the conserved neutralization-relevant surfaces on 
the trimer. Indeed, Env loop V1, V2 and V3, are the primary target of antibodies, but as they are 
hypervariable regions they do not provide a protective role against all HIV-1 strains present in the host. 
In addition to the few number of Env conserved regions, their accessibility to antibodies is restricted 
by the high glycosylation levels of the protein. Finally, the number of Env spike at the surface of the 
virus is suboptimal for cross-linking to B cell receptors, thus rendering it difficult to establish an 
effective humoral memory [297], [298]. 
 
II. Physiopathology of HIV infection and immune defenses 
A. What is HIV-1? 
a. Generalities about the virus 
i. Taxonomy 
HIV-1 is a virus belonging to the Retroviridae family, Otrhoretrovirinae sub-family, lentivirus 
genus. Its genome is composed of two copies of single stranded RNA molecules, which are reverse 
transcribed prior to integration within the host DNA. Diverse groups of HIV-1 exist, due to the fast 
evolution of the viral genome. Indeed, the short generation time (about 17h in CD4+ T cells, and up to  
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Figure 17: HIV-1 virion structure observed by electron microscopy (from [309]) 
A | Ultra-thin cryosection of macrophage infected with HIV-1 for 14 days. Electron microscopy image showing 
immƵnogold labelled pϮϰ͕ HLAͲDR and CDϲϯ͕  as indicaƚed͘ LǇsosomal comparƚmenƚ ;LǇsͿ do noƚ conƚain pϮϰ-
posiƚiǀe parƚicles͘ B ͮ As in A͕ bƵƚ doƵbleͲimmƵnogold labeled for pϮϰ and gp ϭϮϬ͘ 
Arrow: budding of the p24‐positive particles at the limiting membrane; Arrowhead: p24 label; Scale bars: 200 nm 
 
 
 
Figure 18: HIV-1 virion structure 
HIV-1 genome and proteinase (i.e. reverse transcriptase, protease and integrase) are encapsulated in a capsid, 
surrounded by a matrix protein core that also contains accessory proteins. This structure is enveloped with a 
lipid-membrane bearing the viral envelope protein gp41 and gp120, along with host-cell membrane protein that 
were embedded in the viral envelope during viral budding.  
 
Figure 19: HIV-1 genome. 
HIV-1 genome is about 10 kb and encodes for gag, pol and env polyproteins, that are cleaved after translation. 
It also encodes accessory proteins (i.e. Nef, Vif, Vpr, Vpu, Tat, and Rev) that allow the virus to replicate efficiently 
in its host and to escape viral clearance mechanisms induced in the infected cells. At both extremities, the HIV-1 
is flanked by long terminal repeat sequences (LTR), which upon activation enhance the viral genome 
transcription.  
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48h in macrophages) and high propensity of the viral reverse transcriptase to make mistakes (1 error 
every 104 to 105 nucleotides) when transcribing RNA to DNA favour HIV-1 mutations [299]. 
Phylogenetic studies have classified four subgroups of HIV-1 [300]. The main one, group M, comprises 
99.6% of HIV-1 strains and is responsible for the global HIV-1 epidemic. Strains discovered in the 1990s 
in Africa form the outlier group O and infect about 1% of the global population. Group N strains were 
identified in 1998 and are even less prevalent than group O strains, with 13 cases reported, all localized 
in Cameroon. Finally, a fourth group was created in 2009, group P, with a strain that does not present 
any recombination with strains from other groups [301] and that have been reported to infect 2 
women in Cameroon [282]. 
 
ii. Structure and genome 
HIV-1 is a spherical enveloped virus, with an average diameter of 100 nm, a size that depends 
on the maturation state of the virus (Figure 17: virus observed by EM). Its envelope is composed of a 
lipid bilayer derived from the host cell and into which viral glycoproteins, including gp120 and the 
transmembrane gp41 (both derived from the cleavage of the gp160 precursor), are inserted [302]. 
Once a cell is infected, these proteins are present at the surface of the host-infected cell as a complex, 
a trimer of gp120 and gp41 incorporated in the lipid bilayer through the transmembrane region of 
gp41 [303]. A budding virion usually incorporates 7 to 14 trimers in a single viral particle [304]. The 
inner leaflet of the viral envelope is lined up with the matrix protein p17, which surrounds a conical 
capsid, a p24 protein-rich structure that contains the viral genome ʹ  two copies of single-stranded RNA 
ʹ of about 10 kb. The viral RNA is encapsulated with all the needed material for its replication and 
integration, including the nucleoprotein p7, the p10 protease, the p32 integrase and the p66/p51 
reverse transcriptase (see figure 18: HIV-1 viral structure). The HIV-1 genome encodes for three major 
genes common between all viruses: gag, pol and env, encoding respectively for structural proteins of 
the viral core and matrix, enzymes (protease, integrase and reverse transcriptase) and for envelope 
glycoproteins (gp120 and gp41). These different proteins are first synthesized as polyproteins that are 
then cleaved to form their final and active form. The genome also encodes the regulatory proteins Tat 
and Rev, along with accessory proteins: Vif, Vpr, Vpu and Nef. Finally, the genome is edged by long 
terminal repeat non-coding sequences (LTR), involved in viral replication regulation, particularly during 
(reverse) transcription, splicing and encapsulation steps (see genome structure in figure 19).  
Each protein plays its own role during the viral replication cycle, which will be described in 
details in the specific case of macrophage infection in section III.B of the current chapter. Briefly, the 
envelope glycoproteins gp120 and gp41 are responsible for attachment to the main HIV-1 receptor 
CD4 and co-receptor CCR5 or CXCR4, and then fusion between the viral and host cell membranes, 
respectively [305]. Upon entry into the cell, the viral RNA is reverse transcribed into double-stranded 
DNA by the viral reverse transcriptase p66/p51. This DNA then enters the nuclei where the viral 
integrase p32 integrates the viral genome into transcriptionallǇ acƚiǀe regions of ƚhe hosƚ͛s genome 
[306]. The viral genome is then expressed by the host, resulting in the synthesis of viral RNA and 
proteins, Tat and Rev, which are required for the viral replication cycle. Meanwhile, accessory proteins 
facilitate the viral escape from immune recognition [307], ensuring viral persistence, assembly and 
dissemination [308].   
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Figure 20: HIV-1 entry into target cell (from [310]). 
Upon recognition of the entry receptor CD4, the viral protein gp120, organized in trimers, undergoes a 
conformational change, liberating the binding site of gp41. Binding of gp41 to the cell co-receptor induces a 
second conformational change and the injection of HIV-1 fusion peptide into the cell membrane, ultimately 
leading to viral and cell membranes fusion, prior viral entry into the cell. 
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In the team of Dr. I. Maridonneau-Parini, one of my supervisors studied the accessory protein 
Nef, a small protein (27 kDa) that is rapidly and abundantly expressed in the host cell. A significant 
proportion of HIV-1 pathogenesis has been assigned to Nef, including the improvement of viral 
production and infectivity [311]ʹ[313]. One of the main function of Nef is to disrupt intracellular 
trafficking and signaling pathways, especially those related to endosomal protein trafficking. Indeed, 
Nef is responsible for the internalization and sequestration of cell surface proteins such as CD4 (to 
avoid infection with other HIV-1 virion after primo-infection and favours efficient viral replication), 
CD28, and MHC-I and II complexes [314]. In addition, Nef is a master regulator of the cytoskeleton in 
infected host cells [315], [316]. My PhD mentor, Dr. C. Vérollet focused her research on Nef-mediated 
perturbation of the F-actin cytoskeleton in macrophages [317]ʹ[319]. I will detail her work as well as 
that of others, on Nef and the alteration of macrophage function in section III.B.e.  
Altogether, the virus is well equipped to efficiently infect and replicate in its target cells. The 
HIV-1 genome (relatively small) encodes for proteins allowing its replication and integration into the 
host genome, while simultaneously providing accessory proteins to protect it from immune system 
detection. 
 
iii. Viral tropism 
To infect a target cell, viruses need to bind to their cell surface receptor and fuse with the cell 
to finally use its machinery to replicate. The main and mandatory receptor of HIV-1 is the cell surface 
receptor CD4 that is mainly expressed by CD4+ T cells, the main target of the virus, as well as by cells 
of the myeloid lineage, including DC, CD16+ subset of monocytes [11], macrophages and osteoclasts 
[320]ʹ[323]. In fact, the principal characteristic of HIV-1 infection in humans is the depletion of effector 
CD4+ T cells, in which the infection and viral replication are highly efficient compared to resting CD4+ T 
cells. High affinity binding of gp120 to CD4 [324], [325] induces a conformational change of gp120, 
exposing gp120 binding sites to the co-receptor (see Figure 20) [310]. Viral tropism is defined by the 
affinity of gp120 for its co-receptor. Thus, R5 tropic viruses use the co-receptor CCR5 to enter the cells, 
while X4 tropic viruses use CXCR4. Some strains, called R5X4 strains, are able to use either CCR5 or 
CXCR4. These chemokine receptors belong to the G-protein family, involved in different signaling 
pathways, and more specifically in cell migration [326]. In fact, there are three classes of HIV-1: (i) R5 
T cell tropic, (ii) X4 T cell tropic and (iii) M-tropic (for macrophage-tropic). Real M-tropic viruses are 
noticeably more infectious for macrophages than R5-tropic viruses, although all R5-tropic viruses can 
enter macrophages at least to some extent. In addition, M-tropic strains are very efficient at infecting 
cells with low CD4 density, which is not the case for R5-tropic viruses [327]. Whatever the virus strain, 
binding of gp120 to its co-receptor further changes the protein conformation, leading to exposure and 
trimerization of gp41, which injects its fusion peptide into the membrane, leading to cell and viral 
membrane fusion. 
In addition to CD4, the presence of co-receptors is essential for efficient HIV-1 infection of the 
target cell. Indeed, when using co-receptor inhibitors [328], [329], or when downregulating co-
receptor expression using gene constructs [330], the viral infectivity is reduced. Another argument 
supporting this statement is the existence of two patients who were cured of HIV-1 infection. These 
two patients who were infected with the virus also had a leukemia. The first patient Timothy Ray  
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Figure 21: General course of HIV-1 progression (adapted from [331]). 
After transmission (1), the virus replicates and start to disseminate (2) from mucosal site to the lymph node 
(eclipse phase). However, it remains undetectable for any diagnostic test. During the first weeks following HIV-1 
transmission, considered as the acute phase of the infection, the virus multiplies actively (red line) while the 
number of CD4+ T cells drops (blue line) (3). Six weeks post-infection, the humoral immune response occurs and 
the first HIV-1-binding antibodies can be detected in patient plasma (pink line) (4). This is accompanied by an 
increase in CD8+ cytotoxic T cells in the blood (green line). The chronic phase (5), which can last for several years, 
is characterized by a balance between the viral replication and the viral restriction imposed by the host. The 
number of CD4+ and CD8+ T cells stabilizes, along with the viral load, while the levels of neutralizing antibodies 
(purple line) increase until reaching a plateau. Finally, the disease progresses towards AIDS (6), the last phase of 
the infection, which is defined by a drastic drop of CD4+ T cell count, CD8+ T cell exhaustion and death, and 
uncontrolled viral replication. 
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Brown, known as ƚhe ͞Berlin paƚienƚ͟, was the first to receive, in 2007, a stem cell transplant that 
eliminated the virus from his system. Ten years later, he ǁas folloǁed bǇ ƚhe ͞London paƚienƚ͟, who 
was also free of the virus after receiving a bone marrow transplant. These two men received their new 
stem cells from healthy donors carrying the '32 mutation in the CCR5 gene, which proved to be 
protective against the virus since both patients were the only one described to be able to stop their 
antiretroviral therapy without experiencing viral rebound, with undetectable viral loads since their 
remission [332]. These successes have inspired scientists to look for gene therapy-mediated mutations 
of the co-receptor gene in order to reduce HIV-1 spread. Research progress on this topic are reviewed 
in [333]. Particular attention was focused on CCR5, which is thought to be the main co-receptor used 
at the viral entry site in newly-infected hosts. When the virus enters the host mucosa at the 
transmission stage, it is commonly thought that the primary cells to be infected are DC and 
macrophages (expressing higher levels of CCR5 than CXCR4), which upon activation, recruit CD4+ T cells 
[334]. This is important because most R5 tropic viral strains are myeloid cell tropic, although some R5 
strains are T cell tropic as well. Yet, it is thought that transmitted viruses are mostly R5-tropic strains 
that rapidly infect the first cells they encounter in mucosa, mainly the myeloid cells. Also, during 
progression of the infection, the main tropism switches from R5 to X4 or R5X4 [335]. 
Finally, if CCR5 and CXCR4 are the main co-receptors for HIV-1 entry, alternate receptors 
expressed by myeloid cells, in particular lectins and C-type lectins, were also shown to be involved in 
HIV-1 capture and transfer to T cells and will be discussed later in this chapter, section III.D.a.  
 
b. General course of the infection and critical features 
Specific markers, testifying uniformly of the evolution towards AIDS, are used to characterize 
HIV-1 infection (e.g. plasma viral load and, CD4+ T cells counts). Disease progression is assessed 
according to CD4+ T cell count in the patients blood along with plasma viral load [336], and follow four 
defined phases, represented in figure 21. 
The eclipse phase, first to occur, happens when the virus succeeds in infecting a new host, and 
establishes the infection in the exposed local tissue. During this phase, which is believed to last for 10 
days, HIV-1 dissemination in the systemic circulation has not yet occurred [337]. In the majority of the 
cases, HIV-1 enters the host through mucosal routes and crosses the mucosal barrier to reach the 
target cells. To do so, the virus has three options: first, it can cross the barrier via transcytosis through 
the inter-epithelial layer by binding to exposed DC dendrites. Second, the virus is small enough to pass 
through intercellular spaces between epithelial cells and to reach cells present in the lamina propria 
[338], [339]. Last, it has been suggested that HIV-1 gp120 is able to alter the mucosal membrane by 
initiating the secretion of inflammatory cytokines, which in terms leads to increased barrier 
permeability [340]. Once in the lamina propria, HIV-1 encounters DC, macrophages and CD4+ T cells 
that become infected. It is also in this time frame that ART can prevent the virus from establishing 
infection. 
The eclipse phase is followed by the primo-infection or acute infection stage. This step can be 
asymptomatic or carry flu-like symptoms (e.g. headaches, nausea, and muscle pain) [341]. It is this 
stage during which the patient is most contagious, due to a high viral replication rate and increasing 
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viral levels in the blood. It usually lasts for two to four weeks after HIV-1 transmission. Indeed, at this 
step, HIV-1 has already spread to lymphoid tissues and into the blood, and its replication increases 
rapidly to a peak level, with a doubling viral population rate of 20h [337]. During ramp up viremia, only 
the viral RNA can be detected from blood. After seven days, p24 antigen (capsid protein, see Chapter 
II ʹ II.A.a.ii) detection is possible, even before the apparition of HIV-1 neutralizing antibodies [336]. 
Acute phase is characterized by high viremia and a strong immune system activation where the CD4+ 
T cell count transiently drops [342]. After the viremia peak, the viral load dramatically decreases while 
CD4+ T cell count goes back up to normal levels. 
Once normal T cell counts are reached, the infection enters the phase of latency, or chronic 
phase, an asymptomatic period that can last from a few months to years in untreated people, and can 
be largely prolonged in patients receiving cART [343]. During this phase, the virus continues to replicate 
at a slower rate while the number of CD4+ T cells slowly decreases, both because of infection, but 
mainly because of the constant activation leading to apoptosis [344], [345]. The immune system is 
constantly activated, leading to eventual exhaustion.  
Finally, the AIDS phase is declared when the CD4+ T cell count drops under 200 cells/mm3 of 
blood. The antibody titers and CD8+ T cell count drop while viral replication peaks again, no longer 
͞conƚrolled͟ bǇ ƚhe immƵne sǇsƚem [331]. Because of the induced immunodeficiency, AIDS patients 
are highly contagious and highly susceptible to opportunistic infections, disease reactivation (e.g. 
tuberculosis) and to cancers. Without treatment, AIDS patients usually die within 3 years after their 
status has been declared [346].  
 
B. HIV-1-induced immune activation is a critical feature of HIV-1 chronic 
phase establishment 
a. Alteration of the gut barrier and impact on immune system activation  
The gastrointestinal tract (GI) represent a structural and immunological barrier against 
microorganism invasion of the host. It is the system containing the highest proportion of T lymphocytes 
in the entire organism [347]. Alteration of this barrier is a main feature of HIV-1 infection and is partly 
responsible for the establishment of the virus-mediated chronic inflammation that characterizes the 
disease. In 1984, Kotler and colleagues reported the observation of histological abnormalities in GI 
samples collected from jejunal and rectal biopsies in AIDS symptomatic patients. The patients 
presented with D-xylose malabsorption, steatorrhea, partial villus atrophy with crypt hyperplasia, 
increased number of intraepithelial lymphocytes, mast cells infiltration in the lamina propria and focal 
cell degeneration near the crypt base [348]. These enteropathies are also detected in pathogenic SIV 
infection in rhesus macaques and are mainly characterized by inflammatory infiltrates of lymphocytes 
and damage to the epithelial barrier (e.g. atrophy, hyperplasia) [349]. More recent studies found that 
the majority of CD4+ T cells of the GI tract were depleted during the acute phase of both HIV-1 and SIV 
infection [350]ʹ[354]. Depletion of CD4+ T cells of the GI tract continues for the entire course of the 
disease and is poorly reflected by the CD4+ T cell count in the peripheral blood: gut T cell loss is much 
higher than what is observed in the blood circulation, especially after cART, mainly because the 
treatment fails to replenish the gut CD4+ T cell pool. This T cell subset is not the only one to be depleted 
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during the infection. Th17 cells, a specific subset of helper T cells abundant in the gut and essential for 
ƚhe hosƚ͛s proƚecƚion againsƚ fƵngi and bacƚeria͕ are also losƚ sƵbseqƵenƚ ƚo HIV-1 infection [355]. In 
addition, the gene expression landscape in the GI tract biopsies of HIV-1-infected non-progressors 
revealed a downregulation of genes involved in the cell cycle regulation, lipid metabolism and digestive 
functions [356]. The epithelial barrier alteration during the course of HIV-1 comes with translocation 
of the gut commensal microorganisms into the bloodstream. This can be followed by an increasing 
level of LPS deƚecƚable in paƚienƚs͛ plasma͕ parƚicƵlarlǇ high in ƚhe chronic sƚage of ƚhe infecƚion [357], 
which correlates with systemic immune activation; that is high number of activated memory CD8+ T 
cells ʹ immune cells keep encountering microbial antigens and thus remain constantly activated and 
recruit more immune cells to clear the infection ʹ and elevated levels of soluble CD14 and IFND in the 
blood [347].  
 
b. Systemic immune cell activation induces the recruitment of target cells 
to the site of infection, along with premature immune senescence 
Translocation of commensals bacteria into the bloodstream leads to constant danger signal 
detection by immune cells. Recognition of the circulating PAMP by patrolling monocytes, DC and 
macrophages induces the production of pro-inflammatory signals like TNFD, IL-1E, IL-6, CCL5 (also 
known as RANTES) and of IFN-I [358], which favours surrounding cell activation, and lead to systemic 
inflammation. Consequently, patients progress faster to the disease and display accelerated decline of 
overall immune competence. HIV-associated immune activation is mainly characterized by 
dysfunctional T regulatory cells and display an ageing immune phenotype, similar to that seen in the 
elderly, including high expression of IFN-I, which causes thymic dysfunction and impairs the generation 
of new T cells [358], [359]. This immune senescence is defined by a decreased production of naïve T 
cells, decreased proliferative capacity in response to antigen stimulation and a reduced T cell longevity 
[360], [361]. This drop in the lifespan of T cells is notably due to inflammation-mediated cell turnover 
that imposes a strain on their homeostatic mechanisms [347]. Inflammation-mediated changes in 
cytokine release increase cell susceptibility to activation of induced-cell death ([360], [362], 
consequently leading to both CD4+ and CD8+ T cell apoptosis, further feeding inflammation. As a result, 
the T cell compartment undergoes exhaustion and immune senescence [358], [363]. Lastly, sustained 
IFN-I secretion by plasmacytoid DC (pDC) and activated macrophages leads to the synthesis and 
recruitment of more HIV-1 target cells. Infected macrophages are able to activate the recruited resting 
CD4+ T cells to render them permissive to HIV-1 infection. In addition, they also attract CD8+ T cells and 
mediate their death by apoptosis, leading to immunosuppression [364], [365].  
Despite clear evidence that CD8+ T cells are involved in the partial control of viral replication 
[366], [367], they also present intrinsic functional defects. In addition to decreased proliferation, CD8+ 
T cells also have reduced capabilities to produce cytokines such as IL-2 and lack poly-functionality, a 
characteristic that correlates with a better clinical outcome in HIV-1 pathology [368], [369]. This 
prevents CD8+ T cells from acquiring full effector functions, in part explaining their failure to clear the 
infection. Chronic inflammation leads to expression of both activation and negative regulatory 
receptors on T cells, driving their effector activity or their immunosuppression. Programmed death-1 
(PD-1) is a crucial negative regulator of T cell function and was reported as an essential marker of 
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chronic activation. Indeed, PD-1 is highly expressed on HIV-1-specific cytotoxic CD8+ T cells (CTLHIV-1) 
[370], [371] and on CD4+ T cells, and this expression is correlated with viral load [370]. Supporting this 
correlation, lower levels of PD-1 on CTLHIV-1 in HIV-1 non-progressors were reported in long term 
disease compared to HIV-1 progressors [372]. In vitro studies also reported an improvement of CTLHIV-
1 proliferation when PD-1 interactions with its ligand were blocked, further arguing for PD-1 mediated-
immunoregulation. One of the direct effects of PD-1 expression by both CD4 and CD8+ T cells is the 
induction of T cells apoptosis [373], which is part of the immune senescence observed in HIV-1 infected 
people [373]. The expression of PD-1 determines T cells sensitivity to apoptosis and is induced by 
chronic antigen stimulation. The fact that this expression is lowered upon ART-mediated viral 
suppression [370], [371] further indicates that PD-1 is a major component of the compensatory 
immune-downregulation induced during chronic inflammation, which could be targeted to improve 
the anti-HIV-1 functions of T cells. 
Systemic immune activation observed in HIV-1 infected patient is a hallmark of the 
establishment of chronic disease. Consequently, immunoregulatory functions of regulatory T cells are 
impaired, the effector T cell pool is depleted mainly by apoptosis of bystander cells, and cytotoxic CD8+ 
T cells become exhausted (high expression of inhibitory receptors like PD-1 and Tim-3 [374]). All these 
features participate to early immune senescence. Altogether, these changes predispose HIV-1 infected 
individuals to the development of comorbidities like lung immune dysfunction [375], [376] or cancers 
[377], but also to age-related comorbidities, such as osteoporosis [378], arthritis [379], cardiovascular 
[380] and cognitive diseases [381]. As cART increases the lifespan of patients, future drug development 
should aim at reducing this chronic inflammation in order to slow the fasten aging of infected patients. 
 
C. The host IFN-I responses in HIV-1 infection 
HIV-1 infection, as many other viral infections, triggers the establishment of a host IFN-I 
mediated response. Historically, IFN-I therapy proved to be efficient in the case of several viral 
infections, such as hepatitis C virus and influenza. Therefore, IFN-I therapy strategies were rapidly 
applied to treat HIV-1 infection after discovery of the virus, even before understanding the IFN-I 
response mechanisms to HIV-1 at the cellular level, which remain, even today, poorly described (see 
paragraph c of the current section). This strategy was partially efficient on a case-by-case basis in HIV-
1 pathology, indicating that IFN-I responses in HIV-1-infected host are more complicated than originally 
thought. Here, I will describe the results of several clinical studies, which set the starting point of our 
understanding of the role of IFN-I in HIV-1 pathogenesis. 
 
a. Potentials of IFN-I as therapeutic tools in humans 
Historically, few molecules, including recombinant IFND were shown to display efficient 
inhibition of HIV-1 replication in infected individuals, even before the first cART was available in 1996. 
The first studies evaluated the impact of IFND therapy in AIDS-patients with Kaposi sarcoma. One of 
them reported a decrease in plasma p24 antigen levels in one quarter of the patients [382]. The same 
year, the group of Salzman obtained similar results, reporting a tightly higher efficiency of IFND2a 
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therapy [383]. These studies were further confirmed by a randomized double blind trial two years later, 
where the effect of IFND2a therapy versus placebo was assessed. Patients showed a global tolerance 
towards the treatment, despite reported flu-like symptoms and neutropenia, which occurred in a 
treatment dose-dependent manner [384]. In the IFND2a group, 41% of the patients became HIV culture 
negative against only 13% in the placebo group. CD4+ T cell counts were maintained and no progression 
to AIDS was observed in the IFND2a group [384]. Several other studies reported similar results, and 
highlighted the limited potential of using IFN-I as HIV-1 therapy because of the limited number of 
responders to the treatment and significant side effects observed. Indeed, in the majority of clinical 
trials, IFND responders were patients with preserved immune functions (CD4 count > 500/ml) [385]. 
Overall, IFN-I monotherapy had a moderate impact and its effect were transient, controlling HIV-1 
plasma levels for a couple of months at maximum [385].  
In order to decrease IFND2a-induced side effects, new trials were conducted using PEGylated 
IFND2a, a molecule that displayed more favourable pharmacokinetics and safety profiles than the 
previously used IFND formulation. In ART naïve patients with chronic HIV-1 infection and normal CD4+ 
T cell count, PEG-IFND injection led to a decrease in viral loads and correlated with the induction of ISG 
in the patient peripheral blood. However, these positive effects of IFN-I therapy were only observed in 
patients with low basal levels of ISG, contrary to individuals with high IFN-I signatures who proved to 
be non-responsive to PEG-IFND treatment [386]. Altogether, these studies highlight the importance of 
the patient immune system activation status, a criterion that can drive the treatment outcome, along 
with the time and dosage of IFND used to control viral replication. 
These different trials, along with the promising results of cART on the control of viral load and 
increased longevity of infected individuals, opened the field for combined treatments utilizing cART and 
PEG-IFND therapy. In the INTERVAC-ANRS 105 trial published in 2011, which recruited 168 chronically 
HIV-1 infected patients, PEG-IFND administration during cART successive treatment interruptions (STI) 
was evaluated. After randomization, 84 patients received cART for 12 weeks, followed by 4 weeks of 
either PEG-IFND therapy or placebo. This cycle was repeated 3 times. Follow-ups were set at week 48 
and 72, and no significant differences in HIV-1 viral load and reservoir size were observed between the 
two groups. Nonetheless, patients with a low CD4+ T cell count and high baseline HIV-DNA showed 
increased risks of resuming treatment in the IFN-I group, supporting the detrimental role of IFN-I during 
the chronic phase of HIV-1 infection [387]. Similar results were obtained in the INTERPRIM-ANRS 112 
trial, where patients were either treated with: (i) cART for 72 weeks, (ii) cART for 36 weeks followed by 
STI, or (iii) cART combined with PEG-IFND during 36 weeks, followed by STI with PEG-IFND 
administration [388]. Together, these studies suggest that combined therapy using cART and IFN-I did 
not significantly improve the decrease in viral load, CD4/CD8 T cell ratio and global CD4+ T cell counts 
compared to cART alone, nor did it prevent the viral rebound after treatment cessation. On the 
contrary, Azzoni and colleagues performed a proof-of concept clinical trial and found that IFN-I could 
be used against HIV-1 reservoirs when employed in combination with cART. In this study, patients 
received combined cART with PEG-IFND2a for 5 weeks, followed by 12 to 24 weeks of PEG-IFND2a only. 
This treatment led to viral suppression as soon as 12 weeks in the IFN-I group, and more importantly, 
subjects with sustained viral loads had decreased levels of integrated HIV-1 DNA despite residual viral 
loads [389]. This study provides hope that finding effective drug combinations will eventually eliminate 
HIV-1 reservoirs within the host.  
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Altogether, the different clinical trials presented here show the potential of IFN-I-mediated 
therapies. Yet, investigation is still needed to understand the host responses to IFN-I in vivo. To continue 
the development of innovative treatment strategies, research efforts should focus in optimizing the 
balance between the enhancement of the immune response against the virus while avoiding the 
deleterious induction of excessive inflammation. Currently, it is thought that the efficiency of IFN-I 
therapy could be mediated by several strategies. First, the use of other IFN-I subtypes from IFND2a 
should be considered. Indeed, it was shown that IFN-D8, IFND14 and IFNE are more potent at blocking 
HIV-1 infection [390], [391] and display higher affinity for their receptor than IFND2a [391], [392]. In 
particular, IFND8 and IFND14 induce higher expression of antiviral genes (e.g. Myxovirus resistance 2 
(MX2), Tetherin, apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 (APOBEC3)) [391], 
[392]. In addition, gene therapy where IFNE or IFND14 were used conferred a long-term suppression of 
HIV-1 replication in a humanized mouse model [393]. Second, host viral sensors could be modulated 
with agonists in order to induce endogenous IFN-I expression [394], [395]. Finally, the IFN-I signaling 
pathway could be modulated by affecting molecules involved in this pathway [396], [397]. 
 
b. IFN-I responses in HIV-1 pathogenesis: what we have learned from 
animal models 
The variability of results obtained in human clinical trials that tested IFN-I administration as a 
therapy in HIV-1-infected patients shed light on the complexity of IFN-I responses in the host. To better 
understand the dichotomy of IFN-I, animal studies have been performed. Such studies have pioneered 
the current understanding of the different cellular response to IFN-I in the context of co-infection, 
starting by questioning the dogma according to which IFN-I are antiviral cytokines. In fact, it appears 
that IFN-I retain their antiviral properties under certain conditions, involving acute inflammation, but 
become deleterious to the host if sustained for too long or if induced too strongly. Here, I will focus on 
the main results obtained in the context of HIV-1 and SIV infection, which show that IFN-I can mediate 
an efficient antiviral effect, depending on when it is used. 
 
i. Expected antiviral effect in the early phase of the infection 
In this part, I will focus on rhesus macaque models used to test the efficiency of IFN-I or 
blocking IFNAR, the IFN-I receptor as treatment during SIV infection. The challenge of female animals 
with SIV results in viral replication at the mucosal infection site. In this model, during the following 10 
days, the virus replicates in the tissue and corresponding lymphoid organs, before systemic infection 
can be observed, as described in HIV-1 infection (see Chapter II-II.A.b)[398]. During these 10 days 
following infection, cytokine responses are initiated, including the strong and early production of IFN-
I at the mucosa [399]. In a study published in 2016, Veazey and colleagues showed that pre-application 
of IFNE in the vagina of rhesus macaques before SHIV (human and simian immunodeficiency virus 
chimera) challenge protected the animals from being infected by changing the phenotype of local 
immune cells. IFNE pre-exposure resulted in increased immune activation in the vagina, together with 
the up-regulation of restriction factor (for more details on HIV-1 restriction factors, see section II.C.c.iii 
of this chapter) [400].  
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Using two complementary methods, Sandler and colleagues dissected the dichotomy of IFN-I 
in a rhesus macaque model of SIV infection. First, they found that by blocking IFNAR daily for 4 weeks 
after SIV intrarectal challenge, the antiviral gene expression decreased. This was accompanied by a 
decrease in CD4+ T cell count while the SIV reservoir size was enhanced. Despite reduced T-cell 
activation, these animals showed signs of progression to AIDS, arguing for a role of IFN-I in animal 
protection when produced at the beginning of the infection [401]. In the same study, the authors 
showed that IFND2a administration, starting for 1-week prior to SIV infection and lasting for 4 weeks 
after challenge, upregulated antiviral genes, increasing the number of challenges necessary to lead to 
efficient infection and prevented systemic inflammation. However, continued IFND2a treatment led 
to IFN-I desensitization with decreased ISG expression, and consequently, to increased viral reservoirs 
together with an accelerated CD4+ T cell loss [401]. Altogether, these results indicate the importance 
of timing when the host initiates its IFN-I mediated viral response.  
 
ii. Deleterious consequences during chronic infection 
We just saw that when induced at early stage of the infection, IFN-I exert a protective effect 
against the virus, which prevents infection. However, when IFN-I are used too late or for too long, the 
continued exposure to this cytokine renders the cell insensitive to its signal, and antiviral genes are no 
longer expressed to restrict the infection. Evidence of this detrimental role of IFN-I were first observed 
when comparing SIV infection in its natural host, the Sootey Mangabey versus its non-natural host, the 
Rhesus Macaque. While both species display IFN-I mediated immune activation during the acute phase 
of infection, the IFN-I response is rapidly shut down in the natural host, along with decreased 
inflammation. On the contrary, non-natural host sustained high IFN-I responses during the chronic 
phase of the disease, which correlated with immune hyperactivation and CD4+ T cell loss [402], [403]. 
Similar observations were made in HIV-1 infected people who presented various susceptibilities 
towards AIDS progression: rapid progressors, who quickly lose T cells and present with high viral load, 
display stronger IFN-I blood signatures than viremic non-progressors [18], [404].  
Other evidence of the detrimental role of IFN-I has been reported recently in another in vivo 
model. In a BLT (bone marrow, liver and thymus) humanized mouse model of chronic HIV-1 infection, 
exhaustion and activation markers of CD8+ T cells (high level of inhibitory receptor expression such as 
PD-1, CD38 and TIM-324) were increased. IFN-I signaling was also chronically elevated during the course 
of HIV-1, as supported by the constant elevated levels of MX1 gene (antiviral ISG) from 5.5 to 13 weeks 
post-infection [405]. In this study, Zhen and colleagues showed that blocking IFNAR 13 weeks post-
infection lowered ISG expression in the peripheral blood and decreased T cell activation and 
exhaustion markers, and with time, decreased viral loads. They finally showed that, used in 
combination with cART, IFN-I treatment accelerated viral suppression and reduced the viral reservoir 
[405]. 
Taken together, these data demonstrate how subtle the IFN-I response is when induced by 
viral infection. Nonetheless, the promising results obtained with IFN-I administration or blocking in  
                                                          
24 TIM-3:  T-cell immunoglobulin and mucin-domain containing-3 is an inhibitory receptor of CD4 and CD8+ T cells 
that can also regulate macrophages activation. 
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Figure 22: HIV-1 replication cycle and restriction factors (from [406]). 
The different steps of the viral replication cycle can be counteracted by specific restriction factors (yellow) 
expressed by the host cell in response to the infection. Most of these factors are induced by IFN-I. For example, 
TRIM5a, SAMHD1 and APOBEC3, act to block HIV-1 reverse transcription by inhibiting cDNA synthesis, depleting 
the dNTP pool necessary for DNA synthesis or by favouring hypermutation of the viral DNA during reverse 
transcription, respectively. Tetherin prevents the release of budding virion. However, the virus expresses 
accessory proteins (blue) that are able to counteract the action of these restriction factors, allowing an efficient 
viral replication. The cell also express resistance factors (brown), such as IFITM, MX2 or SLFN11, which are not 
counteracted by viral protein. Nevertheless, the virus can escape the cell resistance, for example, by mutating 
the viral capsid, resulting in the failure of host MX2-resistance. 
dsDNA, double-stranded DNA; gRNA, viral genomic RNA; LTR, long terminal repeat; ssDNA, single-stranded DNA 
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animal models of HIV-1/SIV infection, fuel the hope of using IFN-I as an efficient treatment to prevent 
viral dissemination in HIV-1 infected individuals.  
 
 
c. Specific cellular responses to HIV-1 induced IFN-I: a zoom into 
macrophages 
As described in the preamble, IFN-I is expressed in response to pathogen recognition through 
different PRR (Figure 2 in preamble). IFN-I then acts in an autocrine and paracrine manners to (i) 
control the viral replication in infected cells, and (ii) prevent bystander cells from getting infected [18], 
[28], by inducing the expression of IFN-I stimulated genes (ISG) with antiviral properties, usually called 
restriction or resistance factors (Figure 22) [407]. In vivo, it is thought that pDC are the main producers 
of IFND, however, there is evidence that there are other leukocytes that also produce IFN-I. Indeed, in 
the lung, it has been shown that alveolar macrophages are the ones that produce IFN-I during infection 
with RNA viruses [408]. Here, I will discuss what is currently known of IFN-I responses at the cellular 
level in the context of HIV-1 infection, with a particular focus on macrophages. 
 
i. PRR-mediated recognition of HIV-1 leads to antiviral gene 
expression 
As mentioned in the preamble, host cells, and more specifically immune cells, possess an entire 
set of receptors able to detect exogenous material that leads to their activation and, usually, to the 
induction of IFN-I responses after PRR engagement (including TLR and RIG-I) [406]. In the case of HIV-
1, the virus detection and sensing inducing IFN-I production can happen both before and after the viral 
entry into the target cell, and its sensing differs from one cell type to another, depending on the 
different PRR expression [406].  When the virus reverse transcribes its RNA into DNA, cytosolic factors 
such as IFNJ inducible protein 16 (IFI16), which is expressed in cells of the hematopoietic lineage 
including T cells and myeloid cells (DC, monocytes, macrophages), recognize the viral genome [409], 
[410]. In CD4+ T cells, IFI16 senses incomplete HIV-1 DNA intermediates and, in addition to IFN-I 
production, IFI16 is also responsible for the induction of caspase 1 activation, leading to cell death by 
pyroptosis. Importantly, there is evidence indicating that 95% of CD4+ T cells deaths occur in quiescent 
cells, and it points to IFI16-mediated pyroptosis25 as a major contributing mechanism to the decline of 
CD4+ T cells during the course of HIV-1 infection [409], [411].  
Another sensor, cGAS, whose expression is restricted to myeloid cells, is also able to bind to 
HIV-1 DNA [412], [413]. Consequently, cGAS catalyzes cGAMP, a second messenger that activates 
STING and TBK1, leading to IRF3 phosphorylation and its translocation into the nucleus, which results 
in IFN-I production. As part of the PRR family, TLR also play an important role in HIV-1 sensing, 
particularly in pDC. In particular, TLR7 is able to recognize HIV-1 RNA in endosomes and triggers the  
                                                          
25 Pyroptosis: highly inflammatory form of programmed cell death requiring caspase 1 activity and that 
frequently occurs upon intracellular pathogen infections. 
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Figure 23: Sensing of HIV-1 (from [406]). 
Upon HIV-1 entry into the target cell, the viral RNA is reverse transcribed into cDNA. This molecule is detected 
by the cytoplasmic receptors IFI16 and cGAS, which induce cGAMP. Consequently, both cGAMP and IFI16 activate 
STING, which recruit successively TBK1 and IRF3 to activate IFN-I promoter sequence ISRE and lead to IFN-I 
production. In the cGAS/cGAMP pathway, STING can also activate NF-ʃB, leading to activation of the kB site 
promoter and to IFN-I secretion. To avoid this response, HIV-1 uses the cellular protein TREX1, which helps the 
virus to evade cytosolic sensing by degrading viral cDNA in the cytoplasm.In addition viral cDNA sensing, viral 
single stranded (ss) RNA can be detected by TLR, notably in endosomes. TLR7 activation by ssRNA results in the 
activation of MYD88, which then recruits IRF7 to activate the ISRE promoter and finally leads to IFN-I synthesis.   
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activation of the MyD88/NFNB pathway, leading to IFN-I and other cytokines production. Exhaustion 
or death of pDC was responsible for the natural reversal of IFN-I production in SIV-infected cynomolgus 
macaques [414]. Moreover, blocking of TLR7 during acute infection of SIV-infected macaques resulted 
in a diminished IFN-I production, further highlighting the importance of TLR activation in HIV-1 
detection [415]. Following these different sensing pathways, seen in figure 23, IFN-I are produced and 
subsequently activate the JAK/STAT1 signaling pathway (in an autocrine and paracrine manner) to 
generate ISG expression [18], among which several display antiviral properties.  
 
ii. HIV-1 is able to avoid IFN-I induction in macrophages 
In contrast to the IFN-I response induced in pDC, HIV-1 seems to avoid this response in many 
other cells types [416], [417], by preventing IFN-I production. In this regard, the host repair 
exonuclease 1 (TREX1) plays a central role as it degrades excess of HIV-1 cDNA produced during reverse 
transcription and therefore, avoiding viral recognition by IFI16 and cGAS. In human monocyte-derived 
macrophages, depletion of TREX1 allowed the accumulation of HIV-1 DNA in the cell cytoplasm, 
resulting in the induction of IFN-I expression via the STING/TBK1/IRF3 pathway (Figure 23), thereby 
preventing HIV-1 replication and spread [418]. HIV-1 is also capable of altering IFN-I signaling pathways 
either by triggering the induction of IRF2 and IRF8, which downregulates IFN-I signaling [419], or by 
targeting IRF3 to proteasomal degradation by macrophages [420]. This inhibition of IFN-I signaling 
activation in macrophages can also be due to the induction of suppressor of cytokine signaling 3 
(SOCS3) by HIV-1. Akhtar and colleagues showed that SOCS3 expression attenuated macrophage 
responses to IFNE, resulting in lower antiviral gene expression and increased viral replication [421]. 
Another advantage for HIV-1 to prevent IFN-I responses is to avoid the increasing ways through which 
it can be sensed. Indeed, certain ISG, like tetherin and tripartite motif-containing protein 5 (TRIM5D 
are capable to detect the virus assembly and to restrict it while initiating NFNB-dependent intracellular 
signaling pathways [422], [423]. Next, HIV-1 restriction factors will now be discussed. 
 
iii. Restriction factors and how HIV-1 circumvents them in 
macrophages 
Even if HIV-1 is able to prevent IFN-I induction in macrophages, the inhibition of IFN-I 
production is not absolute. Therefore, macrophages are able to respond to IFN-I produced by other 
cell types and upregulate ISG in response to this activation, including genes displaying inhibitory 
activities against HIV-1 [406], [424]. Much of the associated research focuses on the identification of 
these ISG, termed restriction factors or resistance factors, and their mechanisms of action and 
regulation, which can occur at different steps of the viral replication cycle [28]. In the next section, I 
will describe a few and non-exhaustive examples of well-known HIV-1 restriction factors expressed by 
myeloid cells, including macrophages, that participate in HIV-1 replication control. I will also discuss 
the mechanisms by which HIV-1 is able to counteract them.  
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Restriction factors are intrinsic cellular proteins that potently restrict or suppress HIV-1 and 
SIV replication. To be categorized as such, these proteins must possess the following characteristics 
[406]:  
o they are invariant within an individual and cannot be altered by gene mutation processes;  
o they display the hallmark of Darwinian positive selection; 
o they are induced by IFN-I; 
o they are sufficient to suppress viral replication at a single cell level;  
o they are inactive against WT viruses that infect their natural host, (i.e. they are counteracted 
by the virus); 
o they protect the host from infection with viruses from other species; 
o their activities and downregulation are mediated by degradation, mainly in a ubiquitin-
proteasome dependent system. 
Of note, viral resistance factors display many properties of restriction factors, but they are not 
counteracted by the virus.  
To date, several restriction factors have been described, including sterile ɲ moƚif domain and 
histidine aspartic acid (HD) domain 1 (SAMHD1), TRIM5D, APOBEC3, IFITM protein family, tetherin, 
MX2 and others (see Figure 22 and for a detailed review, see [425], [426]). Here, I will discuss three 
important restriction factors expressed notably by macrophages (i.e. SAMHD1, MX2, and Tetherin) 
that either specifically control HIV-1 replication in myeloid cells or have particular effects in 
macrophages.  
In macrophages, IFN-I appears to interrupt early stages of the HIV replication cycle, as opposed 
to T cells, in which it acts on terminal stages of the viral cycle. One of the first restriction factors to 
intervene in HIV-1 replication is SAMHD1, a cytosolic enzyme expressed notably by DC, macrophages 
and CD4+ T cells (but at lower levels than myeloid cells). Its implication in HIV-1 restriction was initially 
discovered in DC, a viral inhibition that is specific of the myeloid cell lineage [427]. Indeed, SAMHD1 
has a phospho-hydrolase activity that induces the degradation of dNTP26 in non-dividing cells. Yet, 
effector CD4+ T cells are highly dividing cells requiring high levels of dNTP in order to expand and 
control the infection. This is why SAMHD1 is unable to control HIV-1 replication in activated CD4+ T 
cells. In fact, SAMHD1 is post-transcriptionally inactivated in dividing cells, including CD4+ T cells [428]. 
Hoǁeǀer͕ Benkirane͛s ƚeam and oƚhers shoǁed ƚhaƚ SAMHDϭ-mediated restriction of HIV-1 in 
quiescent CD4+ T cells is maintained [429], [430]. It is through its hydrolase activity that SAMHD1 was 
shown to inhibit HIV-1 reverse transcription in DC and macrophages, since its depletion markedly 
increased these cells susceptibility to infection [427], [431]. As a restriction factor, SAMHD1 is 
counteracted by the viral protein Vpx. The latter is an accessory protein of HIV-2 and SIV, but is absent 
from the HIV-1 genome. To show how Vpx counteracts SAMHD1, researchers transfected target cells 
with Vpx plasmids or Vpx-bearing virus_like particles (VLP) and evaluated its capacity to promote HIV-
1 infection. It was shown that Vpx targets SAMHD1 for degradation by the proteasome through 
ubiquitination, subsequently allowing efficient infection of target DC and macrophages [406], [821]. 
The majority of the studies cited above used molecular tools to study the role of SAMHD1 during 
                                                          
26 dNTP: mix of the four nucleotide triphosphate that compose the DNA molecule (adenine, thymine, guanine, 
and cytosine). 
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natural HIV-1 infection. The absence of Vpx in HIV-1 and the ability of HIV-1 to replicate in macrophages 
expressing the restriction factor in its antiviral state, suggests that SAMHD1 could be irrelevant in the 
control of the virus reverse transcription [407]. Indeed, the low level of dNTP is an obstacle to HIV-2 
replication but not for HIV-1, which only needs a low concentration of dNTP to efficiently synthetize 
its DNA [432]. Yet, SAMHD1 renders DC and macrophages less permissive to HIV-1; as mentioned 
before, depletion of SAMHD1 increases cell permissiveness to the infection. This effect is more likely 
due to the nuclease activity of SAMHD1. By degrading HIV-1 RNA, the restriction factor protects the 
cell from being efficiently infected [433]. This has a dual effect. Despite single cell protection against 
the infection, SAMHD1 also allows the escape of HIV-ϭ from immƵne deƚecƚion͘ Schǁarƚǌ͛s ƚeam 
reported that during cell-to-cell communication between infected T cell and DC, SAMHD1 prevents 
viral RNA/DNA sensing in DC [434]. Reduced sensing of the virus also led to decrease antigen 
presentation capacities of DC [435]. Altogether, these results suggest that increased myeloid cells 
infection by inhibition of SAMHD1 may shift the balance of antigen presentation and favour specific 
immune responses to the infection, allowing for reduced immune activation and CD4+ T cell turnover. 
This would result in a natural control of HIV-1 infection, as observed with SIV and HIV-2. 
The following restriction factor, MX, is involved at the next step of the HIV-1 replication cycle: 
nƵclear imporƚaƚion of ƚhe ǀiral DNA and inƚegraƚion inƚo ƚhe hosƚ͛s genome͘ There are ƚǁo IFN-
inducible MX dynamin-like guanosine triphosphate hydrolases (GTPases) encoded in the human 
genome: MX1 and MX2 (also known as MXA and MXB, respectively) [436]. MX1 was reported to block 
a wide range of viruses, except HIV-1, who is specifically blocked by MX2 and more efficiently in non-
dividing cells [437], [438]. MX2 is localized at the nuclear envelope, in nuclear pore complexes, but it 
can also be found in the cytoplasm [439], [440]. It seems to act at the level of nuclear entry and viral 
DNA inƚegraƚion inƚo ƚhe ƚargeƚ cell genome͕ since ƚhe abƵndance of Ϯ͛-LTR circular forms of HIV-1 DNA 
and of integrated viral DNA are reduced in monocytic cell lines overexpressing this protein [438], [439]. 
The exact mechanisms by which MX2 inhibits HIV-1 remain unknown to date. Yet, some evidence show 
that the GTPase activity of MX2 is not required for blocking HIV-1 [439]. However, its nuclear location 
is essential for HIV-1 control. Using engineered chimeric MX1/2 proteins, Goujon and colleagues found 
that the amino-terminal domain is responsible for MX2 anti-HIV-1 function. By transferring this 
sequence to the amino terminus of MX1, the engineered protein located to the nucleus and acquired 
anti-HIV-1 activities [438], [441]. Other studies suggested that MX2 antiviral function depends on the 
protein interaction with the viral capsid. During the replication cycle, after successful entry, the viral 
capsid inƚeracƚs ǁiƚh hosƚ͛s proƚeins sƵch as cǇclophilin A ;CYPAͿ͕ nƵcleosporin ϯϱϴ and 
polyadenylation specific factor 6 (CPSF6). The recruitment of these proteins to the reverse 
transcription complexes are thought to shield the viral cDNA from sensing by cGAS, and possibly other 
PRR and ISG, including MX2 [442], [443]. Depletion of CYPA in a 293T cell line abrogated MX2-mediated 
restriction of HIV-1 [444]. In addition, mutations in the viral capsid proteins rendered HIV-1 resistant 
to MX2 restriction [439]. Taken together, these results suggest that MX2 associates with the viral 
capsid-host protein complexes, allowing it to restrict HIV-1 nuclear importation and integration, 
although the exact mechanisms involved in this function remain to be discovered. 
Tetherin, the last restriction factor I will now discuss, acts in the last stage of the HIV-1 
replication cycle: the viral assembly and budding from the host cell. Tetherin, also known as bone 
marrow stromal antigen 2 (BST-2), was discovered in 2008 by Neil et al. and Van Damme et al. [445], 
[446]. It is a lipid raft-associated protein, because of the glycosylphosphatidylinositol (GPI) 
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modification in its C-terminal extracellular domain [447]. It is associated particularly with cholesterol-
rich lipids rafts where newly synthetized HIV-1 particles bud from [448]. Tetherin retains the newly 
synthetized HIV-1 particles at the plasma membrane of virus producing cells. When the virus assembles 
and buds from the infected cell, its envelope contains host-membrane lipid-rafts and proteins, 
including tetherin, usually as a homodimer. Tetherin integration into the viral envelope and host 
plasma membrane allows the retention of viral particles, and subsequently leads to the internalization 
and degradation of the virus in the lysosomes [448], [449]. Several studies have highlighted the 
importance of the viral accessory protein Vpu for cell type-dependent HIV-1 particle release from virus 
producing cells [407], [426]. Indeed, the use of Vpu deleted strains of HIV-1 caused a 5- to 10-fold 
decrease in CD4+ T cell viral release [450]. Additionally, this defect was found to be dependent on the 
cell type: in T cells, viral particles accumulated at the plasma membrane, while in macrophages, 
tetherin-bound virions were stored in intracellular plasma membrane-connected structures called a 
virus-containing compartment (VCC, see Chapter II, section III.B.d.) [451], [452]. Tetherin knock-down 
in macrophages induced a redistribution of VCC, promoting HIV-1 release and cell-to-cell transmission, 
indicating again how important this ISG is for HIV-1 restriction. The evidence above indicates that Vpu 
is responsible for coƵnƚeracƚing ƚeƚherin͛s anƚiǀiral fƵncƚions͘ Seǀeral sƚƵdies have shown that Vpu 
inhibits tetherin function by inducing its sequestration to the endosomal compartment [453]ʹ[455], 
and it can translocate it to the lysosome by interacting with the small GTPase Rab7a [456]. In 
macrophages, Vpu restrains tetherin accumulation in VCC and stimulates viral release by reducing the 
size of VCC [452]. Last, but not least, Vpu is also able to recruit E3 ubiquitin ligase to induce tetherin 
ubiquitination, targeting it for proteasomal degradation [407], [426]. In light of these data, targeting 
Vpu or tetherin to either block or enhance their function (respectively) appears to be a promising 
strategy to help the host to control viral synthesis and dissemination. Yet, such a strategy still needs to 
be combined with others to fully inhibit HIV-1 replication, since tetherin can only reduce the rate of 
newly infected cells.  
 Besides the expression of restriction factors and their role, little is known about the specific 
IFN-I-mediated responses of macrophages upon HIV-1 infection. In the majority of studies, the impact 
of IFN-I was described in DC and T cell compartments, a subject reviewed extensively [457]ʹ[459] and 
that will not be developed here. I will now focus on the role of macrophages within HIV pathology. 
 
III. Intimate relationship between HIV-1 and the host: a focus on 
macrophages 
For about 30 years now, HIV-1 physiopathology has been studied using a variety of in vitro and 
in vivo models. Nonetheless, the cellular and tissue tropism in infected humans remains not completely 
understood and is still open to debate. One particular subject of discrepancy relates to the in vivo 
relevance of the monocyte/macrophage compartment during the course of HIV-1 infection. CD4+ T 
cells have long been described as the major targets for the virus; however, macrophages are also 
infected and participate in infection-associated pathologies. Importantly, macrophages are present in 
the brain of infected patients and significantly contribute to HIV-1 dementia [460]. Today, evidence for 
the presence and implication of infected macrophages in many, if not all, tissues are available. Here, I 
will discuss about the importance of macrophages in HIV-1 disease. 
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A. Contribution of macrophages to AIDS in human and animal models 
a. Mouse model 
Many important aspects of HIV-1 infection cannot be fully evaluated using in vitro models or 
unmodified animal models, in particular with mice who are fully resistant to HIV-1 infection [461]. To 
circumvent this issue, humanized animals have been developed by transplantation of human cells 
and/or tissues [462], along with transgenic mice that have been used to study more specifically the 
role of a given viral protein in a whole-body system. One of the most used models is the Nef-transgenic 
mouse, which allowed the unveiling of the multifactorial effects of Nef during infection. Indeed, Nef 
expression in CD4+ cells in mice is sufficient to cause an AIDS-like syndrome [463]. Moreover, Nef was 
shown to be responsible for enhanced migration of macrophages towards the kidney, liver, and gut 
tissues [317], and for the downregulation of CD4 expression in T cells. Additionally, Nef-expressing 
macrophages migrate faster and mediate lymphocyte chemotaxis and activation, showing the 
importance of macrophages infection in the progression of the disease [317], [464].  
Humanized mouse models have much evolved (for review see [462], [465]), and the 
transplantation of severely combined immunodeficiency (SCID) mice with human bone-marrow, liver 
and thymus (BLT) represents today the best model to study HIV-1 pathogenesis. This is because it 
possesses an entirely humanized immune system, however the kinetic of HIV-1 pathogenesis differs 
from that of humans [465]. Using this model, along with the humanized myeloid-only mice (MoM) who 
are depleted of the T cell compartment, the group of J. Victor Garcia revealed the importance of 
macrophages during HIV-1 infection. They found these leukocytes, in particular tissue macrophages, 
are able to sustain HIV-1 replication in the absence of T cells. These macrophages are located in various 
tissues, including the brain, liver, spleen, bone marrow, and lungs [466]. The same group demonstrated 
that ART, as reflected by a quick drop in the plasma viral load, rapidly suppresses HIV-1 replication in 
tissue macrophages and decreases cell-associated viral DNA and RNA. However, a delayed viral 
rebound occurred in about 33% of infected mice after treatment interruption, indicating that HIV-1 
infection is persistent in macrophages, who are part of the viral reservoir [467] (for further details on 
macrophage reservoirs, see Chapter II section III. A.d.). 
 
b. NHP 
The question of HIV-1 infected macrophages serving as a main reservoir has become a 
significant issue for finding a cure to the infection. Important data on the course of the disease has 
emerged from NHP infection models. It is widely accepted that the loss of CD4+ T cell is a marker of 
disease progression and the main cause for its terminal endpoint [468]. However, evidence from SIV-
infected NHP points to monocyte turnover as a more relevant tool to predict the infection outcome 
[469]. Supporting this, several studies have reported that under physiological conditions, monocyte 
turnover in NHP blood is about 5%, however in SIV infection, this is increased up to 50% prior to 
terminal AIDS progression. Increased turnover of the monocyte population was shown to be predictive 
of severe HIV-1-associated morbidities, including aggravated lung tissue pathology, cardiovascular 
disorders and encephalitis [469]ʹ[471]. These morbidities were associated with an increased 
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macrophages population in the corresponding tissue. In fact, monocyte turnover kinetics was 
associated with a loss of tissue macrophages, notably in the lymph node, leading to enhanced 
recruitment of monocytes to replace them [472], [473]. Despite this, the absolute count of peripheral 
blood monocytes was not impacted, testifying to the high renewal rate of circulating monocytes during 
the disease course. 
The appearance of cardiovascular, neurodegenerative and lung pathology as a result of an 
increased macrophage population supports the fact that these cells play a critical role in disease 
progression. Recently, Avalos and colleagues found that brain macrophages harbored replication 
competent SIV strains in virally suppressed cART-treated macaques. These macrophages were found 
two years after ART initiation, unveiling macrophages as a long-lived viral reservoir in the brain [474]. 
Additional studies indicated that macrophages could be part of the viral reservoirs. Indeed, in light of 
these studies, the lung appeared to be one of the most HIV-1/SIV affected organs under cART, an effect 
thought to be due to the role of macrophages in chronic immune activation within this organ [473], 
[475]. In the lung, both interstitial and alveolar macrophages have been shown to be infected by SIV, 
as they contain viral RNA, but it did not alter the two cell populations equally [468]. SIV infection of 
interstitial macrophages induced their rapid death by apoptosis, causing a continuous transport of 
circulating monocytes to the lung in order to maintain organ homeostasis. By contrast, alveolar 
macrophages showed a low turnover despite their infection, suggesting that this subpopulation of lung 
macrophages could be part of the long-lived viral reservoir [473], [476]. 
 
c. Humans 
As observed in the NHP models, macrophages are also targeted by HIV-1 in humans during the 
acute phase of the infection. Indeed, viral nucleic acids have been detected in macrophages isolated 
from multiple infected patient organs, including Kupffer cells in the liver [477], microglial cells in the 
brain [478], macrophages in the GI tract [479] and in alveolar macrophages in the lung [480]. 
Importantly, similar observations were made in patients under cART in all afore-mentioned organs 
[479], [481], [482], supporting the idea that macrophage are part of the viral reservoir.  
In addition to the evidence that macrophages are the main reservoir for HIV-1, there are also 
reports on their possible role in predicting the progression of the disease. In children infected with 
HIV-1, there is a higher monocyte turnover, correlating to a more rapid progression of the disease, and 
like in adults, could be a more relevant marker to follow this. Indeed, acute plasma viremia in young 
patients is generally increased 10-fold higher than levels seen in adults [483], suggesting that CD4+ T-
cell depletion and the degree of immune activation does not consistently correlate with the 
progression to AIDS [484].  
 
d. Evidence of macrophages as a main reservoir for HIV 
HIV-1 is able to induce the formation of a viral reservoir, a characteristic shared by many 
retroviruses. By definition, a viral reservoir is a cell type, or anatomical site whereby a replication-
competent form of HIV-1, either active or latent, can accumulate and persist stably, either as a provirus 
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or in infected cells [4]. Additionally, reservoirs can be reactivated upon stimulation (e.g. immune 
reactivation, opportunistic infections) and allow the virus to recolonize the host upon treatment 
cessation. 
Macrophages and other cells from the monocytic lineage are more resistant than CD4+ T cells 
to the cytopathic effect of HIV-1 infection. Thus, as they are long-lived, in particular a certain subset of 
tissue macrophages, like alveolar macrophages that derive from embryonic origin, can harbour the 
virus for longer periods of time [485], strongly suggesting that they are part of the long-lived viral 
reservoir installed by HIV-1. Despite several studies in favour of this statement, the extent and 
relevance of macrophage reservoirs in humans has been a strong subject of debate.  Indeed, cART-
mediated reduction in the reservoir size, the limited access to relevant tissue samples (e.g. brain, 
lungs), and the inherent weaknesses of the detection techniques have failed to provide convincing 
data reporting the presence of replication-competent macrophage reservoirs in patients with 
suppressed viremia [486]. Yet, such data exists in infected-patients, who had detectable HIV-1 DNA in 
their myeloid cells. Moreover, macrophages persistence and implication in comorbidities (e.g. 
neurological disorders leading to dementia) argues of their importance, if not central role in the 
constitution of viral reservoir.  
The majority of infected macrophages in vivo are tissular (e.g. microglia, alveolar macrophages, 
Kuppfer cells). For example, evidence of HIV-1 infected macrophages in the brain have been observed 
since the 1980s. In the organ, it is mainly perivascular macrophages and the microglia that are infected 
with HIV-1 [487]. Infiltration of the central nervous system by the virus or infected cells occurs as early 
as eight days after transmission [488], and, structural changes in the brain are readily observable within 
only a year [489]. In cART naïve patients, brain infection causes an increased activation of glial cells, 
which induces detectable neuronal injury [490]. Brain infection, as in other organs, results in a lifetime 
infection and constitutes an important reservoir for HIV-1. Indeed, viral DNA can be detected in the 
cerebrospinal fluid in cART patient while it is not found in their plasma [491]. 
Lung macrophages, and particularly alveolar macrophages, as mentioned previously in this 
section, are also important targeted cells during HIV-1 infection. In SIV infection of macaque, alveolar 
macrophages were found to be infected within 10 day post-infection, as assessed by the detection of 
SIV RNA [492]. This study demonstrated that HIV-1 spreads quite early and rapidly to the lungs, where 
the major cell type infected were alveolar macrophages. In humans, alveolar macrophages isolated 
from broncho-alveolar lavages (BAL) were also positive for HIV-1 RNA and associated to local tissue 
damages, corroborating the results obtain in the SIV infection model [493]. Moreover, Jambo and 
colleagues found HIV-1 material in alveolar macrophages of cART naïve chronically-infected patients. 
They reported that HIV-1+ macrophages displayed impaired phagocytic activity [480]. In cART-treated 
patients whose plasma viral loads were under the detection levels, alveolar macrophages contained 
detectable proviral DNA in about 70% of the cases, and half of them also displayed detectable RNA in 
this cellular compartments [482]. In addition to the brain and lungs, a recent study conducted by Ganor 
and colleagues reported that urethral macrophages are also part of the macrophage reservoir. They 
isolated urethral macrophages from the penis of HIV-1-infected men under cART, and they were able 
to detect HIV-1 DNA, RNA, proteins and even identified the VCC, which will be described in the 
following section). By contrast, viral component were undetectable in the urethral T cells. When 
activated by LPS ex vivo, urethral macrophages started to replicate the virus and to release it into the 
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cell supernatant, indicating that a viral rebound had occurred and therefore showing that these cells 
are part of the HIV-1 reservoir [494].  
Collectively, the different animal models and human data point to the important role of 
macrophages, specifically in tissues, during HIV-1 pathogenesis. Indeed, macrophages are both 
infected and able to sustain HIV-1 replication in vivo, and evidence points to their contribution to the 
establishment of a viral reservoir in patients under cART, while the monocyte turnover in those 
patients is predictive of their progression with the disease.  
 
B. Viral replication cycle in macrophages and its consequences 
Gartner and colleagues were one of the first to report that macrophages could be infected 
with HIV-1 by using 5 different isolates of the virus. They found that in vitro, infected macrophages 
from the healthy donor blood, bone marrow, and cord blood produced large amounts of the virus, a 
production that persisted for at least 40 days, independent of cell proliferation. They also reported 
that some HIV-1 isolates were more prone to infect macrophages than T cells, and vice-versa, 
suggesting for the first time that specific HIV-1 variants could have preferential cell tropism, indicating 
that macrophages are the primary target of these strains of HIV-1 [495]. Since this report, it has been 
shown that the HIV-1 replication cycle in macrophages differs from that in CD4+ T cells in different 
phases. In this section, I will describe the HIV-1 replication cycle in macrophages and point out the 
differences observed in the CD4+ T cell viral cycle. 
 
a. Entry 
In addition to entry through the interaction between gp120 and the main HIV-1 receptor CD4, 
the most efficient mode, viral entry into macrophages can happen through other mechanisms, 
including viral particle macropinocytosis, resulting in the degradation of the majority of virions [496], 
and endocytosis [497]. Upon binding to CD4, gp120 undergoes a conformational change that liberates 
gp41, allowing it to interact with either CCR5 or CXCR4. These interactions lead to the fusion of the cell 
and viral membranes, resulting in the entry of the virus into the target macrophage [498]. It is widely 
accepted that macrophages are mainly infected with R5-tropic viruses, since CCR5 is highly expressed 
by myeloid cells, and that those are responsible for horizontal transmission of the virus. Recently, 
infected individuals predominantly harboring R5 isolates [499] and individuals with the '32 mutation 
in the CCR5 gene (see the Berlin patient in chapter II section II.A.a.iii) have been found to be resistant 
to HIV-1 infection [500]. As opposed to CCR5-mediated viral entry, discrepancies have been reported 
in the literature concerning the use of CXCR4 as the co-receptor in myeloid cells. Despite CXCR4 being 
expressed at low levels both by monocytes and macrophages, it is unclear whether X4 viruses can 
productively infect macrophages. Most of studies evaluating the ability of X4 viruses to infect 
macrophages found a very low rate of infection, if any, and it was usually blocked at a post-entry level, 
concluding that macrophages are refractory to X4 strains [501], [502]. By the contrast, some other 
groups have reported efficient and productive infection of macrophages when using X4 primary 
isolates [503]ʹ[505]. These opposing results may be explained by the differences in experimental 
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conditions, such as macrophage isolation and culture, or assays used to determine HIV-1 replication. 
Moreover, CXCR4 conformation could also be involved in the differences of X4-infectivity in 
macrophages, reported by several groups. Indeed, CXCR4 is expressed as a monomer on monocytes 
and T cells, but it seems to form receptor multimers, of higher molecular weight in macrophages 
compared to T cells [506]. Additionally, co-immunoprecipitation assay showed that CD4, which 
associates with its co-receptor upon gp120 binding, precipitates only with the monomer form of 
CXCR4, providing an explanation as to why there is poor infectivity of X4 strains observed in 
macrophages [506].  
HIV-1 gp120 can also be recognized by alternate receptors present on the cell surface of DC 
and macrophages, which do not necessarily lead to their infection, but have a role in cell-to-cell 
infection. Among these receptors, CLR DC-SIGN and MRC1 bind the virus and efficiently transfer it to 
CD4+ T cells, as discussed in section III.D.a.i. This binding is important, since it has been shown that 60% 
of the initial association of HIV-1 with macrophages is mediated by MRC1 [507].  
 
b. Nuclear import 
After viral and cellular membrane fusion, the HIV-1 capsid is released into the cell cytoplasm. 
At this stage, the viral RNA is reverse transcribed into double stranded DNA by the viral reverse 
transcriptase. During transcription, LTR sequences are generated at both extremities of the viral DNA, 
necessary for viral genome integration and regulation of its expression [508]. This process of viral DNA 
synthesis happens in the so-called reverse transcription complexes (RTC) and as opposed to taking a 
few hours in T cells, it takes about 36 to 48h in macrophages, for unknown reasons [509]. A hypothesis 
that explains this difference is the fact that T cells are actively dividing cells, while macrophages are 
quiescent cells and therefore, the machinery for genome replication is not accessible in the same way 
in both cell types.  
In macrophages, viral DNA and proteins necessary for integration (both from the virus and the 
host) are part of a nucleoprotein complex called the pre-integration complex (PIC). This complex must 
past through the nuclear pores in order to deliver the viral DNA to the host nucleus [510], and this 
occurs through an active, energy-dependent, mechanism [511]. In macrophages, this process can be 
blocked, notably by restriction factors such as MX2 as previously discussed (see chapter II part 
II.C.c.iii.), but also by their activation status. For example, LPS-stimulated macrophages inhibit HIV-1 
nuclear import due to the activation of p38 kinase, which can be reversed upon p38 signaling blockage 
[512]. PIC importation to the nucleus is mediated, notably by the virus central DNA flap, which is a 
stretch of triple-stranded DNA formed due to the presence of two initiation sites for the positive DNA 
strand in the virus. These two sites overlap during the positive strand synthesis and enhance nuclear 
import of the PIC [513]. Viral proteins such as integrase, matrix proteins, and Vpr also promote PIC 
import into the nucleus due to nuclear localization signals for importin-D/E [514], [515] and by 
counteracting restriction factors for Vpr. After successful import of the PIC into the nucleus, the viral 
DNA is integrated in the transcriptionally active region of the genome (i.e. euchromatin). 
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Figure 24: Virus-containing compartments are not late endosomes (from [516]). 
Monocyte from healthy donor where differentiated into macrophages for 7 days, and then infected with HIV-
1BAL. 10 days post-infection, infected cells were fixed and prepared for electron microscopy analysis in order to 
visualize the virus-containing compartments (VCC).  
A | Large cell-surface invaginations are directly connected to the extra-cellular milieu (as shown by the RR 
staining in black: RR is a membrane permeant dye that is not internalized in intracellular compartment) and 
contains numerous RR-stained virions. The inset shows a multivesicular BSA-gold-filled endosome inside the 
same cell. Scale bar: 2 µm. 
B | RR-stained vacuole-like structures containing viral particles. The arrowheads indicate gold-filled endosomes 
that are not RR-stained and significantly smaller than the virus-filled structures. Scale bar: 500 nm. 
 
  
106 
 
c. Transcription 
Following integration, the HIV-1 genome needs to be transcribed; an event differentially 
regulated in macrophages and T cells. In T cells, early transcription of HIV-1 mainly depends on 
transcription factors such as GATA-3, ETS-1, LEF-1 and NFATc [517], [518]. However, in macrophages, 
HIV-1 transcription depends on the isoforms of the transcription factor C/EBPE, which are generated 
by alternative translational initiation. When present under the small form (16-23 kDa), which is the 
dominant isoform and is IFN-I inducible (e.g. induced by Mtb infection in an IFNE-dependent manner 
[519]), C/EBPE inhibits HIV-1 replication [520]. By contrast, the larger isoform (30-37 kDa) is the 
activating form required for HIV-1 replication in macrophages [521]. This transcription factor controls 
the early transcription of the HIV-1 genome, and results in the production of the viral proteins Tat, Rev, 
and Nef. The late transcription phase is controlled by the viral protein Tat, which enhances viral RNA 
elongation [522]. Once the viral genome is expressed under the form of messenger RNA (mRNA), both 
viral RNA and mRNA encoding viral proteins are exported out of the nucleus. Consequently, mRNA is 
translated into proteins and the viral assembly to form new viral particles starts within the cell 
cytoplasm.  
 
d. Assembly and release 
New virions are generated after the assembly and budding of viral particles from the infected 
cell. This process is regulated by the gag polyprotein. In T cells, this process occurs close to the plasma 
membrane [523]. In macrophages, the virus assembles and buds from the intracellular compartments, 
late endosomes/multivesicular bodies [524]. Indeed, Welsch and colleagues found 45% of assembling 
virions on tubular-vesicular endosomal membranes rather than on endosomes themselves. 
Additionally, 10% of the particles were localized in multivesicular bodies with very few at the plasma 
membrane. In fact, it has long been known that HIV-1 particles accumulate in intracellular vacuoles in 
macrophages [525]. At the beginning of the millennium, Raposo and colleagues identified these 
compartments as the ͞MHC-II late endocytic compartments͟ [309]. Moreover, these compartments 
were shown to fail to acidify due to a lack of recruitment of the v-ATPase, thus providing the virus with 
an environment where it can survive for long periods of time [526]. Further studies of these HIV-1 
containing compartments, later termed as VCC, showed that they were characterized by the 
expression of multivesicular bodies proteins such as tetraspanin CD9, CD81, CD53, CD63 and CD82 
[527]. However, the study conducted by Welsch and colleagues revolutionized the identity of the VCC 
when they found that new viral particles budded at the plasma membrane of macrophages. Indeed, 
using ultrastructural approaches, they found that budding virions were mostly localized to the plasma 
membrane (see figure 24), while secreted virions displayed mainly plasma-membrane-derived proteins 
[516]. Since then, VCC have been well characterized (for review see [528], [529]). VCC are unlikely to 
be specific to HIV-1 infection since similar structures do exist in uninfected macrophages [516], 
however, they are enlarged in HIV-1 infection [530]. 3D-studies of their structure have shown that not 
all VCC are homologous and form a complex tubulovesicular membranous web that extends into the  
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Figure 25: Virus-containing compartments ultrastructural reconstitution (from [528]) . 
AʹH | Digital slices (from electron tomography) through a region of a HIV-1-infected macrophage depicting the 
morphological complexity and variability of the virus-containing compartments (VCC). The arrows point to 
membranous protrusions that were initially thought to be a separated form of VCC, but were later shown to be 
part of the overall three-dimensional VCC structure.  
I | Three-dimensional reconstruction of a VCC containing a virus particle (red). Scale bars, 200 nm. 
Extracted from [528].  
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macrophages (see figure 25 from [525]). They do not derive from endosomal origin as shown by BSA-
gold labelled endosomes in macrophages which resulted in low numbers of gold particles in VCC, and 
are positive for the plasma membrane marker CD44, suggesting that they originate from the cell 
surface [516]. In infected macrophages, VCC represent the main site of HIV-1 assembly and budding 
[527] although membrane assembly and budding are not excluded [516], [531], and could serve to 
rapid release of virions for cell free infection of surrounding cells, as opposed to VCC that promote 
long-term storage of the virus. These structures are proposed to participate in the reservoir function 
of macrophages and are highly dynamic. Indeed, time-course experiments demonstrated that VCC 
migrate into the infected macrophage towards the contact zone with T cells, and result in the infection 
of T cell [532]. In addition, other groups have observed HIV-1 Gag vesicles trafficking through inter-
macrophages cytoplasmic bridges [533], [534], further indicating that VCC are dynamic structures 
enabling HIV-1 trafficking throughout the macrophage and can be used to facilitate the infection of 
neighboring cells. This trafficking of HIV-1 containing VCC is mediated by the kinesin KIF3A28, a 
molecular motor that propels cargos along microtubules, and in this case VCC are driven to the plasma 
membrane for viral release. Indeed, upon silencing of KIF3A, HIV-1 particle release was reduced 
whereas VCC volume increased, showing that this kinesin is responsible for the movements of VCC 
within the infected cell [535].  
Tetherin is one of the restriction factors that inhibits HIV-1 particle release from the infected 
cell (see chapter II section II.C.c.iii) by anchoring the virus onto the plasma membrane. In infected 
macrophages, tetherin is not only present at the cell surface but is also in VCC. In fact, it is an essential 
element needed for VCC formation, since its knock-down by siRNA decreases VCC volume and size, 
accompanied by a redistribution of VCC throughout the cell [451]. Furthermore, in HIV-1 infected cells, 
tetherin inhibition leads to an increase of both viral release and cell-to-cell transmission efficiency. 
Therefore, tetherin retains HIV-1 virions in the VCC while maintaining the compartment structure. 
Strikingly, HIV-1 infection induces tetherin expression through the action of Nef, most likely because it 
provides the virus with a long-term storage compartment [451]. In addition to tetherin, another 
molecule, the Siglec-1 lectin receptor (described in section III.D.a.ii.), is able to induce VCC formation, 
independently of macrophage infection. Hammonds and colleagues found that the binding of HIV-1 
and virus like particles (VLPs) was directed into pre-existing VCC in infected macrophages, a process 
that proved to be necessary for subsequent particle transfer and infection of autologous T cells. 
Depletion of Siglec-1 prevented VLPs and virus uptake, and subsequently resulted in a decreased VCC 
volume [536]. 
As main storage centers of HIV-1 particles in infected macrophages, VCC participate in the 
establishment of the viral reservoir that imposes life-long treatment of HIV-1 infected individuals. VCC 
protect the virus against neutralizing antibodies and anti-viral drugs [537], [538], while also conferring 
a long-term storage compartments, allowing the virus to survive within its host for long periods of 
time. Despite several clues, the mechanisms behind VCC formation are still unclear and need further 
investigation. Identifying these mechanisms is key to developing directed therapies to ensure the 
elimination of the viral reservoir. 
                                                          
28 KIF3A: kinesin-like protein is one subunit of the heterotrimeric motor protein, kinesin-2, that transports protein 
complexes, nucleic acids and organelles towards the "plus" ends of microtubule tracks within cells. 
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e. Consequences on macrophage functions 
HIV-1 infection of macrophages has long been described in infected individuals, and results in 
the dysregulation of their main functions, including antigen presentation, intracellular pathogen killing, 
cytokine production, and phagocytosis (reviewed in [539]).  
Upon infection with HIV-1, macrophages produce a wide range of pro-inflammatory cytokines 
and chemokines, such as TNFD, IL-1E, IL-6, MIP1D, MIP1E and CCL5 (RANTES) [540], [541]. These 
cytokines participate in both the pathogenesis and the chronic activation of the immune system, while 
also influencing the response of surrounding cells to the infection. Indeed, cytokine release in the 
extracellular milieu causes the polarization of macrophages towards more or less permissive 
phenotypes to HIV-1 infection (for review see [187], [542]). Cassol and colleagues found that the 
͞classical Mϭ͟ polariǌaƚion of macrophages (see preamble II.B.) are refractory to HIV-1 infection due 
to a decreased expression of CD4 and an increased inhibition of the viral cycle at the early pre-
integration step [543]. By contrast͕ ͞ MϮa anti-inflammatory macrophages͟ inhibited the HIV-1 cycle at 
a post-integration level, and for a longer time than M1. All effects observed in the differentially 
polarized macrophages were reversed 7 days after the removal of the polarization stimuli, suggesting 
that macrophage polarization could be a mechanism that allows HIV-1 to switch between an active 
and latent status [543]. In addition to modulating macrophage sensitivity to HIV-1 infection, cytokine 
production also directly impacts infected cells. For example, IL-1E and IL-6, as well as IL-6 and TNFD 
were shown to act in synergy to stimulate viral replication [544], [545]. In addition, several of the 
above-mentioned cytokines participate in the inhibition of CD4 and CCR5 expression at the cell surface, 
together with the viral protein Nef, a beneficial mechanism for HIV-1 replication [546]. During the 
chronic stage of HIV-1 infection, IFN-I secretion leads to the production of IL-10, an anti-inflammatory 
cytokine that inhibits IL-6 and TNFD production in infected macrophages [547]. However, despite an 
historical anti-viral role of IL-10 [548], [549], this cytokine has been shown to promote HIV-1 infection 
and replication in M(IL-10) macrophages [550]ʹ[553].  
In addition to the modification of the cytokine production, HIV-1 infection modulates 
macrophage phagocytosis. The latter is mediated by several receptors, including complement receptor 
and receptors for the Fc portion of immunoglobulins (FcR), both mediating phagocytosis of the 
opsonized pathogen. FcR-mediated phagocytosis in HIV-1 infected macrophages is altered by the 
inhibition of the phosphorylation of Src kinases and other proteins (including Hck, Syk and Paxillin) 
[554]. The group of Niedergang showed that receptor-mediated phagocytosis is inhibited in HIV-
infected macrophages in a Nef-dependent manner. In fact, Nef inhibited the recruitment of adaptor 
protein-1 (AP-129) to endosomes, thereby preventing optimal phagosome formation [555]. HIV-1 is also 
able to use phagocytosis to its advantage. Indeed, it was reported that phagocytosis of apoptotic cells 
by HIV-1 infected macrophages enhanced the virus replication in these cells, in a TGFE-dependent 
manner [556].  
An important function of macrophages as patrolling cells in the maintenance of tissue 
homeostasis, is their capacity to migrate. In our team, my PhD supervisor showed that HIV-1 infection 
of macrophages altered their migratory function. 2D and amoeboid 3D migration modes of 
                                                          
29 AP-1: proteins that mediate the formation of vesicles for intracellular trafficking and secretion. 
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macrophages were inhibited by HIV-1, while mesenchymal 3D migration mode, dependent on matrix 
degradation by matrix proteases, was enhanced in a Nef-dependent manner [318]. Nef expression was 
necessary and sufficient to induce these effects on macrophages migration, as proven by a Nef-
transgenic mice model in which tissue infiltration of Nef-expressing macrophages was enhanced both 
at steady state and in tumor masses [318]. This mechanism could be a way for the virus to disseminate 
throughout the host. 
Nef can also intervene in macrophages fusion. In fact, my team has shown that the formation 
of multinucleated giant cells (MGC) are a hallmark of HIV-1 infection in macrophages. The viral protein 
Nef was sufficient to induce MGC in RAW264.7 macrophages and depended upon its interaction with 
the host protein p61-Hck isoform, as well as lysosomal proteins (e.g. vacuolar adenosine 
triphosphatase and proteases) [319]. Finally, I participated as a co-author to the study that shows that 
osteoclasts, bone macrophage-like cells specialized in bone degradation, are targets for HIV-1. 
Osteoclast infection leads to increased adhesion and osteolytic activities, through modulation of the 
sealing zone size, which is a particular organization pattern of proteins of the cytoskeleton (e.g. actin, 
vinculin, talin). These effects on bone degradation were found to be mediated by the interaction 
between Nef and Src protein [323]. 
HIV-1 infection leads to a modified activation of macrophages and consequently, alters their 
function. We saw here that HIV-1 induces the production of cytokines that favour its replication in the 
infected cells while polarizing surrounding cells to a permissive state for viral infection, and that the 
virus alters mainly the phagocytosis process either to prevent its degradation or enhance its 
replication. Finally, through the viral protein Nef, HIV-1 alters the macrophage cytoskeleton not only 
to control intracellular compartments, but also the migration of macrophages trough tissues.  
 
 
C. Macrophages in HIV-1 latency and communication with other cell types 
a. Induction of latency in macrophages 
To persist in the host, even under cART, HIV-1 is able to become undetectable by entering a 
state of viral latency, one of the several mechanisms utilized by the virus to survive in its host [557], 
[558]. This latency is defined by an infection during which infected cells do not produce infectious viral 
particles, however, this state can be reversed upon stimulation [559]. Usually, latency can be classified 
into two types: pre-integration latency and post-integration latency. Pre-integration latency is 
characterized by a poor reverse transcription efficiency and the inhibition of the viral DNA importation 
into the nucleus and is a common mechanism in vivo [560]. Indeed, in brain tissue of HIV-1 infected 
patients, unintegrated viral DNA quantities were at least 10 times higher than integrated DNA 
numbers, indicating an essential role for pre-integration latency in this organ [561]. On the contrary, 
post-integration latency occurs after viral DNA integration into the host genome, and is defined by the 
silencing of the HIV-1 genome expression [558], [562]. Several mechanisms have been described to 
explain the induction and maintenance of latency in target cells, including epigenetic gene silencing, 
which regulates the different regions of the genome that are expressed [558], as well as transcription 
gene silencing and post-transcriptional gene silencing [563]. Notably in macrophages, HIV-1 
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preferentially integrates into the transcriptionally active regions of the host chromatin, a process that 
can be regulated by epigenetic regulation [564]. Overall, restriction factors expressed by the target 
cells like MX2, SAMHD1, APOBEC3, and others, participate in the latency mechanism (see chapter 
II.C.c.iii).  
 Importantly, viral latency is thought to be a rare event. Indeed, an estimated one cell out of 
106ʹ107 cells is latently infected [565]. On top of that, in vivo study of HIV-1 latency in macrophages is 
quite difficult to perform due to the small population that can be isolated. To remedy this issue, Brown 
and colleagues developed an in vitro model of a long-term culture of human macrophages derived 
from blood monocytes and infected with HIV-1-GFP [566]. Interestingly, they found that latency can 
be established in these macrophages and can be reversed by a co-infection with herpes virus 8, 
supporting opportunistic infection as a mechanism of HIV-1 reactivation in macrophages [567].  
 
b. Role of macrophage the establishment of CD4+ T cells reservoir 
In infected macrophages, HIV-1 assembles, buds, and is stored in VCC (see chapter III.B.d) 
[568], [569]. These VCC provide a safe environment for the virus to survive since they are not accessible 
by antiretroviral drugs and neutralizing antibodies [570]. Therefore, VCC are a perfect niche for HIV-1 
to establish a stable latent infection in macrophages. Studies reported by Benaroch and colleagues 
indicate that HIV-1 utilizes pre-existing CD36 compartments for its assembly and budding, further 
arguing that VCC are a way for HIV-1 to establish a viral latent reservoir. Moreover, they found that 
CD36 is an important molecule in HIV-1 release since its blockage resulted in the inhibition of virus 
release from infected cells [571].  
Upon infection, macrophages secrete a pool of cytokines and chemokines, such as MIP-ϭɲ͕ 
MIP-ϭɴ͕ MCP-1 and CCL5, which attract CD4+ T target cells and create an ideal situation for viral 
dissemination and memory T cell reservoir establishment [572]. After being recruited, macrophages 
are able to transmit the virus to uninfected T cells, including CD4+ memory cells, mostly through the 
establishment of a virological synapse-like structure, and thereby extend the viral reservoir [573]ʹ
[575]. In addition, HIV-1 infected macrophages can induce anti-apoptotic resistance in CD4+ T cells they 
just infected while promoting the killing of bystander cells [576], [577], and therefore facilitate the 
establishment of a stable infection in these cells in a Nef/TNFD-dependent manner [578]. Through 
these mechanisms, macrophages allow the establishment of a long-lived T cell reservoir, which is 
mainly composed of CD4+ memory T cells. 
Altogether, latent infection of macrophages is part of a mechanism that allows HIV-1 to survive 
in the host, protected from immune system effectors and cART in specific cellular compartments. 
Furthermore, latently infected macrophages are able to recruit uninfected target T cells and transfer 
the virus to them, thereby extending the infection, and possibly the viral reservoir when specific 
memory CD4+ T cells are recruited to the site of infection.  
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c. Interplay with other cell-types: importance of exosomes 
As mentioned previously, HIV-1 infection of macrophages induces a change in their gene 
expression profile, together with the cytokines and chemokines produced. These changes also modify 
the interactions between macrophages and the adaptive immune cells, such as CD4+ and CD8+ T cells, 
usually resulting in the activation or death by apoptosis of these cells [579]. Clayton and colleagues 
evaluated the interaction between CD8+ T cells and HIV-1 infected macrophages, using autologous cells 
isolated from the blood of HIV-1+ patients. They found that the killing of macrophages by CD8+ CTL was 
impaired when compared to that of CD4+ T cells, resulting in inefficient suppression of HIV-1 in culture. 
In addition, impaired killing of macrophages, which requires caspase 3 and granzyme B, prolonged the 
contact time between the effector and target cells, as well as IFNJ production by CTL. This subsequently 
led to production of pro-inflammatory cytokines by macrophages that recruited both monocytes and 
T cells, contributing to viral persistence and establishment of the chronic inflammation associated with 
HIV-1 infection [580]. 
One important way for macrophages to communicate with other cell types, including DC and 
T cells, is through exosome release. In macrophages, specialized MHC-II+ compartments, derived from 
late endosomes or from multivesicular bodies, can traffic to the cell surface and fuse with the plasma 
membrane to be released eventually in the extracellular environment as exosomes [581]. By definition, 
exosomes are small extracellular vesicles (30 to 200 nm in diameter), which contain and traffic nucleic 
acids (RNA, microRNA, and DNA), proteins, and lipids from the donor cell. Most cell types are able to 
secrete these nanoparticles into the extracellular milieu, allowing them to carry messages to 
neighboring cells and to mediate adaptive immune responses against pathogens [581]ʹ[583]. In 
addition to host materials, exosomes that commonly express the tetraspanins CD9 and CD81 can 
contain viral proteins [579], [584]ʹ[587]. In HIV-1 pathogenesis, the role of exosomes is complex and 
controversial. Indeed, some studies reported that exosomes can block HIV-1 infection, notably by 
transferring to target cells some restriction factors like APOBEC3 [588]. Other studies have reported 
enhanced infection through HIV-1 entry receptor transfer by exosome release [589]. The exosome 
pathway was also thought as a Trojan horse by which the immature virus would not only escape 
lysosomal degradation, but also evade recognition by the host immune system (e.g. by not expressing 
Env at the surface [590]) and anti-viral drugs. In this model, immature HIV-1 particles, present at the 
cytoplasmic face of late endosomes or the membrane of multivesicular bodies, are internalized into 
intraluminal vesicles after membrane invagination and fission. These HIV-1-containing vesicles are 
then transported to the cell plasma membrane where they fuse and are finally released into the 
extracellular milieu [590], displaying membrane characteristics of exosome, rendering them invisible 
to the immune system and favouring new infection events [591]. 
Taken together, the studies performed on HIV-1 particle release through exosome pathway 
indicate a potential important role of these nanoparticles in the dissemination of the virus and the 
progression of the disease. As they hide the virus from the immune system as well as target drug 
therapies, while also mediating entry of the virus into target cells independently of the viral receptor, 
exosomes-like viruses represent an potentially efficient mechanism of infection, and could even lead 
to infection of cells that do not express the viral receptors. Consequently, this would cause an increase 
in the viral spread throughout the organism, even in organs that are normally protected by physical 
barriers.   
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D. HIV-1 cell-to-cell transfer: a master in disguise 
Most of the studies described above were performed in free-viral particle models of infection. 
However, cell-to-cell transfer is 100 to 1000 times more efficient than free-viral particle infection and 
may represent at least half of the new infections in vivo [323], [592]ʹ[594]. In the present section, I 
will discuss the different mechanisms of cell-to-cell transfer that have been described to date. 
 
a. Role of lectins in HIV-1 capture and trans-infection 
i. C-type lectins: recognition of the viral protein gp120 
Despite CD4, CCR5 and CXCR4 being the main receptors for HIV-1 entry into target cells, the 
virus also interacts with a wide range of other cell surface molecules, a capacity the virus acquired 
upon different cellular encounters and evolution of its flexible glycoprotein gp120. The CLR family is 
one of the groups of receptors able to interact with HIV-1 and are suspected to support efficient viral 
transfer to CD4+ T cells [595]. Well described CLR expressed by both DC and macrophages found to 
bind HIV-1 are, most notably, DC-SIGN, Langerin and MRC1 [596]. Their primary function is to bind 
carbohydrate domains present on both pathogens and host tissues. Upon binding to host sugar motifs, 
CLR promote cell-to-cell communication, particularly between T cells and antigen presenting cells. 
Alternatively, binding to pathogen sugar motifs can and usually leads to internalization, degradation 
and antigen loading onto MHC molecules for T cell activation [597]. However, certain pathogens like 
HIV-1 have hijacked these molecules for its own benefit. Here, I will focus on DC-SIGN and MRC1, which 
both bind to HIV-1 gp120 [598], [599].  
The role of DC-SIGN in HIV-1 binding has been extensively studied, particularly in DC. Indeed, 
DC-SIGN-expressing cells are particularly numerous at mucosal sites, in particular in the female endo- 
and ectocervix, both considered sites of HIV-1 sexual transmission [600], [601], as well as in the rectum, 
where they efficiently bind and transport the virus [602]. DC-SIGN+ maternal and fetal macrophages in 
the placenta were found to play an important role in materno-fetal transmission of the virus [603]. 
Altogether, the presence of DC-SIGN+ cells in anatomically relevant sites of HIV-1 infection suggest an 
important role for this lectin in the initial viral detection, capture, transport, and transfer to target 
cells. Moreover, several reports have implicated CLR polymorphism (in particular DC-SIGN) as 
increased risks of viral transmission, especially from mother to child, since CLR are expressed by 
placental cells [604]. In spite of the poor permissiveness of DC for HIV-1, interactions between DC-SIGN 
and gp120 have been shown to be involved in enhanced DC infection [605], [606]. In addition, DC-SIGN 
has been suggested to be a way out for neutralizing antibodies, whereby, DC-SIGN-expressing myeloid 
cells have been described for their capacity to bind and efficiently transfer either HIV-1 or SIV to T cells 
[607]ʹ[611], while protecting it from antibody neutralization [612]. This was shown to be mediated by 
a rapid internalization of intact viruses into low pH non-lysosomal compartments [613]. DC-SIGN is also 
highly expressed by macrophages, even more than DC, in the lymph nodes and blood, suggesting that 
macrophages could play an important role in DC-SIGN-mediated HIV-1 transfer in vivo. Of note, both 
human DC and macrophages display DC-SIGN-independent HIV-1 transmission, possibly involving 
other alternative receptors, like MRC1 [614], [615]. 
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Like DC-SIGN, MRC1 is expressed by DC, macrophages, spermatozoa, and epithelial cells, 
particularly at mucosal sites, including the vagina and in semen, and has the potential to capture the 
virus during the first step of infection [616]. Upon binding to MRC1, HIV-1 has two possible fates: it will 
either be efficiently transferred to T cells through a virological synapse-like structure [507], or it will be 
degraded for antigen presentation [617]. Using mass spectrometry, Cunningham and colleagues 
reported that MRC1 can form homodimers in primary human macrophages and that it is the dimer 
that recognizes and binds HIV-1 gp120 [618]. Interestingly, Sukegawa and colleagues reported that 
MRC1 can also display anti-viral protection in ways similar to tetherin. Indeed, the authors found that 
infected macrophages produced full infectious viral particles, but they accumulated in clusters at the 
cell surface in the presence of MRC1. HIV-1 could counteract this action by transcriptionally silencing 
MRC1 mRNA [619]. Moreover, Vigerust and colleagues showed that MRC1 surface expression was 
reduced by 50% in the presence of the viral protein Nef [620], corroborating previous work that had 
shown reduced expression and functioning of MRC1 in alveolar macrophages of HIV-1 infected 
patients. 
Altogether, the different studies elucidating the implication of CLR in HIV-1 pathology seem to 
reveal a role for these receptors in the capture and transmission of the virus to uninfected target cells. 
However, their role in vivo and the modulation between CLR-mediated host protection or diversion 
remain to be clearly established. 
 
ii. Sialic acid-binding immunoglobulin-type lectin: Siglec-1 
Siglec-1 (also known as sialoadhesin or CD169) is a transmembrane lectin receptor whose 
expression is IFN-I-dependent and restricted to myeloid cells. It belongs to the Siglec family of sialic 
acid-binding immunoglobulin-like lectins that represents a subset of immunoglobulin (Ig) superfamily 
molecules. Siglecs exploit the huge diversity of glycans structure to fulfill their functions, which is 
mediated by their amino-terminal V-set immunoglobulin domain that binds to sialic acids present at 
the surface of most mammalian cells [822]. Generally, Siglecs molecules display a low affinity for sialic 
acid N-acetylneuraminic acids bound in D2-3 and D2-6 linkage to galactose, and different Siglecs have 
overlapping specificity for such sialosides. However, each Siglec presents a given specificity profile to 
different sialic acid structures. In the case of Siglec-1, the preferred ligands are 5-N acetylated-
neuraminic acids linked in D2-3 to preceding carbohydrates [823]. Considering that the local 
concentrations of sialic acid are high on immune cell surface, Siglecs interactions with their preferred 
ligands can be masked by low affinity liaisons to conceal sialic acid in cis interactions, which usually 
dominate over trans interaction [822]. Yet, high-affinity ligand for a given Siglec can outcompete these 
interactions, resulting in a dynamic equilibrium of cis and trans interactions where the receptor and its 
ligand can be redistributed and concentrated at the site of interaction [824]. Siglec-1 might be the 
exception to this observation due to its specific structure. Indeed, its large extracellular domain, 
composed of 17 Ig-like domains, renders it taller than the cell glycocallyx (layer of glycolipids and 
proteins expressed at the cell membrane), and allows it to bind to its ligand both in cis and trans [621], 
[622]. In addition to its unique extracellular domain length, Siglec-1 displays a short cytoplasmic tail, 
poorly conserved compared to other Siglecs in most species, except the pig. Moreover, the C-terminal 
domain of the lectin has no identified signaling motif or phosphorylation site, suggesting that the 
primarily function of the molecule could  
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Figure 26: Siglec-1 captures, internalizes particles in virus-containing compartments, and transfers 
HIV-1 from myeloid cell to T cells (adapted from [630]). 
A | Siglec-1, composed of 17 Ig-like domains as an extra-cellular part, a neutral intramembrane domain and a 
short cytoplasmic tail laking any signalling motive or phosphorylation site, binds to GM3 gangliosides present at 
the viral envelope. Tetherin retains budding virion to the cell membrane. Thethered virions, just like cell-free 
viron, can bind to Siglec-1 molecules. 
B | Following capture by Siglec-1, HIV-1 virions are internalized and co-transported with Siglec-1 to the VCC. They 
will be retained and protected in this compartment. 
C | When the HIV-1-containing cell meets another target cell, the viral particles contained in the VCC and bound 
to Siglec-1 are transported back to the cell surface, where they become accessible to uninfected cell. Siglec-1-
bound viruses can be concentrated to the contact zone, therefore Siglec-1 enhances viral cell-to-cell transfer.  
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be more related to cell-cell and cell-extracellular matrix interactions, rather than in cell signaling, 
however, it could still have a signaling function through recruitment of co-receptors [825]. 
Originally, Siglec-1 was reported in mice as a marker of a subpopulation of macrophages able 
to bind to red blood cells found in the lymph node, liver, and spleen [623]. In primates, Siglec-1+ 
macrophages were found between the red pulp and the marginal zone of the spleen, close to the blood 
circulation [823]. To date, the function of Siglec-1+ macrophages remains under investigation, but their 
role in regulating the immune system and maintenance of immune tolerance has been reported [624], 
[625]. For example, some evidence indicates that the close proximity of splenic Siglec-1+ macrophages 
with the circulation is necessary for Siglec-1 physiological functions. This specific location allows the 
capture of circulating microbial antigens, along with antigen loaded-exosomes[627] in the blood 
stream and favors the activation of the appropriate immune response through antigen presentation. 
In fact, Siglec-1+ macrophages appeared to be able to cross-present MHC-I and MHC-II loaded with 
antigenic peptides to CD4+ and CD8+ T cells, a function normally restricted to DC, and allowing for the 
establishment of adaptive immune responses [823]. The development of the Siglec-1-/- mouse model 
has proved to be extremely useful to study Siglec-1 functions in vivo. Indeed, Siglec-1-/- mice exhibit 
decreased levels of soluble IgM, along with B cells and CD8+ T cells subtle alterations, supporting the 
importance of Siglec-1 in priming adaptive immune responses, and likely in vaccine responses [826]. 
Yet, in autoimmune disease models of experimental allergic encephalitis, or in uveoretinis, mice 
knocked-out for Siglec-1 had a reduced disease, characterized by a higher number of regulatory T cells 
in the CNS or the eye, along with a reduced proliferation of CD4+ inflammatory T cells [827], [828], 
providing the first evidence that Siglec-1 directly modulates T cell behavior in vivo. It is also likely that 
the function of Siglec-1+ cells is dependent upon their anatomic localization [626]. In addition to 
antigen presentation and induction of the appropriate inflammatory responses, it is thought that 
Siglec-1 may be a phagocytic receptor to clear sialylated pathogens. Moreover, the phagocytic function 
of Siglec-1+ macrophages could be responsible for the induction of tolerance through phagocytosis of 
debris in the marginal zone [826].  
Several studies have reported the ability of Siglec-1 to bind pathogens, and more particularly viruses 
such as vaccina, ebola [628] and vesicular stomatitis virus [626]. In fact, above 20 pathogens are known 
to have evolved to synthesize and/or capture sialic acids from their host and to incorporate them into 
their own glycoconjugates. This evolution appears to be key in microbial survival in their mammalian 
host, as they could be seen as molecular mimics of the host cell surface, preventing pathogen clearance 
mediated by immune responses [829]. For example, Sewald and colleagues pursued an in vivo study in 
mice to evaluate the ability of Siglec-1 to capture retroviruses and transfer them to their target cells. 
They were able to demonstrate that murine leukemia virus is captured by sinus Siglec-1+ macrophages 
in secondary lymphoid organs, and transferred to B-1 cells, thus enabling viral spread. Using BLT-
humanized mice, they also found that HIV-1 was captured in the spleen, indicating a potential role of 
Siglec-1 in HIV-1 pathology [629]. In fact, Siglec-1 is upregulated in monocytes of HIV-1 infected 
patients, but its expression is reversed to basal level after successful cART [631]. In vitro experiments 
have shown that HIV-1 binds to Siglec-1 expressing macrophages with high affinity, resulting in the 
majority of macrophages being infected by the virus [632]. In mature DC, enhanced Siglec-1 expression 
allows HIV-1 particle capture, independently of the viral envelope, and has been shown to be 
responsible for trans-infection of CD4+ T cells [633]. Indeed, Siglec-1 binds the ganglioside, GM3, 
expressed in abundance on HIV-1 particles, and acquired when budding from the infected cell. Akiyama 
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and colleagues found that upon capture Siglec-1-bound HIV-1 particles are stored and protected from 
degradation in Siglec-1-induced VCC. These virions were then able to trans-infect recipient CD4+ T cells 
(Figure 26) [634]. In an elegant study, Pino and colleagues compared the ability of myeloid cells to 
capture and transfer HIV-1. They found that both DC and macrophages expressed Siglec-1 at higher 
levels than monocytes, and they were able to bind similarly to HIV-1 particles. Similar to Akiyama and 
colleagues, they observed that Siglec-1-bound HIV-1 particles were internalized in intracellular 
compartments, and were able to trans-infect CD4+ T cells. Interestingly, the capture, internalization, 
and transfer of HIV-1 was abrogated in all myeloid populations upon Siglec-1 inhibition [635]. In 
isolated monocytes from HIV-1 infected patients, which expressed high levels of Siglec-1, HIV-1 was 
captured and efficiently transferred to CD4+ T cells. However, these events were reversed after 
successful cART [635], further supporting the importance of Siglec-1 in HIV-1 capture and cell-to-cell 
transfer. 
 
b. The virological synapse 
To date, formation of the so-called ͞ǀirological sǇnapse͟ is ƚhe cell-to-cell transfer mechanism 
most widely described. This structure was first defined between T cells, by the group of Quentin 
SaƚƚenƚaƵ͕ as a ͞cytoskeleton-dependent, stable adhesive junction, across which virus is transmitted 
bǇ direcƚed ƚransfer͟ [636]. It is initiated upon established contact between a HIV-1 infected and non-
infected T cell, a process dependent on the viral tropism, or in other words, dependent on the viral 
envelope. This interaction induces the recruitment of the HIV-1 envelope and core proteins on the 
infected cell, and CD4 and co-receptors, CXCR4 and CCR5, on the uninfected cell at the site of contact 
[637], [638]. The structure is then stabilized by the enrichment of adhesion molecules at the contact 
zone, including LFA-1, ICAM-1, and ICAM-3 [639], and requires intact lipid-rafts to be secured. Indeed, 
cholesterol depletion in the infected cell abolishes the viral protein clusters and prevents the assembly 
of the virological synapse and HIV-1 transfer [640]. Along with both host and viral protein 
clusterization, remodeling of the actin cytoskeleton, and reorganization of the microtubule organizing 
center are required in both donor and recipient cells to allow the viral transfer [641]. This allows the 
polarization of the site of virus assembly and budding at the contact zone, resulting in the rapid, highly 
efficient, and consequent infection of the target cell [642], [643].   
Some studies have reported that infected DC and macrophages are able to infect T cells 
through a virological synapse-like structure [644], [645]. Yet, the mechanisms involved in the formation 
of these virological synapses are not completely characterized. Macrophage/T cell virological synapses 
present similarities with T/T cell synapses, for example, as they involve the rapid recruitment of 
macrophage VCC to the contact site [532], the enrichment of CD4, CCR5, Gag, and Env, and are 
stabilized by LFA-1 and ICAM-1 [573], [646]. However, it appears that viral gp120 is not necessary to 
form the virological synapse between macrophages and T cells, and that the multiplicity of HIV-1 
transferred from macrophages is much higher than in T/T cell synapses. This structure also protects 
HIV-1 from reverse transcriptase inhibitors and neutralizing antibodies [532], [646]. In light of the 
differences observed between the varying T cells virological synapses, the possibility that macrophages 
can be infected through virological synapse transfer from infected T cells, DC or even macrophages is 
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not to be excluded. However, to the best of our knowledge, such structures have not yet been 
described. 
 
c. Phagocytosis of infected T-cells by macrophages 
One of the main functions of macrophages is to maintain tissue homeostasis, notably through 
recognition and engulfment of apoptotic cells via a process called efferocytosis [647]. In infection 
settings, this function is essential in the elimination of pathogen-infected cells, although certain 
pathogens are able to escape this killing and succeed to infect macrophages [648]. As discussed earlier, 
HIV-1 infection of CD4+ T cells induces high degrees of apoptotic cell death as well as that of bystander 
T cells. In vitro, only one study so far has evaluated the possibility that macrophages can become 
infected by HIV-1 after the engulfment of apoptotic infected-T cells. The team of Sattentau reported 
that macrophages selectively capture and phagocytose infected CD4+ T cells, regardless of their 
activation status. This process was found to be independent from HIV-1 entry receptors and co-
receptors, and therefore distinct from virological synapse formation. However, this process was 
strongly dependent on the modulation of the actin cytoskeleton, concordant with the phagocytic 
process. Subsequently, macrophages were productively infected, especially when CCR5-tropic strains 
were used [649]. It is likely that this mechanism of macrophage infection exists in vivo. Indeed, in Asian 
Macaques and African Green Monkeys, both viral DNA and TCRJ/G DNA (specific material of T cells) 
were detected in macrophages isolated from tissues where CD4+ T cells were not highly depleted, 
suggesting that phagocytosis of SIV-infected CD4+ T cells had occurred [650]. Histological observations 
reported by Orenstein and colleagues indicates the presence of p24+ cellular debris within the 
cytoplasm of paracortical macrophages in the lymphoid organs of HIV-1 infected patients, which 
results in a positive hybridization of HIV-1 RNA in macrophages, suggesting that these cells 
phagocytose viral particles from infected cells, and possibly become infected themselves [651]. Finally, 
in HIV-1 infected patients under cART for three years, DiNapoli and colleagues found viral DNA and 
TCR31 DNA in alveolar macrophages, further supporting the existence of this infection mechanism in 
the lung in vivo [652]. 
 
d. HIV-1-induced cell fusion mechanisms  
Early after the discovery of HIV-1, MGC were found in several organs of HIV-1 infected 
individuals, most notably in the brain, lymph nodes, spleen and lungs [653]ʹ[655], adding HIV-1 into 
the fusogenic viruses category. In 1986, Gartner and colleagues showed for the first time that HIV-1 
infection of macrophages led to cell-to-cell fusion. Using infected monocyte-derived macrophages in 
vitro, from the healthy donor blood, bone marrow or cord blood, they showed that these cells 
produced large amounts of virus that persisted for at least 40 days, and in these cultures, MGC were 
frequently observed [495]. This observation led to the hypothesis that cell-cell fusion between infected 
                                                          
30 TCRJ/GT cell receptor containing the J and G chains instead of D and E chains and expressed by a subtype of 
T cells.  
31 TCR: T cell receptor recognizes fragments of antigen as peptides bound to major histocompatibility complex 
(MHC) molecules. 
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cells and non-infected cells could be an indirect mechanism for HIV-1 to infect new target cells. Early 
studies performed with T cells reported the formation of T cell giant syncytia, 5ʹ100 times bigger than 
individual cells [656]. The fusion process was mediated by actin cytoskeleton rearrangements and 
depended upon the interaction between the viral envelope glycoproteins, expressed at the cell surface 
of infected cells, and the CD4 receptor, expressed by target cells [657]ʹ[659]. Of note, it has been 
observed that HIV-1 infected individuals have small T-cell syncytia in their lymph node, containing no 
more than five nuclei [651]. More recent studies performed with HIV-1-infected humanized mouse 
models also reported the presence of motile infected syncytia in lymph nodes, smaller than those 
observed in vitro [660]. While T-cell sincytia are very rare in vivo, the fusion with infected macrophages 
is considered dominant [661]. Yet, the majority of infected MGC found in brains of patient, for 
example, may be bigger than the reported in vivo T cell syncytia, and display phagocytic properties, 
arguing that they derive from myeloid origins, particularly from macrophages. The cellular and 
molecular mechanisms related to their formation remain, to date, poorly understood. In my team, we 
aimed to elucidate the mechanisms that triggered macrophage-to-macrophage fusion upon HIV-1 
infection. My PhD adviser demonstrated that the viral protein Nef, by modulating p61Hck, is 
responsible for macrophages fusion, due to the depletion of Nef from the viral genome or the blocking 
p61Hck reducing the number of MGC in culture [319]. Since CD4+ T cells are the main cell target for 
HIV-1, an interesting question is whether macrophages could become infected through heterotypic 
fusion between infected T cells and non-infected macrophages. This was assessed by the laboratory of 
S. Bénichou. who recently reported that formation of HIV-1 infected MGC occur in a 2-step fusion 
process, leading to productive cell-to-cell viral transfer. The initial contact between the infected T cells 
and the recipient macrophages was found to be necessary for efficient viral transfer and cell fusion. It 
was also dependent on the viral envelope glycoproteins. Subsequently, the heterocaryon acquired the 
ability to fuse with surrounding uninfected macrophages, leading to MGC formation in a short 
timeframe [592]͘ DƵring mǇ Masƚers͛ degree͕ I ǁas able ƚo shoǁ ƚhaƚ ƚhe same mechanism occƵrs 
between infected CD4+ T cells and osteoclasts [323]. In our previous study, we also demonstrated that 
osteoclast infection was much more rapid and efficient through cell-to-cell transfer, while infection 
increased their size and nuclei numbers while also exacerbating their bone-degradation function in a 
Nef-dependent manner (Annex 3, [323]). 
Altogether, these studies suggest that cell-to-cell transfer of HIV-1 can occur via cell-cell fusion, 
an efficient infection mechanism allowing the formation of long-lived infected macrophage-derived 
MGC that sustain viral replication and disseminate the infection in several organs of HIV-1 infected 
individuals. 
 
e. Tunneling nanotubes: bridges for HIV-1 spread 
Tunneling nanotubes (TNT) are a novel type of cell-to-cell communication machinery, allowing 
disƚanƚ cells ƚo eǆchange informaƚion on ƚheir enǀironmenƚ͛s perƚƵrbaƚions͘ TheǇ ǁere firsƚ discoǀered 
in 2004 by Rustom and colleagues, who identified these transient actin-rich structures in rat kidney 
cells and human cell lines [662]. Since then, numerous cells have been reported to form TNT in cultures 
in vitro, including neuronal cells, astrocytes, and immune cells [663]. TNT are defined as F-actin rich 
structures connecting at least two cells without touching the substrate. At steady state, about 10% of 
cultured cells form TNT [664]. Two types of TNT have been reported in macrophages: thin TNT (or 
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short, with a diameter of less than 0.7 µm) which contain only F-actin, and thick (or long TNT with a 
diameter above 0.7 µm) that contain both F-actin and microtubules [534], [665]. Their principal 
function is to transfer cellular materials and signals (e.g. lysosomes, big proteins, and mitochondria by 
thick TNT; calcium flux and soluble factors including cytokines by thin TNT) [662]. In the TNT scientific 
community, it is commonly thought that these structures can, and are hijacked by pathogens, 
specifically HIV-1, which I will briefly introduce since it was the subject of a review I co-wrote and is 
presented hereafter [666]. 
Eugenin and colleagues were the first to report that HIV-1 infection of macrophages led to 
increased number of TNT without altering their length. They reported that short TNT likely transported 
single HIV-1 particles, while long TNT carried larger HIV-1 containing vesicles (maybe exosomes or VCC) 
either inside or outside the structure; a theme that could not be precisely determined [534].  In a 
recent study, connexin 43, a component of the gap junction, accumulated in intracellular 
compartments that localized both at the base and tip of the TNT formed from the infected cell. HIV-1-
infected macrophages formed TNT that allowed gap junction communication between distant cells. 
Blocking these gap junctions resulted in inhibition of TNT formation and decreased HIV-1 spread in 
culture [667], supporting the important roles of both TNT and the gap junctions in HIV-1 cell-to-cell 
transfer. HIV-1 spread was also reported to happen between T cells [668]. Hashimoto and colleagues 
identified the viral protein Nef as a critical inducer of HIV-1-mediated TNT, through its interaction with 
the ubiquitous M-sec32 protein, an important molecular factor in TNT biology [669]. M-sec 
complexation with protein members of the exocyst complex have been shown to be part of the TNT 
formation mechanism [670]. Using tandem mass spectrometry performed in the Jurkat cell line, Nef 
was found to interact with five components of the exocyst complex. Depletion of one of these 
interactions led to a reduction in the number of TNT between the jurkat cells [671]. Finally, a recent 
study reported the ability of Nef to induce TNT formation in infected macrophages in a myosin 10-
dependent manner. It was described that Nef alone was transported from macrophages to T cells via 
TNT, a process that resulted in a decrease of CD4 expression in recipient T cells [672]. 
Taken together, these studies indicate that HIV-1, mainly though Nef-dependent interactions 
with host proteins,  hijacks physiological structures to ensure its spread in the host, as well as a way to 
evade detection by the immune system and drug toxicity. Considering TNT as a potential target to 
inhibit viruses intercellular transport could be an interesting strategy to develop the next generation 
of HIV-1 treatment. 
 
 
                                                          
32 M-sec: 73 kDa cytosolic protein also known as TNFD-induced protein 2 that displays a central role in the 
formation of cell protrusions. 
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Tunneling nanotubes (TNT) are dynamic connections between cells, which represent 
a novel route for cell-to-cell communication. A growing body of evidence points TNT 
towards a role for intercellular exchanges of signals, molecules, organelles, and patho-
gens, involving them in a diverse array of functions. TNT form among several cell types, 
including neuronal cells, epithelial cells, and almost all immune cells. In myeloid cells 
(e.g., macrophages, dendritic cells, and osteoclasts), intercellular communication via 
TNT contributes to their differentiation and immune functions. Importantly, TNT enable 
myeloid cells to communicate with a targeted neighboring or distant cell, as well as 
with other cell types, therefore creating a complex variety of cellular exchanges. TNT 
also contribute to pathogen spread as they serve as “corridors” from a cell to another. 
Herein, we addressed the complexity of the de!nition and in vitro characterization of 
TNT in innate immune cells, the different processes involved in their formation, and their 
relevance in vivo. We also assess our current understanding of how TNT participate in 
immune surveillance and the spread of pathogens, with a particular interest for HIV-1. 
Overall, despite recent progress in this growing research !eld, we highlight that further 
investigation is needed to better unveil the role of TNT in both physiological and patho-
logical conditions.
Keywords: tunneling nanotubes, myeloid cells, innate immunity, pathogens, HIV-1
INTRODUCTION
Tunneling nanotubes (TNT) represent a novel type of intercellular communication machinery, 
which di!ers from the secretion of signaling molecules and the signal transmission through gap or 
synaptic junctions between adjacent cells. Along with exosomes, TNT mediate long-range commu-
nication, independent of soluble factors. "ey are membranous structures displaying a remarkable 
capacity to communicate with selected neighbor or distant cells. "ere are recent reviews covering 
the broad biological role of TNT, which are able to form in multiple cell types (1–3). Here, our focus 
is exclusively on TNT formed by myeloid cells, including macrophages, osteoclasts, and dendritic 
cells (DC). Based on the nascent literature on TNT in these cells, we will discuss the de#nition of 
TNT, their mechanisms of formation, and their role in physiological and pathological contexts. We 
will also address the need of further investigation of these structures to better understand their 
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functions and improve their potential as therapeutic targets in 
pathological conditions.
DEFINITION AND FUNCTION OF TNT
"e main obstacle in reviewing the emerging TNT #eld is the 
di!erent names given to these structures: TNT, cellular and 
membrane nanotubes, #lopodia bridges, conduits or tubes, and 
nanotubules. Also, the huge number of publications on carbon 
nanotubes impedes the track of developments on TNT. Unifying 
terminology for nanotubes would thus be bene#cial. In this mini-
review, the term TNT will be used as done previously (2, 4). TNT 
are membranous channels connecting two or more cells over 
short to long distances. Actually, these structures can extend up to 
200 µm in length in macrophages (5). To de#ne TNT, we adopted 
the three phenotypic criteria proposed in a recent elegant review: 
(i) they connect at least two cells, (ii) they contain F-actin, and 
(iii) they do not touch the substrate (2). "is de#nition allows 
the discrimination of TNT with any other F-actin-rich structures, 
such as #lopodia. Regarding their functional properties, TNT 
transfer cytoplasmic molecules from one cell to another such as 
calcium, proteins or miRNA, mitochondria, several vesicles (e.g., 
lysosomes), pathogens, and cell-surface molecules; this ability 
constitutes the main functional criterion for TNT de#nition (6). 
"e end of the structure can form a junctional border with the 
targeted cell (close-ended TNT) or the cytoplasm of the two con-
nected cells can be mixed (open-ended TNT). On the one hand, 
the transfer of large molecules such as the lipophilic dye DiO is 
used to identify open-ended TNT (7). On the other hand, close-
ended TNT form a junction at their end which are visualized by 
scanning electron microscopy (8). To avoid the past arguments on 
the need of cytoplasmic interactions for TNT, we shall consider in 
this review both close-ended and open-ended TNT (Figure 1A). 
As close-ended TNT mediate signal transfer through distant 
gap junctions (8, 9), they meet the functional criterion to be 
considered as TNT. Also, close-ended TNT could represent an 
intermediary status in the process of open-ended TNT formation. 
Finally, the group of Davis demonstrated that one particularity 
of macrophages is their ability to form di!erent classes of TNT: 
thin ones (<0.7 μm in diameter), containing only F-actin; and 
thick ones (>0.7 μm), containing F-actin and microtubules (7). 
"ese two types of TNT could have di!erent functions, as large 
material (e.g., lysosomes, mitochondria) can only travel between 
macrophages via thick TNT on microtubules (7).
DISCOVERY OF TNT
"e #rst description of functional TNT in vitro was made in rat 
kidney cells (PC12 cells) and human cell lines (10), followed 
immediately by the identi#cation of similar structures in human 
monocytes and macrophages (11). It is now clear that TNT can 
form in several cell types, including cancer cells and most leuko-
cytes. However, to our knowledge, TNT were not described in 
granulocytes. In DC, TNT appeared to be similar to those made 
by monocytes-derived macrophages (6, 12). However, unlike DC 
exposed to anti-in%ammatory conditions, only those activated 
by pro-in%ammatory conditions form complex network of TNT 
able to transfer soluble molecules and pathogens (13). Likewise, 
macrophages undergo di!erent activation programs within 
the broad spectrum of pro- (M1) and anti-in%ammatory (M2) 
polarization. Yet, their activation state has not been linked to 
the formation of TNT. "e only available data concern the early 
HIV-1 infection of macrophages, driving them toward M1 polari-
zation (14) and inducing a signi#cant increase in TNT formation 
(5, 15–18).
While the majority of studies in TNT biology has been 
performed in one cell type (homotypic TNT) at a time, TNT 
formation between di!erent cell types (heterotypic TNT) is not 
rare. In fact, TNT frequently form between macrophages or 
DC with another cell type, enabling the exchange of lysosomes, 
mitochondria, or viral proteins (16, 19–21).
"e reason why TNT were discovered quite recently could be 
attributed to their fragility. Indeed, they are poorly resistant to the 
existing shearing forces in culture media, as well as light exposure 
and classical #xation methods. "us, an appropriate way of per-
forming live imaging is necessary to study TNT. When working 
on #xed cells, gentle #xation (e.g., glutaraldehyde-based #xation) 
should help preserve these highly delicate structures (22, 23).
FORMATION OF TNT
Mechanisms of Formation
Cell examination by time-lapse microscopy suggested two 
mechanisms of TNT formation could exist. "e #rst one pro-
poses that two cells initially in contact separate from each other, 
remaining connected through a thin thread of membrane, which 
will be elongated upon cell separation (Figure 1A, right). "e 
second puts forward that a cell would #rst bulge #lopodia and 
extend them until reaching a neighboring cell, then converting 
towards TNT a&er making contact (24, 25) (Figure  1A, le&). 
While the former is the prevailing mechanism in lymphoid cells, 
the latter one is observed in DC as TNT were reported to develop 
mainly from conversion of their #lopodia (13, 19). In the case 
of macrophages, while they can use both mechanisms (6), the 
murine macrophage cell line (RAW 264.7 cells) mainly forms 
TNT from actin-driven protrusions, also called TNT-precursors 
(26). Of note, these two processes are not necessarily exclusive 
and could both occur between a given pair of cells. In either case, 
the requirement of F-actin is not questioned since treatment 
with latrunculin or cytochalasin D is o&en used to abolish TNT 
formation (2, 27, 28).
Regarding the opening of the conduit, and the potential tran-
sition between close-ended and open-ended TNT (Figure 1A), 
there is no proposed mechanism available. It is likely that the 
formation of open-ended TNT involves a step similar to what 
occurs during virus-to-cell membrane fusion or cell-to-cell 
fusion (29, 30), eventually leading to the generation of multinu-
cleated giant cells (MGC) (Figure 1A).
Molecular Actors
Few data are available to describe TNT at the molecular level. 
M-Sec, also known as tumor necrosis factor-α-induced protein, is 
one of the best characterized protein involved in TNT formation 
FIGURE 1 | Models of tunneling nanotube (TNT) formation and putative role in the generation of multinucleated giant cells (MGC). (A) TNT can form according to 
two mechanisms: the “protrusion elongation” mechanism where the cell extends !lopodia-like protrusion toward a speci!c target cell (left), and the “cell 
dislodgement” mechanism for which two cells initially in contact separate from each other, stuck by a thread of membrane that gives rise to a TNT (right). Each of 
these mechanisms can lead to either close-ended or open-ended TNT, the last one allowing cytoplasmic continuity between interconnected cells. The dynamics of 
close-ended and open-ended TNT formation is still not understood. In addition, TNT could either disconnect cells and thus abrogate their communication or could 
lead to MGC. (B) Confocal image of day 13 HIV-1-infected human monocyte-derived macrophages and MGC interconnected through a TNT. Arrowheads show a 
TNT. HIV-1 Gag (red), F-actin (green), DAPI (blue). Scale bar, 50 µm.
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in macrophages. Its depletion in Raw264.7 cells reduces the 
formation of de novo TNT and their associated function (trans-
fer of calcium %ux) (22). Using the same macrophage cell line, 
the group of D. Cox recently showed that actin polymerization 
factors including the Rho GTPases family Rac1 and Cdc42, and 
their downstream e!ectors WAVE and WASP, participate in 
TNT formation (26). In addition, functional TNT are induced 
by the expression of the leukocyte speci#c transcript 1 (LST1) 
protein in HeLa and HEK cell lines. LST1 recruits the actin 
cross-linking protein #lamin and the small GTPase RalA to the 
plasma membrane where it promotes RalA interaction with the 
exocyst complex, M-Sec, and myosin; these interactions trigger 
TNT formation (22, 23). Whether the mechanisms that operate 
in cell lines derived o&en from tumor origin apply to primary 
cells remains to be con#rmed.
IN VIVO RELEVANCE OF TNT
A remaining question is to determine to what extent the in vitro 
data available in the literature are relevant in  vivo. One of the 
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problems is to apply in vivo the criteria of bona "de TNT (see 
above), in particular the requirement not to touch the substrate, 
which seems unlikely in 3D environments. In addition, testing 
the functionality of TNT in the context of tissues is challenging. 
"erefore, the structures observed in  vivo should be carefully 
indicated as “TNT-like structures.” Key evidence for TNT-like 
structures in vivo comes from the immunology #eld providing 
the #rst images of thick TNT connecting DC in in%amed mouse 
corneas (31). To our knowledge, macrophage TNT have not been 
observed in  vivo yet. "e identi#cation of speci#c molecular 
markers for TNT would be a great tool to con#rm the existence 
of these structures in  vivo. M-Sec, which is involved in TNT 
formation, cannot be considered as a speci#c marker since this 
ubiquitous protein is expressed all over the cytoplasm (5, 18, 28, 
32, 33). "us, one of the priority to progress in the TNT #eld is 
to characterize markers allowing unambiguous identi#cation of 
cell-to-cell tubular connections as TNT.
ROLE OF TNT IN PHYSIOLOGICAL 
CONTEXTS
One of the most studied functions of TNT is the propagation 
of calcium %ux. Calcium signaling through TNT helps regulate 
cell metabolism and communication between neurons (34). 
Interestingly, DC present the ability to establish calcium %uxes 
via TNT transmitted within seconds to other DC as far as 500 µm 
away from the donor cell (12). When TNT are disturbed by M-Sec 
knockdown, this calcium %ux is inhibited (12, 22). DC have also 
the particularity to form TNT networks allowing the intercellular 
exchange of antigens (13), including in the context of MHC mol-
ecules as described between Hela cells (19, 27). "erefore, TNT 
could contribute to a higher e'ciency in the antigen presentation 
process to activate adaptive immunity (19).
Another physiological role for TNT concerns the di!eren-
tiation of osteoclasts (5, 18, 28, 32, 33). Osteoclasts are MGC 
derived from a myeloid precursor that present the unique 
ability to degrade the bone matrix, and thus to regulate bone 
homeostasis. Inhibition of TNT either by latrunculin B or by 
M-Sec depletion signi#cantly suppresses osteoclastogenesis, and 
the M-Sec expression level increases during osteoclastogenesis 
(28, 35). Dendritic cell-speci#c transmembrane protein, a recep-
tor involved in cell-to-cell fusion, has been shown to be trans-
ferred via TNT. "e authors proposed that this process could 
participate in cell fusion among osteoclast precursors (28, 35). 
Moreover, nuclei are found inside large TNT-like structures (36), 
inferring that they participate in cell-cell fusion to generate OC. 
Elucidating the role of TNT in di!erentiation of MGC such as 
placental trophoblast, myotubes, and osteoclasts could be a new 
research area.
ROLE OF TNT IN PATHOLOGICAL 
CONTEXTS
Tunneling nanotubes not only contribute to cell-to-cell commu-
nication in physiological conditions but also in pathological pro-
cesses. For example, the transfer of lysosomes from macrophages 
to #broblasts, and of mitochondria from mesenchymal stromal 
cells to macrophages, are mediated by TNT and have important 
consequences in cystinosis and acute respiratory distress syn-
drome, respectively (20, 21).
Without the shadow of doubt, the most studied consequence 
of TNT in diseases is the transfer of pathogens, including prions, 
bacteria, and viruses [for review, see Ref. (1)]. One of the well-
known example concerns the role of TNT in neurological dis-
eases, especially when caused by prions (34). Actually, in addition 
to the TNT-dependent transfer of the infectious form of the prion 
protein (PrPSc) between neuronal cells, TNT support PrPSc trans-
fer from DC to the neurons in which PrPSc is further synthetized 
and transferred to the rest of the central nervous system (37). 
Regarding bacteria and viruses, some publications propose that 
they “surf ” along TNT to spread from one cell to another (7, 13, 
38–41). For example, in macrophages, live experiments show that 
Mycobacterium bovis bacillus Calmette–Guerin can travel along 
the surface of thin TNT, toward another macrophage, which will 
ingest it (7).
Viruses, including HIV-1, are well known to hijack the 
cytoskeleton in order to enter and travel inside their host cell, as 
well as towards bystander neighbor cells (5, 33, 39, 41, 42). For 
example, HIV-1 can actively induce the generation of #lopodia 
in DC to propel virus particles towards neighboring cells. As 
one of the mechanism of TNT formation starts with membrane 
extension, #lopodia formed upon HIV-1 infection could lead to 
TNT formation (2), especially in DC that develop networks of 
TNT from elongation of their dendrites (13, 19). Importantly, 
the formation of TNT by DC favors trans-infection of targeted 
CD4+ T lymphocytes at a relatively long distance, similar to what 
happens between two distant CD4+ T lymphocytes (8).
In macrophages, HIV-1 induces TNT formation and potentially 
uses them to spread (18). Whether thin or thick TNT are formed 
is unknown. Assuming that thick TNT are induced, HIV-1 could 
travel inside these structures by using a microtubule-dependent 
movement, in addition to the described “sur#ng” of HIV-1 at the 
surface of TNT. Despite the fact that Gag and Nef proteins and 
HIV-1-containing vesicles have been detected inside TNT, there 
are no convincing experiments in living cells available to prove 
that HIV-1 travels inside TNT and infects the targeted cell (5, 
15, 17, 18). Pushing live imaging to super-resolution microscopy 
techniques would be of great help to study how HIV-1 tra'cs 
using TNT.
In light of the importance of macrophages in HIV-1 pathogen-
esis (43–45), it is crucial to bridge the several gaps that blur our 
understanding of the role of TNT in macrophages during HIV-1 
infection. First, it is important to determine whether HIV-1-
induced TNT in macrophages are close- or open-ended to better 
understand how HIV-1 tra'cs via TNT. Second, whether TNT 
from a HIV-infected cell could target non-infected cells remains 
to be elucidated. It would be an e'cient way for the virus to spread 
around without being detected. Finally, the molecular regulation 
of HIV-1-induced TNT in macrophages has only started to be 
elucidated. "e HIV-1 Nef protein could play a central role in 
TNT formation by interacting with members of the exocyst 
complex (16, 18, 46, 47). Moreover, Nef modulates F-actin and 
cell migration (48), two e!ects which could participate in TNT 
5Dupont et al. TNT in Myeloid Cells
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 43
generation. Finally, a hallmark of HIV-1 infection is the formation 
of MGC, a process that can be driven by TNT in order to persist 
during late infection stages, when most infected macrophages are 
MGC (Figure 1B) (32, 33). Interestingly, both HIV-1-induced 
TNT and MGC are reduced when macrophages are infected with 
nef-deleted viruses (18, 32, 33).
Importantly, while TNT spread the virus among HIV-1 target 
cells (T  lymphocytes, macrophages, and DC), TNT also a!ects 
the nature of infection by circumventing the need for classical 
receptor-mediated virus entry or transfer viral components to 
cells that are not susceptible to infection. As a matter of fact, 
the transfer of Nef via TNT between infected macrophages and 
B cells induces drastic B cell abnormalities at the systemic and 
mucosal level (16).
CONCLUSION
"e TNT #eld requires the uni#cation of the terminology and 
de#nition of TNT, as well as the development of new tools 
adapted for the detection and monitoring of these particular 
structures. "e main challenge so far is to discover molecular 
markers to speci#cally identify TNT, especially in vivo. To this 
end, an automated siRNA-based screen could be used in in vitro 
conditions for which TNT formation is controlled, as performed 
for the virological synapse (49). Another issue is the fragility of 
TNT which complicates their manipulation. "us, the use of 
speci#c experimental conditions or devices, such as micro%uidic 
systems (50), is needed. Moreover, it would be helpful to study the 
opening of close-ended TNT in terms of molecular components 
and dynamics. Likewise, it is imperative to determine whether 
TNT formation and regulation can be in%uenced by extracellular 
stimulti and/or tissue microenvironment in pertinent in  vivo 
physiological and pathological contexts. For example, during 
HIV-1 infection, TNT represent a new way for viral spread. 
However, the literature remains scarce, rising far more questions 
than answers. Interestingly, HIV-1 and other microbes can serve 
as e'cient tools to better understand TNT structure and function. 
Furthermore, TNT-based studies in the HIV-1 #eld are needed 
to better understand viral dissemination and pathogenesis. "e 
particularity of TNT to perform “intimate” communication with 
a speci#c partner is probably key in HIV-1 spread. A tempting 
hypothesis is that infected cells could direct their TNT towards 
uninfected cells. "is way, the virus could spread without being 
detected by the surveilling immune system. Finally, new insights 
into the mechanisms of TNT formation and regulation would be 
of high relevance to design novel therapeutics for several diseases, 
including viral infections.
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Figure 27: Historical tim
eline show
ing advances in the co-infection fight ([263]) 
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Chapter III: Mycobacterium tuberculosis-HIV-1 
co-infection - the deadly duo 
 
The co-infection of Mtb and HIV-1 is still a major public health issue on a global scale, 
particularly in Africa and Eastern Europe where the TB-HIV ͞sǇndemic͟ conǀerges. The risk of 
developing TB is estimated to be between 16 to 27 times higher in people living with HIV-1, compared 
to the general population, with 55% of TB notified patients also infected with HIV-1 [1]. Moreover, TB 
is the main aggravating factor and cause of AIDS-related deaths. In 2017, 464 633 (i.e. 51%) new TB 
cases were declared in HIV-1 infected patients, among which 86% were under cART; 300 000 people 
infected with HIV-1 died of TB, representing a quarter of all TB deaths worldwide [1]. In addition, HIV-
1 infected people are particularly at risk of infection and death from multidrug-resistant Mtb infection. 
To answer this threat, the WHO guidelines recommend offering HIV-1 testing to all patients with 
presumptive and diagnosed TB. Likewise, routine TB symptom screening in people living with HIV-1 is 
to be developed in order to treat as quickly as possible new Mtb infections [1].  
 
I. Clinical considerations of the co-infection 
A. Historical overview  
The first report of an association between TB and HIV-1 was established in Haiti in 1983 [673], 
and was followed by a high incidence of HIV-1 infection among people with TB in the Democratic 
Republic of Congo and in other sub-Saharan African regions in 1986 [263]. As soon as 1988, the 
increasing numbers of co-infection cases led to the WHO proposing a joint approach to tackling both 
HIV-1 and TB, and set the long-term goal to decrease the co-infection incidence. In 1995, the first 
evidence of pathogen synergy emerged when people living with HIV-1 and active TB tended to have 
higher viral load and died sooner of AIDS comorbidities than people living with HIV-1 alone [263]. At 
the beginning of 2000, the increasing number of TB cases, especially in Africa fueled by HIV-1 
epidemics, made the diagnosis of co-infection more important than ever. In 2003, only 3% of people 
with TB were tested for HIV-1 co-infection, a number that increased to 22% by 2008 and that, 
thankfully is still increasing today, according to WHO recommendations [1]. For example, in Malawi, 
HIV-1 testing was offered to TB patients who were given cART in priority when eligible. In 2009, due to 
the high prevalence of co-infection in sub-Saharan Africa, and the fact that TB is officially the leading 
cause of AIDS-related deaths, the WHO actualized its guideline for co-infection treatment and 
recommended cART for all co-infected persons, independent of their CD4+ T cell count. The 2011 
CAMELIA study, performed in Cambodia by the Pasteur Institute, showed that among 661 patients 
with TB and HIV-1, 35% were more likely to survive AIDS-related TB when they received cART as soon 
as two weeks post-antibiotherapy [674]. In 2016, the United Nation declaration to end AIDS included 
in its main goal the reduction of TB-related deaths in people living with HIV-1 by 75% by 2020. This  
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Figure 28: HIV-1 and Mtb synergy increases the risk of progression of both pathologies (from 
[675]). 
A | Soon after HIV-1 infection, an individual has an increased (2- to 5- fold above baseline) risk of developing 
active TB. During the chronic HIV-1 infection phase, the risk to develop active TB dramatically increases, up to 
20-fold compared to the general population, and is correlated with CD4+ T cell count drop. In addition, the 
initiation of antiretroviral therapy to control HIV-1 replication does not fully restore the active TB risk to baseline, 
which remains about 4-fold above baseline even after CD4+ T cell counts have recovered.  
B | Infection with Mtb in individuals infected with HIV-1 increases the viral replication and consequently viral 
diversity. With the increased number of viruses, the immune system is strongly required and heavily activated. 
Therefore, Mtb infection potentiates the chronic immune activation observed in HIV-1+ individuals, accelerating 
the progression of HIV-1 disease towards AIDS. 
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goal has been reached by certain countries in Africa (e.g. Eritrea, Malawi, Djobouti, and Togo) and 
India. However, this goal is still far from being achieved in Western Europe where the reduction in TB-
related deaths in co-infected patients was decreased by only 24%, instead of 75% (i.e. France, Poland, 
Turkey) [1], [263]). That is why the United Nations General Assembly adopted a new measure in the 
fight against TB in 2018, committing to the distribution of preventive TB treatment to at least 6 million 
people living with HIV-1 by 2022 
(https://www.unaids.org/sites/default/files/media_asset/tuberculosis-and-hiv-progress-towards-
the-2020-target_en.pdf). 
All these facts and key dates were reported by UNAIDS and the WHO and are summarized in 
Figure 27. 
 
B. Synergy between HIV-1 and Mtb 
It is well-known now that both HIV-1 and Mtb act in synergy within the infected individuals, to 
dǇsregƵlaƚe ƚhe hosƚ immƵne response and ƚo acceleraƚe each oƚher͛s progression ;FigƵre ϮϴͿ͘ HIV-1 
influences the clinical outcomes and phenotype of TB disease in co-infected patients, whereby in 
advanced AIDS where CD4+ T cells depletion is at its highest level, Mtb frequently disseminates 
throughout the host, causing extra-pulmonary TB and mycobacteria circulation in the bloodstream 
[676], [677]. In fact, if HIV-1 patients are more likely to become Mtb infected (up to 27 times more 
susceptible to develop the disease), the risk of developing active TB is increased by HIV-1 co-infection 
[678], [679]. TB pathogenesis evolves with the HIV-1-caused immunosuppression, involving the main 
characteristic of HIV-1 pathology, CD4+ T cell loss, as an important element responsible for TB 
exacerbation for which mechanisms will be discussed further later in this chapter (section II). In 
patients with a CD4+ T cell count above 300 cells/mm3, no difference in the proportion of cavitation or 
disease seen in X-rays of the upper lungs was observed in co-infected patients compared to Mtb mono-
infected patients. However, when the CD4+ T cell count declined to below 300 cells/mm3, lung 
adenopathy (miliary pattern), extension of the disease in the lower pulmonary cavitation, and high 
pleural effusion bacterial burden were more common manifestations of TB pathogenesis [680]. Post-
mortem studies showed that in addition to aggravated lung pathology, co-infected patients displayed 
more disseminated TB than the mono-infected patients. The spleen, liver, lymph nodes, and bone 
marrow are the most commonly affected organs during extra-pulmonary TB (see Chapter I, section 
I.A.c.), which is the most common form of TB in HIV-1 infected people with low T cell counts [681].  
Conversely, active TB is tightly linked to increased viral replication in co-infected hosts, as 
proven by an observed viral load of up to 160 times higher in the co-infected patient blood compared 
to that in the HIV-1-mono-infected patient. This increased viral load is even greater at the anatomical 
sites of co-infection [682]. Indeed, increased p24 HIV-1 antigen and viral loads (up to 200 fold) were 
not only found in BAL in co-infected patients compared to TB patients [683], [684] but also in pleural 
effusions [685], [686], where the virus titers were up to 35-fold higher than that found in the peripheral 
blood of the same patient [687], [688]. This observation of increased viral production is associated with 
macrophages rather than T cell infection [689]. In fact, it was shown that alveolar macrophages 
isolated from co-infected patients, the main target of Mtb and HIV-1 in the lung (see chapter I and II), 
exhibited upregulated viral replication ex vivo [690], [691]. The brain of co-infected patients is also an 
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important anatomical site of sustained HIV-1 replication and is often associated with the development 
of TB meningitis (see chapter I section I.A.c.). Patients presenting this extra-pulmonary TB form have a 
10-fold increase in HIV-1 viral load in the cerebro-spinal fluid compared to the bloodstream, indicating 
that this organ is an important site for viral replication [692].  
Altogether, these clinical data demonstrate the existing synergy between HIV-1 and Mtb, and 
further emphasize the gravity of the co-infection. As discussed in the next section, one of the biggest 
health challenges in the field of infectious diseases is to increase the prevention of TB infection in 
people living with HIV-1, and to ameliorate the diagnosis of this co-infection, in order to treat it as soon 
as possible to decrease the number of AIDS-TB deaths. 
 
C. Clinical challenges raised by the co-infection 
a. Difficulty to diagnosis 
As co-infection with HIV-1 modulates TB clinical manifestations, it renders TB diagnosis (see 
chapter I section I.B.b.) quite complicated. Indeed, the usual tests to detect Mtb infection are less 
sensitive in HIV-1 co-infected patients. Both TST and IGRA tests become imprecise, if not obsolete due 
to Mtb-specific IFNJ+ T cells depletion [693]. Moreover, TB disease often comes with atypical 
manifestation in co-infected patients, including disseminated bacterial loads [694], [695]. In addition, 
given that HIV-1-mediated immunosuppression is associated with reduced cavitation in the lungs, most 
co-infected patients have reduced sputum production compared to HIV-1 uninfected people [696]. In 
regions where resources are limited, the more common and fastest test used to diagnose TB is the 
smear microscopy. It consists of examining by microscopy the presence of acid-fast bacilli present in 
sputum. However, this test is poorly sensitive, particularly in HIV-1 co-infected patients since there are 
fewer bacilli in sputum [697]ʹ[699]. Solid or liquid Mtb cultures remain the standard methods for TB 
diagnosis, however, both are still based on sputum bacilli load; this kind of test requires time and 
specific infrastructures, which are not available everywhere in low-income countries and delay the 
diagnosis. Yet, MTB/RIF detection method overcomes smear microscopy techniques, irrespective of 
HIV-1 status, and is fast enough to reduce the delay before TB treatment initiation [700], [701], but 
this method remains expensive to be routinely used in low-income countries where the co-infection 
burden is the highest. 
 
b. Drug interactions and TB IRIS 
In addition to the difficulty of TB diagnosis in HIV-1 co-infected individuals, the treatment is 
also complicated. Drugs interaction must be considered, since rifampicin interacts with NNRTIs and 
protease inhibitors, leading to sub-therapeutic efficiency of these antiviral drugs and to subsequent 
treatment failure [702]. Consequently, the antiretroviral regimen should be chosen on the basis of 
minimal drug interaction with the antibiotic regimen besides the need to be adapted to the patient 
viral infection characteristics [703]. An important challenge healthcare providers must face in the co-
infection between HIV-1 and Mtb is the fact that people living with the virus are more susceptible to 
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become infected with MDR-TB or XDR-TB. This TB drug resistance in HIV-1 infection settings is thought 
to be due to two major mechanisms: first, rifampin and ethambutol display maladsorption in HIV-1 
infected people, causing TB treatment failure; second, even in the case of low incidence, drug-resistant 
strains enable disease progression because of the immune-depression caused by HIV-1 and of the 
treatment inefficiency [704], [705]. Another problem in co-infection treatment is the order and timing 
of drug initiation. Several studies found that initiation of cART two weeks after TB treatment was more 
beneficial than delaying cART for 8 weeks as it reduced mortality [674], [706].  
The main problem observed after cART initiation in co-infected patients is the risk to develop 
TB immune reconstitution inflammatory syndrome (TB-IRIS), an adverse consequence of the 
restoration of pathogen-specific T cell responses [707]. About 15.7% of the HIV-1-associated IRIS are 
caused by Mtb co-infection [708], [709]. TB-IRIS is an excessive inflammatory response that is 
manifested by high fever, respiratory and renal failures, worsening infection symptoms, and revealing 
new TB infection or reactivation of latent TB [710]. This symptom happens in up to 40% of the co-
infected population, usually between 4 to 8 weeks after cART initiation [711], [712]. TB-IRIS is thought 
to be mainly caused by sustained Th1 responses, characterized by increased IFNJ-mediated responses 
against the mycobacterial antigens, dysregulation of cytokines secretions and recruitment of Mtb-
specific T cells migration to the site of infection [713], [714].  However, cART has been shown to induce 
the macrophage hyperactivation in response to Mtb antigens, indicating that innate cells have a role 
in TB-IRIS occurrence [715]. More precisely, susceptibility to Th1 responses and higher bacterial loads 
in co-infected patients compared to Mtb-mono-infected patient could be related to innate immune 
responses, as they involve elevated production of IL-18 and CXCL10, favouring both Th1 cells 
polarization and attraction to Mtb-infection site [713].  
To conclude, and despite the progress made in the last 10 years to combat either Mtb or HIV-
1 infection, HIV-1/TB co-infection is still a major health issue at the global scale, and particularly in 
Africa where this burden is the highest [1]. This is due to the initial separation of strategies to fight 
individual infection instead of developing collaborative strategies to eradicate both pathogens at the 
same time. Improvement has been made to increase co-infected patients survival, notably by initiating 
cART regardless of the CD4+ T cell count status. Many efforts still remain to be made to efficiently fight 
this co-infection, starting with the understanding of the mechanisms leading to pathogen synergy and 
mutual exacerbation. I will now discuss what is known for HIV-1-mediated enhancement of Mtb 
infection, which have been better explored.  
 
II. HIV-1 exacerbates Mtb growth 
A. Depletion of Mtb-specific effector T cells 
It is well established now that HIV-1 infection impairs the ability of the host to control Mtb 
growth (for review, see [2], [696], [675], [716]). Indeed, several clinical studies shed light to an 
increased risk of developing TB shortly after HIV-1 infection. For example, HIV-1 infected miners in 
South Africa were found to be 2 to 3 times more prone to develop TB within two years of HIV-1 
seroconversion compared to HIV-1 uninfected miners [679], [717]. The most obvious mechanism 
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explaining this increased risk is the depletion of CD4+ T cells after HIV-1 infection. Indeed, enhanced 
propensity to develop both TB and extra-pulmonary TB is strongly correlated to CD4+ T cell counts in 
co-infected patients [675], [718]. In addition, several studies reported a decreased number of CD4+ T 
cells in co-infected patients, notably in BAL [719]ʹ[721] and in the lung, more precisely around the 
granuloma [686], [721]. The remaining cells display altered functions, such as reduced ability to 
produce cytokines [719], [720], an issue that will be discusseMtb trid in the next section. The observed 
T cell depletion in co-infected patients leads to granuloma structure disruption and promotes 
progression towards active TB [722]. Indeed, in the absence of CD4+ T cells, the repartition of CD8+ T 
cells is no longer maintained in the outer ring of the granuloma, but instead sparsely distributed in the 
malformed structure, showing the importance of CD4+ T cells in the granuloma maintenance [723]. 
Interestingly, Mtb-specific T cells are preferentially depleted during HIV-1 infection of patients with TB, 
as demonstrated by several reports. First, Mtb-specific T cells are particularly susceptible to HIV-1 
infection as they frequently display HIV-1 DNA, a characteristic mainly due to their high IL-2 production 
[724], and to the increased expression level of the HIV-1 entry co-receptors CCR5 and CXCR4 after Mtb 
infection [725], [726]. Second, Geldmacher and colleagues reported that within 3 months after HIV-1 
seroconversion, a drastic drop in peripheral Mtb-specific memory CD4+ T cells secreting IFNJ occurs in 
patients with latent TB, leading to TB reactivation [727]. Third, polyfunctional T cells that produce IFNJ, 
TNFDand IL-2, were found to be specifically depleted in HIV-1 infected individuals [719], as further 
shown by the diminished recruitment of IFNJ-producing cells in co-infected patients after TST 
challenge [728].  
Collectively, these studies provide strong evidence that CD4+ T cells depletion, especially that 
of Mtb-specific T cells, is an important mechanism by which HIV-1 triggers Mtb growth in the co-
infected host as it dampens Mtb-specific responses and alters the granuloma structure and function. 
In addition to this, T cells functions are also modified by HIV-1 infection, a topic discussed in the 
following section. 
 
B. Functional changes in Mtb-reactive T cells 
The main alteration in T cell function after HIV-1 infection is the modification of the cytokines 
they produce, together with their proliferation after efficient infection. Zhang and colleagues 
evaluated cytokine patterns in co-infected patients by in vitro stimulation of their PBMCs with heat-
killed Mtb and found a decreased production of IFNJ and IL-2 by Mtb-specific Th1 cells compared to 
HIV-1 seronegative patients. In addition, these cells were less proliferative in co-infected patients, an 
effect independent of CD4+ T cell count. However, the reduced Th1 response was a direct result of 
CD4+ T cell depletion and to high IL-10 levels, indicating the negative impact of immunosuppressive 
cytokines on Mtb growth in co-infection settings [729]. Other studies also reported a defect in IFNJ 
production by T cells in co-infected patients both in the bloodstream [730] and in the airways [731]. In 
addition to IFNJ, T cells isolated from BAL in BCG-vaccinated people living with HIV-1 produce less IL-2 
and TNFD after BCG-stimulation, compared to HIV-1 negative people [719]. Moreover, BAL T cells from 
TB-HIV-1 co-infected patients stimulated with avirulent Mtb strains were found to be less proliferative 
than the one from mono-infected patients, further supporting the HIV-1-mediated alterations on the 
T cell compartment [732].  
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Besides evident modification of the cytokine responses, HIV-1 is well known to induce chronic 
immune activation of T cells (see chapter II section II.B.b.). Indeed, during the chronic stage of the 
disease, HIV-1 is able to switch T cell memory profile towards an effector one, and induces high levels 
of activation markers expression on T cells such as HLA-DR, as well as exhaustion markers like CD57 
and PD-1, particularly on effector memory subsets [733]. In active TB-HIV-1 co-infection settings, PD-
1 expression is particularly elevated on Mtb-specific CD4+ T cells compared to HIV-1 negative persons 
[121]. Blocking the PD-1 interaction with its ligand marginally enhanced the proliferation of CD4+ T cells 
specific for Mtb [734], suggesting that PD-1 overexpression promotes T-cells exhaustion, leading to 
suboptimal Mtb-responses in co-infected individuals. In that same study, the authors evaluated the 
expression of PD-1 ligand (PD-L1) in monocytes and macrophages, which expressed high levels of this 
ligand in active-TB patients compared to healthy control. This high expression and interaction of PD-1 
with PD-L1 decreased macrophages phagocytosis and intracellular killing of Mtb, showing that innate 
immunity is inhibited as well as the CD4+ T cell-mediated response against Mtb. In fact, this is not 
surprising since Th1 responses contribute actively to the recruitment of monocytes and macrophages 
to the site of Mtb infection, where they enhance the macrophage antimicrobial activity [696]. 
Considering this intricate relationship between the innate and adaptive immune responses, the 
importance of innate cells, and particularly of macrophages in HIV-1-mediated exacerbation of TB, 
should not be ignored. 
 
C. Alteration of the macrophage response 
HIV-1 infected people are more susceptible to develop TB, even before CD4+ T cell depletion 
[675], suggesting a role for innate immunity in the observed bacterial burden in co-infected patients. 
HIV-1 infects macrophages in vivo and efficiently establishes viral reservoirs out of these cells in almost 
all organs within the host. In the lung, alveolar macrophages are the main HIV-1-infected cells, a target 
shared by Mtb. Therefore, it is likely that macrophages are a central cellular population in HIV-1-
mediated exacerbation of Mtb growth. Here, I will focus on the probable mechanisms explaining the 
loss of Mtb-growth control that favours TB reactivation in co-infected patients.  
 
a. Alteration of cytokines responses and cell death 
As the principal target for Mtb, macrophages are at the center of the immune response against 
Mtb (see chapter I section II.B.). They are essential to contain the bacteria, as they are the primary cells 
that phagocytize the bacillus targeting it for phagosomal degradation. Even if macrophages fail to kill 
all bacteria, they induce the recruitment of new macrophages and phagocytes to the site of infection, 
notably through secretion of TNFD and cell death apoptosis. This phenomenon leads to the final 
development of the granuloma to contain the bacteria, a structure highly depending on TNFD and Th1 
responses [86], [98]. To determine (at the molecular level) the in vivo immune response against Mtb 
at the site of infection, Bell and colleagues performed a transcriptional profiling of patients with active 
TB and HIV-1 using cells recruited to the site of TST challenge. HIV-1+TST+ patients exhibited preserved 
Th1 responses but were deficient for IL-10-inducible immunoregulatory responses. On the contrary, 
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HIV-1+TST- patients revealed a deep anergy of both innate and adaptive immune cells except for IFN-I 
activity, which paired with the impairment of anti-mycobacterial responses [728].  
Mtb-infected macrophages are high producers of TNFD, a key cytokine involved in the immune 
response to TB by the induction of granuloma formation (see chapter I section II.A.a.). Both alveolar 
macrophages isolated from HIV-1+ BAL and macrophages within the granuloma [735] were found to 
produce less TNFD in response to Mtb infection. This led to extensive lesions necrosis, poorly formed 
granulomas and neutrophils accumulation, indicating the deep alteration of the granuloma structure 
as a consequence for the dampened TNFD production [736]. In addition, co-infected macrophages 
were found to release lower levels of TNFD than Mtb-infected macrophages, which resulted in 
decreased frequency of TNF-mediated macrophages apoptosis [735], [737], [738]. Alveolar 
macrophages from healthy, ex vivo infected with HIV-1 [735], or from HIV-1 infected individuals [738] 
display a decrease in Mtb-mediated apoptosis after Mtb challenge compared to those mono-infected 
with Mtb. This effect was mediated by the viral protein Nef that can be found in the extracellular 
medium. Kumawat and colleagues found that exogenous Nef inhibits TNFD synthesis in Mtb-infected 
macrophages, due to cross-regulation of the individual signaling pathway that lead to TNFD 
production. More specifically, the authors identified the ability of Nef to inhibit the ASK133/p38 MAPK 
signaling pathway, resulting in TNFD mRNA instability in the co-infected cell, as the mechanism 
responsible for TNFD inhibition [737].  
Contradictory results were obtained in other studies, reporting an increased level of TNFD in 
the co-infected patients. Indeed, it was reported that alveolar macrophages isolated from BAL of 
healthy controls, HIV-1 mono-infected or HIV-1 infected patients with suspected TB, spontaneously 
produce TNFD shortly after their isolation and were able to produce pro-inflammatory cytokines in 
response to lipopolysaccharide, indicating a retained ability to respond to danger signals in vivo [739]. 
Another study was conducted in hospitalized patients with severe disseminated TB in HIV-1 co-
infection settings. The authors found that monocytes dysfunction was associated with mortality. In 
patients who died, high activation of the innate immune system was found. This elevated activation 
was characterized by an increased proportion of (i) CD14+CD16+ monocytes, (ii) IL-ϲ͕ ;iiiͿ TNFɲ͕ and ;iǀͿ 
colony-stimulating factor 3 (CSF-3). Increased anti-inflammatory markers (increased IL-1R and lower 
monocyte and neutrophil responses to bacterial stimuli), were also found in dead patients [740]. 
Another study found equivalent numbers of granuloma in HIV-1+ co-infected patients compared to 
Mtb mono-infected ones, but those with HIV-1 expressed more IFNJ, TNFD, IL-12 and IL-4, which 
correlated with the increased number of necrotic granuloma in these patients [741]. Increased necrosis 
is deleterious in TB disease, since necrosis is one of the mechanism used by Mtb to escape macrophage 
killing (see chapter I section II.A.a.).  
Despite the variance obtained in different studies, it is clear that macrophages play a major 
role in HIV-1-mediated exacerbation of Mtb growth by modulating their capacity to produce TNFD and 
by altering the granuloma formation and maintenance. Since differential stages of granuloma 
development can be observed for each subject [742], the contradictory results reported in the studies  
                                                          
33 ASK1: Apoptosis signal-regulating kinase 1 (ASK1) is a member of MAP kinase kinase family. It activates c-Jun 
N-terminal kinase (JNK) and p38 mitogen-activated protein kinases in response to an array of stresses and 
calcium influx.  
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cited above may not have taken into account this granuloma heterogeneity. It is possible that in a 
single individual, some granuloma express high level of TNFD while others have decreased level of this 
cytokine. Nevertheless, the modulation of TNFDleads to a decrease in macrophage apoptosis, 
compensated by an increase in necrosis level, which must then participate to granuloma disruption 
and Mtb spread.  
 
b. Inhibition of phagocytosis and autophagy 
Macrophages are the main effector cell involved in Mtb killing. Consequently, the bacterium 
has evolved strategies to overcome macrophage-mediated killing. One of the main mechanisms for 
this escape is the inhibition of the phagosome maturation (see chapter I section II.B.c.i.). Mwandumba 
and colleagues studied the capacity of alveolar macrophages isolated from healthy or co-infected 
patient to phagocytize and acidify phagosomes. They found that alveolar macrophages from both 
healthy and co-infected individuals had equivalent capacity to phagocytize IgG-coated beads and to 
transport them to acidic compartment, but observed that Mtb was located in different vacuoles that 
failed to accumulate endosomal markers and to acidify [143].  To date, HIV-1 infected macrophages 
were reported to facilitate Mtb intracellular growth in in vitro experiments [743]. Indeed, HIV-1 impairs 
Mtb phagocytosis and phagosomes maturation (Figure 29). The team of Niedergang showed that 
macrophages phagocytosis by various receptors was inhibited by HIV-1 infection in a Nef-dependent 
manner, which has strong consequences on the control of opportunistic bacterial infection [744]. Nef 
prevented the recruitment of adaptor protein 1 (AP-1) expressing endosomes to the phagosome, 
thereby preventing the phagosome maturation [555]. This is supported by the impairment of 
phagocytosis by alveolar macrophages obtained from BAL from healthy or HIV-1 infected adults, and 
by the fact that patient treatment with cART for less than 4 years did not fully restore alveolar 
macrophages functions, as assessed by phagosomal proteolysis [480], [743]. In addition to impaired 
phagocytosis, HIV-1 infection of TB patients also negatively impacts autophagy in macrophages. 
Indeed, Nef is able to inhibit autophagosome maturation through interaction with the autophagy 
regulator protein beclin-1 [745], [746]. Altogether, the inhibition of phagocytosis and autophagy in 
HIV-1 infected macrophages is beneficial for Mtb in co-infection, since it further diminishes anti-
bacterial functions, as shown by the increased bacterial burden in co-infected macrophages compared 
to Mtb-infected cells [743]. In addition to Mtb increased bacterial growth, Pathak and colleagues 
observed that co-infected macrophages were also more susceptible to HIV-1 infection, since they 
displayed enhanced viral replication; suggesting that both pathogens act in synergy within the same 
macrophage [743]. 
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Figure 29: Nef impairs the macrophage phagosome maturation and alters the Mtb control (from 
[675]). 
Macrophage control of Mtb is mainly mediated by bacterial phagocytosis and clearance by the phagosome and 
autophagosome, in a vitamin D-dependant manner. HIV-1 co-infection can undermine this host defence at 
multiple levels. Indeed, the viral accessory protein Nef reduces macrophage phagocytic capacity by inhibiting 
AP1-mediated endosomal recycling that is needed to form nascent phagosomes. Moreover, Nef interaction with 
Beclin 1 inhibits autophagosome maturation and fusion with lysosome, including Mtb-containing 
(auto)phagosome, therefore preventing bacterial clearance. Interestingly, vitamin D supplementation may 
overcome this inhibition of autophagosome maturation to improve both Mtb clearance and HIV-1 restriction by 
autophagy. 
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III. Mtb exacerbates HIV-1 replication 
There is strong evidence supporting the capacity of Mtb to enhance HIV-1 replication in vivo. 
Indeed, increased viral loads are found in co-infected patients, both in the bloodstream [691] and at 
the anatomical site of co-infection, especially in the lungs [683], [688], [689]. However, the  
mechanisms explaining how Mtb exacerbates HIV-1 are just beginning to emerge. In this section, I will 
provide an overview of the few mechanisms that have been proposed to explain this phenomenon. 
 
A. Mtb triggers viral transcription in infected cells 
Importantly, HIV-1 replication is particularly enhanced in the lungs, pleural effusion and BAL of co-
infected patients. In fact, high level of HIV-1 proteins were found in lung segments where Mtb is also 
detected compared to those lacking the bacillus from the same individual. This tendency correlated 
with high TNFD concentration in segments positive for both pathogens, arguing that HIV-1 replication 
is locally exacerbated in co-infected patients [683]. The enriched levels of TNFD that come with Mtb 
infection are in part responsible for enhanced HIV-1 transcription in co-infection settings. Indeed, 30 
years ago, TNFD was reported to increase HIV-1 mRNA levels and transcription in a chronically infected 
T cell line. Using gel mobility shift assays, Duh and colleagues found an increased activation of HIV-1 
LTR sequences because of NFNB binding to these sequences, in response to TNFD stimulation [747]. In 
co-infected macrophages, for which the activation profile is determined in terms of HIV-1 
permissiveness, the inhibition of C/EBPE transcription factor leads to increased activation of NFNB that 
binds subsequently to HIV-1 LTR sequences to enhance viral transcription [748]. This inhibition of 
C/EBPE is mediated by Mtb infection. Alveolar macrophages from healthy tissue express high level of 
C/EBPE under its HIV-1 inhibitory form due to sustained IFN-I stimulation. However, this isoform is 
strongly downregulated at the site of infection with Mtb, allowing high HIV-1 replication levels [749]. 
These results also suggest that the pro-inflammatory milieu of active TB overcomes the IFN-I antiviral 
responses. Direct evidence of this hypothesis was shown in HIV-1 infected macrophages where co-
infection with Mtb primarily inhibited viral transcription, but was followed by a substantial increase 
after IL-10 early responses were attenuated by the virus [750]. In fact, IL-10 was shown to inhibit HIV-
1 transcription by inducing the expression of C/EBPE through STAT3 activation [751]. Conversely, pro-
inflammatory cytokines such as TNFD, IL-6 and IL-1E, all up-regulated during Mtb infection, have long 
been established to act synergistically to promote HIV-1 transcription [544], [545], [747], notably by 
modulating macrophages polarization and therefore permissiveness to HIV-1 infection [187]. It is likely 
that this bystander effect, i.e. the polarization of uninfected macrophages by the cytokines released 
upon Mtb-infection of some macrophages, is the main factor inducing susceptibility to HIV-1 infection. 
Indeed, the direct co-infection of macrophages by Mtb and HIV-1 has recently been observed in vivo 
in a model of TB-SIV co-infected NHP [752]. Moreover, Orenstein and colleagues observed the co-
infection of multi-nucleated macrophages by HIV-1 and Mycobacterium avium [753] (Figure 30). 
However, the direct co-infection of macrophages with both pathogens remains a rare event, which 
excludes the direct interaction between HIV-1 and Mtb as the main mechanism by which infected 
macrophages become particularly permissive to the virus. 
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Figure 30: In vivo evidence of co-infected macrophages (from [753])  
Deparaffinized sections of macrophages infected with HIV-1 and Mycobacterium avium complex (MAC). The 
immunohistochemical staining shows HIV p24ʹpositive (red stain) MAC-infected multinucleated giant Langhans 
cells. The clear needle-like intracytoplasmic structures (arrows) represent negative-stained images of bacilli.  
 
 
 
 
 
Figure 31: Mtb infection and TB-associated environment induce C-type lectin receptor expression 
on macrophages. 
Peripheral blood monocytes from healthy, TB and TB-HIV individuals (thanks to our collaboration with Dr L. 
Balboa, IMEX-CONICET, Argentina) were stained for Siglec-1, DC-SIGN and MRC1. Monocytes isolated from TB 
and TB-HIV patients exhibited higher cell surface expression of the C-type lectin receptors (CLR), MRC1 and DC-
SIGN, compared to that found in healthy donors, while Siglec-1 expression was upregulated in co-infected 
patients only. This data indicate that Mtb infection induces the expression of various CLR involved in HIV-1 
binding, which could then be used by the virus to efficiently infect target myeloid cells. 
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B. Mtb accelerates the progression to AIDS by increasing HIV-1 strains 
diversity 
In co-infected patients, Mtb not only supports HIV-1 replication and dissemination through 
dysregulation of host cells receptors, whose expression are modulated by environmental cytokines 
and chemokines, but it also favours HIV-1 heterogeneity both at the site of infection and systemically 
[754]. By increasing CXCR4 levels in alveolar macrophages, Mtb accelerates the progression to AIDS in 
co-infected people, by skewing the switch from R5 to X4 dominant HIV-1 strains [755]. Indeed, in HIV-
1 pathology, disease progression is related to the evolution of HIV-1 strains towards those that use 
CXCR4 co-receptors to enter the cells, which are mainly T cell tropic strains. This switch is allowed by 
the high rate of error made by the viral reverse transcriptase that induces constant mutation of the 
viral genome (see chapter II section II.A.a.i.). In BAL fluids from TB infected patients, CXCR4 expression 
levels are higher than that of CCR5 [755]. Moreover, Mtb infection of macrophages enhances X4-tropic 
virus DNA but not that of R5 viruses, further supporting the selection of X4 tropism in co-infection 
settings. This is due notably to the natural CCR5 antagonist MIP-1E, which is highly concentrated in 
BAL fluids from TB patients [278]. In addition, BAL from co-infected patients displayed a great number 
of HIV-1 gp120 V3 region substitutions that was associated with greater viral heterogeneity [683]. 
Supporting these findings, Collins and colleagues, as well as Biru et al., found that Mtb-HIV-1 co-
infection led to 2- to 3-fold greater mutation frequency in comparison with HIV-1 infection alone, 
resulting in greater diversity of viral strains [687], [756], [757].  
All in all, these studies show that Mtb is able to influence HIV-1 mutations towards X4-tropic 
strains, however, the mechanisms explaining this selection pressure and the identity of the cells 
involved remain to be explored and understand.  
 
C. Mtb renders cells permissive to HIV-1 infection and favours viral cell-to-cell 
transmission 
During the constant activation of the immune system in chronic disease, both in HIV-1 and TB 
pathologies create an environment that polarizes macrophages towards more or less permissive target 
for intracellular pathogen. Previously, macrophages were thought to be terminally differentiated cells 
that were unable to replicate. However, mouse experiment showed that macrophages are able to re-
enter the cell cycle in response to inflammatory stimuli such as helminth infection [758]. In TB 
granuloma, MGLC were found to do so as well, even if they do not complete cytokinesis [759]. It was 
shown that macrophages who enter the cell cycle, but get arrested in G1 phase, downregulate 
SAMHD1 expression, an important restriction factor of HIV-1. Consequently, these macrophages 
become more permissive to HIV-1 infection, as dividing cells are preferentially targeted by the virus 
[428]. In addition to decreased restriction factors expression, Mtb infection not only up-regulates the 
expression of CCR5 and CXCR4, HIV-1 main co-entry receptors [725], [726], but also the expression of 
alternate HIV-1 receptors such as DC-SIGN and MRC1 (Figure 31), both responsible for gp120 binding 
(see chapter II section III.D.a.i.). The induction of DC-SIGN expression by Mtb infection is likely to be 
detrimental to the host in the case of HIV-1 infection. Indeed, HIV-1 binding to DC-SIGN leads to the 
protection of HIV-1 particles in VCC and promote HIV-1 cell-to-cell transfer to T cells [760]. In vitro co-
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culture experiment showed that co-infected macrophages expanded T cell proliferation and promoted 
HIV-1 transmission to these lymphocytes [761]. Mtb therefore promotes HIV-1 dissemination, not only 
by inducing HIV-1 receptors expression on DC and macrophages, but also by recruiting CD4+ target cells 
to the site of co-infection, and more particularly to the granuloma, where Mtb-specific T cells are 
constantly recruited to maintain the structure [675].  
The diversity of models used to study the effect of direct macrophage co-infection, including 
the monocyte cell line THP-1 (which proliferates as opposed to monocyte-derived-macrophages), 
peripheral blood mononuclear cells (PBMC, rich in T cells) and different virulent, avirulent or killed 
strains of Mtb produced contradictory results. While the majority of studies reported an exacerbated 
viral replication in co-infected macrophages due to TNFD production in response to Mtb [683], [748], 
[749], few studies found the opposite, such as reduced HIV-1 replication [762] or TNFD-independent 
exacerbation mechanisms [761]. Moreover, these studies have been performed in co-infected 
macrophages. However, this event is rare, despite the proximity of Mtb- and HIV-1-infected areas in 
the co-infected lungs. Altogether, these observations suggest that the main mechanisms by which Mtb 
exacerbates HIV-1 replication in macrophages are due to bystander effects of Mtb infection, and more 
precisely to the microenvironment created by the bacterial infection (including notably cytokines, 
chemokines and bacterial products). Moreover, the bystander effect of Mtb infection has not been 
explored as much as the co-infected models of macrophages, despite the probability of this effect to 
be more physiological than direct co-infection. That is why, for my PhD work, I focused my research on 
the effect of TB-associaƚed microenǀironmenƚ on macrophage͛s sƵsceptibility to HIV-1 infection, which 
I hope will be complementary to those found in the models of co-infected cells and help covering the 
full spectrum of what really happens in co-infected individuals. 
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Thesis objectives 
 
As stated in the introduction, TB-HIV-1 co-infection is, to date, a major global health issue. HIV-
1 infected individuals are more susceptible to develop active and extra-pulmonary TB, which is the 
major cause of death in HIV-1 infected people. The reason why co-infection is still a worldwide health 
concern is because of the synergy between HIV-1 and Mtb. The mechanisms by which HIV-1 infection 
enhance Mtb growth in the host have been well described. They are mostly related to the global CD4+ 
T cell loss and the modification of the cytokine profile within the co-infected lungs, causing granuloma 
disruption and allowing uncontrolled Mtb growth and spread. By contrast, clinical evidence shows that 
Mtb is responsible for the exacerbation of HIV-1 replication since co-infected patients present with 
increased viral load in their blood and at the anatomical site of co-infection. And yet, the mechanisms 
for this latter point remain poorly understood. As co-infection diagnosis and treatment is complicated 
due to drug interactions, a better understanding of the mechanisms contributing to the synergy 
between both pathogens, and the interplay with the host, is key for developing new treatment 
strategies. 
The principal objective of my PhD project was to identify and characterize novel factors 
participating in the exacerbation of HIV-1 infection by Mtb. I focused on the role of macrophages 
because they are the cellular convergence point for both pathogens. In HIV-1 pathogenesis, 
macrophages are able to sustain HIV-1 replication independently of T cells, they are particularly long-
lived after viral infection, and are part of the viral reservoir. Additionally, they actively participate in 
the dissemination of HIV-1 in the host.  
To study the role of Mtb infection on HIV-1 replication in macrophages, I used a relevant in 
vitro model developed in the laboratory to mimic TB-associated microenvironments, which consist of 
harvested supernatants from either Mtb (cmMTB) or mock-infected (cmCTR) macrophages. These 
supernatants were used to differentiate healthy primary human monocytes towards macrophages. 
Alternatively, to validate the physiological pertinence of the cmMTB treatment, we also used acellular 
pleural effusion fluid from active TB patients (PE-TB), and made important correlations in lung biopsies 
of NHP co-infected with Mtb and SIV.   
The first objective of my PhD project was to determine whether TB-associated 
microenvironments led to the exacerbation of HIV-1 replication in macrophages, and if so, to identify 
the cellular mechanisms involved. The completion of this objective is reflected in my first publication 
as a co-author, for which I made key contributions and is presented in the Results section, in chapter 
I. Briefly, we found that treatment with both cmMTB and PE-TB exacerbated HIV-1 infection in human 
macrophages. We deciphered that the induction of TNT, dependent on the IL-10/STAT3 axis, is the 
cellular mechanism responsible for this exacerbation. Indeed, inhibition of these structures reversed 
HIV-1 replication in cmMTB-treated macrophages to the level of control cells, which were less 
permissive to HIV-1 infection and spread. 
To identify the molecular factors involved in the process described above, I assessed the gene 
expression landscape of cmCTR- versus cmMTB-treated cells by performing a genome-wide 
transcriptomic analysis. This approach revealed IFN-I/STAT1 as the main altered signaling pathways in 
 143 
 
cmMTB-treated cells. Among the strongly upregulated ISG gene signature, Siglec-1 captured our 
attention due to it being known to enhance HIV-1 uptake and viral cell-to-cell transfer from myeloid 
cells to T cells. Therefore, the second objective of my PhD thesis was to understand how the 
upregulation of Siglec-1 expression in a TB-associated environment participates in the exacerbation 
of HIV-1 infection in human macrophages (Results section, chapter II). 
For the third objective of my PhD, I focused on the IFN-I responses in cmMTB-treated 
macrophages. Indeed, our transcriptomic data showed that IFN-I/STAT1 pathway was the main 
modified signaling pathway upon cmMTB treatment. Surprisingly, cmMTB-treated cells were 
distinguished by the accentuation of an ISG-gene signature, which usually indicates an anti-viral state, 
but in our model, this signature appeared to be inefficient to control HIV-1 replication. Therefore, I 
tackled the unexpected ISG-gene signature obtained from the transcriptome analysis. While IFN-I are 
commonly thought to be antiviral, IFN-I are also recognized to be deleterious in chronic viral infections, 
as well as in Mtb-infection setting. Therefore, I investigated the reasons why, in our model, IFN-I do 
not display their usual antiviral activity (Results section, chapter III).  
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Chapter IV:  Tuberculosis exacerbates HIV-1 
infection through IL-10/STAT3-dependent 
tunneling nanotube formation in macrophages. 
 
I. Paper summary 
To date, HIV-1 infection is responsible for a global epidemic. Worsening this public health issue 
is the co-infection with Mtb, responsible for TB. Indeed, both pathogens act in synergy to weaken the 
host immune system, which leads to the acceleration of both pathogeneses. Moreover, the co-
infection is difficult to diagnose since HIV-1 infection is asymptomatic and TB can present atypical 
features in co-infected patients [59], [694], [695]. It has been well established now that Mtb is an 
aggravating factor for HIV-1 pathogenesis, since co-infected patient have higher viral loads both in the 
blood, and at the site of co-infection [682]. While the general mechanisms explaining TB aggravation 
in HIV-1+ individuals are mainly attributed to CD4+ T cell depletion [675], [718], those explaining how 
Mtb exacerbates HIV-1 replication in co-infected host remain scarce.  
Macrophages represent a convergent target for Mtb and HIV-1, and actively participate to the 
infection-associated pathogenesis. As previously mentioned in the introduction (Part I, chapter II), 
macrophages are important target cells for HIV-1 that strongly participate to the viral pathogenesis. 
Indeed, macrophages can be infected through different mechanisms, such as cell-free viruses, 
phagocytosis of infected cells, and cell-to-cell transfer of infectious virions [644]. Once infected, 
macrophages are able to actively produce new viruses, but also to store them in specific cellular 
compartment, the VCC [528]. Moreover, macrophages participate to the viral dissemination, since 
infected macrophages are found in several organs (e.g. brain, lungs, liver) and are part of the viral 
reservoir [482], [485], [491], [763]. These cells are particularly interesting due to their high plasticity: 
they are able to adapt to their microenvironment and to acquire certain functions, depending on the 
context (see preamble section I.B). Both Mtb and HIV-1 are able to manipulate the activation profile 
of macrophages, allowing the pathogens to thrive within the host and to escape the immune system 
[187], [188]. In the case of TB, my team at IPBS previously showed that TB-associated 
microenvironments induce the differentiation of monocytes towards ͞MϮ͟ macrophages [764]. More 
precisely, the phenotype acquired by these macrophages is driven by IL-10 present in the TB-
associated microenvironment and characterized by the upregulation of CD16, CD163 and MerTK, a 
strong activation of STAT3, an increased capacity to migrate in dense matrices and a higher 
susceptibility to Mtb infection. Moreover, the team also showed that the abundance of these M(IL-10) 
macrophages in TB patients blood and in the lung of Mtb-infected macaques correlated with TB disease 
severity [764]. 
Clinical evidence indicate that co-infected individuals have higher viral loads in their blood and 
at the anatomical site of co-infection. However, it is unknown if this phenomenon is due to the co-
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infection with both Mtb and HIV-1 in the same macrophage, and such an observation has only been 
reported once in vivo in a model of NHP co-infection with Mtb and SIV [752], suggesting that this is a 
rare event. Therefore, we hypothesized that the exacerbation of the viral replication in macrophages 
is due to a bystander effect of Mtb-infection. In this first study, we asked whether the M(IL-10) 
activation profile of macrophages was sustained during subsequent HIV-1 infection and if it could 
affect the viral replication. We showed that TB-associated microenvironments, mimicked with either 
supernatant from Mtb-infected macrophages (cmMTB) or pleural effusion fluids from TB patient (PE-
TB), increase both the  rate of HIV-1 infection of macrophages (3x-fold) and the viral replication (4x-
fold) compared to control cells. This phenomenon is specific of Mtb infection since the conditioning of 
monocytes with pleural effusion from patients with cancer or heart failure did not induce the 
exacerbation of HIV-1 replication in these cells. We also confirmed that the M(IL-10) phenotype is 
conserved after HIV-1 infection, and looked for the mechanism(s) involved in the exacerbation of the 
viral replication. First, we found that the viral entry was not enhanced in cmMTB-macrophages, while 
we observed an increase in CCR5 and CXCR4 cell-surface expression. Second, the expression level of 
the main restriction factors (i.e. IFITM, SAMHD1 and C/EBPE) were not affected in cmMTB-treated 
cells; neither was the autophagic response of these cells. By contrast, we finally observed that cmMTB 
conditioning triggered the formation of TNT (see chapter II, section III.D.e.). Both thin (F-actin 
containing TNT, usually with a diameter < 0.7 µm) and thick (F-actin and microtubule-containing TNT, 
with a diameter > 0.7 µm allowing them to transport small organelles such as mitochondria or vesicles) 
were induced by cmMTB, and further enhanced upon HIV-1 infection. This increased formation of TNT 
is responsible for the enhanced viral replication and dissemination, since the pharmacological 
inhibition of these structures by a published inhibitor (TNTi) [669] reversed the infection levels to that 
of cmCTR-cells (cells differentiated with the supernatant of mock-infected macrophages). Finally, by 
pharmacologically inhibiting STAT3, and by replacing cmMTB conditioning by an IL-10 treatment for 3 
days prior to HIV-1 infection, we identified the IL-10/STAT3 axis as the pathway involved in TNT 
formation.  
During TB pathogenesis, the number of CD14+CD16+ monocytes is increased in the blood of 
Mtb-infected [764]. Here, we assessed the presence of this population, and more particularly the 
presence of M(IL-10) by measuring the soluble form of MerTK and CD163 (sMerTK and sCD163 
respectively), which are both subject to shedding and characteristic of M(IL-10) macrophages. We 
found an increased level of both soluble markers in the plasma of TB patient, which was further 
enhanced in TB-HIV-1 co-infected patients compared to healthy subjects. In addition, the number of 
CD163+ macrophages, which were also pSTAT3+, in the lungs of healthy, SIV-infected, Mtb-infected or 
Mtb-SIV co-infected macaques correlated with the disease severity, which was the strongest in co-
infected animals. Therefore, the cmMTB-model is relevant to mimic the in vivo pathology in the context 
of co-infection.  
In this study, we evidenced that in the context of TB-HIV-1 co-infection, the microenvironment 
associated to Mtb-infection renders macrophages highly susceptible to HIV-1 infection and replication 
through the formation of TNT, which favour the viral dissemination from one cell to another. 
II. Results
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SUMMARY
The tuberculosis (TB) bacillus,Mycobacterium tuber-
culosis (Mtb), and HIV-1 act synergistically; however,
the mechanisms by which Mtb exacerbates HIV-1
pathogenesis are not well known. Using in vitro and
ex vivo cell culture systems, we show that human
M(IL-10) anti-inflammatory macrophages, present in
TB-associated microenvironment, produce high
levels of HIV-1. In vivo, M(IL-10) macrophages are
expanded in lungs of co-infected non-human pri-
mates, which correlates with disease severity.
Furthermore, HIV-1/Mtb co-infected patients display
an accumulation of M(IL-10) macrophage markers
(soluble CD163 and MerTK). These M(IL-10) macro-
phages form direct cell-to-cell bridges, which we
identified as tunneling nanotubes (TNTs) involved in
viral transfer. TNT formation requires the IL-10/
STAT3 signaling pathway, and targeted inhibition of
TNTs substantially reduces the enhancement of
HIV-1 cell-to-cell transfer and overproduction in
M(IL-10) macrophages. Our study reveals that TNTs
facilitate viral transfer and amplification, thereby pro-
moting TNT formation as amechanism to be explored
in TB/AIDS potential therapeutics.
INTRODUCTION
Worldwide, individuals co-infected with Mycobacterium tuber-
culosis (Mtb), the agent of tuberculosis (TB), and the AIDS virus,
HIV-1, pose particular clinical challenges not only because a
significant proportion of co-infected patients remain sputum
smear-negative, hampering TB diagnosis, but also because
HIV-1 infection makes these individuals more prone to TB reac-
tivation (World Health Organization [WHO] TB 2016, Joint United
Nations Programme on HIV and AIDS [UNAIDS] Report 2016)
(Getahun et al., 2007). At the heart of this problem is the synergy
between HIV-1 and Mtb, which interferes with treatment and
promotes the pathogenesis of both pathogens (Diedrich and
Flynn, 2011; Diedrich et al., 2016). On the one hand, CD4+
T cell decay and other mechanisms induced by HIV-1 are a
leading cause for reactivation of latent TB and progression to
active TB disease in AIDS patients (Bell and Noursadeghi,
2018; Tomlinson et al., 2013). On the other hand, clinical and
epidemiological data clearly identify TB as a risk factor ampli-
fying HIV-1-associated morbidity and mortality (Toossi, 2003).
However, the mechanisms by which Mtb exacerbates HIV-1
infection require further investigation (Charles and Shellito,
2016; Esmail et al., 2018; Toossi, 2003; Bell and Noursadeghi,
2018). Addressing this issue should help in developing strate-
gies for the attenuation of viral activation in co-infected subjects
and for a better control of the AIDS epidemic (Diedrich and
Flynn, 2011).
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Lung macrophages are the primary host cells for Mtb (O’Garra
et al., 2013; Russell et al., 2010). While CD4+ T cells are themajor
target cells for HIV-1, macrophages, including those in the lungs,
are also infected by HIV-1 in humans (Bell and Noursadeghi,
2018; Cribbs et al., 2015) and by simian immunodeficiency virus
(SIV) in experimentally infected non-human primates (NHPs)
(Avalos et al., 2016). Recent data indicate that macrophages
play an important role in HIV-1 pathogenesis (Honeycutt et al.,
2016, 2017; Sattentau and Stevenson, 2016) and may also be
involved in HIV-1/Mtb co-infection (Khan and Divangahi, 2018;
Kuroda et al., 2018). In HIV-1-infected individuals with active
TB, for example, macrophages from the lungs and pleural effu-
sions (PEs) exhibit high levels of HIV-1 infection (Lawn et al.,
2001; Toossi, 2003). Furthermore, Mtb increases the level of
HIV-1 infection either in vitro in monocyte-derived macrophages
or ex vivo in lungmacrophages obtained frompatientswith HIV-1
(Mancino et al., 1997; Toossi et al., 1997). It is presently unclear
how a TB-associated microenvironment renders macrophages
more susceptible to HIV-1.
Macrophages display considerable heterogeneity in tissues
(Gordonet al., 2014). Thebroad spectrumofpro- (M1) andanti-in-
flammatory (M2) activation programs are a manifestation of the
different levels of response to HIV-1 and Mtb infections (Cassol
et al., 2009; Lugo-Villarino et al., 2011).Wehave shown that active
TBskewshumanmonocytedifferentiation towardM2-likemacro-
phages, distinguished by a CD16+CD163+MerTK+ phenotype, as
well as by increased immunomodulatory activity andMtb permis-
sivity (Lastrucci et al., 2015). This phenotype is dependent on the
interleukin-10 (IL-10)/STAT3 signaling axis and is closely related
to the so-called ‘‘M(IL-10)’’ activation program (Murray et al.,
2014). We further reported that the abundance of M(IL-10) cells
correlates with TB severity in patients and NHPs (Lastrucci
et al., 2015). Herein, we investigated whether the TB-induced
M(IL-10) macrophage activation program also plays a role in pro-
moting HIV-1 infection in co-infected individuals.
RESULTS
TB-Associated Microenvironment Increases HIV-1
Infection in Human Macrophages
To determine whether HIV-1 replication is modulated in TB-
induced M(IL-10) macrophages, we employed our previously
described in vitro model (Lastrucci et al., 2015), which uses
conditioned medium from either mock-infected macrophages
(CmCTR) or Mtb-infected macrophages (CmMTB). CmMTB
triggered primary human monocytes to differentiate into M(IL-
10) macrophages, which activated STAT3, as well as acquired
a CD16+CD163+MerTK+PD-L1+ receptor signature, similar to
differentiatedM(IL-10) macrophages observed in vivo (Figure S1;
Lastrucci et al., 2015). When macrophages treated with either
CmCTRorCmMTBwere then infectedwithHIV-1ADA (Figure1A)
orNLAD8 strain (data not shown) (Raynaud-Messina et al., 2018),
we observed a substantial increase in viral replication, as
measured by the level of the viral protein p24 in culture superna-
tants, only in the CmMTB-treated M(IL-10) macrophages (Fig-
ures 1B and S2A). In addition, the number of HIV-1-infected cells
increased by 3-fold, as measured by the expression of the HIV-1
Gag protein (Figures 1C and 1D). TheM(IL-10) receptor signature
was maintained upon HIV-1 infection (Figure S1). HIV-1 infection
of macrophages enhanced their migration capacity in dense
3-dimensional matrices, together with their fusion potential,
forming multinucleated giant cells (MGCs) (Orenstein, 2000;
Ve´rollet et al., 2010, 2015a). We found that these properties,
known to contribute to viral dissemination (Ve´rollet et al.,
2015a, 2015b), were further amplified specifically in M(IL-10)
macrophages infected with HIV-1 (Figures S2B–S2E).
PE fluid from TB patients (PE-TB) was used as an ex vivo TB-
associated microenvironment model (Genoula et al., 2018). PE is
observed in up to 30% of TB patients and results from infection-
induced local inflammation and recruitment of leukocytes into
the pleural space (Vorster et al., 2015). In co-infected patients,
the formation of PE is more common than in TB patients and
PE contains high viral titers, compared to serum from the same
patient (Collins et al., 2002; Toossi, 2003). Unlike control PE ob-
tained from non-TB patients (PE-non-TB), differentiation of mac-
rophages in the presence of PE-TB (Table S1; Figure 1A) yielded
theM(IL-10) phenotype (Figures S3A and S3B), similar to macro-
phages isolated fromPE-TB (Lastrucci et al., 2015). ThisM(IL-10)
phenotype also correlated with the high level of soluble IL-10
contained in PE-TB compared to PE-non-TB (Figure S3C). We
found that cell treatment with PE-TB increased the production
of HIV-1 by 6-fold and increased the number of infected macro-
phages and MGCs (Figures 1E–1G and S3D).
Collectively, using CmMTB- and PE-TB-conditioned macro-
phages as model systems, we show that HIV-1 production
by M(IL-10) macrophages is enhanced in a TB-associated
microenvironment.
M(IL-10) Cells Accumulate in Co-infected NHPs and
Patients
To investigate M(IL-10) cells in HIV-1/Mtb co-infections, we
compared, by using CD163 and pSTAT3 staining (Lastrucci
et al., 2015), the number of M(IL-10) macrophages in pulmonary
samples fromNHPs that hadbeen (1) co-infectedwithMtb (active
or latent TB) and SIV; (2) mono-infected with Mtb (active or latent
TB); (3) mono-infected with SIV (Cai et al., 2015; Kuroda et al.,
2018); or (4) uninfected (Tables S2 and S3). Histological staining
revealed abundant CD163+ and nuclear pSTAT3+ cells in co-in-
fected NHPs (Figures 2A and 2B). While the detection of pSTAT3
is not specific to macrophages, double-staining analysis demon-
strated that most CD163+ alveolar macrophages were also posi-
tive for nuclear pSTAT3 (Figure 2C). The increased abundance of
CD163+ and pSTAT3+ cells was correlated with the severity of
lung histopathology (Table S3) and the gross pathological status
of the animals, as analyzed in 30 organs (Figures 2D and 2E).
We have previously shown that CD14+CD16+ circulating
monocytes have a predisposition to differentiate into M(IL-10)
macrophages in patients with active TB (Lastrucci et al., 2015).
Here, we confirmed that CD14+CD16+ monocytes are expanded
in the peripheral blood of TB, HIV-1, and co-infected patients,
compared to healthy subjects (Balboa et al., 2011; Ellery et al.,
2007; Ziegler-Heitbrock, 2007) (Table S1; Figure S4A). We exam-
ined two cell surface markers characteristic of the M(IL-10)
phenotype, which are selectively expressed in the monocytic
lineage, CD163 and MerTK, and which are both subjected to
inflammation-driven shedding (Fabriek et al., 2005; Sather
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et al., 2007). We found that the soluble forms of these receptors
(sCD163 and sMer), but not their membrane-bound forms, were
substantially increased in co-infected patients when compared
to mono-infected patients and healthy subjects (Figure 3). The
amount of these soluble factors correlated with one another
(Figure S4B). Receiver operating characteristic (ROC) curve
analyses for plasma concentration of sCD163 and sMer (Figures
S4C and S4D) suggested both molecules may be useful bio-
markers for co-infection.
Our findings reveal the extent of the in vivo expansion of TB-
induced M(IL-10) cell population in co-infected individuals.
They also identify potential biomarkers for diagnosis and moni-
toring TB in co-infected patients.
TB-Associated Microenvironments Enhance Tunneling
Nanotube Formation
TB-associated microenvironment could increase the level of
HIV-1 in M(IL-10) macrophages by modulating viral (1) entry, (2)
replication, (3) clearance, (4) infectivity of the produced virions,
and/or (5) cell-to-cell transmission. We tested each of these pos-
sibilities in turn. Although cell-surface expression of the HIV-1
entry receptors CD4, CCR5, and CXCR4 was increased in
CmMTB-treated cells compared to control cells (Figure 4A), virus
entry was unchanged in these cells, as shown using the BlaM-
Vpr fusion assay (Cavrois et al., 2002) (Figure 4B). The expres-
sion level of several host factors known to be involved in HIV-1
replication (CEBP-b and CUGBP1) or restriction (IFITM proteins
and SAMHD1) was not modified by CmMTB (Figures 4C–4F). As
autophagy represents a viral clearance mechanism known to be
inhibited by HIV-1 or Mtb infection in macrophages (Espert et al.,
2015), wemeasured the autophagic flux and found it to be similar
between CmMTB- and CmCTR-treated cells (Figure 4G).
Furthermore, the infectivity of viruses produced in CmMTB con-
ditions was comparable to those produced in CmCTR-treated
cells (7.7% ± 2.1% of p24-positive TZM-bl [Ve´rollet et al.,
2015a] for CmMTB-treated macrophages versus 10.3% ±
3.5% for CmCTR-treated cells; n = 3; p = 0.5066).
Finally, we investigated whether cell-to-cell virus transfer was
influenced by TB-associatedmicroenvironment. Tunneling nano-
tube (TNT) formation has been proposed as a macrophage-to-
macrophage transmissionprocess for host andmicrobialmaterial
(Dupont et al., 2018; Eugenin et al., 2009; Hashimoto et al., 2016;
Okafo et al., 2017). Importantly, TNT formation is triggered by
HIV-1 infection of macrophages and it has been associated with
Figure 1. TB-Induced Microenvironment
Exacerbates HIV-1 Infection of M(IL-10)
Macrophages
(A) Representation of the experimental design
of two in vitro models. Briefly, monocytes from
healthy subjects were treated either with condi-
tioned medium from mock-infected (CmCTR)
or Mtb-infected macrophages (CmMTB), or
with pleural effusions (PEs) from TB (PE-TB) or
non-TB (PE-nonTB) patients for 3 days. Cells
were then infected with HIV-1 ADA strain at MOI
of 0.1 and kept in culture for at least 10 more
days.
(B) Vertical scatterplot showing p24 concentra-
tion from day 13 supernatants of HIV-1-infected
macrophages treated with CmCTR or CmMTB.
(C) Vertical scatterplot showing the infection index
of day 13 HIV-1-infected macrophages treated
with CmCTR or CmMTB. Infection index was
calculated as 100 3 the ratio of the area covered
by Gag+ cells over the total cell area, measured
from immunofluorescence (IF) images.
(D) Representative IF images of day 13 HIV-1-
infected macrophages treated with CmCTR or
CmMTB. HIV-1 Gag (red), F-actin (green), and
DAPI (blue). Scale bar, 500 mm. Insets are 43
zooms (lower panels).
(E) Vertical scatterplot showing p24 concentration
from day 13 supernatants of HIV-1-infected mac-
rophages treated with PE-TB or PE-nonTB.
(F) Vertical scatterplot showing the infection index
of day 13 HIV-1-infected macrophages treated
with PE-TB or PE-nonTB.
(G) Representative IF images of day 13 HIV-1-
infected macrophages treated with PE-nonTB or
PE-TB. HIV-1 Gag (red), F-actin (green), and DAPI
(blue). Scale bar, 500 mm. Insets are 43 zooms
(lower panels). Each circle within vertical scatterplots represents a single donor. Mean value is represented as a dark gray line.
In this figure, PE-nonTB are parapneumonic PE. Statistical analyses: two-tailed, Wilcoxon matched-paired signed rank test (B and C); paired t test (E and F).
**p % 0.005; ***p % 0.0005; ****p % 0.0001. See also Figures S1–S3.
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Figure 2. Accumulation of M(IL-10) Macrophages in the Lung of Co-infected NHPs Correlates with Pathology
(A) Representative immunohistochemical images illustrate higher number of CD163+ cells and p-STAT3+ cells in lung biopsies of SIV-Mtb-infected NHPs
compared to Mtb or SIV mono-infected NHPs. Scale bar, 100 mm. Insets are 43 zooms.
(B) Quantification of the number of CD163+ cells (left) and p-STAT3+ cells (right) per square millimeter of lung tissue of healthy (H), SIV-infected, Mtb-infected, and
SIV-Mtb-co-infected NHPs.
(C) Immunohistochemistry staining of lung biopsy of SIV-Mtb co-infected NHP showing the nuclear localization of p-STAT3 (red, center) in CD163 alveolar
macrophages (green, top). Nuclei are stained using DAPI (blue, bottom). Scale bar, 50 mm. Insets are 1.33 zooms.
(legend continued on next page)
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an increase in viral replication (Eugenin et al., 2009; Hashimoto
et al., 2016). TNTs are long-range membranous F-actin-contain-
ing tubes, not in contact with the extracellular substrate, which
are classified into two types based on their thickness and on
whether they contain microtubules (Ariazi et al., 2017; Dupont
et al., 2018;McCoy-Simandle et al., 2016; Onfelt et al., 2006) (Fig-
ure5A). TreatmentwithCmMTB increased thepercentageof cells
forming both types of TNTs by more than 2-fold (Figures 5A and
5B), compared to CmCTR-treated cells, and HIV-1 infection
further amplified this phenomenon (Figures 5B and 5C).
Using different microscopy approaches, we further charac-
terized TNTs in macrophages as induced by TB-associated
microenvironment. TNTs are (1) long (up to 200 mm in length),
actin-containing structures connecting two cells, which are
above the surface of the substrate (Figures 5D, S5A, and
S5B; Videos S1 and S2) (Dupont et al., 2018); (2) positive for
M-Sec, a regulator of TNT formation (Hase et al., 2009) (Fig-
ure S5C; Video S4); and (3) inhibited by cytochalasin D treat-
ment (39% ± 5% of TNTs in HIV-1-infected CmMTB-treated
macrophages versus 6% ± 4% upon 2 mM Cytochalasin D
treatment; n = 3; p = 0.0003). We also observed that
CmMTB-induced TNTs contained HIV-1 material and particles
(Figures 5E and 5F; Video S3). Of note, we detected putative
TNT-like structures in pulmonary samples from NHPs co-in-
fected with Mtb and SIV, as revealed by H&E staining, or by
immunohistochemistry targeting CD163-positive macrophages
(Figure S5D).
Taken together, these data indicate that TB-associatedmicro-
environments do not affect the entry, replication, or turnover
of HIV-1. Instead, they trigger the formation of TNTs in M(IL-10)
macrophages that appear to contain HIV-1 particles.
IL-10/STAT3 Promotes TNTs and Increased Viral
Production in Macrophages
We have previously reported that the expansion of M(IL-10)
macrophages relies on the IL-10/STAT3 signaling pathway
(Lastrucci et al., 2015). To study how TB-associated microenvi-
ronment triggers the formation of TNTs in macrophages, we
examined whether IL-10/STAT3 signaling was required for
TNT formation and increased HIV-1 production induced by
TB-associated microenvironment. Recombinant IL-10 triggered
M(IL-10) macrophage differentiation (Lastrucci et al., 2015) (Fig-
ure S6A), increased TNT formation (Figure 6A) and recapitulated
the TB-driven expansion of HIV-1 infection, as measured by p24
release, number of infected cells (Figure 6B), and formation of
MGCs (Figure S6B). Depletion of IL-10 from CmMTB abolished
enhanced TNT formation, the increase in HIV-1 replication in
M(IL-10) cells, and the increase in MGCs (Figures 6C, 6D, and
S6C). We examined the role of STAT3 activation by pharmaco-
logical inhibition with Stattic, which targets the STAT3 SH2
domain to prevent association with upstream kinases and abro-
gates STAT3 phosphorylation and the associated M(IL-10)
phenotype (Lastrucci et al., 2015). Stattic treatment inhibited
both the CmMTB-driven TNT formation and the increase in
HIV-1 production (Figures 6E and 6F), along with enhanced
cell migration and formation of MGCs (Figures S2E and S6D).
Of note, treatment of monocytes with other cytokines prior
to HIV-1 infection does not trigger TNT formation significantly,
indicating that IL-10 is one of themain factor involved in this pro-
cess (Figure S6E).
Our data demonstrate that TB-associated microenvironment
controls TNT formation and increase HIV-1 infection in macro-
phages. In addition, they reveal the IL-10/STAT3 axis as a
signaling pathway involved in TNT formation.
(D) Vertical scatterplot showing the pathological scoring of NHPs used in this study (see Table S3).
(E) Correlation between CD163+ cells (left) or p-STAT3+ cells (right) per squaremillimeter of lung tissue and pathological score in the indicated NHPs. Each symbol
within vertical scatterplots represents a single animal. Mean value is represented as a dark gray line.
Statistical analyses: two-tailed Mann-Whitney (B and D). *p% 0.05; **p% 0.005; ns, not significant. See also Tables S2 and S3.
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Figure 3. Systemic Expansion of the M(IL-10) Monocyte Population
in Co-infected Patients
(A) Vertical scatterplots showing the median fluorescence intensity (MFI) of
cell-surface marker CD163 on CD14+ monocytes from peripheral blood (PB)
of healthy subjects, TB patients (TB), and HIV/Mtb co-infected patients
(HIV/TB).
(B) Vertical scatterplots showing the amount of sCD163, the cleaved form of
CD163 in the serum of healthy subjects and TB, HIV, and HIV/TB patients.
(C) Vertical scatterplots showing the MFI of cell-surface marker MerTK on
CD14+ monocytes from PB of healthy subjects and TB and HIV/TB patients.
(D) Vertical scatterplots showing the amount of sMer, the cleaved form of
MerTK, in the serum of healthy subjects and TB, HIV, and HIV/TB patients.
Each circle within vertical scatterplots represents a single donor. Mean value is
represented as a dark gray line.
Statistical analyses: two-tailed, Mann-Whitney (A–C); unpaired t test (D).
*p% 0.05; **p% 0.005; ***p% 0.0005; ns, not significant. See also Figure S4
and Table S1.
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Figure 4. The TB-Driven Exacerbation of HIV-1 Infection in Macrophages Is Not Due toModulation in Viral Entry, HIV-1-Related Activation or
Restriction Factors, or Autophagy
(A) Vertical scatterplots showing the median fluorescence intensity (MFI) of cell-surface receptors involved in HIV-1 entry (CD4, CCR5, CXCR4) on monocytes
differentiated for 3 days under the presence of CmCTR and CmMTB. Each circle within vertical scatterplots represents a single donor. Mean value is represented
as a dark gray line.
(B) Histogram showing the percentage of HIV-1 fusion with CmCTR (white)- or CmMTB (black)-pre-treated cells, as determined using the Blam-Vpr assay in the
presence of entry inhibitor Maraviroc (dashed bars).
(C) Left: representative images of western blot analysis illustrating the expression of IFITM1/2/3 and Actin as loading control. Right: quantification of IFITM1/2/3
expressed as a ratio related to actin of monocytes differentiated for 3 days into macrophages under the presence of CmCTR (white) and CmMTB (black). n = 6
donors.
(D) Representative images of western blot analysis illustrating the expression of SAMHD1 and its phosphorylated version (pSAMHD1), and Actin as loading
control (left). Quantification of SAMHD1 (center) pSAMHD1 (right) expressed as a ratio related to actin of monocytes differentiated for 3 days into macrophages
under the presence of CmCTR and CmMTB. n = 11 donors.
(legend continued on next page)
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TNTs Participate in the High Viral Production in M(IL-10)
Macrophages
To determine whether TNT formation is involved in the increased
HIV-1 production in M(IL-10) macrophages, we used a previ-
ously described pharmacological inhibitor of TNT formation,
TNTi (Hashimoto et al., 2016). We observed that TNTi inhibited
the TNT-mediated transfer of fluorescent material between
Di0-stained cells and CellTracker-positive cells (Figure S7A),
without affecting macrophage viability, or F-actin-dependent
processes like podosome formation and phagocytosis (Mari-
donneau-Parini, 2014) (Figures S7B–S7E). In TB-induced
M(IL-10) macrophages infected with HIV-1, TNTi strongly
inhibited TNT formation (Figure 7A), significantly diminished
HIV-1 overproduction (Figure 7B), and reduced MGC formation
(Figure S7F).
Unlike in T lymphocytes, the transfer of HIV-1 particles via
TNTs has been suggested but not formally demonstrated in
macrophages (Dupont et al., 2018; Eugenin et al., 2009; Hashi-
moto et al., 2016; Okafo et al., 2017). Thus, we set up a co-
culture system between M(IL-10) macrophages to assess the
transfer of the viral Gag protein from infected donor cells to
uninfected recipient cells. Uninfected (recipient, CellTracker+,
green) and HIV-1-infected (donor, Gag+, red) macrophages
were either co-cultured or separated by a transwell membrane
that blocks cell-to-cell connections (Figure 7C). Importantly,
TNT quantification showed that productively infected macro-
phages preferentially formed TNT (38% ± 6% of TNT formation
in Gag+ cells compared to 21% ± 7% in non-infected Cell-
Tracker+ cells; n = 5; p = 0.0003). After 24 h in co-culture, we
observed that donormacrophageswere able to transfer the virus
to recipient macrophages, which became HIV-1 positive (Fig-
ure 7D; Videos S5 and S6). By contrast, the transfer of HIV-1
from donor to recipient macrophages was blocked in the trans-
well cultures (Figure 7E), showing that cell-to-cell contacts are
involved in this process. In co-culture experiments, TNTi signifi-
cantly diminished the capacity of M(IL-10) macrophages to
transfer HIV-1 to recipient cells (Figure 7E), indicating that TNT
formation is responsible for cell-to-cell viral spread.
These results establish a role for TNTs in spreading the virus
betweenM(IL-10)macrophages, uncovering a key cellularmech-
anism responsible for HIV-1 overproduction in the context of TB.
DISCUSSION
TB is the most common co-infection among people living with
HIV-1 and is a leading cause of AIDS-related deaths. Here, we
asked whether TB-associated microenvironment influences the
control of HIV-1 infection in human macrophages. We report
that M(IL-10) macrophages (CD163+MerTK+CD16+pSTAT3+),
which accumulate in TB patients and can be derived in vitro
from TB-associated microenvironment, are highly permissive
for HIV-1 production. This exacerbation of HIV-1 infection in-
volves the IL-10/STAT3 signaling axis, which controls TNT for-
mation, thus enhancing cell-to-cell transfer of the virus in our
experimental systems. In vivo, M(IL-10) cells are more abundant
in co-infected individuals compared to mono-infection settings.
We have identified potential biomarkers, sCD163 and sMer,
in the blood of co-infected patients, which could be used to
monitor disease progression, as their expression correlates
with the severity of the pathology. All things considered, our
study makes three important contributions to the general under-
standing of how TB exacerbates HIV-1 infection.
First, we show that M(IL-10) macrophages (CD163+pSTAT3+)
accumulate in co-infected patients and NHPs. In co-infected
NHPs, we observe M(IL-10) macrophages in great abundance
in the lung environment, including the alveolar space and the
lung interstitial tissue. M(IL-10) macrophage abundance in lungs
is correlated with the pathological score of the animals, arguing
for the physiological and pathological pertinence of thesemacro-
phages. Thesemacrophages are likely driven by the IL-10/STAT-
3 signaling pathway and originate from CD14+CD16+ monocytes
(Lastrucci et al., 2015), which are increased in the blood of pa-
tients with active TB, regardless of their HIV-1 infection status
(Ziegler-Heitbrock, 2007). Monocytes are the only circulating leu-
kocytes known to express membrane-bound CD163 and MerTK
(Fabriek et al., 2005; Sather et al., 2007). As these membrane re-
ceptors are subjected to inflammation-driven shedding (Fabriek
et al., 2005; Sather et al., 2007), their soluble form in the blood
can be used as a proxy for estimating the abundance of
CD14+CD16+ monocytes in the circulation. Here, we show that,
in HIV-1+ patients with active TB, the plasma levels of both
sCD163 and sMer are significantly higher than those found in
healthy subjects, HIV-1- or Mtb-infected patients. sCD163 is
already described as a clinical indicator of monocyte activation
in HIV-1 patients (Burdo et al., 2011), as an indicator of lesions
and accumulation of macrophages in the brain of SIV-infected
NHPs (Burdo et al., 2010), and as an independent predictor of
survival in TB (Knudsen et al., 2005). Although our findings will
need to be expanded in larger cohorts, they nevertheless reveal
both sCD163 and sMer as potential tools for the diagnosis and
disease monitoring in HIV-1/Mtb co-infected patients. Because
TB diagnosis in HIV-1-infected individuals remains a major
(E) Representative images of western blot analysis illustrating the expression of C/EBP-b (LAP), C/EBP-b (LIP), and Actin as loading control (left). Quantification of
C/EBP-b (LAP, center left) and C/EBP-b (LIP, center right) expressed as a ratio related to actin, and LAP expressed as a ratio related to LIP (right), of monocytes
differentiated for 3 days intomacrophages under the presence of CmCTR andCmMTB. n = 9 donors. LAP is an activator of HIV-1-LTR, whereas LIP is a repressor
of HIV-1-LTR.
(F) Representative images of western blot analysis illustrating the expression of CUGBP1 and Actin as loading control (left). Quantification of CUGBP1 expressed
as a ratio related to actin (right) of monocytes differentiated for 3 days into macrophages under the presence of CmCTR and CmMTB. n = 9 donors.
(G) Quantification of LC3-II expression as a ratio to actin of monocytes differentiated for 3 days under the presence of CmCTR and CmMTB at the indicated time
points after 2 h treatment with Bafilomycin A1 (BafA1) or DMSO as control, as measured by western blot analysis. Uninfected cells at day 3 of the experiment (left;
n = 6 donors), and HIV-infected cells at 1 (day 4; center; n = 4 donors) and 3 (day 6; right; n = 6 donors) days post-infection. Each circle within vertical scatterplots
represents a single donor. Mean value is represented as a dark gray line.
Data in histograms are represented as mean ± SD. *p% 0.05; **p% 0.005; ***p% 0.0005; ****p% 0.0001.
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Figure 5. TB Enhances HIV-1-Induced TNT Formation
(A) Representative immunofluorescences image (IF) of macrophages interconnected through thick (left) and thin (right) TNTs. F-Actin (red), Tubulin (green), and
DAPI (blue). Scale bar, 20 mm. The arrows point at the thin TNT without microtubules.
(B) Stacked bars showing the percentage of cells with thick (gray) and thin (white) TNTs of day 6 uninfected or HIV-1-infected macrophages treated with CmCTR
or CmMTB. Data in histograms are represented as mean ± SD.
(C) Representative wide-field IF images showing F-actin staining in day 6 HIV-1-infected macrophages, treated with CmCTR or CmMTB. Arrows, thick TNTs;
arrowheads, thin TNTs. Scale bar, 20 mm.
(legend continued on next page)
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clinical challenge (Getahun et al., 2007), sCD163 and sMer may
hold great promise as biomarkers in these populations.
Second, our study reveals that M(IL-10) macrophages are
highly susceptible to HIV-1 infection. This is accompanied by
enhanced MGC formation and protease-dependent migration
capacity, which could play a role in HIV-1 dissemination (Ve´rollet
et al., 2015b). All of these effects are fully dependent on the anti-
inflammatory IL-10/STAT3 signaling pathway. Most of our work
has been done with the ADA HIV-1 strain, which is a useful lab-
oratory strain that can infect efficiently macrophages with low
CD4 levels. However, these viruses are rather rare in the blood
(D) Scanning electron microscopy images showing TNTs of day 6 HIV-1-infected macrophages, treated with CmMTB. Arrows, thick TNTs; arrowheads, thin
TNTs. Scale bar, 20 mm.
(E) Deconvolution microscopy images showing HIV-1 Gag intra-TNT distribution in day 6 HIV-1-infected macrophages, treated with CmMTB. HIV-1 Gag (red),
F-actin (green), and DAPI (blue). Scale bar, 20 mm. Insets are 33 zooms.
(F) Immunofluorescence (IF) images showing viral particles in TNT of day 6 HIV-1-Gag-iGFP-infected macrophages previously treated with CmMTB. HIV-1-Gag-
GFP (green), F-actin (red), and DAPI (blue). Scale bar, 10 mm. Inset is 43 zoom.
Statistical analyses: two-tailed paired t test (B). *p% 0.05; **p% 0.005; ***p% 0.0005; ****p% 0.0001; ns, not significant. See also Figure S5 and Video S3.
Figure 6. TB-Driven TNT Formation and
Increased HIV-1 Infection Are Dependent
on the IL-10/STAT3 Axis
(A) Stacked bars showing the percentage of cells
with thick (gray) and thin (white) TNTs of day 6
HIV-1-infected macrophages untreated or treated
with recombinant IL-10 (10 ng/mL).
(B) Vertical scatterplots showing p24 concentra-
tion (left) and infection index (right) of day 13 HIV-
1-infected macrophages untreated or treated with
recombinant IL-10 (10 ng/mL).
(C) Stacked bars showing the percentage of cells
with thick (gray) and thin (white) TNTs of day 6
HIV-1-infected macrophages treated with IL-10-
depleted (a-IL-10) CmMTB and mock depletion
controls (a-IgG) of CmCTR and CmMTB.
(D) Vertical scatterplots showing p24 concentra-
tion (left) and infection index (right) of day 13 HIV-1-
infectedmacrophages treated with IL-10-depleted
(a-IL-10) CmMTB and mock depletion controls
(a-IgG) of CmCTR and CmMTB.
(E) Stacked bars showing the percentage of cells
with thick (gray) and thin (white) TNTs of day 6 HIV-
1-infected macrophages treated with CmCTR,
CmMTB, or CmMTB in the presence of the STAT3
activation inhibitor, Stattic (1 mM).
(F) Vertical scatterplots showing p24 release (left)
and infection index (right) of day 13 HIV-1-infected
macrophages treated with CmCTR, CmMTB, or
CmMTB in the presence of the STAT3 activation
inhibitor, Stattic (1 mM).
Statistical analyses: two-tailed, Wilcoxon
matched-paired signed rank test (B and D, right,
and F); paired t test (A–D, left, and E). *p % 0.05;
**p % 0.005; ***p % 0.0005; ns, not significant.
See also Figures S2 and S6.
(Joseph and Swanstrom, 2018). As
infected macrophages are found in the
lungs (Bell and Noursadeghi, 2018;
Cribbs et al., 2015), the characterization
of the types of viruses mainly found in
this co-infection sites (lung and pleural cavity) (Collins et al.,
2002; Nakata et al., 1997; Singh et al., 1999) would be of great
interest as we would have the opportunity to assess their effect
in our model. Other reports also show that Mtb infection in-
creases HIV-1 replication in vitro (Diedrich and Flynn, 2011;
Goletti et al., 1998; Hoshino et al., 2002; Lederman et al., 1994;
Zhang et al., 1995). However, unlike our study, they show that
Mtb induces a pro-inflammatory environment resulting in the
auto-activation of NF-kB, which ultimately binds the HIV-1 long
terminal repeat (LTR) and initiates viral transcription in co-
infected macrophages (Collins et al., 2002; Goletti et al., 1998,
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2004; Hoshino et al., 2002; Lederman et al., 1994; Mancino et al.,
1997; Nakata et al., 1997; Orenstein et al., 1997; Queval et al.,
2016; Tanaka et al., 2005; Toossi, 2003; Zhang et al., 1995).
Based on both these published observations and ours, we pro-
pose that TB exacerbates HIV-1 pathogenesis in a two-step
manner: initially, by activating HIV-1 LTR transcription via
short-lived pro-inflammatory signals in resident macrophages,
and then by enhancing HIV-1 infection and spread in newly re-
cruited monocytes predisposed toward the M(IL-10) phenotype,
as a result of the anti-inflammatory signals induced by IL-10. This
two-step model reconciles previous work done in co-infected
cells and the results of our study, which is based on inherent
susceptibility to HIV-1 infection observed in CD16+ monocytes
(Ellery et al., 2007) and macrophages derived from these cells
(Ancuta et al., 2006). In light of recent evidence for macrophages
as targets for HIV-1 pathogenesis (Honeycutt et al., 2016, 2017;
Sattentau and Stevenson, 2016), together with the renewed
appreciation of the importance of IL-10-driven anti-inflammatory
program in macrophages (Ip et al., 2017), we believe that our
in vitro model to generate M(IL-10) cells will help further charac-
terize how TB influences viral infection of macrophages, and
onward viral spread.
Third, based on our findings, we infer that TNT formation is
likely a key cellular mechanism by which the IL-10/STAT3
signaling axis increases virus spread in human macrophages in
a TB context. TNTs are transient membrane projections that
facilitate intercellular communication to allow the transfer of en-
dosomal cargo vesicles, calcium fluxes, and pathogens, such as
bacteria, viruses, and prions (Davis and Sowinski, 2008; Dupont
et al., 2018; Malik and Eugenin, 2016; McCoy-Simandle et al.,
2016; Sherer and Mothes, 2008). In T cells, transmission of
HIV-1 through TNTs is estimated to be approximately 100- to
Figure 7. TB-Driven TNT Formation Is
Necessary for Increased HIV-1 Infection
(A) Stacked bars showing the percentage of
cells with thick (gray) and thin (white) TNTs of
day 6 HIV-1-infected macrophages treated with
CmCTR, CmMTB, or CmMTB in the presence of
TNT inhibitor (TNTi, 20 mM).
(B) Vertical scatterplots showing p24 release (left)
and infection index (right) of day 13 HIV-1-infected
macrophages treated with CmCTR, CmMTB, or
CmMTB in the presence of TNTi.
(C) Experimental setup used for the co-culture
(also referred to as a transfer assay), Transwell,
and cell-free HIV-1 experiments. IL-10-treated
macrophages were either infected with HIV-1
NLAD8-VSVG pseudotyped strain at a MOI of 5 for
48 h (donor cells) or stained with CellTracker
(acceptor cells). For the co-culture experiment,
donor cells were mixed with acceptor cells at a 1:1
ratio. The Transwell assay was designed to sepa-
rate donor and acceptor cells to investigate the
contribution of cell contact to transfer of HIV-1. The
experiment was performed as described in the co-
culture assay, with the exception that acceptor
cells were plated in the well, and then a Transwell
filter was placed containing the donor cells. Finally,
to assess the contribution of cell-free infection in
the propagation of HIV-1, the supernatant of donor
cells (containing the virions produced during 48 h
of infection) was incubated with acceptor cells. To
assess the contribution of TNTs in HIV-1 transfer,
all three experiments were performed in the pres-
ence or not of TNTi (20 mM), and fixed after 24 h.
The cells were stained for HIV-1 Gag protein, and
the percentage of CellTracker+ cells among Gag+
cells was quantified.
(D) Deconvolution microscopy image showing
HIV-1 Gag transfer into CellTracker+ acceptor cell
after 24-h co-culture. HIV-1 Gag (red), Cell Tracker
(green), F-actin (gray), and DAPI (blue). Scale bar,
10 mm.
(E) Stacked bars showing the percentage of
CellTracker+ cells among Gag+ cells after 24 h
co-culture with or without TNTi (20 mM). Data in
histograms are represented as mean ± SD. Each circle within the vertical scatterplots represents a single donor. Mean value is represented as a dark gray line.
Statistical analyses: two-tailed, paired t test (A and E); Wilcoxonmatched-paired signed rank test (B). *p% 0.05; ***p% 0.0005; ****p% 0.0001; ns, not significant.
See also Figure S7 and Videos S5 and S6.
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1,000-fold more efficient than through classical cell-free viral
infection (Sowinski et al., 2008). In macrophages, HIV-1 induces
the formation of TNT via the protein Nef (Hashimoto et al., 2016;
Xu et al., 2004). We confirmed that Nef is also involved in HIV-1-
induced TNT formation in a TB-associated microenvironment
(data not shown). Since the transmission of HIV-1 between mac-
rophages via TNTs had not been formally demonstrated, we
used here transwells to separate HIV-1-infected macrophages
from uninfected macrophages, and we demonstrated that
M(IL-10) macrophages are capable of transferring HIV-1 to
non-infected macrophages through a cell-to-cell contact-
dependent mechanism. While we cannot exclude the contribu-
tion of other cell-to-cell contact-dependent mechanisms of virus
spread, such as virological synapse, cell fusion, phagocytosis, or
efferocytosis (Baxter et al., 2014; Bracq et al., 2017; Jolly and
Sattentau, 2004; Karaji and Sattentau, 2017), we clearly show
that TNTs play a major role in this process. Pharmacological in-
hibition of TNT formation results in both reduced capacity of
M(IL-10) macrophages to transfer viral particles and a substan-
tial decrease of HIV-1 production. TNTs have been observed in
several cell types and their formation is stimulated by different
factors, including lipopolysaccharide (LPS) and interferon-g
(IFN-g), pathogens, and oxidative stress, yet the signaling path-
way(s) involved in TNT formation have not been identified (Ariazi
et al., 2017; Dupont et al., 2018;Malik and Eugenin, 2016; Zhang,
2011). We reveal the IL-10/STAT3-axis as the main signaling
pathway responsible for TNT formation between macrophages,
providing an important contribution to this emerging field and
paving the way for further elucidating the biology of TNTs. It
would be interesting to find out whether TNTs could also form
between M(IL-10) macrophages and other cell types, such as
T or B cells, to transfer HIV-1 and/or viral material (Xu et al.,
2009), which could participate in HIV-1 dissemination and path-
ogenesis within the co-infection context. Finally, whether TNTs
are involved in MGC formation during HIV-1 infection of macro-
phages is suggested by a correlation between TNT formation
and the number ofMGCs that are formed (r2 = 0.7 to 0.9). Another
aspect that needs further improvement is the in vivo relevance of
TNTs. Despite evidence for material transfer via TNT-like struc-
tures in vivo (Naphade et al., 2015; Rocca et al., 2017), the cur-
rent lack of a specific TNT marker prevents the formal demon-
stration of existence of TNT in vivo. In pulmonary tissue lesions
of co-infected NHPs, we observed TNT-like structures between
CD163+ macrophages, suggesting that cell-to-cell transfer of
HIV-1 via TNTs could also occur in vivo. Indeed, M(IL-10) macro-
phages are in close proximity to each other, particularly in the
lungs of co-infected NHPs, a parameter that is critical for TNT
formation and viral transmission. Taking together our results,
we propose that enhanced TNT formation induced by TB-asso-
ciated microenvironment in M(IL-10) macrophages favors HIV-1
cell-to-cell transmission and, consequently, could play a key role
in the high HIV-1 levels usually observed at anatomical sites of
co-infection (Toossi, 2003).
In conclusion, this study highlights the importance of TB-asso-
ciated microenvironment in shaping the response of macro-
phages to HIV-1 infection. Our results are highly relevant to the
investigation of the role of macrophages in the pathogenesis of
HIV-1/Mtb co-infection, cell signaling pathways involved in
TNT formation, and the identification of potential biomarkers to
monitor disease progression. Future research will reveal whether
HIV-1 production and spread through TB-driven TNT formation
occurs among M(IL-10) macrophages only, or also affects
macrophage-to-T cell viral transmission (Groot et al., 2008),
and whether TNT can be considered as a therapeutic target in
co-infected patients.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-human CD14 Biolegend Clone M5E2; RRID:AB_893250
Anti-human CD16 Biolegend Clone 3G8; RRID:AB_314206
Anti-human CD163 Biolegend Clone GHI/61; RRID:AB_1134002
Anti-human CD184 (CXCR4) Biolegend Clone 12G5; RRID:AB_10642818
Anti-human CD195 (CCR5) Biolegend Clone J418F1; RRID:AB_2564073
Anti-human CD274 (B7-H1, PD-L1) Biolegend Clone 29E.2A3; RRID:AB_940366
Anti-human CD4 Biolegend Clone RPA-T4; RRID:AB_314082
Anti-human CD64 Biolegend Clone 10.1; RRID:AB_2734691
Anti-human CD86 Biolegend Clone IT2.2; RRID:AB_2074981
Anti-human HLA-DR Biolegend Clone L243; RRID:AB_2572101
Anti-human MerTK Biolegend Clone 590H11G1E3; RRID:
AB_2687286
Anti-human STAT3 Cell Signaling Technology Clone D1A5; https://media.cellsignal.
com/pdf/8768.pdf
Anti-human phosphoTyr705-STAT3 Cell Signaling Technology Clone D3A7; https://media.cellsignal.
com/pdf/9145.pdf
Anti-human SAMHD1 Gift from Dr. O Schwartz Institut Pasteur, Paris, France Laguette et al., 2011
Anti-human phosphoThr592-SAMHD1 ProSci Cat# 8005; RRID:AB_2316381
Anti-human IFITM1/2/3 Santa Cruz Biotechnology Clone FL-125; http://datasheets.scbt.
com/sc-66827.pdf
Anti-human C/EBP-b Santa Cruz Biotechnology Clone H-7; https://datasheets.scbt.
com/sc-7962.pdf
Anti-human CUGBP1 Santa Cruz Biotechnology Clone 3B1; RRID:AB_627319
Anti-human Actin Sigma-Aldrich Clone 20-33; RRID:AB_476738
Anti-human LC3 Sigma-Aldrich Cat# L8918; RRID:AB_1079382
Anti-human Gag-RD1 Beckman Coulter Clone KC57; https://www.bc-
cytometry.com/PDF/DataSheet/
6604665&6604667%20D.S.pdf
Anti-human CD163 Leica/Novocastra Clone 10D6; RRID:AB_2756375
Anti-human alpha-tubulin Sigma‑Aldrich clone B-5-1-2; RRID:AB_477582
LEAF purified anti-human IL-10 Biolegend Clone JES3-19F1; RRID:AB_315460
LEAF purified rat anti-human IgG2a Biolegend Clone RTK2758; RRID:AB_326523
Goat anti-rabbit IgG, AlexaFluor 555 Thermo Fisher Scientific Cat# A-21430; RRID:AB_2535851
Goat anti-mouse IgG, AlexaFluor 488 Thermo Fisher Scientific Cat# A-10684; RRID:AB_2534064
Goat anti-Mouse IgG, AlexaFluor 555 Cell Signaling Technology Cat# 4409; RRID:AB_1904022
Goat anti-rabbit IgG, HRP Thermo Fisher Scientific Cat# 32460; RRID:AB_1185567
Goat anti-mouse IgG, HRP Thermo Fisher Scientific Cat# 31430; RRID:AB_228307
Bacterial and Virus Strains
M. tuberculosis H37Rv N/A N/A
HIV-1 ADA strain Gift from Dr. S Benichou Institut Cochin, Paris, France Ve´rollet et al., 2015a
HIV-1 ADA Gag-iGFP strain Gift from Dr P. Benaroch Institut Pasteur, Paris, France Gaudin et al., 2013
HIV-1 NLAD8-VSVG Gift from Dr. S Benichou Institut Cochin, Paris, France Bracq et al., 2017
HIV-1 ADA (BlaM-Vpr) N/A N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
Buffy Coat Etablissement Franc¸ais du Sang, Toulouse, France N/A
Patients-derived pleural effusions Divisio´n de Tisioneumonologı´a at the Instituto de
Tisioneumonologı´a Vaccarezza-University of Buenos
Aires, Argentina
N/A
TB patients-derived peripheral blood Divisio´n de Tisioneumonologı´a at the Instituto de
Tisioneumonologı´a Vaccarezza-University of Buenos
Aires, Argentina
N/A
HIV/TB patients-derived peripheral blood Division de SIDA at the Hospital F.J Mun˜iz, Buenos
Aires, Argentina
N/A
Healthy subjects-derived peripheral blood Blood Transfusion Service, Hospital Fernandez,
Buenos Aires, Argentina
N/A
Histological slides of lung biopsies from
rhesus macaques
Tulane National Primate Research Center N/A
Chemicals, Peptides, and Recombinant Proteins
Human M-CSF Peprotech Cat# 300-25
Stattic Sigma-Aldrich Cat# S7947
TNTi Pharmeks N/A
Cytochalasin D Sigma-Aldrich Cat# 22144-77-0
Maraviroc Sigma-Aldrich Cat# 376348-65-1
Bafilomycin A1 Sigma-Aldrich Cat# 88899-55-2
Critical Commercial Assays
Mouse anti-human CD14 microbeads Miltenyi Biotec Cat# 130-050-201
LS magnetic columns Miltenyi Biotec Cat# 130-042-401
Protein G Agarose, Fast Flow Millipore Cat# 16-266
Renilla Luciferase Assay Promega Cat# E2810
Amersham ECL Prisme Western Blotting
Detection Reagent
GE Healthcare Cat# RPN2232
SuperSignal WestPico Chemiluminescent
Substrate
Thermo Scientific Cat# 34080
Matrigel BD Bioscience Cat# 356234
IL-10 ELISA set BD Bioscience Cat# 555157
Human CD163 ELISA kit BD Bioscience Cat# DY1607-05
Human Mer ELISA kit BD Bioscience Cat# DY6488
Human TruStain FcX Biolegend Cat#422302
Cell Dissociation Buffer Thermo Fisher Scientific Cat# 13151014
Phalloidin AlexaFluor 488 Thermo Fisher Scientific Cat# A12379
DAPI Sigma Aldrich Cat# D9542
Vybrant! DiO Thermo Fisher Scientific Cat# V22886
CellTracker Red CMPTX Dye Thermo Fisher Scientific Cat# C34552
CellTracker Green CMFDA Dye Thermo Fisher Scientific Cat# C7025
Fluorescence Mounting Medium Agilent Technologies Cat# S302380-2
Prolong anti-fade reagent Thermo Fisher Scientific Cat# P10144
Experimental Models: Cell Lines
TZM-bl cell line NIH AIDS Reagent Program Cat# 8129
Software and Algorithms
ImageJ ImageJ https://www.imagej.nih.gov/ij/
Prism (v5) GraphPad https://www.graphpad.com/
Photoshop CS3 Adobe https://www.adobe.com/
Illustrator CS3 Adobe https://www.adobe.com/
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents should be directed to and will be fulfilled by the Lead Contact, Geanncarlo Lugo-Vilar-
ino (lugo@ipbs.fr). Sharing of antibodies and other reagents with academic researchers may require UBMTA agreements.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
Monocytes from healthy subjects (HS) were provided by Etablissement Franc¸ais du Sang, Toulouse, France, under contract
21/PLER/TOU/IPBS01/20130042. According to articles L12434 and R124361 of the French Public Health Code, the contract was
approved by the French Ministry of Science and Technology (agreement number AC 2009921). Written informed consents were ob-
tained from the donors before sample collection. The sex of HS is unknown.
Tuberculous (TB) patients from the Divisio´n de Tisioneumonologı´a at the Instituto de Tisioneumonologı´a Vaccarezza-University of
Buenos Aires, Argentina and co-infected HIV/TB patients from the Division de SIDA at the Hospital F.J Mun˜iz, from 2015 to 2016,
were diagnosed by the presence of recent clinical respiratory symptoms, abnormal chest radiography and positive sputum smear
test for acid-fast bacilli. The research was carried out in accordance with the Declaration of Helsinki (2013) of the World Medical
Association, and was approved by the Ethics Committees of the institutes mentioned above (protocol numbers: NIN-1671-12 and
proceedings 37/38). Written informed consent was obtained before sample collection. Exclusion criteria included the presence of
concurrent infectious diseases or non-infectious conditions (cancer, diabetes, or steroid therapy). Blood samples were collected
at 3 to 10 days after start of TB treatment. The diagnosis of tuberculous pleurisy was based on a positive Ziehl–Nielsen stain or
Lowestein–Jensen culture from pleural effusion (PE) and/or histopathology of pleural biopsy, and was further confirmed by an
Mycobacterium tuberculosis-induced IFN-g response and an ADA-positive test (Light, 2010). Effusions were classified as exudates
according to Light (2010). PE and peripheral blood (PB) samples were obtained as described previously (Schierloh et al., 2007). PB
samples from HS were provided by the Blood Transfusion Service, Hospital Fernandez, Buenos Aires (agreement number CEIANM-
52-5-2012). All HS had received BCG vaccination in childhood and their tuberculin-test status (TTS) was unknown. Clinical features
and sex of the experimental groups are summarized in Table S1.
Strategy for randomization and/or stratification
Blood samples from enrolled patients were classified in 3 groups of individuals: 1) TB patients with abnormal chest radiography and
positive sputum smear test for acid-fast bacilli, who received less than one week of anti-TB therapy (TB); 2) HIV-1 infected patients
with active TB, who received less than one week of anti-TB therapy (HIV/TB); and 3) Bacillus Calmette-Guerin-vaccinated healthy
donors (HS). Pleural effusions samples from enrolled patients were classified in 2 groups of individuals: 1) TB pleurisy based on a
positive Ziehl–Nielsen stain or Lowestein–Jensen culture from PE and/or histopathology of pleural biopsy, and confirmed by an
Mtb-induced IFN-g response and an adenosine deaminase-positive test; and 2) no-TB pleurisy including the following etiologies:
malignant effusions (mesothelioma, lung carcinoma or metastatic patients), parapneumonic effusions and heart failure associated
effusions.
Inclusion and Exclusion criteria for blood samples
Inclusion: person > 21 years old diagnosed with TB (clinical or laboratory criteria) having HIV+ serology (HIV/TB) or not and who
consent to participate. Exclusion: the presence of concurrent infectious diseases, except HIV, or non-infectious conditions (cancer,
diabetes, or steroid therapy) and patients who do not provide consent.
Inclusion and Exclusion criteria for pleural effusion samples
Inclusion: person > 21 years old having a pleural effusion requiring drainage by therapeutic thoracentesis and who consent to partic-
ipate. Exclusion: the presence of empyema, pleural effusion that does not require therapeutic drainage and patients who do not pro-
vide consent.
The GPower software was used for sample-size estimation and statistics. No replicates and no blinding were done.
NHPs
All animal procedures were approved by the Institutional Animal Care and Use Committee of Tulane University, NewOrleans, LA, and
were performed in strict accordance with NIH guidelines. The twenty adult rhesus macaques used in this study (Table S2) were bred
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Huygens Professional Version 16.10 Scientific Volume Imaging https://svi.nl/Huygens-Professional
FACS DIVA BD Bioscience http://www.bdbiosciences.com/
FlowJo 7.6.5 TreeStar https://www.flowjo.com/
FCS Express V3 DeNovo Software http://www.denovosoftware.com
Image Lab Bio-Rad Laboratories http://www.bio-rad.com
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and housed at Tulane National Primate Research Center (TNPRC). The sex of animals is specified in Table S2. All macaques were
infected as previously described (Foreman et al., 2016; Mehra et al., 2011). Briefly, macaques were aerosol-exposed to a low dose
(25 CFU implanted) of Mtb CDC1551 and a subset of the macaques were also exposed 9 weeks later to 300 TCID50 of SIVmac239
administrated intravenously in 1mL saline. The control subset received an equal volume of saline intravenously. Criteria for killing
included presentation of four or more of the following conditions: (i) body temperatures consistently greater than 2!F above preinfec-
tion values for 3 or more weeks in a row; (ii) 15% or more loss in body weight; (iii) serum CRP values higher than 10 mg/mL for 3 or
more consecutive weeks, CRP being a marker for systemic inflammation that exhibits a high degree of correlation with active TB in
macaques (Kaushal et al., 2012; Mehra et al., 2011); (iv) CXR values higher than 2 on a scale of 0–4; (v) respiratory discomfort leading
to vocalization; (vi) significant or complete loss of appetite; and (vii) detectable bacilli in BAL samples.
Bacteria
Mtb H37Rv strain was grown in 7H9 media at 37!C, as described (Lastrucci et al., 2015). Exponentially growing Mtb was centrifuged
(460 g) and resuspended in PBS (MgCl2, CaCl2 free, GIBCO). Clumps were dissociated by 20 passages through a 26-G needle then
resuspended in RPMI-1640 containing 10% FBS. Bacterial concentration was determined by measuring OD600.
Viruses
Proviral infectious clones of the macrophage-tropic HIV-1 isolate ADA (Ve´rollet et al., 2015a) was kindly provided by Serge Benichou
(Institut Cochin, Paris, France). Virions were produced by transient transfection of 293T cells with proviral plasmids, as previously
described (Ve´rollet et al., 2015a). HEK293 T cells (the sex of original cells is unknown) were maintained in DMEM, 20% FBS, 5%
CO2. HIV-1 p24 antigen concentration of viral stocks was assessed by an home-made ELISA. HIV-1 infectious units were quantified,
as reported (Ve´rollet et al., 2015a) using TZM-bl cells. TZM-bl cells are HeLa cell lines (female origin) that were obtained through NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc). In some exper-
iments, we used Betalactamase (BlaM)-Vpr-containing ADA virus and NLAD8-VSVG pseudotyped viruses and HIV-1 ADA Gag-iGFP
strain (see Key Resources Table).
Preparation of human monocytes and monocyte-derived macrophages
Monocytes from healthy subjects (HS) were isolated and differentiated into macrophages as previously described (Balboa et al.,
2011; Lastrucci et al., 2015; Ve´rollet et al., 2015a). Briefly, purified CD14+ monocytes from HS were differentiated for 5-7 days in
RPMI-1640 medium (GIBCO), 10% Fetal Bovine Serum (FBS, Sigma-Aldrich) and human M-CSF (Peprotech) at 20 ng/mL. Differen-
tiated macrophages were used as the cellular source to prepare the CmMTB after infection with Mtb. The cell medium was renewed
every 3 or 4 days.
For the human samples of peripheral blood and pleural effusion (PE) from nonTB, TB and HIV/TB patients and HS, mononuclear
cells were isolated by Ficoll-Hypaque gradient centrifugation (Pharmacia, Uppsala, Sweden), as described previously (Balboa et al.,
2011; Lastrucci et al., 2015). Isolated monocytes from patients were allowed to adhere to 24-well plates, at 5x105 cells/well for 1 h at
37!C in warm RPMI-1640 medium. The medium was then supplemented to a final concentration of 10% FBS and human recombi-
nant M-CSF at 10 ng/mL. Flow cytometry analysis was performed in mononuclear cells, gating within the CD14+ population.
METHODS DETAILS
Chemicals
When stated, monocytes (day 0) are treated with STAT3 activation inhibitor Stattic (1mM, kindly provided by FabienneMeggetto from
CRCT, INSERM Toulouse). In some conditions, monocytes (day 0) were treated with an inhibitor of TNT formation (TNTi, 20mM,
Pharmeks), which was renewed after HIV-1 infection. In some experiments, macrophages were treated with Cytochalasin D
(Sigma-Aldrich) at 2 mM. DMSO alone was used as vehicle control.
Preparation of conditioned media and cytokine depletion
The preparation of the conditioned medium of Mtb-infected macrophages (CmMTB) has been reported previously (Lastrucci et al.,
2015). Briefly, macrophages were infected with Mtb H37Rv at a MOI of 3. The conditioned control medium (CmCTR) was obtained
from uninfected macrophages. After incubation at 37!C for 18h, culture media were collected, sterilized by double filtration (0.2mm
pores) and aliquots were stored at"80!C. For cytokine depletion experiments, CmCTR or CmMTB were incubated with 10 mg/mL of
control IgG or neutralizing IL-10 antibody (JES3-19F1, Biolegend) for 1h at 4!C. Afterwards, 50 mg/mL of 50% slurry Protein G
agarose beads (EMDMillipore) were added and incubated for 1h at 4!C. Conditioned media were centrifuged (300 g) to remove anti-
body-bead complexes and then filtered (0.2 mm pores) before use. The depletion was controlled by ELISA.
Conditioning of monocytes with the secretome of Mtb-infected macrophages or pleural effusions from TB patients
Freshly isolated CD14+monocytes fromHSwere allowed to adhere in the absence of serum (43 105cells/24-well in 500mL or 23 106
cells/6-well in 1.5mL). After 1h of culture, 80%CmMTB or CmCTR supplemented with 20 ng/mLM-CSF and 20%FBSwere added to
the cells (vol/vol). For experiments with PE, samples were collected in heparin tubes and centrifuged at 300 g for 10 minutes at room
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temperature without brake. The cell-free supernatant was transferred into new plastic tubes, further centrifuged at 12000 g for
10 minutes and aliquots were stored at "80!C. After having the diagnosis of the PE, pools were prepared by mixing same amounts
of individual PE associated to a specific etiology. The pools were de-complemented at 56!C for 30minutes, and filtered by 0.22 mm in
order to remove any remaining debris or residual bacteria. Particularly, we studied 21 patients with PE that were divided according
their etiology. First group had 8 patients with tuberculous PE (PE-TB), second group had 8 patients with parapneumonic PE (PE-NPI),
and third group had 5 patients with transudates secondary to heart failure (PE-HF). PE-TB or PE-nonTB (PE-NPI and PE-HF)
supplemented with 40ng/mLM-CSF and 40% FBS were added to the cells (25% vol/vol). Cells were then cultured for 3 days. Mono-
cytes were also conditioned in presence of 10 ng/mL M-CSF and 10 ng/mL recombinant human Interleukin-10 (IL-10) (PeproTech).
Cell-surface expression of macrophage activation markers was measured by flow cytometry using standard procedures detailed in
Star Methods.
HIV-1 infection of cells
Cells were infected with HIV-1 ADA strain at day 3 of culture at MOI 0.1. HIV-1 infection and replication were assessed 10 days post-
infection by measuring p24-positive cells by immunostaining and the level of p24 released in culture media by ELISA.
Blam-Vpr fusion assay
Experiments were carried out as described previously (Garcia-Perez et al., 2015). Briefly, monocytes adhered on glass coverslips
were conditioned for 3 days with CmMTB or CmCTR medium and then collected with cell dissociation buffer (Thermo Fisher
Scientific). Then, 1.53 105 cells were incubated for 3 h at 37!Cwith 100 ng p24 of a Betalactamase (BlaM)-vpr-containing ADA virus.
Infected cells were next incubated for 2 h with the CCF2/AM dye according to the manufacturer’s instructions (Invitrogen). After
washing, cells were fixed in 2% paraformaldehyde. Enzymatic cleavage of CCF2 by BlaM, which causes a blue-shift in the CCF2
fluorescence emission spectrum, was measured by flow cytometry (FACSCanto, BD Biosciences).
Flow cytometry
Staining of conditioned monocytes-to-macrophage population was performed as previously described (Lastrucci et al., 2015).
Adherent cells were harvested using Cell Dissociation Buffer (Life Technologies), centrifuged for 5 min at 340 g, incubated in staining
buffer (PBS, 2mMEDTA, 0.5%FBS) with a 1:100 dilution of Human TruStain FcX (Biolegend) for 5minutes at room temperature. Cells
were then stained in cold staining buffer for 25minwith fluorophore-conjugated antibodies (see Key Resources Table) and, in parallel,
with the corresponding isotype control antibody using a general dilution of 1:400. After staining, the cells were washed with cold
staining buffer, centrifuged for 5 min at 340g at 4!C (twice), and analyzed by flow cytometry using LSR-II flow cytometer (BD Biosci-
ences) and the associated BD FACSDiva software. Data was then analyzed using the FlowJo 7.6.5 software (TreeStar). The mono-
cyte-to-macrophage population was first gated according to its Forward Scatter (FSC) and Size Scatter (SSC) properties before
singlet selection and analysis of the percentage of positive cells and the median fluorescence intensity (MFI) for each staining.
Cells from nonTB, TB and HIV/TB patients and related controls from HS (2 3 105 cells) were labeled as described above and ac-
quired in a FACSAria II cytometer (BD Biosciences) and analyzed using FCS Express V3 software (De Novo Software, Los Angeles,
CA, USA).
Immunofluorescence microscopy
Cells were fixed with PFA 3.7%, Sucrose 30mM in PBS. Stainings were performed as described (Ve´rollet et al., 2015a). Briefly, cells
were permeabilizedwith Triton X-100 0.3% for 10minutes, and saturatedwith PBSBSA 1% for 30minutes. Cells were incubatedwith
anti-Gag KC57 antibody (1:100, Beckman Coulter) in PBS BSA 1% for 1 hour, washed and then incubated with Alexa Fluor 555 Goat
anti-Mouse IgG secondary antibody (1:1000, Cell Signaling Technology), Alexa Fluor 488 Phalloidin (1:500, Thermo Fisher Scientific)
and DAPI (500 ng/mL, Sigma Aldrich) in PBS BSA 1% for 30 minutes. Coverslips were mounted on a glass slide using Fluorescence
Mounting Medium (Dako). Slides were visualized with a Leica DM-RB fluorescence microscope or a FV1000 confocal microscope
(Olympus). For deconvolution images shown in Figures 5E, S5A, and S5C, macrophages were imaged over nine planes at
100 nm intervals with a 100x/1.49 Nikon objective mounted on a Nikon Eclipse Ti-E and an Hamamatsu Orca flash 4.0 LT sCMOS.
All images were deconvolved with Huygens Professional version 16.10 (Scientific Volume Imaging, the Netherlands), using the CMLE
algorithm, with SNR:20 and 40 iterations.
For the deconvolution image shown in Figure 7D, imaging was performed using a dragonfly multimodal imaging platform in three-
dimensional fast confocal mode using a 63x/1.47 objective and a Zyla 4.2 PLUS sCMOS camera (Andor).
TNTs were detected and counted using Phalloidin and microtubules staining. We quantified both thick and thin nanotubes: thin
membrane nanotubes contained only F-actin, whereas thick TNTs contained both F-actin and microtubules.
As HIV-1 infection of macrophagesmakes them fuse intoMGCs (Orenstein, 2001; Ve´rollet et al., 2010), the number of infected cells
largely underestimates the rate of infection. Thus, to better reflect the rate of infection, we quantified HIV infection index (HIV-stained
area divided by total cell area x 100), percentage of nuclei in multinucleated cells and percentage of multinucleated cells. These pa-
rameters were assessed by using semi-automatic quantification with home-made ImageJ macros, allowing the study of more than
5,000 cells per condition in at least five independent donors.
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HIV-1 and DiO transfer monitoring
Freshly isolated CD14+monocytes fromHSwere allowed to adhere in the absence of serum (23 106 cells/6-well in 1.5mL). After 1h of
culture, RPMI medium supplemented with 20 ng/mL M-CSF and 20% FBS and 20ng/mL IL-10 were added to the cells (vol/vol). At
day 3, half cells are infected with 120ng p24 of a HIV-1 NLAD8 strain pseudotyped with a VSVG envelope. The other half cells are
stained with CellTracker Green CMFDA Dye at day 5 (Thermo Fisher Scientific). Briefly, cells are washed with Mg2+/Ca2+-containing
PBS and stained for 30 minutes in Mg2+/Ca2+-containing PBS supplemented with 500 ng/mL CellTracker, then washed with FBS-
containing RPMI medium. HIV+ and CellTracker+ were then detached using accutase and co-cultured at a 1:1 ratio. In order to
co-culture HIV+ and CellTracker+ cells in conditions that allow their physical separation, HIV+ cells were plated on 6.5-mm transwell
filters with 0.4 mmpore polyester membrane insert (Sigma-Aldrich) while CellTracker+ cells were plated on coverslips at the bottom of
24-well plates holding the transwell filters. The cells therefore shared only the culture medium but were unable to physically contact
each other. For the cell-free HIV-1 control, CellTracker+ cells were incubated with the supernatant of HIV+ cells containing produced
virions. After 24 h, cells were fixed, stained and imaged.
For DiO transfer monitoring, cells were stained either with CellTracker Red CMPTX Dye (Thermo Fisher Scientific) as described
above, or with a lypophylic tracer Vybrant! DiO (Thermo Fisher Scientific), according to manufacturer’s instructions. Then, cells
were detached using accutase, co-cultured at a 1:1 ratio in 8-well Lab-Tek! chambers for 24h and imaged.
Scanning electron microscopy
Scanning electron microscopy observations were performed as previously described (Lastrucci et al., 2015). Briefly, HIV-1-infected
macrophages were fixed in 2.5% glutaraldehyde/3.7% PFA/0.1M sodium cacodylate (pH 7.4), post-fixed in 1% osmium tetraoxide
(in 0.2M cacodylate buffer), dehydrated in a series of increasing ethanol. Critical point was dried using carbon dioxide in a Leica
EMCPD300. After coating with gold, cells were examined with a FEI Quanta FEG250 scanning electron microscope.
Immunoblot analyses
Total protein lysates were extracted as previously described (Lastrucci et al., 2015; Ve´rollet et al., 2015a). Total proteins were sepa-
rated through SDS-polyacrylamide gel electrophoresis, transferred and immunoblotted overnight at 4!C with indicated primary an-
tibodies (See Key Resources Table). Secondary antibodies were the following: Anti-rabbit and anti-mouse IgG, HRP-linked Antibody
(Cell Signaling Technology). Proteins were visualized with Amersham ECL Prime Western Blotting Detection Reagent (GE Health-
care). Chemiluminescence was detected with ChemiDoc Touch Imaging System (Bio-Rad Laboratories) and quantified using Image
Lab software (Bio-Rad Laboratories).
For the detection of LC3 autophagy protein, monocytes were seeded on 12-well plates at a density of 0.83 106 cells by well. After
infection and treatment with Bafilomycin A1 (100 nM) or DMSO vehicle control for 2 h, cells were lysed. Proteins harvested were
subjected to a SDS-polyacrylamide gel electrophoresis, 4%–15% gradient (Biorad). Blots were blocked with 5% dried milk in
PBS, incubated with LC3 primary antibody and then with the corresponding horseradish peroxidase-conjugated secondary antibody
(ThermoScientific). Staining was detected with SuperSignal WestPico Chemiluminescent Substrate (ThermoScientific), and immu-
nostained proteins were visualized using the ChemidocTouch Imaging System (Biorad). Densitometric LC3-II/actin ratios were
measured using the ImageJ software.
3D migration assays
3D migration assays of cells in Matrigel (10–12 mg/mL, BD Biosciences) were performed as described (Ve´rollet et al., 2015a) and
quantified at 48h. Briefly, pictures of cells were taken automatically with a 10X objective at constant intervals using the motorized
stage of an inverted microscope (Leica DMIRB, Leica Microsystems). Cells were counted using ImageJ software as described pre-
viously (Ve´rollet et al., 2015a). The number of cells inside the matrix (% of migration measured after 48h of migration) was quantified.
Protein quantifications in cell-free fluids by ELISA
Soluble protein concentration was measured in cell supernatants by ELISA using kits from BD Bioscience (IL-10) and R&D Systems
(sCD163 and sMer), according to manufacturer’s instructions.
Cytotoxicity assay
To exclude any impact of cytotoxicity of TNTi used in this study wemeasured lactate dehydrogenase (LDH) activity released from the
cytosol of damaged cells into the supernatant. LDH release was measured using the Cytotoxicity Detection kit (Roche, Mannheim,
Germany) according to the manufacturer’s instructions. Monocytes were treated with TNTi (20mM) or DMSO as a control for 13 days.
Cell-free culture supernatants were collected and incubated with LDH assay solution at 25!C for 30 min. The optical density values
were analyzed at 490 nm by subtracting the reference value at 620 nm.
Phagocytosis assay
IgG-opsonized zymosan was prepared by incubating particles in suspension in PBS with human IgG (13 mg/mL, 30 min at 37!C) and
washing as described (Le Cabec andMaridonneau-Parini, 1994). The number of particles was counted in aMalassez chamber. FITC-
labeled zymosan particles were then added at a MOI of 5 and incubated for 30 minutes at 37!C. Cells were then extensively washed
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with PBS and fixed in 3.7% PFA. To exclusively quantify phagocytosis and not binding, extracellular zymosan was stained as
described (Le Cabec et al., 2000).
Histological analyses
Paraffin embedded tissue samples were sectioned and stained with hematoxylin and eosin for histomorphological analysis.
Immunohistochemical staining was performed on paraffin-embedded tissue sections, using anti-CD163 (10D6, mouse mAb,
Leica/Novocastra) and anti-pSTAT3 (D3A7 rabbit mAb, Cell Signaling Technology). Immunostaining of paraffin sections was pre-
ceded by different antigen unmasking methods. After incubation with primary antibodies, sections were incubated with biotin-con-
jugated polyclonal anti-mouse or anti-rabbit immunoglobulin antibodies followed by the streptavidin-biotin-peroxidase complex
(ABC) method (Vector Laboratories) and then were counter-stained with hematoxylin. Slides were scanned with the Panoramic
250 Flash II (3DHISTECH). Virtual slides were automatically quantified for macrophage distribution as previously described (Lastrucci
et al., 2015; Ve´rollet et al., 2015a). For confocal microscopy, samples were stained with primary antibodies as described above and
followed by anti-mouse IgG isotype specific or anti-rabbit IgG antibodies labeled with Alexa488 and Alexa555 (Molecular Probes).
Samples were mounted with Prolong! Antifade reagent (Molecular Probes) and examined using a 60x/1.40N.A. objective of an
Olympus FV1000 confocal microscope.
QUANTIFICATION AND STATISTICAL ANALYSIS
Information on the statistical tests used, and the exact values of n (number of donors) can be found in the Figure Legends. All sta-
tistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc.). The statistical tests were chosen according to
the following. Two-tailed paired or unpaired t test was applied on datasets with a normal distribution (determined using Kolmogorov-
Smirnov test), whereas two-tailedMann-Whitney (unpaired test) orWilcoxonmatched-paired signed rank tests were used otherwise.
p < 0.05 was considered as the level of statistical significance (* p% 0.05; ** p% 0.005; *** p% 0.0005; **** p% 0.0001).
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SUPPLEMENTAL FIGURES 
 
Figure S1 (Related to Figure 1). M(IL-10) phenotype of cells conditioned with CmCTR or CmMTB is 
conserved upon HIV-1 infection. 
(A) Representation of the experimental design. Briefly, monocytes from healthy subjects were treated with 
conditioned medium from mock- (CmCTR) or Mtb-infected macrophages (CmMTB) for 3 days. Cells were then 
infected with HIV-1 ADA strain at MOI of 0.1 or left uninfected and kept in culture for 3 more days. (B) Flow 
cytometry gating strategy of representative sample of monocytes treated for 3 days with CmCTR or CmMTB. (C) 
Histograms showing the Median Fluorescence Intensity (MFI) of anti-inflammatory cell-surface markers CD16, 
CD163, MerTK and PD-L1 (top) and pro-inflammatory markers CD64, HLA-DR and CD86 (bottom) on cells 
treated with CmCTR and CmMTB at day 3, and HIV-1-infected or uninfected at day 6. n = 7 donors. (D) Left: 
Representative images of Western Blot illustrating the expression of pY705-STAT3, STAT3 and GAPDH as loading 
control. Right: Histogram showing the quantification of the pY705-STAT3 on total STAT3 ratio of cells treated 
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with CmCTR and CmMTB at day 3, and HIV-1-infected or uninfected at day 6. n = 6 donors. Data in histograms 
are represented as mean ± SD. * p≤0.05; ** p≤0.005; ns, not significant.   
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Figure S2 (Related to Figure 1 and 6). TB-associated microenvironment increased HIV-induced 
multinucleated giant cells (MGC) formation and HIV-induced cell migration (in a STAT3-dependent 
manner). 
(A) Kinetics of HIV-1 protein p24 release in the supernatant of cells from a representative donor, treated with 
either CmCTR or CmMTB. (B) Vertical scatter plots showing the percentages of MGC (left) and nuclei within 
MGC (right) of day 13 HIV-1 infected macrophages treated with CmCTR or CmMTB. (C-E) Day 5 uninfected 
(NI) or HIV-1 infected macrophages, previously treated with CmCTR, CmMTB and CmMTB in the presence of 
Stattic were seeded on the top of Matrigel matrices and allowed to migrate for 48h.  (C) Representative brightfield 
images of HIV-1 infected macrophages previously treated either with CmCTR (top) or CmMTB (bottom), and 
visualized either on top (left) or inside (right) the matrix. Scale bar, 50µm.  (D) 3D positions of migrating HIV-1 
infected macrophages, previously treated with CmCTR, CmMTB, for a representative donor, reported using 
TopCat software. (E) Vertical scatter plot showing the percentage of migrating cells after 48h.  Each circle within 
vertical scatter plots represents a single donor. Mean value is represented as a dark grey line. * p≤0.05; ** p≤0.005; 
*** p≤0.0005; **** p≤0.0001.    
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Figure S3 (Related to Figure 1). Monocytes treated with pleural effusions (PE) from TB patients exhibit a 
M(IL-10) phenotype,  STAT3 activation and high HIV-induced multinucleated giant cells (MGC) 
formation. 
(A) Vertical scatter plots showing the Median Fluorescence Intensity (MFI) of cell-surface markers characteristic 
of the M(IL-10) phenotype, including CD16, CD163, MerTK and PD-L1 (top), and markers typical of M1 
phenotype such as CD64, HLA-DR and CD86 (bottom), on monocytes differentiated 3 days into macrophages 
under the presence of PE-TB or PE-nonTB (normalized over the corresponding MFI of untreated cells). (B) Left: 
Representative images of Western Blot illustrating the expression of pY705-STAT3, STAT3 and GAPDH as loading 
control. Right: Quantification of the pY705-STAT3 on total STAT3 ratio of monocytes differentiated 3 days in the 
presence of PE-TB or PE-nonTB. (C) Vertical scatter plots showing the dosage of interleukin-10 (IL-10) in PE-
TB and PE-nonTB. (D) Vertical scatter plots showing the percentages of MGC (left panel) and nuclei within MGC 
(right) of day 13 HIV-1 infected macrophages treated with PE-nonTB or PE-TB. Each circle within vertical scatter 
plots represents a single donor. Mean value is represented as a dark grey line. In this figure, PE-nonTB are 
parapneumonic PEs (PE-NPI, empty circle) and Heart Failure PEs (PE-HF, empty square). * p≤0.05; ** p≤0.005; 
*** p≤0.0005; ns, not significant. 
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Figure S4 (Related to Figure 3). Systemic expansion of the M(IL-10) monocyte population in co-infected 
patients. 
(A) Vertical scatter plots showing the Median Fluorescence Intensity (MFI) of cell-surface marker CD16 on 
CD14+ monocytes from peripheral blood (PB) of healthy subjects (PB-HS), tuberculous patients (PB-TB) and 
HIV/Mtb co-infected patients (PB-HIV/TB). (B) Vertical scatter plot showing sMer vs sCD163 in HS (blue), HIV 
(green), TB (orange) and HIV/TB (pink) patients. Median values are indicated as a dashed line. (C) Receiver 
Operating Characteristic (ROC) curve of sCD163 concentration in the serum of HS (left), TB (middle), HIV (right) 
compared to HIV/TB patients. The red circle represents the optimal cut point. (D) ROC curve of sMer 
concentration in the serum of HS (left), TB (middle), HIV (right) compared to HIV/TB patients. The red circle 
represents the optimal cut point. Each circle within vertical scatter plots represents a single donor. Mean value is 
represented as a dark grey line. Abbreviation: AUC, area under the curve; CI, confidence interval. **** p≤0.0001; 
ns, not significant. 
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Figure S5 (Related to Figure 5, and Movies 1, 2 and 4). TB-induced microenvironment increases tunneling 
nanotube (TNT) formation. 
(A) Deconvolution microscopy images showing F-actin staining in day 6 HIV-1 infected macrophages, treated 
with CmMTB. Arrow: thick TNT (left, see Movie 1); arrowheads: thin TNTs (right, see Movie 2). Scale bars, 
20µm.  (B) Representative scanning electron microscopy images, showing TNTs on day 6 HIV-infected 
macrophages previously treated with CmMTB. Scale bars, 10µm. (C) Deconvolution microscopy images showing 
M-Sec distribution in day 6 HIV-1 infected macrophages, treated with CmMTB. M-Sec (red), F-actin (green), 
DAPI (blue). Scale bar, 20µm. See movie 4. (D) Immunohistochemical images illustrate TNT-like structures 
(arrows) in lung biopsy of a SIV/Mtb co-infected NHP stained with Eosin (left) or CD163 (middle and right). 
Nuclei are counterstained with Hematoxylin. Scale bar, 10ȝm. 
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Figure S6 (Related to Figure 6). The IL-10/STAT3 axis is responsible for the M(IL-10) phenotype as well as 
increased HIV-1- induced multinucleated giant cells (MGC) and tunneling nanotubes (TNT) formation. 
(A) Vertical scatter plots showing the Median Fluorescence Intensity (MFI) of M(IL-10) cell-surface markers such 
as CD16, CD163, MerTK and PD-L1 on monocytes differentiated 3 days in culture medium or culture medium 
supplemented with recombinant IL-10. (B) Vertical scatter plots showing the percentages of multinucleated giant 
cells (MGC) (left) and nuclei within MGC (right) of day 13 HIV-1 infected macrophages treated with IL-10 or 
not.  (C) Vertical scatter plots showing the percentages of MGC (left) and nuclei within MGC (right) of day 13 
HIV-1 infected macrophages treated with IL-10-depleted (Į−IL-10) CmMTB, or mock-depleted (Į−IgG) CmCTR 
and CmMTB. (D) Vertical scatter plots showing the percentages of multinucleated giant cells (MGC) (left) and 
nuclei within MGC (right) of day 13 HIV-1 infected macrophages treated with CmCTR, CmMTB or CmMTB 
and Stattic. Each circle within vertical scatter plots represents a single donor. Mean value is represented as a dark 
grey line. (E) Stacked bars showing the percentage of cells with thick (grey) and thin (white) TNTs of day 6 HIV-
1 infected macrophages untreated (Medium) or treated with CmCTR, CmMTB, recombinant IL-10 (10ng/mL), 
recombinant IL-4 (20ng/mL), recombinant IFN-J (2ng/mL). * p≤0.05; ** p≤0.005; *** p≤0.0005; **** p≤0.0001; 
ns, not significant.  
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Figure S7 (Related to Figure 7). Effects of TNTi (20µM) on several macrophage characteristics and functions. 
(A) Histograms showing the effect of TNTi on fluorescent material transfer between DiO- and CellTracker-stained 
cells, in macrophages treated (or not) with IL-10 or IL-10 + TNTi, measured using live cell imaging. More than 
1300 cells per condition were analyzed. n = 3 donors. (B) Histograms showing the viability of TNTi-treated 
macrophages relative to DMSO-treated cells, as measured with LDH assay. n = 6 donors. (C) Vertical scatter plot 
showing the cell density of day 13 HIV-1 infected macrophages treated with CmCTR, CmMTB of CmMTB + 
TNTi, measured on immunofluorescence images. More than 3000 cells per conditions were analyzed. (D) 
Histograms showing the percentage of cells with podosomes of TNTi-treated macrophages compared to DMSO-
treated cells, as measured on immunofluorescence images. More than 500 cells per conditions were analyzed. n = 
6 donors. (E) Histograms showing the percentage of phagocytic cells (left) and the number of phagocytosed 
particles per cell (right) of TNTi-treated macrophages compared to DMSO-treated cells, as measured on 
immunofluorescence images. n = 4 donors. Cytochalasin D was used at 2ȝM (n = 2 donors). (F) Vertical scatter 
plots showing the percentages of multinucleated giant cells (MGC) (left) and nuclei within MGC (right) of day 13 
HIV-1 infected macrophages treated with CmCTR, CmMTB or CmMTB +TNTi. Each circle within vertical 
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scatter plots represents a single donor. Mean value is represented as a dark grey line. Data in histograms are 
represented as mean ± SD. * p≤0.05; ** p≤0.005; ns, not significant. 
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SUPPLEMENTAL TABLES 
Table S1 (Related to Figure 3). Clinical data of tuberculous (TB), co-infected (HIV/TB) 
Patients and Healthy Subjects (HS) from Argentina.  PB-HS PB-TB PB-HIV/TB PE-TB PE-nonTB 
Age, years 
(range) 37 (21-65) 38 (19-66) 37 (31-58) 37 (19-58) 46 (27-69) 
Gender, % M, 84% M, 92% M, 100% M, 96% M, 67% 
Nationality, % Arg., 100% Arg., 70% Bol., 23% Peru, 7% 
Arg., 88% Bol., 12% 
Arg., 45% Bol., 44% Peru, 11% 
Bol., 67% Arg., 33% 
TB disease 
localization, 
% - 
Pulmonary, 100 %  (Pleural, 46%) 
Pulmonary, 88%     (Pleural, 43%) Ganglionar, 12% 
Pleural, 100% - 
AFB in 
sputum, % - 
3+, 56% 2+, 12% 1+, 30% -, 2% 
3+, 50% 2+, 25% 1+, 25% -, 0% 
ND - 
ART 
treatment, % 
- - 21 % - - 
Leukocyte 
count, mean ± 
SEM, cell/µL 9348 ±  954 8965 ± 1247 5356 ± 788,3 ND ND 
Lymphocyte 
mean ± SEM, % 25 ± 5 23 ± 6 21 ± 4 ND ND 
Monocyte 
mean ± SEM, % 7 ± 3 7 ± 3 16 ± 3 ND ND Abbreviations: M.: Male, Arg.: Argentina, Bol.: Bolivia, ND: No data 
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Table S2 (Related to Figure 2). Clinical data of NHPs. 
Animals Status Sex Age of death 
(years) 
Days after  
infection* Viral load** 
EC61 - M 8.99 - - 
GI53 - M 5.02 - - 
IT02 - M 4.69 - - 
BK48 SIV M 12.06 322 8.58 x 106 
DD87 SIV F 9.84 540 3.03 x 104 
DT18 SIV M 8.85 764 4.40 x 104 
BA34 SIV M 16.79 750 1.91 x 105 
DR28 SIV M 8.84 120 1.48 x 107 
CA75 LTB M 11.7 106 - 
FE10 LTB M 7 166 - 
FJ05 LTB M 6.81 181 - 
CL10 ATB M 13.84 51 - 
CG58 ATB M 7.71 75 - 
GK87 ATB F 7.76 38 - 
ER44 SIV/LTB M 8.61 167 1.93 x 105 
HB12 SIV/LTB M 4.97 167 1.04 x 106 
ID01 SIV/LTB M 3.58 153 2.17 x 106 
HP22 SIV/ATB M 3.79 113 3.7 x 108 
HP41 SIV/ATB M 3.78 111 6 x 105 
HT09 SIV/ATB M 3.72 104 7.5 x 106 
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* Infection 1: Mtb CDC1551 and infection 2: SIVmac239. For co-infected macaques, days after first Mtb infection. Abbreviations: LTB: latent TB, ATB: active TB, M: male, F: female.   
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Table S3 (Related to Figure 2): Histopathological scoring of lung lesions in NHPs. 
Animals Status 
Lung 
Disease 
severity 
Granulomatous lesions 
Non- Granulomatous 
lesions 
Granul
oma 
Size 
Type of 
granuloma 
Distribution 
pattern 
Cellular composition 
EC61 - None - - - - 
- Few & small perivascular 
lymphohistiocytic infiltrates, 
PMN+ 
GI53 - None - - - - 
- Few & small perivascular 
lymphohistiocytic infiltrates, 
PMN+ 
IT02 - None - - - - 
- Few & small perivascular 
lymphohistiocytic infiltrates 
-PMN+ 
-peribronchial iBALT 
BK48 SIV Minimal - - - - 
- small perivascular 
lymphohistiocytic infiltrates 
DD87 SIV Minimal - - - - 
- small perivascular 
lymphohistiocytic infiltrates 
DT18 SIV Minimal - - - - -polymorph infiltrates 
BA34 SIV Mild - - - - 
- Focal interstitial 
pneumonia, 
- interstitial 
lymphohistiocytic infiltrates, 
- thickening of the alveolar 
wall, 
- collagen deposit, - type-2 
pneumocyte hyperplasia 
DR28 SIV Minimal - - - - 
thickening of the alveolar 
wall closed to the pleura 
CA75 LTB Mild small 
Non 
Necrotizing, 
Poorly 
organized 
multifocal 
- Lymphocytic cuff 
- ESiWheliRid & FRam\ Mĳ 
- MGC, - Fibrosis [+] 
Interstitial pneumopathy 
 
FE10 LTB Mild large 
Nonnecrotizing 
Suppurative 
focal solid 
coalescent 
- Lymphocytic cuff 
- ESiWheliRid & FRam\ Mĳ 
- MGC 
Thickening of the alveolar 
wall 
FJ05 LTB Mild medium caseous multifocal 
- Lymphocytic cuff 
- peripheral fibrosis 
Strong interstitial 
pneumopathy 
CL10 ATB Moderate 
Small & 
medium 
Caseous & 
solid 
Multifocal 
coalescent 
- Lymphocytic cuff 
- Strong interstitial 
pneumopathy 
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- ESiWheliRid Mĳ, - 
MGC++ 
& haemorrhage 
CG58 ATB Mild 
Small, 
medium 
& large 
Necrotic & solid 
Multifocal 
coalescent 
- Lymphocytic cuff 
- ESiWheliRid Mĳ, - 
MGC++ 
- 
GK87 ATB Moderate 
Medium 
& large 
Necrotic, 
caseous and 
supurative 
Multifocal 
coalescent 
- Lymphocytic cuff 
- ESiWheliRid Mĳ, 
MGC++, PMN++ 
-transudat in the alveolar 
space, 
- collagen deposits 
-Interstitial pneumopathy 
ER44 SIV/LTB Mild large 
Necrotic & 
caseous 
focal 
2 coalescent follicles, 
Loss of the lymphocytic 
cuff, 
ESiWheliRid Mĳ- MGC++, 
-Interstitial pneumopathy, 
- haemorrhage & fibrosis 
HB12 SIV/LTB Severe none - - - 
-Interstitial pneumopathy, 
iBALT 
- haemorrhage & alveolitis, 
- fibrosis, syncitia and 
PMN++ 
ID01 SIV/LTB Moderate none - - - 
-Interstitial pneumopathy, 
iBALT 
- haemorrhage & alveolitis, 
HP22 SIV/ATB Moderate medium 
Solid, necrotic, 
fibrotic & 
mineralized 
multifocal 
- Lymphocytic cuff 
- ESiWheliRid Mĳ, MGC++ 
-Interstitial pneumopathy 
- haemorrhage & syncitia 
HP41 SIV/ATB Severe large Necrotic coalescent 
- Lymphocytic cuff 
- ESiWheliRid Mĳ, 
MGC++ 
-strong Interstitial 
pneumopathy, 
- haemorrhage & alveolitis, 
fibrosis, PMN++ 
HT09 SIV/ATB Severe large Supurative 
Multifocal, 
coalscent & 
invasive 
Loss of the lymphocytic 
cuff, 
ESiWheliRid Mĳ, 
MGC++, PMN++ 
fibrosis 
- Interstitial pneumopathy, 
- haemorrhage 
Abbreviations: PMN: ploymorphonuclear leukocytes, iBALT: inducible Bronchus-associated lymphoid tissue, Mφ: Macrophages, MGC: Multinucleated giant cells. 
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III. Scientific contribution to the paper 
In this paper, where we show that cmMTB-induced TNT are responsible for the increased viral 
replication and dissemination observed in macrophages in the context of co-infection, my main 
contribution was to reproduce the experiments showing the exacerbation of HIV-1 replication in 
cmMTB macrophages and to perform the experiments requested during the revision process of the 
manuscript in October-November 2018.  
One of the main points raised by the reviewers concerned the use of HIV-1ADA strain, which 
infects efficiently macrophages but is not sexually transmitted. The reviewers argued that HIV-1-
infected patient are poorly infected with macrophage-tropic strains, therefore the use of HIV-1ADA 
might represent a caveat in our study. It is true that most transmitted/founder viruses are generally 
non-macrophage tropic, albeit most of them are R5-tropic. Actually, Swanstrom and colleagues 
described that M-tropic viruses are enriched in the brain, where they efficiently infect the microglia 
through their high affinity for CD4. These viruses are rather rare in the blood, where T-cell tropic viruses 
are predominant [327]. However, T-tropic viruses showing a certain degree of infection of 
macrophages have also been described [765]ʹ[767]. In addition, macrophage tropism is a relative and 
complex concept that greatly depends on how viruses are transferred into the macrophages. For 
instance, it has been shown that T/F viruses can infect macrophages through phagocytosis of infected 
T-cells [649]. In humanized mouse, some M-tropic T/F viruses such as CHO40 are able to sustain 
systemic replication and are found in various tissues including the lung [768]. Altogether, these studies 
strongly suggest that under certain circumstances, T-tropic viruses (including T/F viruses) with a certain 
capacity to infect macrophages (though less efficiently than infection of T cell) are less rare in patients 
than thought. To answer the reviewers concerns, we performed additional experiments using the T/F 
HIV-1 strain SUMA. Our preliminary results showed that, in macrophages, the replication of this virus 
is quite low (around 0.1 ng/mL of p24 was measured at 10 days post-infection), but 3x-fold enhanced 
in cells conditioned with cmMTB, indicating that independently of the viral strain used, Mtb-
environment enhances HIV-1 replication. It is likely that restriction at the viral entry step explains why 
the replication of SUMA remains low in macrophages, despite cmMTB treatment. This is consistent 
with our finding that cmMTB conditioning has no effects on the viral entry efficiency in macrophages 
(Figure 4B).  
Another interesting question asked by the reviewers was to know whether TNT formation is 
specific of M(IL-10) macrophages or if other phenotypes could also form such structures. To answer 
that question, I differentiated monocytes from 6 independent healthy donors into macrophages with 
IL-4, IFNJ and LPS, IL-10, cmMTB or left untreated and compared their capacity to form TNT after 3 
days of infection with HIV-1. Only IL-10 and cmMTB treatment increased the number of cells forming 
TNT significantly, while IL-4 treatment showed a tendency to increase TNT formation (Figure 32A), 
suggesting that TNT induction is not specific of M(IL-10) macrophages. I also assessed whether fully 
differentiated macrophages with different activation profiles (M(IL-4), M(IL-10), and M(IFNJ)) could 
form TNT, at day 8 of differentiation and in absence of HIV-1 infection. I found that cmMTB-
macrophages and M(IL-10) macrophages could still form TNT, but it was M(IFNJ) that was more 
efficient at forming TNT (Figure 32B, n=4 independent donors), suggesting that these macrophages are  
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Figure 32: Quantification of tunneling nanotube (TNT) formation in several conditions.  
A | Freshly isolated monocytes were treated with M-CSF alone (M0), or M-CSF with cmCTR, cmMTB, IL-10 (20 
ng/mL), IL-4 (20 ng/mL) or IFNJ (2 ng/mL) and infected at day 3 with HIV-1ADA. Stacked bars shows the 
quantification of the percentage of cells with thick (grey) and thin (white) TNTs at day 6 (3 days post-infection). 
n = 6 donors.  
B | Freshly isolated monocytes were cultured with M-CSF for 6 days to obtain macrophages. Then, cells were 
treated with M-CSF (M0), cmCTR, cmMTB, IL-10 (20 ng/mL), IL-4 (20 ng/mL) or ,)1J (2 ng/mL) for 48h. Stacked 
bars shows the quantification of the percentage of cells with thick (grey) and thin (white) TNTs at day 8. n = 4 
donors. Histograms are represented as mean ± SD. 
C | Differentiated macrophages were infected with BCG-mCherry or Mtb (H37Rv) for 24h at a MOI of 1. After 
washing, cells were fixed and stained for TNT. Stacked bars shows the quantification of the percentage of cells 
with thick (grey) and thin (white) TNTs at day 8. n = 4 donors. Histograms are represented as mean ± SD. 
Statistical analyses: Two-tailed, Wilcoxon unpaired signed rank test (A), paired t-ƚesƚ ;BͿ͘ Ύ pчϬ͘Ϭϱ͖ ΎΎ pчϬ͘ϬϬϱ͖ 
ns, not significant. 
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strongly involved in cell-to-cell communication. In addition, we evaluated the capacity of Mtb and BCG 
to induce TNT formation after infection. We infected non-polarized, differentiated macrophages with 
either BCG or Mtb at an MOI of 1. After 24h of infection, we observed that Mtb infection induces a 2x-
fold increase in the number of cells with TNT, while BCG infection did not (Figure 32C), suggesting that 
TNT induction in infectious context is dependent on the pathogen. 
The findings obtained in this study constitute the basis of my PhD project, which was to identify 
novel factors involved in the exacerbation of HIV-1 replication in a co-infection context. To do so, we 
performed a transcriptomic analysis of cmCTR- and cmMTB-macrophages, and identified the lectin 
receptor Siglec-1 as a strong candidate. In the first part of my PhD, I assessed the role of this lectin in 
the viral exacerbation observed in cmMTB-cells, and found it to be expressed by a subset of thick TNT, 
which were identified in the present article as one of the mechanism participating to the dissemination 
of HIV-1 in the context of co-infection. The results obtained during my thesis are presented in the next 
chapter. 
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Chapter V: Tuberculosis-associated IFN-I induces 
Siglec-1 on microtubule-containing tunneling 
nanotubes and favours HIV-1 spread in 
macrophages. 
 
I. Paper summary 
As discussed in the introduction, chapter III, and in the previous article, co-infection with Mtb 
and HIV-1 remains a challenging global health issue, difficult to diagnose and to treat, especially in low-
income countries where the centers able to detect Mtb-infection are rare.  
The present work, for which I am the first author of a manuscript just submitted, follows the 
one presented in the result section, chapter IV; and is currently under review process in a peer-review 
journal. In the previous study, we found that in the context of co-infection with Mtb, the exacerbation 
of HIV-1 infection and replication in macrophages was mediated by the IL-10/STAT3-dependent 
induction of TNT. Here, to assess the gene expression landscape of cmMTB-cells and identify specific 
factors involved in the exacerbation of the viral infection and replication, we performed a genome-
wide transcriptomic analysis. We defined a 60 gene-transcript signature in cmMTB-macrophages, 
among which 9 were down-regulated and 51 were upregulated compared to cmCTR-cells. Among 
those, we focused on the lectin Siglec-1 that was strongly induced in cmMTB-treated cells. We verified 
that Siglec-1 was also upregulated at the protein level by cmMTB conditioning, and found that the 
abundance of Siglec-1+ alveolar macrophages was increased in the lung of TB and TB-SIV co-infected 
NHP compared to SIV or healthy animals. Moreover, the abundance of these cells correlated with the 
disease severity. As an ISG [769], we validated that Siglec-1 expression was induced by the IFN-I present 
in cmMTB conditioning media, and that its expression was not due to IL-10, as observed in the previous 
study for the CD163 and MerTK markers (Chapter IV). In our NHP model, the number of Siglec-1+ 
alveolar macrophages also correlated with the number of IFN-I activated macrophages, as measured 
by immunohistology detection of phosphorylated STAT1 in the nucleus. Therefore, in this study, we 
evidenced that the IFN-I/STAT1 axis, together with the IL-10/STAT3 axis (Chapter IV), is involved in the 
viral exacerbation observed in the co-infection context. 
Siglec-1, whose expression is restricted to myeloid cells (i.e. DC, monocytes and macrophages), 
has been previously described for its role in HIV-1 pathogenesis. Indeed, Siglec-1 efficiently binds to 
the gangliosides present at the viral envelope of retroviruses and, upon uptake, induces the 
internalization of captured virions into VCC in DC and macrophages [536], [634]. Moreover, Siglec-1 
expressed by DC and macrophages has been shown to actively increase HIV-1 trans-infection of CD4+ 
T cells [633], [635]. As Siglec-1 is upregulated by cmMTB treatment, we suspected an increased viral 
uptake by cmMTB-macrophages. We found that was the case, and reversed the viral uptake by the 
lectin using a blocking antibody. These observations led us to suspect the expression of Siglec-1 on 
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TNT, which could increase the number of molecule and the surface perimeter accessible for viral 
uptake, thereby explaining the increase in Siglec-1 expression and HIV-1 capture in cmMTB-cells that 
could result in higher viral entry efficiency, independently of the entry receptor. We found that a 
subtype of thick TNT (containing microtubules) expressed Siglec-1 and were longer than Siglec-1- TNT. 
At the functional level, we observed that Siglec-1+ TNT contained higher HIV-1 and mitochondria 
cargos, suggesting that Siglec-1+ TNT are preferentially used by HIV-1 to spread in distant cells. Finally, 
we found that the depletion of Siglec-1 had no impact on TNT formation but had a significant effect on 
their length. Siglec-1 inhibition also led to a decrease uptake of viral particle, a diminished transfer of 
HIV-1 from macrophage to macrophage (independently of the entry efficiency) and to a strong 
reduction in HIV-1 replication. 
In this work, we further characterized the mechanisms involved in the exacerbation of the viral 
replication in the co-infection context by identifying Siglec-1 as a novel marker of a subtype of thick 
TNT, which are preferentially used by HIV-1 to disseminate from one macrophage to another.  
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II. Results 
Tuberculosis-associated type I interferon  
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Summary  
 
While tuberculosis (TB) is a risk factor in HIV-1-infected individuals, the mechanisms by which 
Mycobacterium tuberculosis worsens HIV-1 pathogenesis remain poorly understood. Recently, we 
showed that HIV-1 spread is exacerbated in macrophages exposed to TB-associated 
microenvironments due to tunneling nanotube (TNT) formation. To identify factors associated with 
TNT function, we performed a transcriptomic analysis in these macrophages, and revealed the up-
regulation of Siglec-1 receptor, which is dependent on TB-mediated production of type I interferon 
(IFN-I). In co-infected non-human primates, Siglec-1 is highly expressed by alveolar macrophages, 
whose abundance correlates with pathology and activation of IFN-I/STAT1 pathway. Intriguingly, 
Siglec-1 expression localizes exclusively on long microtubule-containing TNT that carry HIV-1 cargo. 
Siglec-1 depletion in macrophages decreases TNT length, HIV-1 capture and cell-to-cell transfer, and 
abrogates TB-driven exacerbation of HIV-1 infection. Altogether, we uncover a deleterious role for 
Siglec-1 in TB-HIV-1 co-infection, and its localization on TNT opens avenues to understand viral spread.   
 
 
 
Keywords 
Tuberculosis, AIDS, Mycobacterium tuberculosis, HIV-1, co-infection, macrophages, monocytes, Siglec-
1, CD169, TNT, type I Interferon 
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INTRODUCTION  
 
Co-infection with Mycobacterium tuberculosis (Mtb) and the human immunodeficiency virus (HIV-1), 
the agents of tuberculosis (TB) and acquired immunodeficiency syndrome (AIDS), respectively, is a 
major health issue. Indeed, TB is the most common illness in HIV-1-infected individuals, about 55% of 
TB notified patients are also infected with HIV-1, and about a fifth of the TB death toll occurs in HIV-1 
co-infected individuals (WHO health report 2017). Clinical studies evidence a synergy between these 
two pathogens, which is associated with a spectrum of aberration in immune function (Esmail et al., 
2018). Yet, while progress has been made towards understanding how HIV-1 enhances Mtb growth 
and spread, the mechanisms by which Mtb exacerbates HIV-1 infection require further investigation 
(Bell and Noursadeghi, 2018; Deffur et al., 2013; Diedrich and Flynn, 2011). 
 
Besides CD4+ T cells, macrophages are infected by HIV-1 in humans and by the simian 
immunodeficiency virus (SIV), the most closely related lentivirus to HIV, in non-human primates (NHP) 
(Cribbs et al., 2015; Rodrigues et al., 2017). Recently, using a humanized mouse model, macrophages 
were shown to sustain HIV-1 infection and replication, even in the absence of T cells (Honeycutt et al., 
2017; Honeycutt et al., 2016). This is in line with several studies characterizing tissue macrophages, 
such as alveolar, microglia and gut macrophages, as reservoirs in HIV-1 patients undergoing 
antiretroviral therapy (Ganor et al., 2019; Jambo et al., 2014; Mathews et al., 2019; Sattentau and 
Stevenson, 2016).  
 
Macrophages are key host cells for Mtb (O'Garra et al., 2013; VanderVen et al., 2016). We recently 
reported the importance of macrophages in HIV-1 exacerbation within the TB co-infection context 
(Souriant et al., 2019). Using relevant in vitro and in vivo models, we showed that TB-associated 
microenvironments activate macrophages towards an M(IL-10) profile, distinguished by a 
CD16+CD163+MerTK+ phenotype. Acquisition of this phenotype is dependent on the IL-10/STAT3 
signaling pathway (Lastrucci et al., 2015). M(IL-10) macrophages are highly susceptible not only to Mtb 
infection (Lastrucci et al., 2015), but also to HIV-1 infection and spread (Souriant et al., 2019). At the 
functional level, we demonstrated that TB-associated microenvironments stimulate the formation of 
tunneling nanotubes (TNT), membranous channels connecting two or more cells over short to long 
distances above substrates. TNT are subdivided in two classes based on their thickness and 
cǇƚoskeleƚon composiƚion͗ ͞ƚhin͟ TNT ;фϬ͘ϳ ʅm in diameƚerͿ conƚaining F-acƚin͕ and ͞ƚhick͟ TNT ;хϬ͘ϳ 
ʅm in diameƚerͿ are enriched in F-actin and microtubules (MTs) (Souriant et al., 2019). Thick TNT are 
functionally distinguished by the transfer of large organelles, such as lysosomes and mitochondria 
(Dupont et al., 2018; Eugenin et al., 2009; Hashimoto et al., 2016). While the contribution for each TNT 
class to HIV-1 pathogenesis has not been explored (Dupont et al., 2018; Eugenin et al., 2009; 
Hashimoto et al., 2016), we reported that total inhibition of TNT formation in M(IL-10) macrophages 
resulted in the abrogation of HIV-1 exacerbation induced by Mtb (Souriant et al., 2019). Factors 
influencing TNT function in M(IL-10) macrophages remain unknown at large. 
 
In this study, global mapping of the M(IL-10) macrophage transcriptome revealed Siglec-1 (CD169, or 
sialoadhesin) as a potential factor responsible for HIV-1 dissemination in the co-infection context with 
TB. As a type I transmembrane lectin receptor, Siglec-1 possesses a large extracellular domain 
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composed of 17 immunoglobulin-like domains, including the N-terminal V-set domain, which allows 
the trans recognition of terminal D2,3-linked sialic acid residues in O- and N-linked glycans and 
glycolipids, such as those surface-exposed in HIV-1 and SIV particles (Izquierdo-Useros et al., 2012a; 
Puryear et al., 2012). While Siglec-1 has yet to be implicated in the TB context, it is clearly involved in 
the pathogenesis of HIV-1, SIV and other retroviruses (Martinez-Picado et al., 2017). Siglec-1 is mainly 
expressed in myeloid cells (macrophages and dendritic cells) and participates in HIV-1 transfer from 
myeloid cells to T cells, as well as in the initiation of virus-containing compartment (VCC) formation in 
macrophages (Izquierdo-Useros et al., 2012a; Izquierdo-Useros et al., 2012b; Puryear et al., 2013; 
Puryear et al., 2012), and in the viral dissemination in vivo (Akiyama et al., 2017; Izquierdo-Useros et 
al., 2012a; Sewald et al., 2015). Indeed, HIV-1 and other retroviruses have evolved the capacity to 
hijack the immune surveillance and housekeeping immunoregulatory functions of Siglec-1 (Izquierdo-
Useros et al., 2014; O'Neill et al., 2013). Here, we investigate how Siglec-1 expression is induced by TB, 
and the role it has in the capture and transfer of HIV-1 by TB-induced M(IL-10) macrophages, in 
particular in the context of TNT. 
 
RESULTS  
 
Tuberculosis-associated microenvironments induce Siglec-1 in macrophages 
 
TB-induced M(IL-10) macrophages are highly susceptible to HIV-1 infection and spread (Souriant et al., 
2019). To assess the global gene expression landscape in these cells, we performed a genome-wide 
transcriptome analysis. To this end, we employed our published in vitro model (Lastrucci et al., 2015), 
which relies on the use of conditioned medium from either mock- (cmCTR) or Mtb-infected (cmMTB) 
human macrophages. As we described and observed before and herein, cmMTB-treated cells were 
positive for the M(IL-10) markers (CD16+CD163+MerTK+ and phosphorylated STAT3), and displayed a 
high rate of HIV-1 infection, as compared to those treated with cmCTR (Lastrucci et al., 2015; Souriant 
et al., 2019). A distinct 60 gene-transcript signature was defined in cmMTB-treated cells, using a 
combination of the expression level, statistical filters and hierarchical clustering; 51 genes were up-
regulated and 9 genes were down-regulated in cmMTB- compared to cmCTR-treated cells (Figure 1A). 
We compared expression data of cmMTB- and cmCTR-treated cells to public genesets available from 
MSigDB (Broad Institute) using the gene set enrichment analysis (GSEA) algorithm (Subramanian et al., 
2005). As shown in Figure S1A, a significant fraction of genes that were up-regulated in response to 
interferon (IFN) type I (e.g. IFND) and II (i.e. IFNJ), were also found, as a group, significantly up-
regulated in cmMTB-treated cells in comparison to control samples (FDR q-value: < 10E-3). IFN-
stimulated genes (ISG) usually exert antiviral activities (McNab et al., 2015; Schneider et al., 2014) and 
cannot be inferred as obvious candidates to facilitate HIV-1 infection. However, among this ISG 
signature, the up-regulation of Siglec-1 (7.4-fold, adjusted p value of 0.0162) in cmMTB-treated cells 
captured our attention due to its known role in HIV-1 pathogenesis (Izquierdo-Useros et al., 2014; 
O'Neill et al., 2013). We confirmed high Siglec-1 expression in cmMTB-treated macrophages at the 
mRNA (Figure 1B) and cell-surface protein (Figure 1C, Figure S1B) levels, which was superior to the 
level obtained in HIV-1-infected cells (Figure S1C). Particularly, cmMTB-treated macrophages displayed 
high density of Siglec-1 surface expression applying a quantitative FACS assay that determines the 
absolute number of Siglec-1 antibody binding sites per cell (Figure 1D).  
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These data indicate that Siglec-1 is highly expressed in human macrophages exposed to TB-associated 
microenvironments and potentially in the context of TB-HIV co-infection. 
 
Siglec-1+ alveolar macrophage abundance correlates with pathology in co-infected primates  
 
NHP has been an invaluable in vivo model to better understand the role of macrophages in SIV/HIV 
pathogenesis (Merino et al., 2017). Considering Siglec-1 binds sialylated lipids present in the envelop 
of HIV-1 and SIV (Izquierdo-Useros et al., 2012a; Puryear et al., 2012), we examined the presence of 
Siglec-1 positive alveolar macrophages in lung biopsies obtained from different NHP groups: (i) co-
infected with Mtb (active or latent TB) and SIV, (ii) mono-infected with Mtb (active or latent TB), (iii) 
mono-infected with SIV, and (iv) healthy (Table S1, Figure S2A) (Cai et al., 2015; Kuroda et al., 2018; 
Souriant et al., 2019). Histological immuno-staining confirmed the presence of Siglec-1+ alveolar 
macrophages in the lungs of healthy NHP (Figure 1E-F and S2A), and revealed its significant increase in 
NHP mono-infected with either Mtb or SIV (Figure 1E-F and S2A). Strikingly, we noticed a massive 
abundance of these cells in co-infected NHP (Figure 1E-F and S2A). Concerning the overall abundance 
of Siglec-1+ leukocytes in lungs, we observed a significant increased in all infected NHP in comparison 
to healthy, with a higher tendency in active TB or co-infected NHP (Figure 1G and S2A). In fact, the 
number of Siglec-1+ leukocytes correlated positively with the severity of NHP pathology (Figure 1H, 
Table S2). Based on their cell morphology, localization in alveoli, and co-expression with the 
macrophage marker CD163 (Figure S2A-C), Siglec-1+ cells were identified as alveolar macrophages.  
 
Collectively, these data show that Siglec-1 is up-regulated in alveolar macrophages in the context of a 
retroviral co-infection with active TB. 
 
Siglec-1 expression is dependent on TB-mediated type I IFN signaling 
 
Siglec-1 is an ISG whose expression is induced by IFN-I in myeloid cells (Hartnell et al., 2001). In addition 
to viral infection, IFN-I is also induced in TB and known to mainly play a detrimental role (McNab et al., 
2015; Moreira-Teixeira et al., 2018). Siglec-1 expression has not been described in the TB context or in 
co-infection with retroviruses such as SIV or HIV-1, therefore we assessed whether IFN-I stimulates 
Siglec-1 expression in TB-associated microenvironments. First, we found that cmMTB contains high 
amounts of IFN-I compared to cmCTR (Figure 2A). Next, we showed that recombinant IFNE significantly 
increased Siglec-1 cell-surface expression in macrophages, close to the level induced by cmMTB (Figure 
2B). Interestingly, we observed a modest, albeit significant, induction of Siglec-1 expression in cells 
treated with interleukin 10 (IL-10), a cytokine we have previously showed to be abundant in cmMTB 
(Lastrucci et al., 2015) and that renders macrophages highly susceptible to HIV-1 infection (Souriant et 
al., 2019). However, IL-10 depletion had no effect on Siglec-1 expression by cmMTB-treated cells 
(Figure 2C). By contrast, blocking the IFN-I receptor (IFNAR2) during cmMTB treatment fully abolished 
expression of Siglec-1 (Figure 2D), indicating that IFN-I is the responsible factor for Siglec-1 up-
regulation in cmMTB-treated cells.  
 
IFN-I binding to IFNAR leads to the phosphorylation and nuclear translocation of the transcription 
factor STAT1, whose role is essential for transcription of ISG (Ivashkiv and Donlin, 2014). We thus 
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examined the status of STAT1 activation in co-infected NHP lung tissue. Histological staining of serial 
sections of co-infected lungs revealed that zones rich in Siglec-1+ leukocytes also exhibited positivity 
for nuclear phosphorylated STAT1 (pSTAT1) (Figure 2E), and the abundance of these two markers 
strongly correlated with the active status of TB in the different NHP groups (Figure 2F). Moreover, we 
found that the majority of Siglec-1+ alveolar macrophages were also positive for nuclear pSTAT1 in the 
infected NHP groups compared to healthy (Figure 2E and 2G). In fact, there was a higher number of 
pSTAT1+ alveolar macrophages in TB-SIV co-infected lungs when compared to those from mono-
infected NHP (Figure 2G-H).  
 
Altogether, these data demonstrate that Siglec-1 expression in human macrophages is controlled by 
IFN-I in a TB-associated microenvironment, and suggest the involvement of the IFN-I/STAT1/Siglec-1 
axis in the pathogenesis of TB and co-infection with retroviruses. 
 
Siglec-1 localization on thick TNT is associated with their length and HIV-1 cargo 
 
TNT formation is responsible for the increase in HIV-1 spread between human macrophages in TB-
associated microenvironments (Souriant et al., 2019). To investigate whether Siglec-1 expression is 
involved in this process, we first examined its localization in the context of TNT formed by cmMTB-
treated cells infected by HIV-1. We observed that Siglec-1 is localized exclusively on microtubule (MT)-
positive thick TNT, and not on thin TNT (Figure 3A and Movie 1). Semi-automatic quantification of 
hundreds of TNT showed that about 50% of thick TNT were positive for Siglec-1 (Figure 3B and S3A). 
These TNT exhibited a greater length compared to those lacking Siglec-1 (Figure 3C). Importantly, 
unlike thin TNT, HIV-1 viral proteins are found mainly inside Siglec-1+ thick TNT (Figure 3D-E and Movie 
2). In addition, these thick TNT also contain large organelles such as mitochondria (Figure 3F and S3B), 
another characteristic distinguishing thick from thin TNT (Dupont et al., 2018; Onfelt et al., 2006). In 
general, we also noticed that the incidence of Siglec-1+ thick TNT between HIV-1 infected macrophages 
persisted for more than one week upon HIV-1 infection (Figure S3C), suggesting a high degree of 
stability for these TNT. 
 
These findings reveal an exclusive localization of Siglec-1 on MT-positive thick TNT that correlates 
positively with a greater length and high cargo of HIV-1 and mitochondria, arguing for a functional 
capacity of Siglec-1+ TNT to transfer material to recipient cells over long distances. 
 
TB-driven exacerbation of HIV-1 infection and spread in macrophages requires Siglec-1 
 
To demonstrate a functional role for Siglec-1 in the susceptibility of macrophages to HIV-1 infection 
and spread induced by TB, Siglec-1 was depleted in cmMTB-treated cells by siRNA-mediated gene 
silencing (Figure 4A and S4A). While this depletion did not affect the total number of thick TNT (Figure 
4B and S4B), we observed a 2-fold shortening of thick TNT in cells lacking Siglec-1 when compared to 
control cells (Figure 4C). Then, we performed a viral uptake assay in these cells using HIV-1 Gag-eGFP 
virus-like particles (GFP VLP) lacking the viral envelope glycoprotein but bearing sialylated lipids that 
interact with Siglec-1 on myeloid cells (Izquierdo-Useros et al., 2012b; Puryear et al., 2013). We 
consistently observed binding of VLP along Siglec-1+ thick TNT (Figure S4C). Yet, in the absence of 
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Siglec-1, we noticed a significant reduction of VLP binding in comparison to control cells (Figure S4D). 
We confirmed this functional observation using a blocking monoclonal antibody against Siglec-1, 
showing that this receptor is involved in HIV-1 binding in cmMTB-treated cells (Figure S4E).  
 
We then assessed the role of Siglec-1 in HIV-1 transfer between macrophages, as this receptor is also 
important for the transfer of the virus to CD4+ T cells, (Akiyama et al., 2015; Izquierdo-Useros et al., 
2012a; Puryear et al., 2013). We used an established co-culture system between cmMTB-treated 
macrophages that allows the transfer of the viral Gag protein from infected (donor, Gag+, red) to 
uninfected (recipient, CellTracker+, green) cells over 24 hours (Souriant et al., 2019) (Figure S4F). Of 
note, since Siglec-1 facilitates the infection of macrophages (Zou et al., 2011), we used VSV-G 
pseudotyped viruses to avoid any effect on HIV-1 primo-infection. Like this, we ensured the viral 
content was equal in cells at the time of the co-culture despite the loss of Siglec-1 (Figure S4G). The 
siRNA-mediated depletion of Siglec-1 significantly diminished the capacity of cmMTB-treated 
macrophages to transfer HIV-1 to recipient cells (Figure 4D), indicating that this receptor is involved in 
TB-driven macrophage-to-macrophage viral spread (Souriant et al., 2019). Intriguinly, there was a 
decreasing tendency for the capacity of Siglec-1-depleted cmMTB-treated macrophages to transfer 
mitochondria to recipient cells compared to controls (Figure 4E and S4F), alluding to a possible defect 
in mechanisms involved in intercellular material transfer including through thick TNT (Torralba et al., 
2016). Remarkably, using replicative HIV-1 ADA strain (Figure 4A), we showed that silencing Siglec-1 
expression in cmMTB-treated cells abolished the exacerbation of HIV-1 infection and production, as 
well as the enhanced formation of multinucleated giant cells (Figures 4F-G), which are pathological 
hallmarks of HIV-1 infection of macrophages (Verollet et al., 2015; Verollet et al., 2010).  
 
These results determine that TB-induced Siglec-1 expression plays a key part in HIV-1 uptake and 
efficient cell-to-cell transfer, resulting in the exacerbation of HIV-1 infection and production in M(IL-
10) macrophages.  
 
DISCUSSION  
 
In this study, we investigated potential mechanisms by which Mtb exacerbates HIV-1 infection in 
macrophages, and uncovered a deleterious role for Siglec-1 in this process. These findings have 
different contributions to our understanding of this receptor in the synergy between Mtb and distinct 
retroviral infections, and also for TNT biology in host-pathogen interactions. 
 
Our global transcriptomic approach revealed the up-regulation of Siglec-1, as part of an ISG-signature 
enhanced in macrophages exposed to a TB-associated microenvironment. Although pulmonary active 
TB has been characterized as an IFN-I-driven disease (Berry et al., 2010; McNab et al., 2015; Moreira-
Teixeira et al., 2018), there are no reports in the literature about a role for Siglec-1 in TB or in Mtb co-
infection with retroviruses. Expression of Siglec-1 is restricted to myeloid cells except circulating 
monocytes (Crocker et al., 2007), and is enhanced by IFN-I (Puryear et al., 2013; Rempel et al., 2008) 
and during HIV-1 infection (Pino et al., 2015). In addition, human alveolar macrophages are 
distinguished from lung interstitial macrophages by Siglec-1 expression (Yu et al., 2016). In this study, 
we determined that IFN-I present in TB-associated environments is responsible for Siglec-1 
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overexpression in human macrophages, which resembled that obtained in HIV-1-infected cells. While 
we saw a modest induction of Siglec-1 in macrophages upon IL-10 treatment, its depletion from the 
TB-associated microenvironment had no effect on Siglec-1 expression. This could be explained by the 
fact that IL-10 induces the autocrine production of IFN-I (Ziegler-Heitbrock et al., 2003) to indirectly 
modulate Siglec-1 expression in M(IL-10), which then contributes to the exacerbation of HIV-1 
infection as we previously reported (Souriant et al., 2019). In the context of the most closely related 
lentivirus to HIV, namely SIV, we not only confirmed the presence of Siglec-1+ alveolar macrophages in 
SIV-infected NHP, but also reported the high abundance of these cells in active TB and in co-infected 
NHP groups, when compared to healthy ones. Importantly, we associated the high abundance of 
Siglec-1+ leukocytes with the increase NHP pathological scores, and it correlated positively to the 
detection of pSTAT1+ macrophage nuclei in histological staining of serial sections of lung biopsies from 
co-infected NHP. This is in line with a recent report on the presence of IFN-I, IFNAR and different ISGs 
in alveolar and lung interstitial tissue from NHP with active TB (Mattila, 2019), and with the fact that 
the in vivo expression of Siglec-1 is up-regulated early in myeloid cells after SIV infection and 
maintained thereafter in the pathogenic NHP model (Jaroenpool et al., 2007). In TB-SIV co-infection, 
we hypothesized that IFN-I is not exerting the expected antiviral effect, but instead is concomitant with 
chronic immune activation and attenuated by the high expression of Siglec-1 in myeloid cells, as 
recently proposed in the HIV-1 context (Akiyama et al., 2017). Altogether, these findings uncover the 
IFN-I/STAT1/Siglec-1 axis as a mechanism established by Mtb to exacerbate HIV-1 infection in myeloid 
cells, and call for the need to further investigate this signaling pathway in TB pathogenesis. 
 
Another aspect worth highlighting is the impact that Siglec-1 expression has in the capture and transfer 
of HIV-1 by M(IL-10) macrophages, in particular in the context of TNT. First, we reported that Siglec-1 
is located on MT-positive thick (and not on thin) TNT, correlating positively with increased length and 
HIV-1 cargo. To our knowledge, no receptor has been described so far to be present exclusively on 
thick TNT, making Siglec-1 an unprecedented potential marker for this subtype of TNT (Dupont et al., 
2018). Second, viral uptake assays demonstrated the functional capacity of Siglec-1, including on thick 
TNT, to interact with viral-like particles bearing sialylated lipids; loss-of-function approaches showed 
Siglec-1 is important in the capture of these viral particles. Third, Siglec-1 depletion correlated with a 
decrease in thick TNT length, but had no effect in the total number of thick TNT. This suggests that, 
while the IFN-I/STAT1 axis is responsible for Siglec-1 expression in M(IL-10) macrophages, it does not 
contribute to TNT formation. This is line with our previous report where TNT formation induced by TB-
associated microenvironments depends on the IL-10/STAT3 axis (Souriant et al., 2019). Concerning the 
shortening of thick TNT length, we infer that it may reflect a fragile state due to an altered cell 
membrane composition in the absence of Siglec-1; TNT are known for their fragility towards light 
exposure, shearing force and chemical fixation (Rustom et al., 2004). We hypothesize that the longer 
the TNT is, the more rigidity it requires to be stabilized. Cholesterol and lipids are known to increase 
membrane rigidity (Redondo-Morata et al., 2012) and are thought to be critical for TNT stability (Lokar 
et al., 2012; Thayanithy et al., 2014). Thus, the presence of Siglec-1 in thick TNT may affect the 
cholesterol and lipid composition via the recruitment of GM1/GM3 glycosphingolipid-enriched 
microvesicles (Halasz et al., 2018). In fact, TNT formation depends on GM1/GM3 ganglioside and 
cholesterol content (Kabaso et al., 2011; Lokar et al., 2012; Osteikoetxea-Molnar et al., 2016; Toth et 
al., 2017). Since GM1 and GM3 glycosphingolipids are bona fide ligands for Siglec-1 (Puryear et al., 
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2013), it is likely that Siglec-1+ thick TNT exhibit a higher lipid and cholesterol content, and hence an 
increase of membrane rigidity that favours the stability of longer TNT. Fourth, Siglec-1-depleted donor 
macrophages were less capable to transfer HIV-1, and to some extend mitochondria, to recipient cells. 
While infectious synapse and exososome release are mechanisms attributed to Siglec-1 that contribute 
to cell-to-cell transfer of HIV-1 (Bracq et al., 2018; Gummuluru et al., 2014; Izquierdo-Useros et al., 
2014), they accomplish so extracellularly. Here, we speculate that Siglec-1 participates indirectly in the 
intracellular HIV-1 transfer via TNT as a tunnel over long distance, suggesting that factors affecting TNT 
rigidity favour distal viral dissemination while ensuring protection against immune detection. Finally, 
the depletion of Siglec-1 abrogated the exacerbation of HIV-1 infection and production induced by TB 
in M(IL-10) macrophages. This is likely to result from an accumulative effect of deficient capture and 
transfer of HIV-1 in the absence of Siglec-1. However, these results do not discern the specific 
contribution of Siglec-1 to the cell-to-cell transmission of HIV-1 via TNT from that obtained through 
other mechanisms (Bracq et al., 2018). Future studies will address whether the contribution of Siglec-
1 to cell-to-cell transfer mechanisms has an impact in Mtb dissemination (Onfelt et al., 2006). 
 
In conclusion, our study identifies Siglec-1 as a key TB-driven factor for the exacerbation of HIV-1 
infection in macrophages, and as a new potential therapeutic target to limit viral dissemination in the 
co-infection context. It also sheds light on yet another housekeeping function for Siglec-1 with the 
potential to be hijacked by pathogens including HIV-1, such as intercellular communication facilitated 
by TNT. We argue that Siglec-1 localization on thick TNT has a physiological significance to macrophage 
biology in health and disease. 
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Figure 1. Tuberculosis-associated microenvironment induces Siglec-1 expression in macrophages 
(see also Figure S1 and S2).   
(A-D) For 3 days, human monocytes were differentiated into macrophages with cmCTR (white) or 
cmMTB (black) supernatants.  
(A) Heatmap from a transcriptomic analysis illustrating the top 60 differentially expressed genes (DEGs) 
between cmCTR- or cmMTB-cells. Selection of the top DEGs was performed using an adjusted p-value 
ч Ϭ͘Ϭϱ͕ a fold change of at least 2, and a minimal expression of 6 in a log2 scale. Hierarchical clustering 
was performed using the complete linkage method and the Pearson correlation metric with Morpheus 
(Broad Institute). Interferon-stimulated genes (ISG) are labelled with an asterisk and Siglec-1 is 
indicated in red.  
(B-D) Validation of Siglec-1 expression in cmMTB-treated macrophages. Vertical scatter plots showing 
the relative abundance to mRNA (B), median fluorescent intensity (MFI) (C), and mean number of 
Siglec-1 antibody binding sites per cell (D). Each circle represents a single donor and histograms median 
values. 
(E) Representative immunohistochemical images of Siglec-1 staining (brown) in lung biopsies of 
healthy, SIV infected (SIV), active TB (ATB), and co-infected (ATB-SIV) non-human primates (NHP). Scale 
bar, 100 µm. Insets are 2x zoom.  
(F) Vertical Box and Whisker plot indicating the distribution of the percentage of Siglec-1+ alveolar 
macrophages in lung biopsies from the indicated NHP groups. n=800 alveolar macrophages analyzed 
per condition from one representative animal per NHP group. 
(G) Vertical scatter plots displaying the number of cells that are positive for Siglec-1 per mm² of lung 
biopsies from the indicated NHP groups. Each symbol represents a single animal per NHP group. 
(H) Correlation between Siglec-1+ cells per mm² of lung tissue and the pathological score for healthy 
(white circle), SIV+ (white triangles), latent (black circle) or active (black square) TB, and SIV+ with latent 
(grey circle) or active (grey square) TB. Each symbol represents a single animal per NHP group. Mean 
value is represented as a black line. 
Statistical analyses: Two-tailed, Wilcoxon signed-rank test (B-D), Mann-Whitney unpaired test (F-G), 
Spearman correlation (H). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns: not significant. 
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Figure 2. Siglec-1 expression is dependent on TB-mediated type I IFN signaling. 
(A) Vertical scatter plot showing the relative abundance of IFN-I in cmCTR (white) and cmMTB (black) 
media, as measured indirectly after 24h exposure to the HEK-Blue IFN- /  reporter cell line yielding 
reporter activity in units (U) per mL. 
(B-D) For 3 days, monocytes were differentiated into macrophages either with cmMTB (black) or 
cmCTR (white), the indicated recombinant cytokines (B), the presence of an IL-10 depletion ( -IL-10) 
or a control ( -IgG) antibodies (C), or the presence of an IFNAR-2 blocking ( -IFNAR) or control ( -IgG) 
antibodies (D).  
(E) Representative serial immunohistochemical images of lung biopsies of a co-infected (ATB-SIV) NHP 
stained for Siglec-1 (brown, top) and pSTAT1 (brown, bottom). Scale bar, 250 µm. Insets are 10x zooms.  
(F) Correlation of the percentage of cells positive for Siglec-1 and pSTAT1, as measured per mm2 of 
lung tissue from the indicated NHP groups. Mean value is represented as a black line.  
(G) Representative immunohistochemical images of lung biopsies from the indicated NHP group 
stained for pSTAT1 (brown). Arrowheads show pSTAT1-positive nuclei. Scale bar, 500 µm.  
(H) Vertical Box and Whisker plot illustrating the percentage of pSTAT1+ alveolar macrophages in lung 
biopsies from the indicated NHP groups. N=450 alveolar macrophages analyzed per condition from 
one representative animal per NHP group. 
(A-D) Each circle within vertical scatter plots represents a single donor and histograms median value. 
(B-D) Vertical scatter plots displaying the median fluorescent intensity (MFI) of Siglec-1 cell-surface 
expression. Statistical analyses: Two-tailed, Wilcoxon signed-rank test (A-D), Spearman correlation (F), 
and Mann-Whitney unpaired test (H). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns: not 
significant. 
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Figure 3. Siglec-1 localization on thick TNT is associated with their length and HIV/mitochondria 
cargo (see also Figure S3).   
(A-F) Human monocytes were differentiated into macrophages with cmMTB for 3 days, and then 
infected with HIV-1-ADA strain (unless indicated otherwise) and fixed 3 days post-infection.  
(A) Representative immunofluorescence images of cmMTB-treated macrophages infected with HIV-1-
ADA, and stained for extracellular Siglec-1 (red), intracellular tubulin (MT, green) and Wheat Germ 
Agglutinin (WGA, blue). Inserts are 3x zooms. Red arrowheads show Siglec-1 localization on TNT. Scale 
bar, 20 µm.  
(B) Vertical bar plot showing the semi-automatic quantification of Siglec-1+ TNT (black) and Siglec-1-  
TNT (white) in thick (WGA+, MT+) and thin (WGA+, MT-) TNT. 400 TNT were analyzed from 2 
independent donors.  
(C) Siglec-1+ TNT exhibit a larger length index. Violin plots displaying the semi-automatic quantification 
of TNT length (in m) for thin (WGA+, MT-), and thick TNT (WGA+, MT+) expressing Siglec-1 or not.  400 
TNT were analyzed per condition from two independent donors.  
(D) Representative immunofluorescence images of cmMTB-treated macrophages 3-day post-infection 
with HIV-1-NLAD8-VSVG strain, and stained for extracellular Siglec-1 (red), intracellular HIV-1Gag 
(green) and WGA (grey). Scale bar, 10 µm.  
(E) Vertical bar plots indicating the quantification of presence (dark grey) or absence (light grey) of HIV-
1Gag in thick TNT (WGA+, MT+) expressing Siglec-1 or not. 120 TNT in at least 1000 cells were analyzed 
from four independent donors.  
(F) Representative immunofluorescence images of cmMTB-treated macrophages infected with HIV-1-
ADA loaded with MitoTracker (MitoT, green), and stained for extracellular Siglec-1 (red) and WGA 
(grey). Inserts are 3x zooms. Green arrowheads show mitochondria inside TNT. Scale bar, 10 µm. 
Statistical analyses: Two-way ANOVA comparing the presence of Siglec-1 in thin and thick TNT (B), and 
two-tailed Mann-Whitney unpaired test comparing TNT length (C) and the presence of HIV-1 in TNT 
(E). *P < 0.05, ****P < 0.0001.  
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Figure 4. TB-driven exacerbation of HIV-1 infection and spread in macrophages requires Siglec-1 (see 
also Figure S4).   
(A) Experimental design. Monocytes from healthy subjects were transfected with siRNA targeting of 
Siglec-1 (siSiglec-1, black) or not (siCtrl, white). A day after, monocytes were differentiated into 
macrophages with cmMTB for 3 days. Cells were then infected with HIV-1-ADA (blue protocol) to 
measure the formation (B) and length (C) of TNT at day 7, or assess HIV-1 production and 
multinucleated giant cell (MGC) formation at day 14 (F-G). In parallel, cells were either infected with 
HIV-NLAD8-VSVG or labelled with mitoTracker to measure the transfer (red protocol) of HIV-1 (D) or 
mitochondria (E), respectively. 
(B) Before-and-after plots showing the percentage of cells forming thick TNT (F-actin+, WGA+, MT+). 
(C) Violin plots displaying the semi-automatic quantification of TNT length (in m) for thick (WGA+, 
MT+) TNT; 300 TNT were analyzed per condition from two independent donors.  
(D-E) Before-and-after plots indicating the percentage of HIV-1Gag+ cells (D) or MitoTracker+ cells (E) 
among CellTracker+ cells after 24h co-culture.  
(F) Representative immunofluorescence images of siRNA transfected cells, treated with cmMTB 14 
days post-HIV-1 infection. Cells were stained for intracellular HIV-1Gag (green), F-actin (red) and DAPI 
(blue). Scale bar, 500 µm.  
(G) Vertical scatter plots showing HIV-1-p24 concentration in cell supernatants (upper panel) and 
percentage of MGC (lower panel) at day 14 post-HIV-1 infection in cells represented in F (siSiglec-1, 
black; siCtrl, white).  
(B, D, E and G) Each circle represents a single donor and histograms median value. Statistical analyses: 
Two-tailed, Wilcoxon signed-rank test (B-E, G). *P < 0.05, **P < 0.01, ****P < 0.0001.  
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STAR METHODS  
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for reagents should be directed to and will be fulfilled by the Lead 
Contact, Geanncarlo Lugo-Villarino (lugo@ipbs.fr). Sharing of antibodies and other reagents with 
academic researchers may require UBMTA agreements. 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Human Subjects 
Monocytes from healthy subjects were provided by Etablissement Français du Sang (EFS), Toulouse, 
France, under contract 21/PLER/TOU/IPBS01/20130042. According to articles L12434 and R124361 of 
the French Public Health Code, the contract was approved by the French Ministry of Science and 
Technology (agreement number AC 2009921). Written informed consents were obtained from the 
donors before sample collection. 
 
Non-Human Primate (NHP) samples 
All animal procedures were approved by the Institutional Animal Care and Use Committee of Tulane 
University, New Orleans, LA, and were performed in strict accordance with NIH guidelines. The twenty 
adult rhesus macaques used in this study (Table S1 and S2) were bred and housed at the Tulane 
National Primate Research Center (TNPRC). All macaques were infected as previously described 
(Foreman et al., 2016; Mehra et al., 2011; Souriant et al., 2019). Briefly, aerosol infection was 
performed on macaques using a low dose (25 CFU implanted) of Mtb CDC1551. Nine weeks later, a 
subgroup of the animals was additionally intravenously injected with 300 TCID50 of SIVmac239 in 1mL 
saline, while controls received an equal volume of saline solution. Euthanasia criteria were 
presentation of four or more of the following conditions: (i) body temperatures consistently greater 
than 2°F above pre-infection values for 3 or more weeks in a row; (ii) 15% or more loss in body weight; 
(iii) serum CRP values higher than 10 mg/mL for 3 or more consecutive weeks, CRP being a marker for 
systemic inflammation that exhibits a high degree of correlation with active TB in macaques (Kaushal 
et al., 2012; Mehra et al., 2011); (iv) CXR values higher than 2 on a scale of 0ʹ4; (v) respiratory 
discomfort leading to vocalization; (vi) significant or complete loss of appetite; and (vii) detectable 
bacilli in BAL samples. 
 
METHODS DETAILS 
 
Bacteria 
Mtb H37Rv strain was grown in suspension in Middlebrook 7H9 medium (Difco) supplemented with 
10% albumin-dextrose-catalase (ADC, Difco) and 0.05% Twen-80 (Sigma-Aldrich) (Lastrucci et al., 
2015). For infection, growing Mtb was centrifuged (3000 RPM) at exponential phase stage and 
resuspended in PBS (MgCl2, CaCl2 free, Gibco). Twenty passages through a 26-G needle were done for 
dissociation of bacterial aggregates. Bacterial suspension concentration was then determined by 
measuring OD600, and then resuspended in RPMI-1640 containing 10% FBS for infection. 
 
Viruses 
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Virus stocks were generated by transient transfection of 293T cells with proviral plasmids coding for 
HIV-1 ADA and HIV-1 NLAD8-VSVG isolates, kindly provided by Serge Benichou (Institut Cochin, Paris, 
France), as previously described (Verollet et al., 2015). Supernatant were harvested 2 days post-
transfection and HIV-1 p24 antigen concentration was assessed by a homemade enzyme-linked 
immunosorbent assay (ELISA). HIV-1 infectious units were quantified, as reported (Souriant et al., 
2019) using TZM-bl cells (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. John C. 
Kappes, Dr. Xiaoyun Wu and Tranzyme Inc).  
 
HIV-VLP stock (GFP VLP) was generated by transfecting the molecular clone pGag-eGFP obtained from 
the NIH AIDS Research and Reference Reagent Program. HEK-293 T cells were transfected with calcium 
phosphate (CalPhos, Clontech) in T75 flasks using 30 ʅg of plasmid DNA. Supernatants containing VLPs 
were filtered (Millex HV, 0.45 ʅm͖ MilliporeͿ and froǌen aƚ оϴϬΣC Ƶnƚil Ƶse͘ The pϮϰ Gag conƚenƚ of ƚhe 
VLPs was determined by an ELISA (Perkin-Elmer). 
 
Preparation of human monocytes and monocyte-derived macrophages 
Human monocytes were isolated from healthy subject (HS) buffy coat (from EFS) and differentiated 
towards macrophages as described (Souriant et al., 2019). Briefly, peripheral blood mononuclear cells 
(PBMCs) were recovered by gradient centrifugation on Ficoll-Paque Plus (GE Healthcare). CD14+ 
monocytes were then isolated by positive selection magnetic sorting, using human CD14 Microbeads 
and LS columns (Miltenyi Biotec). Cells were then plated at 1.6 x 106 cells per 6-well and allowed to 
differentiate for 5-7 days in RPMI-1640 medium (GIBCO), 10% Fetal Bovine Serum (FBS, Sigma-Aldrich) 
and human M-CSF (20 ng/mL) Peprotech) before infection with Mtb H37Rv for conditioned-media 
preparation. The cell medium was renewed every 3 or 4 days.  
 
Preparation of conditioned media  
Conditioned-media from Mtb-infected macrophages (cmMTB) has been reported previously (Lastrucci 
et al., 2015; Souriant et al., 2019). Succinctly, hMDM were infected with Mtb H37Rv at a MOI of 3. 
After 18h of infection at 37°C, culture supernatants were collected, sterilized by double filtration 
(0.2µm pores) and aliquots were stored at -80°C. We then tested the capacity of individual cmMTB to 
differentiate freshly isolated CD14+ monocytes towards the M(IL-10) cell-surface marker phenotype, 
as assessed by FACS analyses. Those supernatants yielding a positive readout were then pooled 
together (5-10 donors) to minimize the inter-variability obtained between donors. Control media 
(cmCTR) was obtained from uninfected macrophages supernatant. When specified, IL-10 was 
eliminated from cmMTB by antibody depletion as described previously (Lastrucci et al., 2015; Souriant 
et al., 2019). The depletion was verified by ELISA (BD-BioscienceͿ͕ according ƚo manƵfacƚƵrer͛s 
protocol.  
 
Conditioning of monocytes with the secretome of Mtb-infected macrophages or cytokines 
Human CD14+ sorted monocytes from HS buffy coat were allowed to adhere in the absence of serum 
(0.4 × 106 cells / 24-well in 500 µL) on glass coverslips, and then cultured for 3 days with 40% dilution 
(vol/vol) of cmCTR or cmMTB supplemented with 20% FBS and M-CSF (20 ng/mL, Peprotech). Blocking 
IFNAR receptor was performed by pre-incubation with mouse anti-IFNAR antibody (20 µg/mL, Thermo 
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Fischer Scientific) in a 200 L for 30 min prior to conditioning. After 3 days, cells were washed and 
collected for phenotyping. 
 
When specified, monocytes were also conditioned in presence of 20 ng/mL M-CSF and 10 ng/mL 
recombinant human IL-10 (PeproTech) or 10 U/mL of IFN  (Peprotech). Cell-surface expression of 
Siglec-1 was measured by flow cytometry using standard procedures detailed hereafter. 
 
RNA extraction and transcriptomic analysis 
Cells conditioned with cmCTR and cmMTB supernatants (approximately 1.5 million cells) were treated 
with TRIzol Reagent (Invitrogen) and stored at -80°C. Total RNA was extracted from the TRIzol samples 
using the RNeasy mini kit (Qiagen). RNA amount and purity (absorbance at 260/280 nm) was measured 
with the Nanodrop ND-1000 apparatus (Thermo Scientific). According to the manufacturer's protocol, 
complementary DNA was then reverse transcribed from 1 µg total RNA with Moloney murine leukemia 
virus reverse transcriptase (Invitrogen), using random hexamer oligonucleotides for priming. The 
microarray analysis was performed using the Agilent Human GE 4x44 v2 (single color), as previously 
described (Lugo-Villarino et al., 2018). Briefly, we performed hybridization with 2 g Cy3-cDNA and the 
hybridization kit (Roche NimbleGen). The samples were then incubated for 5 min at 65°C, and 5 min at 
42°C before loading for 17h at 42°C, according to manufacturer's protocol. After washing, the 
microarrays were scanned with MS200 microarray scanner (Roche NimbleGen), and using Feature 
Extraction software, the Agilent raw files were extracted and then processed through Bioconductor 
(version 3.1) in the R statistical environment (version 3.6.0). Using the limma package, raw expression 
valƵes ǁere backgroƵnd correcƚed in a ͚normeǆp͛ fashion and ƚhen qƵanƚile normaliǌed and log2 
transformed (Ritchie et al., 2015). Density plots, boxplots, principal component analyses, and 
hierarchical clustering assessed the quality of the hybridizations. Differentially expressed genes 
between macrophages exposed to cmCTR or cmMTB supernatants were extracted based on the p-
value corrected using the Benjamini-Hochberg procedure. The log2 normalized expression values were 
used to perform Gene Set Enrichment Analyses (GSEA). The GSEA method allows to statistically test 
whether a set of genes of interest (referred to as a geneset) is distributed randomly or not in the list 
of genes that were pre-ranked according to their differential expression ratio between macrophages 
exposed to cmCTR or cmMTB supernatants. The output of GSEA is a GeneSet enrichment plot. The 
vertical black lines represent the projection onto the ranked GeneList of the individual genes of the 
GeneSet. The top curve in green corresponds to the calculation of the enrichment score (ES). The more 
the ES curve is shifted to the upper left of the graph, the more the GeneSet is enriched in the red cell 
population. Conversely, the more the ES curve is shifted to the lower right of the graph, the more the 
GeneSet is enriched in the blue cell population. 
 
siRNA silencing 
Targets silencing in monocytes was performed using reverse transfection protocol as previously 
described (Troegeler et al., 2014). Shortly, human primary monocytes were transfected with 200 nM 
of ON-TARGETplus SMARTpool siRNA targeting Siglec-1 (Horizon Discovery) or non-targeting siRNA 
(control) using HiPerfect transfection system (Qiagen). Four hours post-transfection, transfected cells 
were incubated for 24h in RPMI-1640 medium, 10% FBS, 20 ng/mL of M-CSF, before addition of cmMTB 
media (40% vol/vol). After 3 additional days, cells were infected with HIV-1 ADA or HIV-1- NLAD8-VSV-
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G strain and kept in culture for 10 more days (48h, respectively). As soon as 3-day post-transfection, 
this protocol led to the efficient depletion of Siglec-1 between a range of 50-95%, as measured by flow 
cytometry. 
 
HIV-1 infection 
For HIV-1 infection, at day 3 of differentiation, 0.4 x 106 human monocytes-derived macrophages 
(hMDM) were infected with HIV-1 ADA strain (or specified) at MOI 0.1. HIV-1 infection and replication 
were assessed 10-day post-infection by measuring p24-positive cells by immunostaining and the level 
of p24 released in culture media by ELISA. For the infection and TNT quantification at day 6 post-
infection, the same protocol was used. For HIV-1 transfer, higher MOI of HIV-1 VSVG pseudotyped 
NLAD8 virus was used, as described below (see section HIV-1 and cell-to-cell transfer) and in (Souriant 
et al., 2019). 
 
Uptake of Virus-Like Particles 
Uptake experiment were performed as previously described (Izquierdo-Useros et al., 2012; Izquierdo-
Useros et al., 2014; Pino et al., 2015) using p24Gag HIV-1GagоeGFP VLP (GFP VLP). Briefly, monocytes 
transfected or not with control siRNA or with siRNA directed against Siglec-1 and differentiated for 3 
days in cmCTR or cmMTB were washed once with PBS prior to addition of 2 ng/mL of GFP VLP. Binding 
was performed during 3.5h at 37°C in a 5 % CO2 incubator. Cells were then detached with cell 
dissociation buffer (Gibco) and prepared for flow cytometry analysis on a BD LSRFortessa (TRI-
Genotoul platerform). Same experiment was also performed blocking monocyte-derived macrophages 
at RT for 15 min with 10 ʅg/ml of mAb ɲ-Siglec-1 7ʹ239 (Abcam), IgG1 isotype control (BD Biosciences) 
or leaving cells untreated before VLP addition. 
 
Flow cytometry and Siglec-1 quantitation 
Staining of conditioned macrophages was performed as previously described (Souriant et al., 2019). 
Adherent cells were harvested after 5 min incubation in trypsin 0.05% EDTA (Gibco) and washes with 
PBS (Gibco). After 10 min centrifugation at 320g, pellets were resuspended in cold staining buffer (PBS, 
2mM EDTA, 0.5% FBS) with fluorophore-conjugated antibodies (See Key Resource Table) and in 
parallel, with the corresponding isotype control antibody using a general concentration of 1 µg/mL. 
After staining, cells were washed with cold staining buffer, centrifuged for 2 min at 320g at 4°C, and 
analyzed by flow cytometry using BD LSRFortessa flow cytometer (BD Biosciences, TRI Genotoul 
plateform) and the associated BD FACSDiva software. Data were then analyzed using the FlowJo_V10 
software (FlowJo, LLC). Gating on macrophage population was set according to its Forward Scatter 
(FSC) and Size Scatter (SSC) properties before doublet exclusion and analysis of the median 
fluorescence intensity (MFI) for each staining. 
 
To determine Siglec-1 expression we applied a quantitative FACS assay. Briefly, cmCTR- and cmMTB-
treated macrophages were detached using Accutase solution (Gibco) for 10 min at 37ºC, washed, 
blocked with 1 mg/mL human IgG (Privigen, Behring CSL) and stained with mAb 7ʹ239 ɲ-Siglec-1-PE or 
matched isotype-PE control (Biolegend) at 4°C for 30 min. The mean number of Siglec-1 mAb binding 
sites per cell was obtained with a Quantibrite kit (Becton Dickinson) as previously described (Izquierdo-
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Useros et. al 2012b). Samples were analyzed with FACSCalibur using CellQuest software to evaluate 
collected data.  
 
 
Immunofluorescence microscopy 
Cells were fixed with PFA 3.7%, Sucrose 30 mM in PBS. After washing with PBS, cells were saturated 
with blocking buffer (PBS-BSA 1%). Membrane proteins were then stained for 2h with primary 
antibodies: anti-Siglec-1 (10 µg/mL, Novus Biologicals). Cells were then incubated with appropriate 
secondary antibodies for 1h: Alexa Fluor 488 or 555 or 647 Goat anti-Mouse IgG (2 µg/mL, Cell Signaling 
Technology). Cells were then permeabilized as previously described (Souriant et al., 2019) with Triton 
X-100 0,3% for 10 minutes, washed in PBS before saturation with 0.6 µg/mL mouse IgG2 diluted in 
Dako Antibody Reducing Background buffer (Dako) for 30 min. Intracellular proteins were then stained 
with anti-Gag KC57 RD1 antibody (1/100, Beckman Coulter) and/or anti- -tubulin (5 µg/mL, Abcam) 
for 2h. Cells were washed and finally incubated with Alexa Fluor 488, 555 or 647 Goat anti-Mouse or 
Goat anti-Rabbit IgG secondary antibodies (2 µg/mL, Cell Signaling Technology), Alexa Fluor 488 or 555 
Phalloidin (33 mM, Thermo Fisher Scientific), Wheat Germ Agglutinin (CF®350 WGA, Thermofischer) 
and DAPI (500 ng/mL, Sigma Aldrich) in blocking buffer for 1h. Coverslips were mounted on a glass 
slide using Fluorescence Mounting Medium (Dako) and visualized with a spinning disk (Olympus) (Fig. 
S2C; 3A; 3F; S3A, S3B, S3C; movie 1), a Zeiss confocal LSM880 with Airyscan (Fig. 3D,  Movie 2) and a 
FV1000 confocal microscope (Olympus) (Fig. 4F). 
 
TNT were identified by WGA or phalloidin and tubulin staining, and counted on at least 1000 cells per 
condition and per donor. 
 
As HIV-1 infection induces macrophages fusion into MGC (Verollet et al., 2010) the number of infected 
cells largely underestimates the rate of infection. Thus, to better reflect the rate of infection, we 
quantified the percentage of multinucleated cells. Using semi-automatic quantification with 
homemade Image J macros, allowing the study of more than 5,000 cells per condition in at least five 
independent donors, assessed these parameters.  
 
HIV-1 and cell-to-cell transfer 
Freshly isolated CD14+ monocytes from HS transfected with siRNA against Siglec-1 or siRNA control 
were allowed to adhere in the absence of serum (2×106 cells/6-well in 1.5 mL). After 4h of culture, 
RPMI-1640 supplemented with 20 ng/mL M-CSF and 20% FBS were added to the cells (vol/vol). After 
24h, cells were conditioned with cmMTB media. At day 4, 120 ng p24 of a HIV-1 NLAD8 strain 
pseudotyped with a VSVG envelope was used to infect half of the cells, kept in culture for 2 more days. 
At day 6, before co-culture, uninfected cells were stained with CellTracker Green CMFDA Dye (Thermo 
Fisher Scientific). For mitochondria transfer, half of the macrophages were pre-stained with Green 
CellTracker, and the other half, uninfected, was stained with mitoTracker Deep-Red prior to co-culture. 
Briefly, cells were washed with PBS Mg2+/Ca2+ and stained for 30 min with 500 ng/mL CellTracker or 
mitoTracker, before washing with RPMI-1640 10% FBS. HIV-1+ or mitoTracker+ and CellTracker+ cells 
were then detached using accutase (Sigma) and co-cultured at a 1:1 ratio on glass coverslips in 24-well. 
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Histological analyses 
Paraffin embedded tissue samples were sectioned and stained with hematoxylin and eosin for 
histomorphological analysis. Different antigen unmasking methods where used on tissue slides for 
immunohistochemical staining, which was performed using anti-CD163 (Leica/Novocastra), anti-
Siglec-1 (Novus Biologicals) and anti-pSTAT1 (Cell Signaling Technology). Sections were then incubated 
with biotin-conjugated polyclonal anti-mouse or anti-rabbit immunoglobulin antibodies followed by 
the streptavidin-biotin-peroxidase complex (ABC) method (Vector Laboratories). Finally, sections were 
counter-stained with hematoxylin. Slides were scanned with the Panoramic 250 Flash II (3DHISTECH). 
Virtual slides were automatically quantified for macrophage distribution as previously described 
(Souriant et al., 2019). Immunofluorescence staining of the sections was performed as described above 
and followed by anti-mouse IgG isotype specific or anti-rabbit IgG antibodies labelled with Alexa488 
and Alexa555 (Molecular Probes). Samples were mounted with Prolong® Antifade reagent (Molecular 
Probes) and examined using a 60x/1.40N.A. objective of an Olympus spinning disk microscope.  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
Information on the statistical tests used and the exact values of n (donors) can be found in the Figure 
Legends. All statistical analyses were performed using GraphPad Prism 8.0.0 (GraphPad Software Inc.). 
Two-tailed paired or unpaired t-test was applied on data sets with a normal distribution (determined 
using Kolmogorov-Smirnov test), whereas two-tailed Mann-Whitney (unpaired test) or Wilcoxon 
matched-paired signed rank tests were used otherwise. p<0.05 was considered as the level of 
statistical significance ;Ύ pчϬ͘Ϭϱ͖ ΎΎ pчϬ͘ϬϬϱ͖ ΎΎΎ pчϬ͘ϬϬϬϱ͖ ΎΎΎΎ pчϬ͘ϬϬϬϭͿ. 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-human 
Siglec-1 (clone 7-293) 
Biolegend 
Cat# 346008; 
RRID:AB_1114794
8 
Mouse monoclonal anti-human 
CD16 (clone 3G8) 
Biolegend 
Cat# 302019 and 
302018; 
RRID:AB_492974 
and AB_314218 
Mouse monoclonal nti-human 
CD163 (clone GHI/61) 
Biolegend 
Cat# 333608; 
RRID:AB_2228986 
Mouse monoclonal anti-human 
MerTK (clone 590H11G1E3) 
Biolegend 
Cat# 367607; 
RRID:AB_2566400 
Rabbit monoclonal anti-human 
STAT1 (clone 42H3)  
Cell Signaling Technology 
Cat# 9175; 
RRID:AB_2197984 
Rabbit anti-human actin (a.a. 20-33) Sigma-Aldrich 
Cat# A5060; 
RRID:AB_476738 
Rabbit polyclonal anti- tubulin Abcam 
Cat# ab18251; 
RRID:AB_2210057 
Mouse monoclonal anti-Siglec-1 
(clone hsn 7D2)  
Novus Biologicals 
Cat# NB 600-534; 
RRID:AB_526814 
Mouse monoclonal anti-Gag  RD1 
(clone KC57) 
NIH AIDS Reagent program Cat# 13449 
Monoclonal mouse anti-HIV p24 
(clone Kal-1) 
Dako Agilent technologies 
Cat# M0857, 
RRID:AB_2335686 
Mouse monoclonal anti-HIV-1 p24 
(clone 183-H12-5C) 
NIH AIDS Reagent Program Cat# 3537 
Human polyclonal anti-HIV Immune 
Globulin (HIVIG) 
NIH AIDS Reagent Program Cat# 3957 
Polyclonal goat anti-human IgG Sigma-Aldrich Cat# A0170 
Mouse monoclonal anti-human 
CD163 (clone 10D6) 
Leica/Novocastra 
Cat# NCL-L-CD163; 
RRID:AB_2756375 
Anti-pSTAT1  Cell Signaling Technology 
Cat# 9167 
RRID:AB_561284 
Mouse monoclonal anti-IFNAR2 
(clone MMHAR-2) 
Thermo Fisher Scientific 
Cat# 213851; 
RRID:AB_223508 
Mouse IgG2a isotype control  Thermo Fisher Scientific 
Cat# 02-6200; 
RRID:AB_2532943 
Polyclonal F(ab)2 goat anti-rabbit 
IgG, AlexaFluor 555 
Thermo Fisher Scientific 
Cat# A-21430, 
RRID:AB_2535851 
Polyclonal F(ab)2 goat anti-mouse 
IgG, AlexaFluor 488 
Thermo Fisher Scientific 
Cat# A-10684, 
RRID:AB_2534064 
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Plyclonal F(ab)2 goat anti-mouse IgG, 
AlexaFluor 555 
Cell Signaling Technology 
Cat# 4409, 
RRID:AB_1904022 
Polyclonal goat anti-rabbit IgG, HRP Thermo Fisher Scientific 
Cat# 32460; 
RRID:AB_1185567 
Polyclonal goat anti-mouse IgG, HRP Thermo Fisher Scientific 
Cat# 31430; 
RRID:AB_228307 
Bacterial and Virus Strains  
M. tuberculosis H37Rv N/A N/A 
HIV-1 ADA  Gift from Dr. S Benichou 
Institut Cochin, 
Paris, France 
HIV-1 ADA Gag-iGFP  
Gift from Dr P. Benaroch and 
Dr.  M. Schindler  
Institu Pasteur, 
Paris, France 
Institute of 
Virology, Munich, 
Germany 
HIV-1 NLAD8-VSVG Gift from Dr. S Benichou 
Institut Cochin, 
Paris, France 
HIV-1 ADA Gag-iGFP-VSVG N/A N/A 
HIV-1 ADA-VSVG Gift from Dr. S Benichou 
Institut Cochin, 
Paris, France 
HIV-1 Gag-eGFP 
NIH research reagent 
program 
Catalogue number 
11468 
Lot number: 2 
070514 
Biological Samples   
Buffy Coat 
Etablissement Français du 
Sang, Toulouse, France 
N/A 
Histological slides of lung biopsies 
from rhesus macaques 
Tulane National Primate 
Research Center 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
Human recombinant M-CSF Peprotech Cat# 300-25 
Human recombinant IFN  Peprotech Cat# 300-02BC 
Human recombinant IL-10 Peprotech Cat# 200-10 
Critical Commercial Assays 
Mouse anti-human CD14 microbeads  Miltenyi Biotec Cat# 130-050-201 
LS magnetic columns Miltenyi Biotec Cat# 130-042-401 
Amersham ECL Prisme Western 
Blotting Detection Reagent 
GE Healthcare Cat# RPN2232 
SuperSignal WestPico 
Chemiluminescent Substrate 
Thermo Scientific Cat# 34080 
IL-10 ELISA set BD Bioscience Cat# 555157 
Trypsin EDTA 0.05% Thermo Fisher Scientific Cat# 25200072 
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Accutase  Sigma-Aldrich Cat# A-6964 
Phalloidin AlexaFluor 488 Thermo Fisher Scientific Cat# A12379 
Phalloidin Alexa Fluor 647 Thermo Fisher Scientific Cat# A22287 
DAPI Sigma Aldrich Cat# D9542 
CellTracker Red CMPTX Dye Thermo Fisher Scientific Cat# C34552 
CellTracker Green CMFDA Dye Thermo Fisher Scientific Cat# C7025 
MitoTracker Deep Red FM Invitrogen Cat# M22426 
Fluorescence Mounting Medium Agilent Technologies Cat# S302380-2 
Antibody diluent, Background 
reducing  
DAKO, Agilent Technologies 
Cat# S302283-2 
Experimental Models: Cell Lines 
TZM-bl cell line NIH AIDS Reagent Program Cat# 8129 
HEK 293T cell line NIH AIDS Reagent Program Cat# 3318 
HKB-IFNAB Invivogen Cat# hb-detE 
Software and Algorithms 
ImageJ ImageJ 
http://www.imag
ej.nih.gov/ij 
Prism (v8.0.0) GraphPad 
http://www.graph
pad.com 
Photoshop CS3 Adobe 
http://www.adob
e.com 
Adobe Illustrator CS5 Adobe 
https://www.adob
e.com/fr/products
/illustrator.html 
Huygens Professional Version 16.10 Scientific Volume Imaging 
https://svi.nl/Huy
gensProfessional 
FACS DIVA BD Bioscience 
http://www.bdbio
sciences.com/ 
FlowJo_v10 FlowJo 
https://www.flowj
o.com/ 
FCS Express V3 DeNovo Software 
http://www.deno
vosoftware.com 
Image Lab Bio-Rad Laboratories 
http://www.bio-ra
d.com 
Pannoramic Viewer  3DHISTECH 
https://www.3dhi
stech.com/pannor
amic_viewer 
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Figure S1. Tuberculosis-associated microenvironment increases Siglec-1 expression in human 
macrophages (see also Figure 1).   
(A-C) For 3 days, human monocytes were differentiated into macrophages with cmCTR (white) or 
cmMTB (black) supernatants. 
(A) (Left) Gene set enrichment plot of the interferon alpha (IFN ) response (hallmark collection of 
MSigDB). This plot shows the distribution of the barcode between macrophages exposed to cmCTR 
(red) versus cmMTB (blue) supernatants. Each bar of the barcode corresponds to a signature gene of 
the gene set. The skewing to the right indicates enrichment in macrophages exposed to cmMTB versus 
cmCTR supernatant of genes up-regulated in response to IFN . (Right) Gene set enrichment plot of the 
IFN  response (hallmark collection of MSigDB).  
(B-C) Flow cytometry gating strategy to assess Siglec-1 cell-surface expression in human macrophages 
exposed to cmCTR (white) and cmMTB (black) (B), or cmCTR-treated cells infected with HIV-1 (C). (B) 
Left: Based on size (FCS-A) and granularity (SSC-A), a gate was created to separate human macrophages 
from cell debris and dying cells. Macrophages were then subjected through a second gate based FSC 
Area Scaling (FCS-A and FCS-H) to separate singlets from doublets. Right: Based on the singlet gate, the 
histogram plot illustrates Siglec-1 expression that is higher in cmMTB- than in cmCTR-treated 
macrophages. (C) The histogram plot illustrates the time-course of Siglec-1 expression that is 
upregulated after HIV-1 infection in cmCTR-treated cells compared to uninfected ones. 
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Figure S2. Tuberculosis-associated microenvironment increases Siglec-1 expression in non-human 
primate alveolar macrophages (see also Figure 1). 
 (A) Accumulation of Siglec-1+ alveolar macrophages in the lung of co-infected non-human primates 
(NHP). Representative immunohistochemical images of Siglec-1 staining (brown) in lung biopsies of 
healthy, SIV-infected (SIV), active tuberculosis (ATB) and co-infected with SIV (ATB-SIV) NHP. Scale bars 
from top to bottom: 2 mm, 500 µm and 50 µm.  
(B-C) Siglec-1+ cells display the alveolar macrophage morphology. (B) Representative 
immunohistochemistry image from lung biopsy of an ATB-SIV NHP stained for Siglec-1 (brown). 
Siglec-1+ cells display a cell morphology with a single nucleus and large cytoplasm reminiscent of 
macrophage (black arrowhead); Siglec-1- cells display a different nucleus morphology and small 
cytoplasm reminiscent of neutrophils (red arrowhead). Scale bar, 20 µm. (C) Representative 
immunofluorescence images of alveolar macrophages found in lung biopsy of a representative ATB-
SIV NHP stained for Siglec-1 (red), CD163 (green) and DAPI (nuclei, blue). Scale bar, 20 µm. 
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Figure S3. Siglec-1 localizes specifically on thick tunneling nanotubes that contain HIV-1 Gag and 
mitochondria (see also Figure 3).   
(A-C) Human monocytes were differentiated into macrophages with cmMTB for 3 days, infected with 
HIV-1-ADA strain (unless indicated otherwise) and then fixed at day 3 (A-B) or 10 (C) post-infection. 
(A) Representative immunofluorescence images used for semi-automatic quantification of TNT in 
cmMTB-treated macrophages infected with HIV-1. Cells were stained for extracellular Siglec-1 (red), 
intracellular tubulin (MT, grey) and Wheat Germ Agglutinin (WGA, not shown). Blue lines show all TNT 
considered. Thick (WGA+, MT+) and thin (WGA+, MT-) TNT were assessed for Siglec-1 positivity by 
applying a threshold and measured in length. Scale bar, 20 µm. 
(B) Representative immunofluorescence images of cmMTB-treated macrophages infected with HIV-1-
NLAD8-VSVG, loaded with Mitotracker (MitoT, red) and stained for intracellular HIV-1 Gag (green) and 
WGA (grey). Red arrowheads show mitochondria inside HIV-1 Gag-containing TNT. Inserts are 2x zoom. 
Scale bar, 20 µm. 
(C) Representative immunofluorescence images of cmMTB-treated macrophages infected with HIV-1 
and kept in culture until day 10 post-infection. Cells were fixed and stained for intracellular HIV-1 Gag 
(green), extracellular Siglec-1 (red) and WGA (grey). Red arrowheads show Siglec-1 on HIV-1 Gag-
containing TNT emanating from an infected multinucleated giant cell (MGC). Scale bar, 20 µm 
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Figure S4. Siglec-1 is required for the capture and transfer of HIV-1 in cmMTB-treated macrophages 
(see also Figure 4).   
(A-D, F-G) Monocytes from healthy subjects were transfected with siRNA targeting of Siglec-1 (siSiglec-
1, black) or not (siCtrl, white). A day after, monocytes were differentiated into macrophages with 
cmMTB for 3 days.  
(A) Representative histogram (left) and vertical scatter plot showing the median fluorescent intensity 
(MFI) (right) of Siglec-1 expression on the indicated cell populations. 
(B) Vertical scatter plot indicating the percentage of cells forming TNT in cells.   
(C-E) Inhibition of Siglec-1 reduces binding of HIV-ϭ GagоeGFP VLP ;GFP VLPͿ͘ ;CͿ Represenƚaƚiǀe 
immunofluorescence (IF) images of cmMTB-treated cells incubated with GFP VLP (green) for 3.5h. Cells 
were fixed and stained for Siglec-1 (red) and Wheat Germ Agglutinin (WGA, blue). Scale bar, 500 µm. 
(D) Representative histogram (left) and vertical scatter plot showing the median fluorescent intensity 
(MFI) (right) displaying of GFP VLP binding in the indicated cell populations. (E) Vertical scatter plot 
showing the percentage of GFP VLP binding in cmMTB treated cells pre-incubated with specific anti-
Siglec-ϭ ;ɲ-Siglec-ϭ͕ greǇͿ͕ isoƚǇpe conƚrol anƚibodǇ ;ɲ-IgG, black) or mock (white). 
(F) Experimental model for the cell-to-cell transfer experiment. siRNA-transfected donor (red) cells 
were either labelled with MitoTracker (1h prior co-culture) or infected with HIV-1-NLAD8-VSVG (48h 
prior to co-culture), while autologous recipient cells (green) were stained with cell tracker (1h prior co-
culture). Both donor and recipient cells were co-culture for 24h. Red fluorescence was then measured 
in recipient cells by IF. 
(G) Vertical scatter plot showing the percentage of HIV-1Gag+ cells at the time of co-culture experiment 
in the indicated cells. 
Statistical analyses: Two-tailed, Wilcoxon matched-pairs signed rank test (A, B, D-E, G). *P < 0.05, ***P 
< 0.001. ns: not significant. 
 
  
 230 
 
SUPPLEMENTAL TABLES 
 
Table S1. Clinical data of NHPs (related to Figure 1E-H and 2E-H, and Figure S2A). 
Animals Status Sex 
Age of death 
(years) 
Days after 
infection* 
Viral load** 
EC61 - M 8.99 - - 
GI53 - M 5.02 - - 
IT02 - M 4.69 - - 
BK48 SIV M 12.06 322 8.58 x 106 
DD87 SIV F 9.84 540 3.03 x 104 
DT18 SIV M 8.85 764 4.40 x 104 
BA34 SIV M 16.79 750 1.91 x 105 
DR28 SIV M 8.84 120 1.48 x 107 
CA75 LTB M 11.7 106 - 
FE10 LTB M 7 166 - 
FJ05 LTB M 6.81 181 - 
CL10 ATB M 13.84 51 - 
CG58 ATB M 7.71 75 - 
GK87 ATB F 7.76 38 - 
ER44 SIV/LTB M 8.61 167 1.93 x 105 
HB12 SIV/LTB M 4.97 167 1.04 x 106 
ID01 SIV/LTB M 3.58 153 2.17 x 106 
HP22 SIV/ATB M 3.79 113 3.7 x 108 
HP41 SIV/ATB M 3.78 111 6 x 105 
HT09 SIV/ATB M 3.72 104 7.5 x 106 
* Infection 1: Mtb CDC1551 and infection 2: SIVmac239. For co-infected macaques, days after 
first Mtb infection. Abbreviations: LTB: latent TB, ATB: active TB, M: male, F: female.  
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Table S2. Histopathological scoring of lung lesions in NHPs (related to Figure 1E-H and 2E-H, and 
Figure S2A). 
Anima
ls 
Status 
Lung 
Diseas
e 
severi
ty 
Granulomatous lesions 
Non- 
Granulomatous 
lesions 
Gran
ulom
a Size 
Type of 
granulom
a 
Distributi
on 
pattern 
Cellular 
composition 
EC61 - None - - - - 
- Few & small 
perivascular 
lymphohistiocytic 
infiltrates, PMN+ 
GI53 - None - - - - 
- Few & small 
perivascular 
lymphohistiocytic 
infiltrates, PMN+ 
IT02 - None - - - - 
- Few & small 
perivascular 
lymphohistiocytic 
infiltrates 
-PMN+ 
-peribronchial 
iBALT 
BK48 SIV 
Mini
mal 
- - - - 
- small 
perivascular 
lymphohistiocytic 
infiltrates 
DD87 SIV 
Mini
mal 
- - - - 
- small 
perivascular 
lymphohistiocytic 
infiltrates 
DT18 SIV 
Mini
mal 
- - - - 
-polymorph 
infiltrates 
BA34 SIV Mild - - - - 
- Focal interstitial 
pneumonia, 
- interstitial 
lymphohistiocytic 
infiltrates, 
- thickening of the 
alveolar wall, 
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- collagen deposit, 
- type-2 
pneumocyte 
hyperplasia 
DR28 SIV 
Mini
mal 
- - - - 
thickening of the 
alveolar wall 
closed to the 
pleura 
CA75 LTB Mild small 
Non 
Necrotizi
ng, 
Poorly 
organized 
multifoca
l 
- Lymphocytic 
cuff 
- Epithelioid & 
Foamy Mʔ 
- MGC, - 
Fibrosis [+] 
Interstitial 
pneumopathy 
 
FE10 LTB Mild large 
Nonnecro
tizing 
Suppurati
ve 
focal 
solid 
coalesce
nt 
- Lymphocytic 
cuff 
- Epithelioid & 
Foamy Mʔ 
- MGC 
Thickening of the 
alveolar wall 
FJ05 LTB Mild 
medi
um 
caseous 
multifoca
l 
- Lymphocytic 
cuff 
- peripheral 
fibrosis 
Strong interstitial 
pneumopathy 
CL10 ATB 
Mode
rate 
Small 
& 
medi
um 
Caseous 
& solid 
Multifoc
al 
coalesce
nt 
- Lymphocytic 
cuff 
- Epithelioid 
Mʔ, - MGC++ 
- Strong 
interstitial 
pneumopathy 
& haemorrhage 
CG58 ATB Mild 
Small
, 
medi
um & 
large 
Necrotic 
& solid 
Multifoc
al 
coalesce
nt 
- Lymphocytic 
cuff 
- Epithelioid 
Mʔ, - MGC++ 
- 
GK87 ATB 
Mode
rate 
Medi
um & 
large 
Necrotic, 
caseous 
and 
supurativ
e 
Multifoc
al 
coalesce
nt 
- Lymphocytic 
cuff 
- Epithelioid 
Mʔ, MGC++, 
PMN++ 
-transudat in the 
alveolar space, 
- collagen 
deposits 
-Interstitial 
pneumopathy 
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ER44 
SIV/LT
B 
Mild large 
Necrotic 
& caseous 
focal 
2 coalescent 
follicles, 
Loss of the 
lymphocytic 
cuff, 
Epithelioid 
Mʔ- MGC++, 
-Interstitial 
pneumopathy, 
- haemorrhage & 
fibrosis 
HB12 
SIV/LT
B 
Sever
e 
none - - - 
-Interstitial 
pneumopathy, 
iBALT 
- haemorrhage & 
alveolitis, 
- fibrosis, syncitia 
and PMN++ 
ID01 
SIV/LT
B 
Mode
rate 
none - - - 
-Interstitial 
pneumopathy, 
iBALT 
- haemorrhage & 
alveolitis, 
HP22 
SIV/A
TB 
Mode
rate 
medi
um 
Solid, 
necrotic, 
fibrotic & 
mineraliz
ed 
multifoca
l 
- Lymphocytic 
cuff 
- Epithelioid 
Mʔ, MGC++ 
-Interstitial 
pneumopathy 
- haemorrhage & 
syncitia 
HP41 
SIV/A
TB 
Sever
e 
large Necrotic 
coalesce
nt 
- Lymphocytic 
cuff 
- Epithelioid 
Mʔ, MGC++ 
-strong Interstitial 
pneumopathy, 
- haemorrhage & 
alveolitis, fibrosis, 
PMN++ 
HT09 
SIV/A
TB 
Sever
e 
large 
Supurativ
e 
Multifoc
al, 
coalscent 
& 
invasive 
Loss of the 
lymphocytic 
cuff, 
Epithelioid 
Mʔ, MGC++, 
PMN++ 
fibrosis 
- Interstitial 
pneumopathy, 
- haemorrhage 
Abbreviations: PMN: ploymorphonuclear leukocytes, iBALT: inducible Bronchus-associated 
lymphoid tissue, M੮: Macrophages, MGC: Multinucleated giant cells. 
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III. Discussion 
Here, we evidence that the TB-associated microenvironment induces the formation of TNT, 
together with the IFN-I inducible receptor Siglec-1 that was previously shown to efficiently capture and 
transfer HIV-1 from DC to CD4+ T cells. We found that Siglec-1 was specifically expressed by a subtype 
of thick TNT, longer than Siglec-1- TNT, which contained high HIV-1 and mitochondria cargos. In 
addition, Siglec-1+ alveolar macrophage abundance in the lung of Mtb-SIV co-infected macaques 
correlated with the disease severity and the activation of the IFN-I/STAT1 pathway. We also observed 
that the depletion of Siglec-1 decreased HIV-1 capture, while the viral replication dropped to the levels 
observed in control cells. Therefore, Siglec-1 is a key factor involved in the exacerbation of HIV-1 
replication in the context of co-infection with Mtb, at least in part in a TNT-dependent manner. 
By means of co-culture experiments, we showed that Siglec-1 depletion reduced the 
intracellular cell-to-cell transfer of HIV-1, since we used a VSVG-pseudotyped strain of HIV-1 to avoid 
differences of viral uptake in presence or absence of Siglec-1. Moreover, prior to co-culture, infected 
cells were washed to remove viruses that did not infect the cells, and the production of new virions in 
macrophages is longer than 24h. We correlated this diminution with the reduced TNT length and the 
diminished capacity of silenced cells to transfer mitochondria. However, we could not prove that the 
decreased transfer of both HIV-1 and mitochondria in Siglec-1-depleted macrophages was due to TNT 
transport inhibition. Indeed, HIV-1 proteins, full viruses and mitochondria elements, such as DNA, can 
also be transferred from one cell to another through the exosome pathway. To assess to what extend 
TNT or exosome-like particle, secreted through the exosome pathway, are involved in cell-to-cell 
transfer of HIV-1 and mitochondria, co-culture experiments combining the depletion of Siglec-1 and 
use of TNT inhibitor [550], [669] could be performed. In addition, proper exosomes secreted by Mtb-
infected cells could also be filtered and extracted from cmMTB conditioning media, and used in 
independent culture of non-polarized macrophages infected with HIV-1 to evaluate the role of cmMTB-
exosome in the enhancement of HIV-1 dissemination. In parallel, exosome-free and vesicles-free 
cmMTB could be used to differentiate monocytes and to reiterate the co-culture experiment, in 
comparison ǁiƚh ͞compleƚe͟ cmMTB ƚreaƚmenƚ͘ I ǁoƵld eǆpecƚ ƚhaƚ eǆosomes and ǀesicles plaǇ a 
minor role in the exacerbation of HIV-1 replication and spread. Indeed, we previously performed the 
co-culture experiment of infected macrophages with uninfected one using transwells, of which pores 
are large enough to allow exosome to pass from one side of the transwell to the other ([550], Chapter 
IV). Donor macrophages separated by a transwell from uninfected recipient cells failed to transfer HIV-
1, as compared to co-culture where TNT were strongly induced.  Moreover, this transfer was inhibited 
when TNTi was used during the co-culture ([550], Chapter IV), suggesting that the main mechanism 
through which HIV-1 spread from one macrophage to the other is dependent on cell-to-cell contact.  
In this study, we observed that Siglec-1 expression had an impact on the length of TNT. 
Moreover, we observed that Siglec-1+ TNT were still present in the culture after 10 days of infection 
with HIV-1, whereas Siglec-1- thick TNT were rarer, suggesting that Siglec-1+ TNT are possibly more 
stable than other TNT. Interestingly, Siglec-1 binds both in cis and trans to D2,3-sialic acid expressed 
at the cell surface [621], [622]. One of its ligand, GM3, is strongly expressed both at the cell surface  
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Figure 33: Siglec-1 and GM3 are localized on thick TNTs. 
Representative immunofluorescence images of cmMTB-treated macrophages differentiated for 3 days prior to 
HIV-1ADA infection and fixation 3 days post-infection. Cells were stained for extracellular Siglec-1 (red), GM3 
(green) and intracellular tubulin (microtubule, grey). Scale bar: 100 µm. 
  
  
Figure 34: Structure and stability of TNT. 
A | Schematic diagram depicting the structure of TNT. TNT formed between two cells can either be single thick 
connections or an association between thinner individual TNT. Both type of TNT structure can contain 
intracellular cargos, such as small vesicles, mitochondria for the bigger ones, and pathogens. Vesicles trafficking 
inside TNT are connected to the TNT plasma membrane through thin connecting coil composed of actin 
filaments. Individual TNT are connected with one another through actin and N-cadherin proteins that act as 
membrane anchors (not represented). Adapted from [770]. 
B | Schematic representation of Siglec-1-GM3 bound TNT in the context of HIV-1 infection. Individual 
TNT are connected to one another through the interaction of Siglec-1 and GM3 expressed all along 
TNT; stabilizing the structure for a longer period of time or longer distance, allowing for enhanced 
viral transport. 
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and on HIV-1 virion when budding from infected cells [633]. In a preliminary experiment, I observed 
that GM3 is the main ganglioside present at the surface of cmMTB-treated macrophages, and more 
specifically, I found that both Siglec-1 and GM3 are present on TNT (Figure 33). According to these 
observations, one can hypothesize that the expression of Siglec-1 and GM3 on TNT are involved in the 
stability of these structures and would therefore allow the transport of soluble factors, organelles and 
pathogens for longer period of time or to longer distance. However, Siglec-1 is also able to bind several 
ligands, including mucin-1 and CD43, which were suggested previously to be putative ligands for Siglec-
1 in breast cancer and T cells respectively [822], and could be, as much as GM3, part of the molecules 
stabilizing Siglec-1+ TNT. Importantly, counter receptors, such as MRC1, are also capable of binding to 
Siglec-1 [830]. Considering that MRC1 is highly expressed by macrophages (especially in the TB context) 
and its involvement in the capture of HIV-1 (see chapter II section D.a.i.), it would be interesting to find 
out the role of MRC1-Siglec-1 interactions in the enhanced capture of HIV-1 virions and potential role 
in the stabilization of TNT structures.  
The group of Dr C. Zurzolo have identified the structure of neuronal cell TNT using highly resolutive 
cryo-electron microscopy technique and found that a single TNT observed by immunofluorescence is 
in fact constituted of several individual small TNT (diameter comprised between 145 and 700 nm) 
(Figure 34A), connected with one another by actin filament and N-cadherin anchors. Individual TNT 
were found to contain small vesicles and mitochondria that efficiently transferred from one cell to 
another, unidirectionally [770]. It would be interesting to study if macrophages TNT display the same 
organization, and what are the proteins involved in the connection between individual TNT. My 
hypothesis is that, under physiological conditions, macrophages TNT are composed of several 
individual TNT and that are maintained by adhesion molecules, such as ICAM or integrin. However, in 
pathological condition such as Mtb-HIV-1 mono- or co-infection, the upregulation of Siglec-1 could 
strengthen the stability of TNT by providing an additional anchor between individual TNT. Indeed, it is 
possible that one individual TNT expresses GM3, or another ligand or counter-receptor (e.g. MRC1),  
while the other expresses Siglec-1, which bind to each other and stabilize the entire structure (Figure 
34B). To verify this hypothesis, the same methodology than that used by Dr C. Zurzolo could be used. 
In addition, to establish the role of Siglec-1 in TNT stabilization, video-microscopy experiment following 
the same TNT for several hours, or maximum few days, could be performed on cmMTB-macrophages 
depleted or not for Siglec-1. To go further with TNT stability, it could be interesting to investigate the 
involvement of lipid-rafts, and more particularly on cholesterol function in TNT formation and/or 
stabilization. Indeed, GM3 are inserted in lipid rafts rich in cholesterol [771]. In addition, cholesterol 
was previously reported to be involved in TNT stabilization [772], [773]. To do so, we could study the 
formation of TNT in cells where cholesterol was depleted with E-methylcyclodextrin, and evaluate the 
capacity of cholesterol replenishment to induce TNT formation. In terms of stability, live cell imaging 
experiments following the same principle as for Siglec-1+ cells could be performed, with or without 
cholesterol.  
Another interesting question relative to TNT-mediated exacerbation of HIV-1 replication in the 
context of TB co-infection would be to assess the part of HIV-1 trafficking inside TNT and the part of 
external Siglec-1-bound HIV-1 particles in the infection mechanisms of macrophages. Indeed, it was 
previously suggested that HIV-1 proteins [669], [774] and particles [668], [775] were present inside 
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TNT and spread from one cell to another by intracellular trafficking. However, the clear demonstration 
of internal viral transfer remains to be done and is a quite challenging question in the field since even 
super-resolution microscopy has a resolution range of about the diameter of TNT. One technique that 
could answer the question whether HIV-1 virus are inside or outside TNT is to use electron microscopy 
where a TNT can be found and cut to see the inside. Here, we found that Siglec-1 is mainly expressed 
at the cell surface and on TNT membrane. Moreover, we saw that Siglec-1 present on TNT captured 
efficiently the viral-like particles through GM3 recognition. Therefore, and considering that cell 
membranes are highly dynamic structures, it is highly possible that HIV-1 particles bound to Siglec-1 
are transported from the infected to the non-infected cell through Siglec-1 membrane ͞sliding͕͟ as 
previously observed with BCG [665]. This process could also be enhanced by the expression of other 
lectins on TNT. In the context of Mtb infection, we found that DC-SIGN, MRC1 and DCIR, all described 
to bind to the viral protein gp120, were induced by cmMTB in macrophages. Assessing whether these 
lectins are also involved in TNT stabilization or HIV-1 TNT-mediated transfer could further help to 
characterize certain subtype of TNT, which actively transport HIV-1 particles. For instance, if DC-SIGN 
or MRC1 are expressed on TNT, it could represent an increased binding site for the virus, just like Siglec-
1, and therefore participate to the increase viral capture and transfer from one cell to another. I 
suspect that DC-SIGN and MRC1 would display similar role than Siglec-1 in stabilizing the transfer, 
notably through interaction with their ligand on another individual TNT. For example, it has been 
shown that a decrease in cholesterol levels in HIV-1 non-progressors resulted in the absence of HIV-1 
trans-infection between target cells. This was directly linked to the number of DC-SIGN+ macrophages, 
which were low in non-progressors [776]. Considering that cholesterol was shown to stabilize TNT 
[773], [777], it is likely that DC-SIGN interacts with cholesterol-enriched membrane region, and thereby 
participate in TNT stabilization. Combining cholesterol deprivation and DC-SIGN depletion could be a 
way to evaluate their combined role in TNT biology and function. At a larger scale, several studies have 
reported the competitive interaction of DC-SIGN with HIV-1 or other molecules, including the C-type 
lectin surfactant protein D [608], lactoferrin present in colorectal mucus [778], or Lewis antigens 
glycans [779] which all prevented HIV-1 uptake and transfer. Hence, enrichment or administration of 
such molecules in cell culture or in patient could prevent DC-SIGN-mediated HIV-1 spread.  
Beside from their role in molecules and organelles transport, few things are known about TNT 
physiology. In the infection context, the mechanisms of TNT formation are unknown other than the 
implication by the viral protein Nef [669] and the IL-10/STAT3 axis ([550], Chapter IV). VCC represent 
an intracellular compartment where the virus can assemble and bud safely from the immune system 
detection [528]. Hammonds and colleagues have reported that upon capture by Siglec-1, HIV-1 
particles are internalized into pre-existing VCC [536]. First, it would be interesting to assess if in the co-
infection context, the size and volume of VCC are increased in cmMTB-macrophages, and if this is 
dependent on Siglec-1 expression. This could be performed by immunofluorescence experiments 
and/or video-microscopy, in the presence or absence of Siglec-1 (siRNA depletion or use of blocking 
antibodies to prevent VCC formation upon HIV-1 capture). Second, it was previously showed that 
Siglec-1-bound HIV-1 particles stored in VCC in DC were then transferred efficiently to CD4+ T cells in a 
cell-to-cell contact dependent manner [633]. Considering that cmMTB induces the expression of TNT, 
it would be interesting to evaluate if the formation of VCC or if pre-existing VCC could lead to the 
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formation of TNT, providing HIV-1-infected cells with a rapid and efficient mechanism to transport HIV-
1 from one cell to another.  
Finally, a key issue to address is the existence and importance of Siglec-1+ TNT in vivo. The 
existence and characterization of such structures in vivo is quite complicated since no specific marker 
of TNT has been described yet. Moreover, the definition of TNT in vitro ( (i) connect at least two cells, 
(ii) contain F-actin and (iii) do not touch the substrate), cannot be fully applied to in vivo systems; the 
criteria of not touching the substrate is not applicable in 3D organisms or cultures. Few studies though 
report the existence of TNT-like structure in vivo, notably during the embryo development or in the 
eye. Indeed, Chinnery and colleagues evidenced the formation of long and thin protrusions connecting 
MHC-II+ DC in the cornea of mice [780]. Other developmental studies also reported TNT-like structures 
during the embryogenesis of mice [781], chicken [782], zebrafish [783] and sea urchin [784]. In the 
context of cancer, notably in the brain, microtubes have been observed between cancerous cells by 
intravital microscopy [785]. In humans, TNT have been mainly studied ex vivo in tumor explant, stained 
with hematoxylin and eosin [786], but such structures were also observed in ovarian cancer explants 
by phase contrast imaging [787]. Taken together, these studies suggest that TNT are not cell culture 
artefact and do exist in vivo. However, an applicable definition of these structures in 3D context and 
specific markers are required to precisely prove their existence. Moreover, most human studies 
focused on the cancer cell ability to form TNT, along with their function of mitochondria transfer, but 
none has shown the formation of TNT between macrophages. We observed the first evidence of TNTʹ
like structure existence between macrophages ex vivo, in the lung of Mtb-SIV co-infected NHP, which 
we reported in ([550]; Chapter IV). However, the strict demonstration of the existence of TNT in vivo 
has yet to be made. Here, we propose that Siglec-1 could help to define and to demonstrate the 
existence of TNT in vivo. For example, we could use previously published models of mice infection with 
murine-leukemia virus (MLV) or use GFP-HIV-1 virus like particles (GFP-HIV-1-VLP) to study the 
formation and function of TNT in vivo  in Siglec-1+ macrophages of the spleen or lymph node by 
intravital microscopy [629]. To establish the relevance of Siglec-1+ TNT in vivo, comparative 
experiments of GFP-MLV or GFP-HIV-1-VLP infection in WT or Siglec-1-/- mice could be performed.  
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Chapter VI: Dysregulation of the Type-I 
Interferon signaling pathway by Mycobacterium 
tuberculosis leads to HIV-1 exacerbation in 
human macrophages 
 
I will here discuss the unpublished data obtained for the second part of my PhD project, which 
will be submitted for publication early in 2020. 
 
I. Introduction 
As seen in the last chapter of the introduction, the co-infection between Mtb and HIV-1 is, to 
date, a global health issue due to pathogen synergy. Indeed, it is well known that HIV-1 infection 
enhances Mtb growth and increases the risk of developing active TB, however, the mechanisms by 
which the bacilli exacerbates HIV-1 replication need further investigation.  
In the laboratory, we have been studying this issue, using an in vitro model that mimics a TB-
associated environment. The model consists in differentiating primary human monocytes towards 
macrophages by incubating them with supernatant harvested from Mtb- or mock-infected 
macrophages (cmMTB and cmCTR, respectively). We previously showed that this TB-associated 
microenvironment orients macrophages towards an anti-inflammaƚorǇ ͞MϮ-like͟ polariǌaƚion 
distinguished by a CD16+CD163+MerTK+ phenotype and an increased Mtb permissiveness, both of 
which were dependent on the IL-10/STAT3 signaling pathway [764]. Moreover, we found that cmMTB-
macrophages were highly susceptible to HIV-1 infection and replication. The exacerbation of HIV-1 
replication in these cells depends on the induction of TNT, which favours the HIV-1 cell-to-cell transfer 
and feed the viral infection and dissemination (Chapter IV, [550]). We later identified the upregulated 
lectin receptor Siglec-1 as part of the IFN-I transcriptomic signature of cmMTB-macrophages, together 
with another 50 upregulated interferon inducible genes (ISG). We showed that this molecule is present 
on Mtb-induced TNT in which HIV-1 cargos are abundant and are crucial for the exacerbation of the 
viral replication in cmMTB-macrophages (Chapter V). We also found that Siglec-1 expression is 
mediated by the IFN-I present in the cmMTB media, and its expression on alveolar macrophages in 
Mtb-SIV co-infected macaques correlated with both the disease severity and the activation of STAT1, 
the first transcription factor involved in IFN-I signaling pathway. 
Our previous results suggested that the activation of the IFN-I signaling pathway promotes HIV-
1 replication in our model. However, IFN-I are historically well known for their antiviral functions [788], 
[789], including during HIV-1 infection of monocytes and macrophages [790], [791]. For the second 
axis of my PhD work, I focused on this pathway to understand why IFN-I pre-exposure of macrophages 
during cmMTB conditioning did not induce antiviral immunity against HIV-1. We hypothesized that  
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IFN-I production by Mtb infected macrophages could be deleterious to the control of the viral infection 
in bystander HIV-1-infected macrophages, as it is observed in TB pathogenesis [18], [27]. By analysing 
the cmMTB-macrophage response to exogenous IFN-I stimuli, we found here that cmMTB-treated cells 
are hypo-responsive to exogenous IFN-I, a phenomenon that prevents macrophage activation against 
HIV-1. We also identified the negative regulator of IFN-I signaling, USP18, as a key factor involved in 
cmMTB-treated macrophage hypo-responsiveness to IFN-I.  
 
II. Results 
The global gene landscape in cmMTB-treated macrophages displays an enrichment of the IFN-I 
response signature, matching that described in active TB patients 
To assess the gene expression landscape of cmMTB-treated macrophages and to identify 
potential factors involved in the exacerbation of HIV-1 replication in these cells, a genome-wide 
transcriptomic analysis was performed. Compared to cmCTR-conditioned cells, cmMTB-treated 
macrophages displayed a distinct gene transcript signature, comprising 51 genes upregulated, most of 
which belonged to the ISG family (Chapter V, Figure 1, S1). We compared this gene signature to those 
obtained from transcriptome analyses performed in whole blood and monocytes from active TB 
patients [221], using the gene set enrichment analysis (GSEA) algorithm. All genes analyzed in cmMTB-
treated cells were used as a signature to compare transcriptomic data from healthy versus active TB 
patients. As shown in figure 35A, the group of genes upregulated in cmMTB-treated macrophages were 
significantly enriched in monocytes of TB patients (left, FDR q-value: < 10-3) or in their whole blood 
(right, FDR q-value: < 10-3), indicating that the gene signature obtained in cmMTB-treated cells is similar 
to that found in active TB patient leukocytes. These results confirmed that cmMTB is a relevant model 
to mimic TB-associated microenvironment and active TB patient monocytes activation profile in vitro. 
We confirmed the upregulation of several ISG in cmMTB-treated cells compared to cmCTR-treated 
macrophages, including three antiviral genes: MX1, which blocks viruses integration to the host 
genome; MX2, known to block HIV-1 entry in the host nucleus; and ISG15 that induces ISGylation of 
viral proteins, rendering them non-functional. We also included Siglec-1 as internal control (Table 4, 
Figure 35B). All genes analyzed were significantly upregulated in cmMTB-treated cells by a 3-10-fold. 
In addition, we analyzed the corresponding protein levels, and found increased levels of MX1, MX2 
(Figure 35C), Siglec-1 (Figure 1C, D, chapter V) and STAT1, confirming the activation of IFN-I signaling 
(Chapter V, figure 1C, D) in cmMTB-differentiated cells. 
It has been described previously that the time of exposure and quantity of IFN-I strongly 
impacts the response of cells to this stimulus [406], [457]. Moreover, as cmMTB contains both IL-10, 
responsible for the CD16+CD163+MerTK+ phenotype [261], and IFN-I, responsible for Siglec-1 induction 
among other ISG (Chapter V, Figure 2), we asked whether cmMTB-treated macrophage gene signature 
and phenotype is dependent on the time of exposure to cmMTB. To address that question, primary  
  
 242 
 
human monocytes were either incubated with RPMI-10% FCS for two days, followed by 12h of cmMTB 
conditioning, or differentiated in cmMTB for 72h (Figure 36A). Interestingly, all ISG transcripts analyzed 
were highly expressed after 12h of conditioning with cmMTB compared to cmCTR (Figure 36B). 
Moreover, we observed a significant induction of MX2 and a tendency of higher induction of the 
antiviral ISG MX1 and ISG15 at 12h of conditioning compared to 72h in cmMTB condition, suggesting 
that the antiviral state established in cmMTB-macrophages is stronger when IFN-I exposure is shorter. 
The reduction in antiviral ISG transcript levels suggests that after 3 days of cmMTB conditioning, 
macrophages are no longer protected against viral infection. By contrast, Siglec-1 transcript abundance 
was maintained after 72h of treatment (Figure 36B), supporting its deleterious role in TB-HIV-1 co-
infection (Chater V, Figure 4). As 72h of cmMTB conditioning activate macrophages towards a M(IL-10) 
profile, characterized by the upregulation of CD16, CD163, MerTK [550], [764] and Siglec-1 (Chapter V, 
Figure 1C, D), we next  assessed the phenotype of cmMTB-treated cells after 12h or 72h of conditioning 
by flow cytometry. As expected, with the exception of CD163, M(IL-10) markers were significantly 
upregulated in cmMTB after 12h and 72h of treatment, but the expression level of each marker was 
higher at 72h than at 12h, indicating that a relatively long exposure to TB-microenvironment is 
necessary to obtain the M(IL-10)-like phenotype (Figure 36C). 
Collectively, these data indicate that the IFN-I signature displayed by cmMTB-treated cells, 
which reproduces that found in leukocytes from active TB patients, and coincides with the M(IL-10) 
phenotype, is specific to long-term exposure to the TB-associated microenvironment. 
 
Precocious activation of the IFN-I/STAT-1 signaling in cmMTB-cells is deleterious for the control of 
HIV-1 replication 
 Despite a historical protective and antiviral function, recent studies point at the deleterious 
effect of IFN-I in chronic diseases [457], [792]. Indeed, in a viral chronic infection, IFN-I are pro-viral 
since they favour the systemic inflammation, which enhances viral replication [18], [406]. Therefore, 
it is currently thought that IFN-I effects are dependent on the dose and timing at which they are 
induced, a theory that applies to the results found in figure 36. As TB is also a chronic disease, and 
considering the exacerbation of HIV-1 replication in the TB co-infection context [775], we next asked 
if IFN-I signaling could also have a detrimental role in HIV-1 disease. We inhibited the IFN-I signaling 
pathway during cmMTB conditioning by depleting the transcription factor STAT1 by siRNA-mediated 
gene silencing (Figure 37A). This was confirmed by western blot analysis showing that STAT1 protein 
was efficiently depleted at the time of HIV-1 infection (Figure 37B). Noticeably, we found that 
depletion of STAT1 during cmMTB-conditioning dampened the exacerbation of HIV-1 infection, as 
indicated by the decrease in the viral production measured by the level of the viral protein p24 released 
in the cell supernatant (Figure 37C).  
Together, these data indicate that the constant activation of the IFN-I signaling during cmMTB 
treatment is deleterious for the control of HIV-1 replication in macrophages.  
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IFN-I present in cmMTB conditioning media renders macrophages hypo-responsive to stimulation to 
exogenous IFNE 
As mentioned in the introduction chapter I II.C. and II. II.C.b.ii., prolonged IFN-I exposure and 
signaling is associated with negative outcome in chronic diseases, notably by inducing immune cell 
exhaustion and apoptosis [793]. As cmMTB-treated macrophages are unable to control their viral load 
due to IFN-I signaling occurring during their conditioning, we hypothesized that cmMTB-treated cells 
are hypo-responsive to further IFN-I stimulation, which is produced in response to HIV-1 infection 
[794], after 3 days of conditioned-media treatment. To mimic the production of IFN-I in response to 
viral infection, we used recombinant IFN-I. Specifically, we stimulated cells with IFNE since it displays 
a higher affinity to IFNAR than the majority of IFND subtypes and potently inhibits HIV-1 replication in 
peripheral mononuclear cells in vitro [393], [795]. First, we evaluated the capacity of exogenous IFNE 
to activate STAT1 and STAT2, the main transcription factors involved in IFN-I signaling pathway (Figure 
2 in preamble). After 3 days of cmCTR or cmMTB differentiation, macrophages were stimulated with 
100 U/ml of recombinant IFNE (Figure 38A). Upon IFN-I stimulation, we found that STAT1 activation 
was significantly reduced in cmMTB-treated macrophages compared to control cells (Figure 38B), 
indicating that cmMTB pre-exposure decreases the macrophage capacity to elicit an IFN-I-mediated 
response. This decreased activation was specific of STAT1 since no significant diminution of STAT2 was 
observed (Figure 38C). Second, we assessed the capacity of IFNE stimulation to induce the expression 
of the ISG signature defined in figure 35. Without IFNE stimulation, we obtained the same increase in 
the ISG expression in cmMTB-treated cells as described earlier (Figure 38D, bars on the left), thereby 
reproducing the results obtained in the transcriptome validation. Upon IFNE stimulation, ISG 
expression in cmCTR-treated macrophages were all induced by 3-80-fold (Figure 38D, white bars). In 
cmMTB-cells, ISG were upregulated as well after IFNE stimulation, but to a lesser extent than in cmCTR-
cells (maximum fold change of 17, Figure 38D, black bars), suggesting a reduced sensitivity to IFN-I 
stimuli.  
Finally, we confirmed that the reduced response to further IFN-I stimulation in cmMTB-
macrophages was due to the pre-exposure to IFN-I. We differentiated monocytes for 3 days with 
cmCTR in the presence (or absence) of 20 or 100 U/ml of recombinant IFNE to mimic cmMTB media. 
Indeed, IFNE is the major subtype of IFN-I induced by Mtb infection in macrophages, thereby 
appropriate to mimic cmMTB [796]. After an extra-stimulation with 100 U/ml of IFNE, we measured 
STAT1 activation levels and found that it was down-modulated in cells treated with cmCTR media 
supplemented with IFN-I in a dose-dependent manner, as shown by the reduced level of pSTAT1 
(Figure 38E). Moreover, MX1, MX2, and Siglec-1 gene expression were also downregulated in cells 
treated with cmCTR supplemented with IFNE (Figure 38F), further supporting the induction of hypo-
responsiveness to IFN-I observed in cmMTB-cells.  
Altogether, we showed here that IFN-I desensitization of macrophages is mediated by the IFN-
I present in cmMTB media, which can be reproduced by supplementing cmCTR media with exogenous 
IFNEand that the induced hypo-responsiveness to further stimuli is dependent on the dose of IFN-I 
present in the conditioning media.  
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The IFN-I-inducible USP18 regulatory factor is a potential actor involved in the exacerbation of HIV-
1 replication in cmMTB-macrophages. 
To uncover how the IFN-I exposure during cmMTB treatment renders macrophages hypo-
responsive to further IFN-I stimulation, we looked for a potential negative regulator of IFN-I signaling 
pathway induced by cmMTB. Indeed, as many other pathways, IFN-I needs to be tightly controlled to 
avoid excessive inflammation or auto-immune diseases such as interferonopathies [19]. Therefore, it 
is common that cells become desensitized to IFN-I for a short time, in order to recover from sustained 
IFN-I signaling [425], [797]. The desensitization state established by the cells occurs through several 
mechanisms, some of them being intrinsic and others being mediated by the action of ISG [425]. The 
IFN-I-induced negative regulator Ubiquitin specific peptidase 18 (USP18) was previously shown to be 
upregulated in the context of bacterial infection in mice [798], where it plays a deleterious role in the 
control of the bacteria. Here, we found that cmMTB-conditioning of macrophages induces the 
expression of USP18 at the mRNA level and was part of the ISG signature found in the transcriptome 
of cmMTB macrophages (Fold change: 4.3; adjusted p-value: 0.06) (Figure 39A and Chapter V, Figure 
1A).  
We then asked whether USP18 could have a deleterious role on HIV-1 replication control in 
the context of co-infection with Mtb. Indeed, it was previously shown that HIV-1 infection of 
monocyte-derived macrophages upregulates USP18, allowing HIV-1 replication. This phenomenon was 
due to the minimized IFN-I response of infected cells, which displayed low antiviral responses due to 
USP18 upregulation [799]. We reproduced on two independent donors the induction of USP18 after 
HIV-1 infection in cmCTR- and cmMTB-treated cells (Figure 39B). Interestingly, USP18 expression was 
enhanced in cells from both donors by cmMTB treatment, and even further by HIV-1 infection in these 
cells. Consequently, we suspected a role for USP18 in the control of HIV-1 replication. To address this 
question, we silenced USP18 gene expression by siRNA-mediated gene silencing during cmMTB-
treatment, before infecting these cells with HIV-1ADA, using the same protocol as described in Figure 
37A. Ten days post-infection, we found that USP18 silencing reduced the number of HIV-1 infected 
MGC (Figure 39C, left), along with the exacerbation of HIV-1 replication in cmMTB macrophages 
(Figure 39C, right). However, we were not able to confirm USP18 depletion by western blot (data not 
shown). Consequently, these experiments need to be repeated to confirm that the restoration of the 
control of HIV-1 replication is mediated by USP18 depletion. 
Considering the reduced viral replication in siUSP18 condition, it is likely that inhibition of 
USP18 would restore the macrophage capacity to elicit antiviral response to IFN-I stimuli.  
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Figure 35: The cmMTB-treated macrophages are characterized by an IFN-I signature, which is also 
found in TB patient monocytes and whole blood. 
(A-C) For three days, human monocytes were differentiated into macrophages with cmCTR (white) or 
cmMTB (black). 
(A) Left. Gene set enrichment plot obtained with the GSEA software, using as a signature the genes 
found significantly (FDR<0.05) upregulated in cmMTB-treated cells as compared to control cells. The 
plot shows the distribution of the signature genes (barcode) in the comparison between monocytes 
from healthy (red) versus active TB (blue) patients. The skewing to the right indicates an (significant, 
FDR<0.001) enrichment of cmMTB-upregulated genes as a group, in the monocytes from active TB 
patients. Right. Gene set enrichment plot using the same signature applied to the comparison between 
the whole blood of healthy versus active TB patients.  
(B) Validation of the four ISG expression induced in cmMTB-treated cells. Vertical scatter plot showing 
the relative transcript abundance to GAPDH mRNA. Each circle represents a single donor and histogram 
median value. 
(C) Top. Representative images of western blot analysis illustrating the expression of STAT1 (left), MX1 
(middle) and MX2 (right), with actin as a loading control. Bottom. Quantification of protein levels 
expressed as the ratio related to actin expression. Each circle represents a single donor and histogram 
mean value. 
Statistical analyses: When data display a normal distribution according to Kolmogorov-Smirnov 
normality test, paired student t-test (C, right), otherwise two-tailed, Wilcoxon signed-rank test (B-C, 
left, middle). *P<0.05, **P<0.01, P***<0.001. 
 
 
 
 
 
Table 4: Gene transcriptomic signature and expression in cmMTB-treated cells compared to control. 
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Figure 36: The interferon-stimulated gene signature obtained in the transcriptome and cell 
phenotype depend on the timing of cmMTB conditioning. 
(A) Experimental design. Monocytes from healthy subjects were isolated and treated with cmMTB 
(black) or cmCTR (white) for either 72h or 12h prior phenotyping by RT-qPCR and flow cytometry. 
(B) Gene expression of four ISG normally induced in cmMTB-treated cells. Vertical scatter plot showing 
the relative transcript abundance to GAPDH mRNA. Each circle represents a single donor and histogram 
median value. 
(C) Median fluorescent intensity (MFI) of cmMTB-treated cells markers. Each circle represents a single 
donor and histogram mean value. 
Statistical analyses: When data display a normal distribution according to Kolmogorov-Smirnov 
normality test, paired student t-test (C, top middle, bottom left and right), otherwise two-tailed, 
Wilcoxon signed-rank test (B-C, top left and right, bottom middle). *P<0.05, **P<0.01, P***<0.001. ns: 
not significant (p-value > 0.2) 
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Figure 37: The interferon-stimulated gene signature of cmMTB cells is deleterious for the control of 
HIV-1 replication. 
(A) Experimental design. Monocytes from healthy subjects were transfected with siRNA targeting 
STAT1 (siSTAT1, black) or off target mRNA (siCtrl, white). One day later, monocytes were differentiated 
into macrophages with cmMTB for 3 days. Cells were then infected with HIV-1ADA and viral replication 
was measured by ELISA at day 15. 
(B) Left. Representative images of western blot analysis illustrating the expression of STAT1 with actin 
as a loading control. Right. Quantification of protein levels expressed as the ratio related to actin 
expression. Each circle represents a single donor and histogram median value. 
(C) Left. Representative immunofluorescence images of cmMTB-treated macrophages transfected 
siCtrl (top) or siSTAT1 (bottom) and infected with HIV-1ADA at day 4. Staining show HIV-1Gag (green) and 
F-actin (red). Scale bar: 200 µm. Right. Vertical scatter plot showing HIV-1-p24 concentration in cell 
supernatant at day 15 post-HIV-1 infection in STAT1-depleted cells. Each circle represents a single 
donor and histogram median value. 
Statistical analyses: When data display a normal distribution according to Kolmogorov-Smirnov 
normality test, paired student t-test (B, C). *P<0.05, **P<0.01, P***<0.001. ns: not significant (p-value 
> 0.2) 
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Figure 38: IFN-I exposure upon cmMTB treatment renders cells hypo-responsive to additional 
stimulation with IFNE 
(A) Experimental design. Monocytes from healthy subjects were treated with cmMTB (black) or cmCTR 
(white, black line) (panel B, C) or with conditioned media supplemented with recombinant IFNE (panel 
D, E). After 3 days, cells were stimulated with IFNE and their response was evaluated by Western blot 
(1h) and RT-qPCR (3h) after stimulation.  
(B) Left. Representative images of western blot analysis illustrating the expression of pSTAT1 and 
STAT1 with actin as loading control. Right. Quantification of the ratio of pSTAT1/STAT1 after 
IFNEstimulation.  
(C) Left. Representative images of western blot analysis illustrating the expression of pSTAT2 and 
STAT2 with actin as loading control. Right. Quantification of the ratio of pSTAT2/STAT2 after 
IFNEstimulation.  
(D) Vertical scatter plot showing the transcript abundance of cmCTR or cmMTB cells with (+) or without 
(-) IFNEstimulation at day 3. The number in brackets represents the fold change of gene expression 
between conditions. 
(E) Top. Representative images of western blot analysis illustrating the expression of pSTAT1 and STAT1 
with actin as a loading control in cells conditioned with cmCTR supplemented (or not) with 
recombinant IFNEBottom. The quantification of protein levels is expressed as the ratio of pSTAT1 over 
STAT1 after normalization to actin. 
(F) Vertical scatter plot showing the expression of MX1 (left), MX2 (center) and Siglec-1 (right) protein 
levels in cells treated with cmCTR supplemented (or not) with IFNE 
(B-E) Each circle represents a single donor and histogram median value. 
Statistical analyses: When data display a normal distribution according to Kolmogorov-Smirnov 
normality test, paired student t-test (B, right), otherwise two-tailed, Wilcoxon signed-rank test (B, left, 
C). *P<0.05, **P<0.01, P***<0.001. ns: not significant (p-value > 0.2) 
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Figure 39: The IFN-I inducible USP18 regulatory factor seems responsible for the exacerbation of 
HIV-1 replication in cmMTB cells. 
(A) Vertical scatter plot showing USP18 gene expression in human macrophages after 3 days of cmCTR 
(white) or cmMTB (black) conditioning.  
(B) Monocytes were differentiated for 3 days with cmCTR (white) or cmMTB (black) and infected with 
HIV-1ADA. USP18 gene expression was assessed prior HIV-1 infection (day 3) and 3 days post-infection 
(day 6). Vertical scatter plot showing the fold change of USP18 expression compared to uninfected 
cmCTR condition. n=2 independent donors. 
(C) Monocytes from healthy subjects were transfected with siRNA targeting USP18 (siUSP18, black) or 
off target mRNA (siCtrl, white). One day later, monocytes were differentiated into macrophages with 
cmMTB for 3 days. Cells were then infected with HIV-1ADA and viral replication was measured by ELISA 
at day 14. Representative immunofluorescence images showing HIV-1 infected macrophages 
transfected with siCtrl (top) or siUSP18 (bottom) after 14 days in culture. Staining show HIV-1Gag (green) 
and F-actin (red). Scale bar 200 µm. Right. Vertical scatter plot showing HIV-1-p24 concentration in cell 
supernatant at day 10 post-HIV-1 infection in USP18-depleted cells. Each circle represents a single 
donor and histogram median value. 
Statistical analyses: Wilcoxon signed-rank test (C). *P<0.05.  
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Figure 40: cmMTB-treatment induces the expression of the IFN-I receptor IFNAR. 
Monocytes from healthy donors were isolated and differentiated for 3 days with cmCTR or cmMTB prior to 
phenotyping by flow cytometry. Vertical scatter plot showing the median fluorescent intensity (MFI) of IFNAR2 
surface expression. Each circle represents a single donor and histograms median value. 
Statistical analysis: passed Kolmogorov-Smirnov normality test, paired student t-test. *P<0.05, **P<0.01. 
 
 
 
 
 
 
Figure 41: cmMTB upregulates OASL and IRF7 gene expression, but not IRF7 protein level. 
Monocytes from healthy donors were isolated and differentiated for 3 days with cmCTR or cmMTB prior to gene 
expression assessment by RT-qPCR and protein level evaluation by western blot. 
(A) Vertical scatter plot showing OASL gene transcript abundance relative to GAPDH in cmCTR- (white) or cmMTB-
treated cells (black). Each circle represents a single donor and histograms median value. 
(B) Vertical scatter plot showing IRF7 gene transcript abundance relative to GAPDH in cmCTR- (white) or cmMTB-
treated cells (black). Each circle represents a single donor and histograms median value. 
(C) Left. Representative images of western blot analysis illustrating the expression of IRF7 with GAPDH as a 
loading control. Right. Quantification of IRF7 protein level are represented as IRF7/GAPDH ratio. Each circle 
represents a single donor and histograms median value. 
Statistical analysis: When data display a normal distribution according to Kolmogorov-Smirnov normality test, 
paired student t-test (A), otherwise, Wilcoxon matcher-pairs signed rank test (B, right). *P<0.05, **P<0.01. 
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III. Discussion 
In this part of my PhD project, I investigated the implication of IFN-I in the exacerbation of HIV-
1 replication in macrophages in the context of co-infection with Mtb. I found that cmMTB-conditioning 
renders macrophages hypo-responsive to further stimulation with IFNE, and that inhibiting the IFN-I 
signaling by blocking the transcription factor STAT1 restored the control of the viral replication in 
macrophages. To confirm these results, experiments are currently being performed using IFNAR 
blocking antibodies during cmMTB conditioning to prevent the precocious activation IFN-I signaling 
prior to HIV-1 infection. Moreover, the genes signature and cell phenotype rendering cells hypo-
responsive to IFN-I and highly susceptible to HIV-1 infection was dependent on the time of exposure 
to cmMTB. Indeed, 72h of cmMTB conditioning were necessary to induce the expression of M(IL-10) 
markers. Concerning the gene signature, cells treated with cmMTB for 12h displayed strong induction 
of antiviral ISG compared to cells treated for 72h. However, this experiment needs to be reproduced 
to confirm our observation, since we found a strong tendency of MX2 and ISG15 induction by cmMTB 
treatment (albeit not significant) compared to cmCTR-macrophages at 72h. One reason that could 
explain this is the low quantity or mRNA available for the RT-qPCR, which renders gene induction 
analysis delicate. Moreover, despite the use of pool of cmMTB media to attenuate donor response 
variability during media preparation, the answer of healthy donor to cmMTB conditioning remains also 
highly variable and might explain why we could not observe a significant induction of MX2 and ISG15 
in cmMTB-cells.  
Most cells are able to respond to IFN-I stimulation. However, to avoid strong inflammation and 
associated tissue damage, IFN-I responding cells can enter a desensitized state that can last for several 
days [797]. This state allows cells to recover from IFN-I signaling and is tightly regulated. 
Desensitization establishment in cells can be induced by intrinsic mechanisms or by action of negative 
regulator of the IFN signaling pathway [425]. For example, receptor endocytosis and turnover have an 
important role in rapidly inhibiting the activation of JAK and STAT proteins, which consequently 
reduces ISG expression. To assess if cmMTB-macrophages displayed an endocytosis process of IFNAR 
during the conditioning, we evaluated at day 3 the cell surface expression of the receptor in cmCTR 
versus cmMTB-cells by flow cytometry. Interestingly, IFNAR2 expression was upregulated in cmMTB-
macrophages (Figure 40), suggesting that the desensitization of cmMTB cells is not due to IFN-I 
receptor recycling process. 
To demonstrate that cmMTB-treated macrophages are hypo-responsive to IFN-I stimulation, 
we assessed the induction of ISG after 3 days of conditioning, in response to exogenous IFNE. We found 
a strong upregulation of ISG in control cells compared to cmMTB-treated macrophages, yet, there was 
no significant difference in the overall ISG expression between cmCTR- and cmMTB-macrophages 
stimulated with IFNE. In the present case, it is possible that the difference in gene induction fold 
change obtained after IFNE stimulation is due to the saturation of the system, mRNA levels having 
reached a plateau of maximum expression in cmMTB-stimulated cells. Nevertheless, we also found a 
decreased activation of STAT1 in response to IFNE stimulation, and were able to induce cell hypo-
responsiveness upon conditioning with cmCTR media supplemented with IFN-I, which provide further  
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evidence of cmMTB-induced desensitization to IFN-I. Considering that HIV-1 infection of macrophages 
induces IFN-I synthesis [794], we hypothesize that this new wave of IFN-I upon HIV-1 infection of 
cmMTB-macrophages will not induce the antiviral function related to IFN-I signaling, due to Mtb-
mediated desensitization to IFN-I. This may be a mechanism explaining why cmMTB-macrophages are 
unable to contain HIV-1 replication (Chapter IV and V). 
A potential mechanism explaining the IFN-I desensitization and loss of antiviral function 
observed in cmMTB-macrophages is the induction of USP18, which is the most important factor in the 
establishment and maintenance of IFN-I long-term desensitization. It has been shown that USP18-/- 
mice are hypersensitive to IFN-I, and consequently, more resistant to viral infections [800]. Moreover, 
studies performed in USP18-deficient murine cell culture revealed that STAT1 activation and 
subsequent ISG induction were prolonged in response to IFNE in comparison to WT cells, further 
supporting the role of this factor in the negative regulation of IFN-I signaling [801]. In a mouse model 
of infection with vesicular stomatitis virus, Honke and colleagues found that USP18 expression was 
upregulated in Siglec-1+ macrophages of the marginal zone in the kidney. These cells locally supported 
an enhanced viral replication [802], suggesting a deleterious role of USP18 in the control of the virus 
life cycle. Similarly, we found USP18 to be induced at the mRNA level, both by cmMTB treatment 
(Figure 39A) and after HIV-1 infection (Figure 39B). By inhibiting USP18, we partially restored the 
control of the viral replication in cmMTB-macrophages, indicating that the IFN-I antiviral effect was 
partially recovered. However, this experiment needs to be reproduced, in order to validate the gene 
depletion efficiency. In addition, to confirm that the inhibition of HIV-1 replication is mediated by the 
reconstruction of IFN-I signaling, we need to verify that in the absence of USP18, the activation of 
STAT1 along with the induction of ISG upon exogenous IFNE stimulation are equivalent to that found 
in cmCTR-cells. It is likely that the IFN-I response will not be fully restored by silencing USP18, for two 
reasons. First, siRNA-silencing efficiency is usually comprised between 50 to 95%. Therefore, the 
remaining mRNA can still be actively translated and produce sufficient levels of protein to exert the 
negative regulation feedback loop on IFN-I signaling. Second, USP18 needs STAT2 to efficiently 
downregulate IFN-I signaling [803]. Arimoto and colleagues showed that STAT2 recruits USP18 to 
IFNAR2 intracytoplasmic chain, where it favours the replacement of JAK1 from its IFNAR2-binding site 
by USP18, therefore preventing the initiation of IFN-I/STAT signaling pathway [803]. We found here 
that STAT2 activation is not affected by the long exposure to IFN-I during cmMTB conditioning, and as 
such, could be part of the desensitization process observed in cmMTB-macrophages (Figure 38C). To 
verify this hypothesis, a double inhibition of STAT2 and USP18 could be performed prior to cmMTB 
conditioning. If the hypothesis is correct, the double knock-down strategy should restore IFN-I signaling 
after cmMTB treatment and abolish HIV-1 replication in macrophages, although the IFN-I signaling 
observed will activate STAT2-independent signaling (see Figure 2 in preamble). Finally, USP18 is an 
isopeptidase, i.e.  an enzyme responsible for the deubiquitination of ISGylated proteins, that could also 
down-modulate IFN-I signaling through its enzymatic activity. Another important molecule to study, 
when considering USP18, is Siglec-1. Indeed, since USP18 expression was induced in infected Siglec-1+ 
macrophages in mice spleen [802], it is legitimate to ask whether Siglec-1 expression could modulate 
IFN-I responses probably via USP18 expression. In fact, the group of Gumuluru recently showed that 
infection of a macrophages cell line (THP-1), or of primary MDM, with HIV-1 or pseudotyped HIV-1 
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parƚicles ǁiƚh ƚhe MLV enǀelope ǁas enhanced afƚer cell eǆposƵre ƚo IFNɲ͘ This observation was 
dependent on Siglec-1, and supported by the enhanced in vivo expression of Siglec-1 in pigtail macaque 
lymph nodes after infection with SHIV (a modified HIV-1 virus expressing SIV envelope). Interestingly, 
there was an important co-localization of the viral protein Gag and Siglec-1 in these organs, suggesting 
a productive infection of Siglec-1+ myeloid cells in vivo. This enhanced replication of HIV in Siglec-1+ 
cells was due to the fact that the lectin counteracted the protective antiviral function of IFND by 
enhancing viral capture and transfer to CD4+ T cells [831]. In addition, a study conducted by Zheng and 
colleagues indicated that Siglec-1 might be responsible for inducing the downregulation of IFN-I 
signaling cascade upon viral infection (i.e. VSV, Sendai virus and HSV). The mechanism behind this 
observation seemed to involve Siglec1 association with DAP12, which consequently induced the 
recruitment and activation of the scaffolding function of SHP2. Upon activation, SHP2 recruited the E3 
ubiquitin ligase TRIM27, leading to TBK1 degradation via ubiquitination. Altogether, these findings 
demonstrated that the upregulation of Siglec-1 induced by the viral infection led to a feedback loop, 
which inhibited IFN-I production and suppressed antiviral innate immune responses [832]. Therefore, 
it would be interesting to evaluate whether the IFN-I signaling of cmMTB-treated cells is restored upon 
Siglec-1 silencing, along with a reduced expression of USP18. 
Other molecules known as ISG can also negatively regulate the IFN-I signaling pathway through 
actions downstream of STAT activation. An example of such factor is OASL, which we found to be 
strongly upregulated in the transcriptome of cmMTB-treated cells (Figure 41A). OASL is known to bind 
to IRF7 mRNA in mice, and inhibits its translation [804], thereby preventing activated IRF7 to 
translocate into the nucleus to activate IFN-I synthesis and subsequent antiviral responses (Figure 42). 
Depletion of OASL1 gene in mice was shown to induce stronger IFN-I responses and to diminish viral 
replication in vivo [804]. However, the human OASL does not seem to share this binding property. 
Actually, Zhu and colleagues found opposing results to that observed in mice and proposed that human 
OASL enhances RIG-Iʹmediated signaling, supporting strong antiviral responses [805]. Our preliminary 
data on the expression of IRF7 in cmMTB-macrophages are in contradiction with these findings. 
Indeed, despite the increased expression of IRF7 mRNA after 3 days of cmMTB-conditioning (Figure 
41B), we found that the protein level was lower in these cells compared to cmCTR-cells (Figure 41C). 
This observation suggests that OASL, in the context of co-infection with Mtb, is negatively affecting the 
IFN-I-mediated antiviral responses. It would be interesting to inhibit OASL function, either by 
pharmacological inhibition or by siRNA-mediated silencing, to evaluate if the expression of IRF7 at the 
protein level is restored in cmMTB-macrophages. To confirm the negative regulation of IFN-I by OASL, 
silenced cells should be then evaluated for their capacity to translocate activated IRF7 into the nucleus, 
along with their ability to express antiviral ISG. Finally, if OASL is involved in cell hypo-responsiveness 
of cmMTB-macrophages, its inhibition should lead to an increased control of HIV-1 replication in the 
context of co-infection. 
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Figure 42: OASL inhibits type I interferon signaling by degrading IRF7 mRNA (inspired from [804]). 
In mouse, OASL has been described to bind to IRF7 mRNA and to prevent its translation [801]. Consequently, less 
IRF7 proteins are available for recruitment to STAT1-STAT2 heterodimers. This prevents further translocation of 
STAT1-STAT2-IRF7 complexes to the nucleus, which leads to a decreased binding to interferon-stimulated 
response element (ISRE) promoter and result in a reduction of the activation of interferon-stimulated genes (ISG). 
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Here, we found that the IFN-I/STAT1 axis induces the expression of molecular factors involved 
in cmMTB-macrophages hypo-responsiveness to IFNE, preventing macrophages from establishing an 
efficient antiviral response. We also published that the IL-10/STAT3 axis induces the formation of TNT 
that participate to HIV-1 infection and dissemination in the co-infection context (Chapter IV). Since IL-
10 is produced downstream of IFN-I signaling as an immuno-modulatory cytokine, we propose that 
both axis act in synergy to favour HIV-1 replication in cmMTB-treated macrophages. This synergy 
would occur both at the cellular and molecular levels. At the cellular scale, IL-10 induces TNT and IFN-
I induces Siglec-1, both enhancing all crucial steps in the viral cycle success. To begin with, Siglec-1 
favours the viral uptake, which is more important in cmMTB-treated cells because the area and 
number of Siglec-1 molecules is higher than in cmCTR-treated macrophages (Chapter V Figure 1B-D). 
Then, Mtb-induced TNT enhance the viral spread between macrophages, increasing the number of 
productively infected cells (Chapter IV Figure 6A and 7E). The IFN-I/IL-10 synergy could also occur at 
the molecular level, since both signaling pathways are interconnected [550]. First, STAT1 and STAT3 
can heterodimerize. Increased amount of activated STAT3 can therefore sequester STAT1 molecules, 
preventing them from homodimerizing or heterodimerizing with STAT2, subsequently inhibiting the 
induction of ISG by ISGF3 [806]. Second, STAT3 can induce factors such as phospholipid scramblase 2 
(PLSCR2) to suppress the recruitment of ISGF3 to the ISRE promoter sequence of ISG [807]. Third, 
STAT3 itself is able to suppress the expression of various component of the ISGF3 complex (i.e. STAT1, 
STAT2, IRF9), but also the expression of IRF7 [808], which could be degraded by STAT3- and OASL-
dependent mechanisms. Finally, STAT3 inhibits IFN-I signal transduction by inducing negative 
regulators such as SOCS3, which prevents the activation of the janus kinases JAK1 and TYK2 by 
targeting them to proteasomal degradation through poly-ubiquitination [425], [809]. Importantly, 
SOCS3 has been described to prevent human macrophages IFN-I-antiviral responses following HIV-1 
infection [421]. In addition, SOCS3 expression was reported to be induced in response to 
Mycobacterium avium infection [810]. We found that SOCS3, which is part of the transcriptomic 
signature (Fold change: 3.1; adjusted p-value: 0.07), is induced by cmMTB treatment in macrophages, 
both at the mRNA (Figure 43A) and protein level (Figure 43B). Moreover, we found that SOCS3 
expression is further increased days after HIV-1 infection in cmMTB-macrophages (Figure 43B, left), 
and is equally induced in macrophages treated with cmMTB and stimulated with IFN prior to HIV-1 
infection Figure 43B, right . These preliminary data were performed in two independent donors and 
suggest that SOCS3 upregulation by a TB-associated microenvironment might have a role in the 
desensitization of macrophages to IFN-I. Moreover, we found that the expression of the restriction 
factor MX2 decreases during the course of HIV-1 infection (Figure 43C, left) in cmMTB-treated cells, as 
well as in cells pre-treated with IFN prior to infection (Figure 43C, right). Taken together, these 
observations suggest that the negative regulation of IFN-I signaling in cmMTB-macrophages is 
mediated by either SOCS3, OASL, USP18, or as a combination. These results must be reproduced in the 
near future. Also, we cannot exclude additional factors that could lead to macrophages hypo-
responsiveness to IFN-I produced in response to HIV-1 infection. As a result, protective antiviral ISG 
expression like MX2 is inhibited, causing a defect in the restriction of HIV-1 replication. 
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Figure 43: IFN-I negative regulators are enhanced by cmMTB during the course of HIV-1 infection, 
while restriction factors are downregulated.  
Monocytes from healthy donors were isolated and differentiated for 3 days with cmCTR or cmMTB and 
stimulated (Right. B, C) or not (A, Left , B, C) with 100 U/ml of recombinant IFNE for 30 min  prior to infection 
with HIV-1ADA. Cell lysates were collected at day 0, 4 and 11 post-HIV-1 infection to assess the expression of ISG. 
(A) Vertical scatter plot showing SOCS3 gene transcript abundance relative to GAPDH in cmCTR- (white) or 
cmMTB-treated cells (black) after 3 days of conditioning, prior to HIV-1 infection. Each circle represents a single 
donor and histograms median value. 
(B) Vertical histograms showing SOCS3 expression after HIV-1 infection with (right) or without (left) IFNE 
stimulation. n= 2 independent donors. 
(C) Vertical histograms showing MX2 expression after HIV-1 infection in presence (right) or absence (left) of IFNE 
stimulation. n= 2 independent donors. 
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To conclude, a better understanding of the modulation of the IFN-I response triggered by Mtb 
infection is required to improve our comprehension on how these cytokines favour HIV-1 replication 
instead of the expected antiviral state. Also, this study promotes the need for in vivo investigation of 
the IFN-I/STAT1 axis as a potential contributor to pathogenesis in co-infected patients, suggesting the 
modulation of this signaling pathway as a suitable target for treatment and disease outcome. 
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To date, the co-infection between HIV-1 and Mtb remains a major public health problem at 
the global scale, and more particularly in world regions like Africa, India, and China, where the burden 
of the epidemic associated to each pathogen is the strongest. Since the first report of co-infection 
event in Haiti in 1983, many efforts have been made to diagnose and treat co-infection, both of which 
are particularly challenging due to atypical presentation of TB symptoms and drug interactions. Despite 
the progresses made the last 10 years, TB-HIV-1 co-infection remains a challenging threat to human 
health, mainly because of the separated strategies applied to treat either TB or HIV-1 infection.  The 
improvements necessary to fight co-infection will require a joint-effort on TB and HIV-1 eradication 
strategies, which will most likely rely on the better understanding of Mtb and HIV-1 synergy. It is well 
known that HIV-1 infected patients are more susceptible to develop active TB, mainly because of the 
depletion of Mtb-specific CD4+ T cells responses and the disruption of the granuloma structure that 
usually contain the bacteria in a latent, dormant replicative state (Introduction ʹ Chapter 1). In 
addition, clinical evidence indicates increased viral loads in co-infected patients, both in the blood and 
at the anatomical site of co-infection, arguing for an Mtb-driven exacerbation of the viral replication. 
However, the mechanisms explaining this enhanced replication of HIV-1 remain to be investigated. 
In the collaborative project between the team composing the LIA agreement, one of the main 
objective was to understand how Mtb-associated microenvironment exacerbates HIV-1 replication in 
its host. We focused our research on the role of macrophages in the co-infection, since they are the 
main target for Mtb and important cells in HIV-1 pathogenesis. Indeed, together with CD4+ T cells, 
macrophages are the principal cells capable of efficiently produce HIV-1 in vivo [768], are long-lived 
after infection since they are resistant to the cytopathogenic effect of the infection [485] and are part 
of the viral reservoir established in many tissues, including the brain and the lungs [480], [491], which 
are difficult to reach with cART.  
My contribution to the field of co-infection during my PhD was to identify novel factors 
involved in the exacerbation of HIV-1 replication in macrophages, in a context of co-infection with Mtb. 
I used relevant in vitro models of TB-associated microenvironments (cmMTB or PE-TB) to mimic the 
bystander effect of Mtb-infection on surrounding cells. Indeed, direct co-infection of macrophages 
with Mtb and HIV-1 has never been described in vivo but does exist as recently shown by the co-
staining of Mtb and SIV in alveolar macrophages in a NHP model of co-infection [811]. Yet, it is likely 
that this event is quite rare. Consequently, the major consequence of Mtb-infection must be indirect 
and involve the activation of bystander cells, depending on the cytokines present in their environment. 
In our model, we found that monocytes differentiated with cmMTB displayed an IFN-I signature, 
supposed to be antiviral. This correlates with the recent evidence that Mtb infection of macrophages 
induces IFN-I responses to set an antiviral state and distract the host from establishing an efficient 
antibacterial state [812]. Yet, in the context of TB, IFN-I are mainly detrimental to the control of the 
disease. Indeed, the dominant IFN-I-dependent ISG signature in active TB patients was found to 
positively correlate to the disease severity, and diminished after successful treatment [221]. In 
addition, the early overexpression of several IFN-I inducible genes in the blood of apparently healthy 
individuals in contact with TB patients correlated with the development of the active disease in these 
persons [222], [223]. Moreover, mice deficient for IFN-I signaling (e.g. IFNAR-/-, WT mice injected with 
blocking IFN-I antibodies) have decreased bacterial loads and improved survival compared to WT 
counterparts [217]ʹ[219]. In patients infected with HCV virus receiving IFND therapy, TB reactivation  
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Figure 44: The number of Siglec-1+ blood monocytes is increased in TB and TB-HIV-1 patients. 
Siglec-1 expression was assessed by flow cytometry on freshly isolated peripheral blood monocytes of healthy, 
TB or TB-HIV-1 patients.  
(A) Vertical scatter plot showing the median fluorescent intensity (MFI) of Siglec-1. Each circle represents a single 
donor and histogram median value. 
(B) Vertical scatter plot showing the percentage of blood monocytes expressing Siglec-1. Each circle represents 
a single donor and histogram median value. 
Statistical analysis: When data display a normal distribution according to Kolmogorov-Smirnov normality test, 
paired student t-test (A), otherwise, Wilcoxon matcher-pairs signed rank test (B, right). *P<0.05, **P<0.01. 
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has been well reported [224], [225], and further supports the deleterious outcome of IFN-I in TB 
pathogenesis. Similarly, IFN-I have a deleterious impact on the host global immune response in the 
context of chronic viral infections, including HIV-1 pathology. In SIV natural host, the induction of IFN-
I responses is quickly shut down, as opposed to non-natural host infection, where IFN-I responses are 
maintained and correlate with the immune system hyperactivation and CD4+ T cell loss [402], [403], a 
phenomenon also observed between HIV-1 non-progressors and HIV-1 progressors patients. 
Moreover, IFND therapy used at the beginning of the epidemic was poorly efficient (few HIV-1 
individuals responded to this treatment) and only transient [385]. Considering these facts, it is likely 
that IFN-I are highly detrimental to the host in the co-infection context. Therefore, developing 
strategies to reverse IFN-I negative effect on the host could improve the patient quality of life. One 
option to do so would be to treat patients with blocking antibodies against IFN-I or their receptor 
IFNAR, in combination with antibiotics and cART, in order to diminish the chronic immune activation 
in TB-HIV-1 co-infected patients. Changes in blood transcriptomic analysis, or a in a pre-established 
gene list part of the general signature by qPCR (to reduce costs for low-income countries) could be 
ƚhen Ƶsed ƚo moniƚor paƚienƚ͛s reaction to treatment and to modulate it accordingly [813]. Another 
strategy to improve co-infected patient treatment is to optimize the balance between the immune 
system reaction to clear both pathogens and the immune-regulation dampening IFN-I responses. One 
possibility would be to increase eicosanoid levels in the blood circulation of patients in order to 
decrease IFN-I responses. In a mouse model of TB infection, Dorhoi and colleagues found that IL-1 
conferred mice resistance to deleterious IFN-I during TB infection by inducing eicosanoids. 
Consequently, mice were able to better contain bacterial growth. The authors further showed that 
both in mouse and human, reduced IL-1 responses and excessive IFN-I induction were linked to an 
imbalance in eicosanoids, and led to TB disease exacerbation [242]. Among eicosanoids, PGE2 was 
previously shown to be a critical mediator of TB resistance, notably by preventing macrophage necrosis 
upon Mtb infection [27]. The use of host-directed immunotherapy clinically approved drugs improved 
the disease outcome in TB mice model of Mtb infection [242]. Interestingly, PGE2 was also part of the 
transcriptomic signature of cmMTB-macrophages (fold change: 1.4; adjusted p-value: 0.6). To assess 
the potential protective role of this molecule in the co-infection context, we will need to validate its 
upregulation at the protein level in our model. If, like IRF7, it is decreased, it would be interesting to 
add PGE2 in our culture system to see if we can prevent HIV-1 infection and spread. Depending on the 
result, the use of PGE2, maybe in combination with blocking IFN-I induction by IFNAR blocking antibody 
in co-infected patient could limit the replication of both Mtb and HIV-1 by inducing apoptosis of 
infected macrophages.  
 In addition to the direct deleterious effect of IFN-I responses in the co-infection context, these 
cytokines are responsible for the upregulation of detrimental factors for the control of HIV-1. Among 
those, we identified Siglec-1, a lectin receptor previously shown to be involved in HIV-1 uptake and 
transfer to CD4+ T cells [629], [633]. In HIV-1+ individuals, Siglec-1 expression is increased in circulating 
monocytes, a phenomenon reversed after successful cART [631]. In addition, its expression in SIV 
natural host remains low compared to non-natural host [814], indicating that Siglec-1 has a role in the 
disease progression, either as a marker of progression or as a factor enhancing viral spread. In our 
model, we found that cmMTB treatment increases the expression of Siglec-1 at the mRNA and protein 
levels in macrophages. Thanks to the LIA collaboration consortium with L. Balboa in Argentina, we 
could assess the expression of Siglec-1 in peripheral blood monocytes and pleural effusion cells from  
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TB or TB-HIV-1 co-infected patients. We found that the median fluorescent intensity of Siglec-1 was 
increased in co-infected patients only, compared to healthy subject or TB patients (Figure 44A). 
However, when comparing the percentage of cells positive for the lectin, we found it significantly 
increased in TB patient compared to healthy subjects, and even further increased in co-infected 
individuals (Figure 44B). These results are in accordance with our observations in NHP lungs, where we 
found an increased number of Siglec-1+ alveolar macrophages in Mtb-infected animals, further 
enhanced in co-infected NHP (Chapter V, figure 1E-H). However, in pleural effusion CD14+ cells, we 
failed to observe an increase in Siglec-1 expression, compared to pleural effusion cells from heart 
failure. It is possible that in the lungs and in peripheral blood monocytes from TB patients, Siglec-1 is 
shed, just like MerTK and CD163. Indeed, a soluble form of Siglec-1 has been reported previously in 
patients with systemic lupus erythematosus and used as a potential biomarker of the disease [815]. To 
evaluate the potential use of soluble Siglec-1 as a biomarker of TB-HIV-1 co-infection, ELISA 
measurement of Siglec-ϭ presenƚ in paƚienƚ͛s plasma coƵld be performed͘ In ƚhe case ǁhere Siglec-1 is 
indeed shed in TB or co-infection settings, Siglec-1 plasma levels, along with soluble MerTK and CD163 
could represent a novel valuable diagnostic tool and marker to monitor co-infection progression. 
Nevertheless, additional fundamental research on this lectin is required, since its role in TB disease has 
never been reported, apart from one single study that associated one particular Siglec-1 polymorphism 
with a decreased production of IL-1E in active TB patient, suggesting a role of the lectin in the 
inflammasome pathway [816]. Another polymorphism causing Siglec-1 loss of function (the GluTer88 
truncation mutation) was reported in the context of HIV-1-infected individuals. Ex vivo, cells haplo-
insufficient34 or null for Siglec-1 function were unable to capture and transfer the virus to bystander 
CD4+ T cells. In patients, this null mutation only delayed HIV-1 acquisition or AIDS progression in 
infected patients, suggesting that classical route of infection and, potentially other molecules involved 
in HIV-1 capture and transfer to other cells (e.g. the C-type lectin receptors DC-SIGN or MRC1), may 
compensate for the lack of Siglec-1 in fuelling the viral dissemination [817]. In collaboration with us, 
the same group has assessed the effect of Siglec-1 GluTer88 polymorphism on HIV-1 co-infection into 
two large cohorts (> 6 200 individuals) and found a significant association between Siglec-1 loss-of-
function and extrapulmonary dissemination of Mtb. They confirmed these findings in Siglec-1 knocked-
out mice, who presented with larger and less structured pulmonary lesions upon Mtb infection 
compared to WT mice [818]. As Siglec-1͛s role at steady state is to regulate immune responses by 
modulating antigen presentation, it is possible that the null mutation in Siglec-1 gene leads to a delay 
in Mtb-induced immunity, by limiting antigen spread and T cell responses, thereby allowing an early 
dissemination of the virus. As a result, in the co-infection setting, it is more likely that Siglec-1 
represents a promising diagnostic tool rather than a potential drug target, since its inhibition will 
probably reduce HIV-1 spread, but favour Mtb dissemination.  
 Last but not least, my PhD work allowed the identification of TNT as a major mechanism 
through which HIV-1 infection is exacerbated in the context of co-infection. Both cmMTB conditioning 
and HIV-1 infection of macrophages induced these structures, and inhibiting them decreased the viral 
replication and spread. Several studies report that cell-to-cell transfer is the most efficient mechanism 
of HIV-1 infection, especially compared to cell-free viruses [323], [592]ʹ[594]. Cell-to-cell transfer also 
protects the virus from immune detection and neutralization by anti-HIV-1 antibodies [612] and even 
                                                          
34 Haplo-insufficient: one allele is encoded by the WT gene while the other allele is mutated and non-functional. 
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from cART drugs [570]. Moreover, it has been reported that the antiviral properties of IFN-I have 
moderate effect on viral cell-to-cell transfer [819]. Vendrame and colleagues have reported that T cells 
pre-treated with IFN-I control the viral replication, but that the number of infected cells increased with 
time, despite the low production of virus by the infected cells, indicating that IFN-I are not as efficient 
as previously thought in inhibiting the global life cycle of HIV-1 [819]. However, other studies have 
shown that antiviral factors and more specifically IFND-induced ISG can be transferred from one cell 
to another through exosome release and subsequent capture and endocytosis [820]. Hence, combining 
TNT capacity to transfer material and blocking HIV-1 trafficking represent a potential strategy to 
enhance antiviral factors from one cell to another, particularly in those desensitized to IFN-I. TNT 
function could also be used as tools for delivering drugs in specific cell target, notably HIV-1 reservoirs 
such as macrophages or CD4+ memory T cells, and help to eliminate them. Combined to cART, TNT-
delivered drugs to viral reservoir might allow the elimination of HIV-1 from the organism. However, to 
reach such promising goals, further research on TNT biology is needed. First, it is necessary to validate 
TNT existence in vivo, particularly their formation and function between immune cells. Evidence 
obtained from mice model suggest the existence of functional TNT in vivo, notably in the eye during 
embryonic development [780] or in tumor brain cancers [785]. Second, once the formal demonstration 
of their formation done, TNT functions in vivo should be addressed but represent a quite challenging 
question on the technical level. For example, it will be difficult to distinguish materials transfer from 
inside TNT or outside of these structures, a key element in the design of potential use of TNT for drug 
delivery. Finally, instead of being used to spread chemical compounds, TNT could be blocked to reduce 
pathogen transfer from one cell to another in infectious context. To do so, drugs like TNTi [669] could 
be evaluated for their in vivo potency at inhibiting pathogen transfer, including HIV-1 or Mtb. 
Importantly, TNT specific markers, such as Siglec-1 and potentially others (e.g. DC-SIGN and MRC1), 
should be carefully studied, in order to optimize drug-designed strategies and specifically target 
pathways involved in auto-immune disease, cancers, or pathogen exacerbation and spread.  
Altogether, the work realized during my PhD thesis contributes to a better understanding of 
the synergy between Mtb and HIV-1 and proposes Siglec-1, TNT and IFN-I-dependent signaling as 
potential diagnostic tools to follow the disease progression, along with possible new targets to prevent 
viral dissemination and replication in co-infected patients.  
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Annex 
 
I. Formation of Foamy Macrophages by Tuberculous Pleural Effusions Is 
Triggered by the Interleukin-10/Signal Transducer and Activator of 
Transcription 3 Axis through ACAT Upregulation. 
 
 
II. Tuberculosis is associated with expansion of a motile, permissive and 
immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 
axis. 
 
 
III. Bone degradation machinery of osteoclasts: An HIV-1 target that 
contributes to bone loss. 
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The ability of Mycobacterium tuberculosis (Mtb) to persist in its human host relies on 
numerous immune evasion strategies, such as the deregulation of the lipid metabolism 
leading to the formation of foamy macrophages (FM). Yet, the speci!c host factors lead-
ing to the foamy phenotype of Mtb-infected macrophages remain unknown. Herein, we 
aimed to address whether host cytokines contribute to FM formation in the context of 
Mtb infection. Our approach is based on the use of an acellular fraction of tuberculous 
pleural effusions (TB-PE) as a physiological source of local factors released during Mtb 
infection. We found that TB-PE induced FM differentiation as observed by the increase 
in lipid bodies, intracellular cholesterol, and expression of the scavenger receptor CD36, 
as well as the enzyme acyl CoA:cholesterol acyl transferase (ACAT). Importantly, interleu-
kin-10 (IL-10) depletion from TB-PE prevented the augmentation of all these parameters. 
Moreover, we observed a positive correlation between the levels of IL-10 and the number 
of lipid-laden CD14+ cells among the pleural cells in TB patients, demonstrating that FM 
differentiation occurs within the pleural environment. Downstream of IL-10 signaling, we 
2Genoula et al. IL-10 Promotes FM in TB
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noticed that the transcription factor signal transducer and activator of transcription 3 
was activated by TB-PE, and its chemical inhibition prevented the accumulation of lipid 
bodies and ACAT expression in macrophages. In terms of the host immune response, 
TB-PE-treated macrophages displayed immunosuppressive properties and bore higher 
bacillary loads. Finally, we con!rmed our results using bone marrow-derived macrophage 
from IL-10−/− mice demonstrating that IL-10 de!ciency partially prevented foamy phe-
notype induction after Mtb lipids exposure. In conclusion, our results evidence a role of 
IL-10 in promoting the differentiation of FM in the context of Mtb infection, contributing to 
our understanding of how alterations of the host metabolic factors may favor pathogen 
persistence.
Keywords: ACAT, interleukin-10, foamy macrophages, lipids, signal transducer and activator of transcription 3, 
tuberculosis
INTRODUCTION
Tuberculosis (TB) is a highly contagious disease caused by 
Mycobacterium tuberculosis (Mtb) infection. Even though the 
treatment of the disease has been standardized for a while, 
TB still remains one of the top 10 causes of death worldwide 
with 10.4 million new cases and 1.3 million deaths from 
TB among HIV-negative people in 2016 (1). Chronic host– 
pathogen interaction in TB leads to extensive metabolic remod-
eling in both the host and the pathogen (2). In fact, the success 
of Mtb as a pathogen derives from its e!cient adaptation to 
the intracellular milieu of human macrophages. An important 
strategy to reach this metabolic adaptation is the promotion 
of lipid body accumulation by the host macrophage leading 
to foamy macrophages (FM) di"erentiation. #e formation of 
lipid-laden macrophages is caused by infectious agents through 
deregulation in the balance between the in$ux and e%ux of 
lipids. Key for the biogenesis of lipid bodies is the enzyme acyl 
CoA:cholesterol acyltransferase (ACAT), which represents an 
ideal target for pathogens (3).
Lipid body accumulation within leukocytes is a common 
feature in both clinical and experimental infections, especially 
in mycobacterial infections (4, 5). Mtb infection leads to the 
induction of FM, a process which is promoted by several myco-
bacterial lipids (6–8). #is event enables the fusion between 
Mtb-containing phagosomes and lipid bodies resulting in an 
abundant supply of lipids for the pathogen (7), allowing Mtb to 
switch into a dormancy phenotype and to become tolerant to 
several front-line antibiotics (9). For this reason, lipid bodies are 
considered to be a secure niche for Mtb conferring protection 
from bactericidal mechanisms, such as respiratory burst (10). 
Moreover, the presence of FM within granulomatous structures 
was demonstrated in both experimentally infected animals and 
patients, especially in individuals developing secondary TB 
(5, 11). #erefore, FM may play a central role in mycobacterial 
persistence and reactivation (12, 13).
Concerning the impact of FM on the host immunity against 
Mtb, it was shown that human macrophages exposed to lipids 
prior to Mtb infection failed to produce TNF-α and to clear 
the infection (14, 15). Taking into account that FM generated 
prior to Mtb infection impair the host immune response, 
there is a keen interest to identify the host-derived cytokines 
released at the site of Mtb infection, and to understand how 
these signals contribute to FM differentiation and alter host 
defense against Mtb. In this regard, it is well known that 
different activation programs in macrophages driven by pro 
or anti-inflammatory cytokines are associated to changes 
in the lipid metabolism (16). Therefore, it is likely that host 
cytokines produced in response to Mtb infection contribute 
to lipids turnover promoting FM formation, and consequently 
lead to Mtb persistence.
In this work, we report that a TB-associated microenviron-
ment induces FM di"erentiation program dependent partially 
on the interleukin-10 (IL-10)/signal transducer and activator 
of transcription 3 (STAT3) axis through ACAT upregulation. 
Our approach was to model a genuine TB-associated micro-
environment by employing a physiological relevant sample 
derived from active TB patients, such as the acellular fraction 
of tuberculous pleural e"usions (TB-PE). Indeed, TB-PE are 
manifested in up to 30% of patients with TB, and they are caused 
by the spread of Mtb into the pleural space and subsequent local 
in$ammation and recruitment of leukocytes (17). Based on 
this, we show that the acquisition of the foamy phenotype with 
immunosuppressive properties involves high IL-10 release, low 
TNF-α production, impaired #1 activation, and high bacil-
lary loads. We also con&rmed that IL-10-de&ciency in bone 
marrow-derived macrophages (BMDM) prevented partially 
foamy phenotype induction upon exposure to Mtb lipids. 
In conclusion, our results provide evidence for a role of IL-10 
in promoting foamy di"erentiation of macrophages in the con-
text of Mtb infection.
MATERIALS AND METHODS
Bacterial Strain and Antigens
Mycobacterium tuberculosis H37Rv strain was grown at 37°C 
in Middlebrook 7H9 medium (Difco) supplemented with 10% 
albumin-dextrose-catalase (Difco) and 0.05% Tween-80 (Sigma-
Aldrich). #e Mtb γ-irradiated H37Rv strain (NR-49098) and 
its total lipids’ preparation (NR-14837) were obtained from BEI 
Resource, USA.
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Preparation of Human Monocyte-Derived 
Macrophages (MDM)
Bu"y coats from healthy donors were prepared at Centro Regional 
de Hemoterapia Garrahan (Buenos Aires, Argentina) according 
to institutional guidelines (resolution number CEIANM-664/07). 
Informed consent was obtained from each donor before blood 
collection. Peripheral blood mononuclear cells were obtained 
by Ficoll gradient separation on Ficoll-Paque (GE Healthcare). 
#en, monocytes were puri&ed by centrifugation on a discontinu-
ous Percoll gradient (Amersham) as previously described (18). 
A'er that, monocytes were allowed to adhere to 24-well plates 
(Costar) at 5 × 105 cells/well for 1 h at 37°C in warm RPMI-1640 
medium (GIBCO). #e cells were then washed with warm PBS 
twice. #e &nal purity was checked by $uorescence-activated 
cell sorting analysis using an anti-CD14 monoclonal antibody 
(mAb) and was found to be >90%. #e medium was then sup-
plemented to a &nal concentration of 10% fetal bovine serum 
(FBS, Sigma-Aldrich) and human recombinant Macrophage 
Colony-Stimulating Factor (M-CSF, Peprotech) at 10  ng/ml. 
Cells were allowed to di"erentiate for 5–7 days.
Preparation of Pleural Effusion (PE) Pools
Pleural e"usions were obtained by therapeutic thoracentesis by 
physicians at the Hospital F. J Muñiz (Buenos Aires, Argentina). 
#e research was carried out in accordance with the Declaration 
of Helsinki (2013) of the World Medical Association, and was 
approved by the Ethics Committees of the Hospital F. J Muñiz 
and the Academia Nacional de Medicina de Buenos Aires (pro-
tocol number: NIN-1671-12). Written informed consent was 
obtained before sample collection. We collected a total of 43 
PE samples which were classi&ed according to their etiology, 
being 38 of them associated to TB (TB-PE) and 5 to heart failure 
(HF-PE). Individual samples of con&rmed TB patients were 
used for correlation analysis. A group of samples (n = 10) were 
pooled and used for in vitro assays to treat macrophages. #e 
selection of these samples was based merely on practical reasons, 
involving those samples that have been collected earlier through 
the course of this study. #e diagnosis of TB pleurisy was based 
on a positive Ziehl–Nielsen stain or Lowestein–Jensen culture 
from PE and/or histopathology of pleural biopsy, and was 
further con&rmed by an Mtb-induced IFN-γ response and an 
ADA-positive test (19). Exclusion criteria included a positive 
HIV test, and the presence of concurrent infectious diseases or 
non-infectious conditions (cancer, diabetes, or steroid therapy). 
None of the patients had multidrug-resistant TB. #ose PE 
samples derived from patients with pleural transudates second-
ary to heart failure (HF-PE, n = 5) were employed to prepare a 
second pool of PE, used as control of non-infectious in$amma-
tory PE. #e PE were collected in heparin tubes and centrifuged 
at 300  g for 10 min at room temperature without brake. #e 
cell-free supernatant was transferred into new plastic tubes, 
further centrifuged at 12,000  g for 10 min and aliquots were 
stored at −80°C. A'er having the diagnosis of the PE, pools 
were prepared by mixing same amounts of individual PE associ-
ated to a speci&c etiology. #e pools were decomplemented at 
56°C for 30 min, and &ltered by 0.22 µm in order to remove any 
remaining debris or residual bacteria.
FM Induction
Macrophages were plated on glass coverslips within a 24-well tissue 
culture plate (Costar) at a density of 5 × 105 cells/ml per well with 
or without 20% v/v of PE, 10 µg/ml of Mtb lipids (BEI resources) 
or infected with Mtb (MOI 2:1) for 24 h. When indicated, cells 
were pre-incubated with either Cucurbitacin I (50–100  nM, 
Sigma-Aldrich), or the STAT3 inhibitor Stattic (1–20 µM, Sigma-
Aldrich), or the ACAT inhibitor Sandoz 58-035 (5–50  µg/ml, 
Sigma-Aldrich) for 2  h prior TB-PE addition and for further 
24 h during TB-PE incubation. DMSO alone was used as con-
trol. Alternatively, cells were treated with recombinant human 
IL-10 (Peprotech) at the indicated doses. Foam cell formation 
was followed by Oil Red O (ORO) staining (Sigma-Aldrich) 
as previously described (20) at 37°C for 1–5 min, and washed 
with water three times. For the visualization of the lipid bodies, 
slides were prepared using the aqueous mounting medium Poly-
Mount (Polysciences), observed via light microscope (Leica) and 
&nally photographed using the Leica Application Suite so'ware. 
Alternatively, a'er &xation, cells were labeled with 1 µg/ml of 
BODIPY 493/503 (Life technologies) for 15  min in order to 
visualize the lipid bodies by green $uorescence emission using a 
confocal microscope (Olympus BX51).
Infection of Human Macrophages  
with Mtb
Infections were performed in the biosafety level 3 laboratory at 
the Unidad Operativa Centro de Contención Biológica, ANLIS-
MALBRAN (Buenos Aires), according to the biosafety institu-
tional guidelines. Macrophages seeded on glass coverslips within 
a 24-well tissue culture plate (Costar) at a density of 5 × 105 cells/ml 
were infected with Mtb H37Rv strain at a MOI of 2:1 during 
1 h at 37°C. #en, extracellular bacteria were removed gently by 
washing with pre-warmed PBS, and cells were cultured in RPMI- 
1640 medium supplemented with 10% FBS and gentamicin 
(50 µg/ml) for 24 h. #e glass coverslips were &xed with PFA 4% 
and stained with ORO, as was previously described.
Quanti!cation of Total Cholesterol
Total cholesterol was determined in TB-PE or cell lysates using the 
Colestat Enzimatico kit according to manufacturer instructions 
(Wiener Lab, Argentina). #is assay is based in Trinder reaction 
in which cholesterol in the sample is quanti&ed by enzymatic 
hydrolysis of cholesterol esters (21).
Lipid Analysis
Total lipids were extracted from the same number of macrophages 
with methanol/chloroform (2:1 v/v) as described by Bligh and 
Dyer (22). A'er extraction, lipids were dried and analyzed by 
thin layer chromatography on silica gel 60 F254 plates (Merck), 
using hexane/diethyl ether/acetic acid (75:25:1, v/v/v) as the 
developing solvent. Chemical staining with Cu-phosphoric was 
used for detection.
Phenotypic Characterization  
by Flow Cytometry
Macrophages were centrifuged for 7 min at 1,200 rpm and then 
stained for 40 min at 4°C with $uorophore-conjugated antibodies 
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FITC-anti-CD36 (clone 5-271), PerCP.Cy5.5-anti-CD14 (clone 
HCD14), PE-anti-CD163 (clone GHI/61), FITC-anti-CD206 
(clone C068C2) (Biolegend), FITC-anti-HLA-DR (clone G46-6), 
or PE-anti-CD274 (clone MIH1) (BD Biosciences), and in 
paral lel, with the corresponding isotype control antibody. A'er 
staining, the cells were washed with PBS 1×, centrifuged and 
analyzed by $ow cytometry using FACSCalibur cytometer (BD 
Biosciences). #e median $uorescence intensity were analyzed 
using FCS Express V3 so'ware (De Novo So'ware, Los Angeles, 
CA, USA). #e mean of the median $uorescence intensities 
(MFI) of the independent assays were used for comparisons 
between experimental conditions.
Soluble Cytokine Determinations
#e amounts of human TNF-α, IL-1β, IL-10, IL-6, IFN-γ, and 
IL-4 were measured by ELISA, according to manufacturers’ 
instructions kits (TNF-α, IL-4, and IFN-γ Ready-SET-Go!™ 
Kits from eBioscience; IL-10, IL-1β, and IL-6 ELISA MAX™ 
Deluxe Kits from Biolegend). #e detection limit was 3 pg/ml 
for TNF-α; 8 pg/ml for IL-10 and IL-6; 6.25 pg/ml for IFN-γ and 
IL-4; and 15.6 pg/ml for IL-1β. Murine TNF-α and IL-10 were 
measured by ELISA, according to manufacturer’s instructions 
(OptEIA™ Set kits from BD Bioscience) with a detection limit 
at 30 pg/ml.
Cytokine Depletions of PE
Tuberculosis-PE were incubated with 10 µg/ml of the following 
neutralizing antibodies for 1 h at 4°C for the speci&c depletion of 
IL-10 (αIL-10, clone 19F1; Biolegend), IL-6 (αIL-6, clone MQ2-
13A5; BD Bioscience), IL-1β (αIL-1β, clone 8516.311; SIGMA), 
or TNF-α (αTNF-α, clone MAb1; Biolegend). #en, 100 µl/ml of 
Protein G Sepharose beads (Amersham) were added and incu-
bated for 1 h at 4°C. Finally, TB-PE were centrifuged at 12,000 g 
to remove antibody-bead complexes and then &ltered (0.22-µm 
pores) before use. IFN-γ depletion was performed by incubat-
ing TB-PE for 2 h in sterile 96-well plates that had been coated 
with the capture antibody provided by the Human IFN-γ ELISA 
Kit (BD Bioscience). In all cases, depletions were controlled 
by ELISA.
Electron Microscopy
Macrophages exposed (or not) to TB-PE, and depleted (or not) 
for IL-10, were prepared for transmission electron microscopy 
study. For this purpose, cells were centrifuged at 6,000 rpm for 
1 min, &xed in 1% glutaraldehyde dissolved in 0.1 M cacodylate 
bu"er (pH 7); post-&xed in 2% osmium tetroxide; dehydrated 
with increasing concentrations of ethanol and gradually in&l-
trated with Epon resin (Pelco). #in sections were contrasted 
with uranyl acetate and lead citrate (Electron Microscopy 
Sciences, Fort Washington, PA, USA) and examined with a 
FEI Tecnai transmission electron microscope (Hillsboro, OR, 
USA). For morphometry, 30  cells from each condition were 
randomly selected and digitalized at 40,000× magni&cation. 
#en the area of lipid electron dense vacuoles per cell were 
measured and compared in each experimental group by auto-
mated morphometry.
Proliferation of Antimycobacterial  
CD4 T Cells Induced by Macrophages
We puri&ed and maintained CD4 T  cells from blood derived 
from healthy PPD+ donors as previously demonstrated (23). 
In parallel, we cultured autologous monocytes to generate mac-
rophages and exposed them or not to TB-PE 20% v/v for 24 h. 
#e next day, the medium was replaced, and macrophages were 
loaded with mycobacterial antigens by adding γ-irradiated Mtb 
at 2 bacteria to 1 macrophage ratio for further 24 h. #erea'er, 
the medium was replaced and autologous carboxy$uorescein 
succinimidyl ester (CFSE)-labeled CD4 T cells (Invitrogen) were 
added at a ratio of 10 lymphocytes to 1 macrophage for 5 days, 
as detailed previously (24). To determine IFN-γ production 
among proliferating CD4 T cells (CFSElow), brefeldin A (5 µg/ml; 
Sigma Chemical Co.) was added 4  h prior the end of the 
coculture to block cytokine secretion. #erea'er, CFSE-labeled 
lymphocytes were &rst stained with anti-CD4-PerCP-Cy5.5 
mAbs (eBioscience), then &xed with 0.5% PFA for 15  min. 
Second, cells were permeabilized with 500  µl Perm2 (Becton 
Dickinson, Cockysville, MD, USA) for 10 min and incubated 
with anti-IFN-γ-PE mAb (Invitrogen, CA, USA). Cells were 
gated according to its FSC and side scatter (SSC) properties ana-
lyzed on FACScan (Becton Dickinson). In order to gate out dead 
lymphocytes, the gate of CD4 T cells with increased SSC and low 
FSC was excluded (25). Isotype matched controls were used to 
determine auto-$uorescence and non-speci&c staining. Analysis 
was performed using the FCS Express (De Novo So'ware) and 
results were expressed as percentages of IFN-γpos/CFSElow/
CD4pos T cells induced by the di"erent macrophage populations. 
To complement these results, the amounts of IFN-γ released 
in the supernatant throughout the coculture were determined 
by ELISA according to the manufacturer’s kit indications (BD 
Bioscience).
Measurement of Bacterial Intracellular 
Growth in Macrophages by Colony 
Forming Unit (CFU) Assay
Macrophages exposed (or not) to TB-PE, were infected with 
H37Rv Mtb strain at a MOI of 1  bacteria/cell in triplicates. 
A'er 2 h, extracellular bacteria were removed by gently washing 
four times with pre-warmed PBS. At 4 h and days 3, 6, and 10, 
cells were lysed in 0.1% SDS and neutralized with 20% Bovine 
Serum Albumine in Middlebrook 7H9 broth. Serial dilutions of 
the lysates were plated in triplicate, onto 7H11-Oleic Albumin 
Dextrose Catalase (OADC, Difco) agar medium for CFU scoring 
at 21 days later.
Western Blots
Macrophages were treated (or not) with TB-PE. Following the 
different experimental treatments, cells were lysed in ice-cold 
buffer consisting of 150 mM NaCl, 10 mM Tris, 5 mM EDTA, 
1% SDS, 1% Triton X-100, 1% sodium deoxycholate, gen-
tamicin/streptomycin, 0.2% azide plus a cocktail of protease 
inhibitors (Sigma-Aldrich). Lysates were incubated on ice for 
3 h and cleared by centrifugation for 15 min at 14,000  rpm 
at 4°C. Protein concentrations were determined using the 
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BCA protein assay (Pierce). Equal amounts of protein (40 µg) 
were then resolved on a 10% SDS-PAGE. Proteins were 
then transferred to Hybond-ECL nitrocellulose membranes 
(Amersham) for 2 h at 100 V and blocked with 1% BSA-0.05% 
Tween-20 for 1  h at room temperature. Membranes were 
then probed with primary anti-human ACAT (1:200 dilution, 
SOAT; Santa Cruz) or anti-human pY705-STAT3 (1:1,000 
dilution, Cell Signaling Technology, clone D3A7) overnight 
at 4°C. After extensive washing, blots were incubated with a 
HRP-conjugated goat anti-rabbit IgG Ab (1:5,000 dilution; 
Santa Cruz Biotechnology) or HRP-conjugated goat anti-
mouse IgG Ab (1:2,000 dilution; Santa Cruz Biotechnology) 
for 1 h at room temperature. Immunoreactivity was detected 
using ECL Western Blotting Substrate (Pierce). Protein 
bands were visualized using Kodak Medical X-Ray General 
Purpose Film. For internal loading controls, membranes were 
stripped by incubating in buffer consisting of 1.5% Glycine, 
0.1% SDS, 1% Tween-20, pH 2.2 for 10 min twice, extensively 
washed and then reprobed with anti-β-actin (1:2,000 dilution; 
ThermoFisher, clone AC-15) or anti-STAT3 Ab (1:1,000 dilu-
tion; Cell Signaling Technology, clone D1A5). Results from 
Western blot were analyzed by densitometric analysis (Image 
J software).
Immunostaining
Macrophages were plated on glass coverslips and were treated 
with or without 20% v/v of TB-PE for 24  h. Cells were &xed 
with PFA 4% for 20 min at room temperature and then PFA was 
quenched with 50 mM NH4Cl for 2 min. Cells were rinsed in PBS 
once and then were labeled with 1 µg/ml of BODIPY 493/503 
(Life technologies) for 15 min before permeabilization with PBS-
Triton X-100 0.1% for 10 min. Cells were then incubated with 
PBS-BSA 3% w/v for 30 min prior to overnight incubation at 4°C 
with primary anti-human pY705-STAT3 (dilution 1/100, Cell 
Signaling Technology, Clone D3A7). Cells were then washed and 
incubated with Goat anti-Mouse IgG, AlexaFluor 555 (dilution 
1/1,000, Cell Signaling Technology) for 1 h at room temperature. 
Cells were extensively washed and then incubated for 10 min with 
DAPI in PBS-BSA 1% (500 ng/ml, Sigma-Aldrich). Finally, slides 
were mounted and visualized with a Leica DM-RB $uorescence 
microscope.
Mice
Wild-type (WT) BALB/c and IL-10 knockout (IL-10 KO) 
(C.129P2(B6)-IL-10 tm1Cgn/J) BALB/c male mice (8–12 weeks 
old), were obtained from the Leloir Institute Foundation. Ani-
mals were bred and housed in accordance with the guidelines 
established by the Institutional Animal Care and Use Committee 
of Institute of Experimental Medicine (IMEX)-CONICET-
ANM. All animal procedures were shaped to the principles 
set forth in the Guide for the Care and Use of Laboratory 
Animals (26).
Generation of BMDMs
Femurs and tibia from WT and IL-10 KO mice were removed a'er 
euthanasia and the bones were $ushed with RPMI-1640 medium 
by using syringes and 25-Gauge needles. #e cellular suspension 
was centrifuged and the red blood cells were removed. #e 
BMDMs were obtained by culturing the cells with RPMI-1640 
medium containing l-glutamine, pyruvate, β-mercaptoethanol 
(all from Sigma-Aldrich), 10% FCS and 20  ng/ml of murine 
recombinant M-CSF (Biolegend) at 37°C in a humidi&ed incu-
bator for 7–8 days. Di"erentiated BMDMs were re-plated into 
24-well tissue culture plates in complete medium prior to cell 
stimulation with Mtb lipids for 24 h. Alternatively, recombinant 
murine IL-10 (Peprotech) at 10 ng/ml was added to the cultures 
for 24 h.
Statistical Analysis
All values are presented as mean and SEM of a number of inde-
pendent experiments. Independent experiments are de&ned as 
those performed with macrophages derived from monocytes 
isolated independently from di"erent donors. As most of our 
datasets did not pass the normality tests, non-parametric tests 
were applied. Comparisons between more than two paired data 
sets were made using the Friedman test followed by Dunn’s 
Multiple Comparison Test. Comparisons between two paired 
experimental conditions were made using the two-tailed 
Wilcoxon Signed Rank. Correlation analyses were determined 
using the Spearman’s rank test. For all statistical comparisons, 
a p value < 0.05 was considered signi&cant.
RESULTS
Tuberculous PE Fluids Induce Lipid  
Bodies Accumulation in Macrophages
It has been demonstrated that Mtb induces a lipid-rich foam cell 
phenotype in host macrophages (6–8, 27), possibly via TLR2 
and TLR6 activation (28). Moreover, merely isolated lipids from 
Mtb were able to induce the foamy phenotype (7, 27). Based on 
this knowledge, we aimed to determine whether soluble factors 
found in physiological samples derived from active TB patients 
could promote the generation of FM. To this end, we treated 
human M-CSF-driven macrophages with cell-free prepara-
tions of PE derived from patients with tuberculosis (TB-PE) in 
order to mimic a genuine microenvironment derived during 
Mtb infection. According to the pattern of staining of neutral 
lipids with ORO, we observed that TB-PE treatment induced 
lipid bodies accumulation in macrophages to the same extent as 
Mtb infection or exposure to Mtb-derived lipids (Figure 1A). 
We also demonstrated that the formation of lipid bodies was 
speci&c for TB-PE treatment in comparison to PE from patients 
with heart failure (HF-PE) (Figure 1B). Moreover, biochemical 
analysis of the lipids recovered from macrophages identi&ed 
higher abundance of cholesteryl esters and triacylglycerols 
in TB-PE-treated macrophages in comparison to control or 
HF-PE-treated macrophages (Figure 1C). Additionally, unlike 
HF-PE, the treatment with TB-PE resulted in an increase of the 
total intracellular cholesterol content (Figure 1D) and a twofold 
increase of CD36 expression (Figure 1E). #erefore, soluble fac-
tors released during pleural Mtb infection induced lipid body 
accumulation in human macrophages that typically con&rm the 
FM phenotype.
FIGURE 1 | Continued
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FIGURE 1 | Tuberculous pleural effusions (TB-PE) induce lipid bodies accumulation in macrophages. (A) Human monocyte-derived macrophages (MDM)  
were treated either with TB-PE or with Mycobacterium tuberculosis (Mtb) lipids, or infected with Mtb H37Rv for 24 h and then stained with Oil Red O (ORO). 
Representative images are shown in left panels (40× magni!cation) and the integrated density of ORO staining is shown in right panels. Values are expressed as 
means ± SEM of six independent experiments, considering !ve microphotographs per experiment. Wilcoxon signed rank test: *p < 0.05. (B) MDM were treated 
with TB-PE or PE from heart failure patients (HF-PE) and stained with ORO (n = 5). (C) Left panel shows a representative thin layer chromatographic analysis of 
lipids from MDM treated or not with either TB-PE or HF-PE. Total lipids were extracted from untreated MDM (lane 1), TB-PE-treated MDM (lane 2), HF-PE-treated 
MDM (lane 3), and the standard lipids triacylglycerol (TAG, lane 4) and free cholesterol (CHO, lane 5). Cholesterol esters (CE) are also indicated. Right panels depict 
the area of spots for CE, TAG, and CHO in control and TB-PE or HF-PE treated MDM (n = 4). (D) Intracellular total cholesterol (CHO) content in MDM exposed or 
not to TB-PE or HF-PE measured by an enzymatic method (n = 5). (E) Mean #uorescence intensity (MFI) of CD36 cell-surface expression in MDM exposed or not  
to TB-PE or HF-PE measured by #ow cytometry (n = 5). (B–E) Friedman test followed by Dunn’s Multiple Comparison Test: *p < 0.05; **p < 0.01 for TB-PE vs Ctl  
or as depicted by lines.
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FM Induced by Tuberculous PE Display 
Immunosuppressive Properties
In order to assess whether the di"erentiation into FM induced 
by TB-PE may have a negative impact on the development of 
the antimycobacterial response, we determined phenotype and 
functions of TB-PE-induced FM. As observed in Figure  2A, 
macrophages treated with TB-PE displayed a higher expression 
of anti-in$ammatory markers such as CD163, mannose receptor 
or CD206 (MRC1), and PD-L1, and a lower expression of the 
MHC class II cell-surface receptor, HLA-DR. In accordance 
with the acquisition of this anti-in$ammatory pro&le, TB-PE-
induced FM secreted higher levels of IL-10 and lower levels 
of TNF-α upon stimulation with irradiated Mycobacterium 
tuberculosis (iMtb) than untreated cells (Figure 2B). In order 
to assess the e"ect of TB-PE treatment on the presentation of 
mycobacterial antigens, macrophages were treated with or 
without TB-PE for 24 h, washed and stimulated with iMtb for 
further 24 h. #erea'er, cells were washed and cocultured with 
autologous CFSE-labeled CD4 T  cells derived from healthy 
PPD positive subjects for 5 days. Based on the CFSE labeling of 
CD4 T cells, while TB-PE-treated macrophages did not induce 
di"erential levels of proliferation of antimycobacterial CD4 
T cells (Figure 2C), they promoted di"erential distribution of 
the IFN-γ producing clones (Figure 2D). In particular, those 
macrophages treated with TB-PE induced lower percentages 
of IFN-γ producing clones (Figure 2D) and a lower release of 
IFN-γ (Figure 2E), as compared to untreated macrophages in 
response to iMtb stimulation. Of note, IL-4 and IL-17 contents 
were undetectable in these assays (data not shown). #erefore, 
the activation of Ag-speci&c IFN-γ-producing CD4 T cells was 
impaired when macrophages were exposed to TB-PE, suggest-
ing that the accumulation of lipid bodies is accompanied by a 
reduced capacity to activate antimycobacterial #1 cells.
Next, we assessed whether the treatment with TB-PE had an 
impact on the control of the bacillary load. To accomplish this, 
macrophages were treated with TB-PE for 24  h, washed and 
infected with Mtb. Although no di"erences were observed in 
the uptake of the mycobacteria as judged by the scoring of the 
CFU at 4 h post-infection (Figure 2F), a signi&cant increase in 
the bacillary load was observed in TB-PE-treated macrophages at 
later time points (Figure 2G). #erefore, FM induced by TB-PE 
are more susceptible to Mtb intracellular growth.
IL-10 Promotes Accumulation of Lipid 
Bodies in Macrophages under TB-PE 
Treatment
In order to evaluate the host factors involved in promoting the 
accumulation of lipid bodies by TB-PE, we depleted di"e rent 
cytokines known to be highly present in this $uids (29, 30), 
including IL-10, TNF-α, IL-1β, IL-6, and IFN-γ. We then 
evaluated the ability of these depleted-PE to induce the foamy 
phenotype in macrophages. #e depletion of each individual 
cytokine was con&rmed by ELISA (Figure S1A in Supplementary 
Material). Interestingly, only the depletion of IL-10 from TB-PE 
was capable of preventing lipid bodies accumulation (Figure 3A). 
#is result was also con&rmed by labeling the cells with Bodipy 
staining (Figure S1B in Supplementary Material). In addition, 
macrophages exposed to IL-10-depleted TB-PE showed a reduc-
tion of intracellular cholesterol content and CD36 cell-surface 
expression in comparison to those cells treated with non-depleted 
or depleted of any other cytokines (Figures 3B,C). In line with 
these results, the addition of recombinant IL-10 to the IL-10-
depleted TB-PE restored the acquisition of the foamy phenotype 
in a dose-dependent manner (Figure 3D). Of note, the addition 
of IL-10 in the absence of TB-PE did not induce the foamy 
phenotype (Figure 3D). #erea'er, we determined the presence 
of the lipidic vacuoles by electron microscopy in macrophages 
treated with TB-PE depleted (or not) of IL-10. As it is shown 
in Figure 3E, while untreated macrophages showed numerous 
pseudopodia and empty cytoplasmic vacuoles, TB-PE-treated 
macrophages displayed electron dense lipid osmiophilic vacuoles, 
FIGURE 2 | Continued
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which correspond to lipid bodies. Interestingly, macrophages 
treated with IL-10-depleted TB-PE showed smaller-sized lipidic 
vacuoles than those exposed to non-depleted TB-PE. #ese 
results indicate that the IL-10 present in TB-PE is a key host 
factor promoting the lipid-laden phenotype in the presence of 
exogenous lipids.
IL-10 Levels Correlate with FM  
Abundance in PE
In order to evaluate whether IL-10 level is associated to the 
acquisition of the foamy phenotype in the course of a Mtb natural 
infection, we assessed the levels of IL-10 and total cholesterol in 
individual preparations of TB-PE, and the numbers of FM found 
FIGURE 3 | Interleukin-10 (IL-10) promotes lipid bodies accumulation in macrophages treated with tuberculous pleural effusion (TB-PE). (A–C) Human monocyte-
derived macrophages (MDM) were treated with TB-PE depleted or not for different cytokines for 24 h and (A) lipid bodies’ content was measured by Oil Red O 
(ORO) staining (n = 4). (B) Intracellular cholesterol (CHO) content measured by an enzymatic method (n = 4) was determined. (C) Mean #uorescence intensity (MFI) 
of CD36 cell-surface expression was measured by #ow cytometry (n = 4). (D) MDM were treated (or not) with TB-PE depleted or not of IL-10 in the presence of 
different amounts of recombinant human IL-10 (rIL-10) for 24 h and lipid bodies content was measured by ORO staining (n = 6). (E) Representative electron 
microscopy micrographs of MDM treated with TB-PE depleted or not of IL-10. White asterisks indicate large electron dense osmiophilic vacuoles and arrows point 
small sized ones. Morphometric study of the area per vacuole in each condition is shown (n = 14). (A–E) Friedman test followed by Dunn’s Multiple Comparison 
Test: *p < 0.05; **p < 0.01; ***p < 0.001 for experimental condition vs Ctl or as depicted by lines.
FIGURE 2 | Macrophages treated with tuberculous pleural effusion (TB-PE) display immunosuppressive properties. (A) Mean #uorescence intensity (MFI)  
of CD163, PDL-1, MR, and HLA-DR measured by #ow cytometry in human monocyte-derived macrophages (MDM) exposed or not to TB-PE (n = 5). Wilcoxon 
signed rank test: *p < 0.05. (B) Levels of secreted IL-10 and TNF-α by MDM exposed or not to TB-PE in response to irradiated Mycobacterium tuberculosis (iMtb) 
measured by ELISA (n = 5). Friedman test followed by Dunn’s Multiple Comparison Test: *p < 0.05; **p < 0.01, for iMtb-stimulated vs unstimulated, or as indicated 
in the graph. (C–E) MDM from healthy PPD+ donors exposed or not to TB-PE for 24 h, were stimulated or not with iMtb for 24 h and then used as antigen 
presenting cells (APC) in autologous proliferation assays. Cocultures were performed with autologous carboxy#uorescein succinimidyl ester (CFSE)-labeled CD4 
T cells at a ratio of 10 T cells: 1MDM. (C) Representative histograms showing CFSE labeling in CD4pos T cells activated by macrophages exposed (or not) to TB-PE, 
loaded (or not) with iMtb. Right panel shows the quanti!cation of the percentages of proliferating CD4pos T cells (CFSElow/CD4pos cells) in each condition. Loaded vs 
unloaded with iMtb: *p ≤ 0.05 (n = 4). (D) Representative dot plots showing CD4 and IFN-γ expression among CFSElow/CD4pos T cells activated by MDM exposed 
(or not) to TB-PE, loaded (or not) with iMtb. Right panel shows the quanti!cation of the percentages of proliferating IFN-γ-producing CD4pos T cells (IFN-γpos/CFSElow/
CD4pos T cells) in each condition (n = 4). Friedman test followed by Dunn’s Multiple Comparison Test: *p < 0.05, for iMtb-stimulated vs unstimulated, or as indicated 
in the graph. (E) The amounts of IFN-γ released throughout the coculture were determined by ELISA. Friedman test followed by Dunn’s Multiple Comparison Test: 
*p < 0.05; **p < 0.01, for iMtb-stimulated vs unstimulated, or as indicated in the graph. (F) Bacillary loads in MDM treated (or not) with TB-PE, washed, and infected 
with Mycobacterium tuberculosis (Mtb) strain H37Rv for 4 h (n = 6). Wilcoxon signed rank test. (G) Intracellular colony forming units were determined at different 
time points in MDM treated with TB-PE for 24 h, washed and infected with Mtb (n = 10). Wilcoxon signed rank test: *p < 0.05; **p < 0.01; ***p < 0.001 for TB-PE 
treated vs Ctl.
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within the pleural $uids mononuclear cells (PFMC). We found 
that levels of IL-10 and total cholesterol were positively correlated 
(Figure 4A), unlike other cytokines such as IFN-γ, IL-6, TNF-α, 
and IL-1β (Figure S2 in Supplementary Material). Noticeably, 
there was also a positive correlation between the level of IL-10 
and the number of FM among the PFMC (Figure 4B). Moreover, 
lipid-laden CD14+ cells were found in the pleural compartment 
but not in paired peripheral blood (Figure  4C). #ese results 
FIGURE 4 | Cholesterol levels and foamy macrophages (FM) are associated with interleukin-10 (IL-10) amounts present in tuberculous pleural effusion (TB-PE). 
(A,B) Correlation analysis between the levels of IL-10 and (A) the cholesterol content (n = 38) or (B) the number of lipid-laden CD14+ cells within the pleural #uids 
mononuclear cells (PFMC) (n = 12) found in individual preparations of TB-PE. In B log-10 scale for both axes is used. Linear regression lines are shown. Spearman’s 
rank test. (C) Representative image of ORO staining of CD14+ cells isolated from paired peripheral blood mononuclear cells (PBMC) and PFMC is shown (40× 
magni!cation).
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support the idea that IL-10 potentiates the acquisition of the 
foamy program in human macrophages in the context of a natural 
infection.
IL-10 De!ciency Prevents the Foamy 
Phenotype in BMDM
To con&rm the role of IL-10 in the di"erentiation of FM, we evalu-
ated whether BMDM derived from IL-10-knock out (KO) mice 
could indeed become FM a'er the treatment with lipids from 
Mtb. First, we determined IL-10 production in M-CSF-derived 
BMDM from WT mice stimulated with mycobacterial lipids for 
24 h. As shown in Figure 5A, unlike the undetectable level of 
TNF-α (data not shown), BMDM secreted IL-10 in response to 
mycobacterial lipid-stimulation. Second, we compared whether 
BMDM derived from WT or IL-10-KO mice di"ered in their 
propensity to accumulate lipid bodies in response to Mtb-derived 
lipids. As illustrated in Figures 5B,C, IL-10-de&ciency prevented 
the foamy phenotype induced by Mtb lipids, which in turn 
could be partially reverted by the addition of exogenous IL-10. 
In agreement with our previous results, exogenous IL-10 did 
not induce the foamy phenotype in the absence of the source of 
lipids in BMDM. #ese results obtained in murine macrophages 
con&rm those obtained in human TB-PE-treated macrophages, 
demonstrating the key role of IL-10 in favor of the di"erentiation 
program toward foamy cells.
The IL-10/STAT3 Axis Is Involved in the  
FM Differentiation Induced by TB-PE
Considering the role of IL-10 in promoting the di"erentiation 
of macrophages into FM, and that STAT3 is a pivotal tran-
scriptional factor induced by IL-10 (31, 32), we studied the 
contribution of STAT3 activation in the induction of the foamy 
phenotype by measuring its phosphorylated form (pSTAT3). 
First, we determined that STAT3 was activated in TB-PE-treated 
macrophages detecting its phosphorylated form by western 
blot and immuno$uorescence microscopy (Figures  6A,B). 
As depicted in Figure  6B FM induced by TB-PE showed 
nuclear localization of STAT3 phosphorylated on tyrosine 
705, re$ecting STAT3 activation. Importantly, pharmaco-
logical inhibition of STAT3 with Stattic (or with cucurbitacin 
I) prevented the accumulation of lipid bodies in macrophages 
in a dose-dependent manner (Figure  6C; Figures S3A,B in 
Supplementary Material). #erefore, the enhancement of FM 
di"erentiation driven by IL-10 is mediated by STAT3.
IL-10 Enhances ACAT Expression  
in TB-PE-Treated Macrophages  
Leading to FM Differentiation
In order to elucidate the mechanism by which IL-10 promotes 
FM di"erentiation, we assessed the expression of ACAT, which is 
central for the biogenesis of lipid bodies by converting free- into 
FIGURE 5 | Interleukin-10 (IL-10) de!ciency reduces lipid bodies accumulation in bone marrow-derived mouse macrophages (BMDM) in response to 
Mycobacterium tuberculosis (Mtb) lipids. (A) BMDM from wt mice were treated or not with Mtb lipids for 24 h and the levels of secreted IL-10 were measured by 
ELISA (n = 5) Wilcoxon signed rank test: *p < 0.05. (B,C) BMDM from wt or IL-10−/− mice were treated or not with Mtb lipids in the presence or not of recombinant 
murine IL-10 for 24 h and then stained with Oil Red O (ORO). The integrated density of ORO staining (B) and representative images (C) are shown (n = 6). Friedman 
test followed by Dunn’s Multiple Comparison Test: *p < 0.05; **p < 0.01; ***p < 0.001 as depicted by lines.
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esteri&ed-cholesterol that are eventually packed inside the lipid 
droplets (33). We &rst showed that the foamy phenotype induced 
by TB-PE was dependent on ACAT activity, as judged both by the 
increase of ACAT expression a'er TB-PE treatment (Figure 7A), 
and by the blocking of the accumulation of lipid bodies in the 
presence of Sandoz, a speci&c inhibitor of ACAT (Figure 7B). 
Noticeably, the inhibition of ACAT lead to reduced amounts 
of both cholesteryl esters and triacylglycerols in TB-PE-treated 
macrophages (Figure 7C), con&rming the involvement of ACAT 
in FM formation upon TB-PE treatment. We then assessed ACAT 
expression in IL-10-depleted TB-PE and we found that its expres-
sion was reduced in the absence of IL-10 (Figure 7A). In agree-
ment with this result, ACAT induction by TB-PE was abolished 
when STAT3 activity was inhibited (Figure 7D). #erefore, the 
IL-10/STAT3 axis activated by TB-PE enhances FM di"erentia-
tion through the upregulation of ACAT expression, leading to an 
increased biogenesis and accumulation of lipid bodies.
Based on our &ndings, we propose a model for the modula-
tion of FM in the context of a physiologically relevant microen-
vironment promoted by Mtb infection for which the axis IL-10/
STAT3 induces the accumulation of lipid bodies via ACAT 
upregulation. #is in turn is accompanied by an increase of 
CD36 and the acquisition of immunosuppressive properties, 
such as a reduced induction of antimycobacterial #1 clones, an 
enhanced production of IL-10 and a more permissive phenotype 
for bacillary growth (Figure 8).
DISCUSSION
Tuberculosis, as a chronic condition, entails the establishment 
of extensive metabolic remodeling in both host and pathogen. 
One of the consequences of this adaptation is the formation of 
FM. Since FM have been associated with the bacilli persistence 
and tissue pathology (6, 8, 12, 27, 34), we aimed to determine 
which host factors may contribute to enlarge the pool of FM 
in TB. In this sense, we used the acellular fraction of TB-PE 
to mimic those soluble factors released locally during Mtb 
infection. Although pleural disease due to Mtb is generally 
categorized as extra-pulmonary, there is an intimate anatomic 
relationship between the pleura and the pulmonary parenchyma 
(35, 36). Current literature supports the notion that TB-PE is 
the consequence of a direct local infection with a cascade of 
events, including an immunological response, instead of the 
result of a pure delayed hypersensitivity reaction, as previously 
thought (37). Even though we cannot state that macrophages 
in&ltrating the pleural cavity will reproduce with &delity those 
macrophages in the infected alveolar space or lung interstitial 
tissue, we can a!rm that TB-PE represents microenvironment 
from a human respiratory cavity that is impacted by the infec-
tion. To our knowledge, this is the &rst time that such a complex 
but physiologically relevant human sample has been used in 
order to study the biology of FM. Using this in vitro model, we 
demonstrated that the acellular fraction of TB-PE induces the 
accumulation of lipid bodies in human macrophages. Moreover, 
our &nding was validated by the detection of lipid-laden CD14+ 
cells isolated directly from the mononuclear cells of the PE, pro-
viding physiological relevance to our in vitro model. Taking into 
account that tuberculous PE has, if any, very few bacilli content 
(38), and that it displays high cholesterol content, we infer that 
in our model the source of lipids feeding the lipid bodies in the 
macrophages are likely host-derived components instead of 
mycobacterial ones.
FIGURE 6 | Signal transducer and activator of transcription 3 (STAT3) activation enhances lipid bodies accumulation induced by treatment of macrophages with 
tuberculous pleural effusion (TB-PE). (A) Analysis of p705-STAT3, STAT3, and β-actin protein expression level by western Blot (left panel) and quanti!cation (right 
panel; n = 4) in human monocyte-derived macrophages (MDM) treated with TB-PE for 24 h. Wilcoxon signed rank test: *p < 0.05 (B) MDM were treated or not with 
TB-PE for 24 h and then were !xed, labeled with Bodipy 493/503 (green), permeabilized, and stained for p705-STAT3 (Red) and DAPI (blue). Representative images 
are shown. Scale bar, 10 µm. (C) MDM were treated or not with different concentrations of Stattic (STAT3 inhibitor, ST) for 2 h and then exposed or not to TB-PE for 
24 h. Lipid bodies’ content was determined by Oil red O (ORO) staining (n = 6). Representative images are shown and the integrated density of ORO staining is 
shown. Friedman test followed by Dunn’s Multiple Comparison Test: *p < 0.05; **p < 0.01 for TB-PE treated vs Ctl, or as depicted by lines.
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Although lipid bodies were quali&ed as passive organelles 
involved in lipid storage, it became clear that these organelles 
play a central role in several in$ammatory (e.g., atherosclerosis) 
or chronic infectious diseases (e.g., TB) (8, 13). In this work, we 
provide evidence that FM di"erentiation induced by TB-PE is 
potentiated by IL-10 in association with the acquisition immu-
nosuppressive properties, impairing the activation of antimyco-
bacterial #1 clones, producing the anti-in$ammatory cytokine 
IL-10 and bearing higher bacillary loads. #is is in line with 
previous reports characterizing the immunosuppressive pro&le 
in macrophages activated by the IL-10/STAT3 signaling pathway 
(39, 40). In this study, we show that FM formation depends 
(albeit partially) on the IL-10/STAT3 axis, and thus establish-
ing an association between both processes (accumulation of 
lipid bodies and immunosuppression). Within this context, we 
observed that both processes are enhanced by the IL-10/STAT3 
signaling pathway, arguing for likelihood of two independent 
outcomes emanating from the same signaling axis (Figure 8). 
Of note, it has been reported that the synthetic glucocorticoid 
dexamethasone can upregulate ACAT expression promoting 
formation of FM (41). Although there are extensive reports 
demonstrating transcriptional interactions between STAT3 and 
glucocorticoids leading to repression or synergism of target genes 
(42), it is interesting to notice that both IL-10 and glucocorticoids 
can polarize macrophages into an immunoregulatory pro&le (43). 
Based on that, we propose that the establishment of a foamy phe-
notype is accompanied by the acquisition of immunosuppressive 
properties.
It should be mentioned that Stattic is not an inhibitor com-
pletely speci&c for STAT3 (44). In this regard, a desirable goal 
is the discrimination between STAT3 and STAT1 involvement 
because both transcription factors can be activated by IL-10 
(albeit at di"erent levels), and because of their high degree 
of homology, particularly in their SH2 domains (44). Under 
our experimental conditions, unlike the strong activation of 
STAT3, we did not observe the phosphorylation of STAT1 
FIGURE 7 | The interleukin-10 (IL-10)/signal transducer and activator of transcription 3 (STAT3) axis promotes foamy macrophage formation through ACAT 
upregulation. (A) Analysis of ACAT and β-actin protein expression level by western Blot (left panel) and quanti!cation (right panel; n = 5) in human monocyte-derived 
macrophages (MDM) treated with tuberculous pleural effusion (TB-PE) for 24 h depleted or not for IL-10. (B) MDM were treated or not with different concentrations 
of Sandoz (Sz, ACAT inhibitor) for 1 h, exposed or not to TB-PE for 24 h, and then stained with Oil Red O (ORO). The Integrated density and representative images 
are shown (n = 6). (A,B) Friedman test followed by Dunn’s Multiple Comparison Test: *p < 0.05; **p < 0.01 for TB-PE treated vs Ctl, or as depicted by lines. (C) Thin 
layer chromatographic analysis of lipids from MDM treated or not with TB-PE in the presence or not of Sz. Total lipids were extracted from untreated MDM (lane 1), 
TB-PE-treated MDM (lane 2), TB-PE-treated MDM in the presence of Sz (lane 3), and the standard lipids triacylglycerol (TAG, lane 4) and cholesterol (CHO, lane 5). 
Cholesterol esters (CE) are also indicated. Right panels depict the area of spots for CE, TAG, and CHO in control and TB-PE in the presence or not of Sz treated 
MDM (n = 2). (D) Analysis of ACAT and β-actin protein expression level by Western Blot (left panel) and quanti!cation (right panel; n = 3) in MDM treated or not with 
different concentrations of Stattic (ST) for 2 h and then exposed or not to TB-PE for 24 h. Friedman test followed by Dunn’s Multiple Comparison Test: *p < 0.05 for 
TB-PE treated vs Ctl.
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in macrophages treated with TB-PE (data not shown and 
Figure 6). Likewise, the depletion of IFN-γ (a STAT1 activat-
ing cytokine) from TB-PE did not prevent the accumulation 
lipid bodies in macrophages (Figures  3A–C). #erefore, we 
consider that our experimental model is dependent of STAT3 
instead of STAT1.
FIGURE 8 | Interleukin-10 (IL-10) promotes foamy macrophage (FM) formation in an IL-10/signal transducer and activator of transcription 3 (STAT3)-dependent 
manner in tuberculosis (TB). According to our results, FM induced by pleural effusion from TB patients display immunosuppressive properties such as high IL-10 
release, low TNF-α production, impaired Th1 activation, and high bacillary loads. At the same time, lipid bodies’ accumulation is enhanced by IL-10/STAT3 axis 
through an increase of CD36 cell-surface expression levels and ACAT expression. It has been demonstrated that Mycobacterium tuberculosis (Mtb)-containing 
phagosomes migrate toward these lipid bodies and engulf them (7). This mechanism ensures protection from microbicidal pathways and allows persistence of the 
bacilli inside host. Our results provide additional mechanisms by which the environment created by the infection context drives the FM differentiation even in the 
absence of the pathogen.
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Our &ndings are in agreement with previous reports that 
demonstrated that macrophages exposed to lipids displayed 
impaired immune functions. Particularly, FM generated in vitro 
by the incubation with acetylated LDL displayed a reduced 
expression of pro-in$ammatory genes (45). In addition, the liga-
tion of the pregnane X receptor in human macrophages, which 
was associated to foamy formation, resulted in the impairment 
of the secretion of pro-in$ammatory cytokines, phagolysosomal 
fusion and apoptosis (46). Moreover, a recent study showed that 
the treatment of human macrophages with surfactant lipids 
resulted in the reduction of TNF-α release and the enhance-
ment of Mtb growth (14). Likewise, cholesterol-exposed THP1 
macrophages failed both to produce TNF-α in response to Mtb 
and to clear the infection (15). To the best of our knowledge, 
we provide the &rst evidence that FM display a reduced ability 
to activate a recall #1 response of speci&c antimycobacterial 
T cell clones. #erefore, we propose that FM signi&cantly subvert 
the host immune response by impairing both the innate and 
the adaptive immune branches, and we predict a close relation-
ship between lipid exposure, foamy phenotype acquisition and 
immu nosuppressive properties.
Our study also provides additional mechanisms by which 
the environment created during infection can drive the foamy 
di"erentiation even in the absence of a direct contact with 
the pathogen. On the one hand, Mtb-infected macrophages 
can acquire a foamy phenotype as demonstrated in this study 
and several others (6–9, 27). Indeed, the accumulation of lipid 
bodies within infected cells has undesirable e"ects for the host, 
such as the protection of the pathogen against microbicidal 
mechanisms (10) and the acquisition of a dormancy phenotype, 
which confers tolerance to several front-line antibiotics (9). 
On the other hand, uninfected macrophages can also be dri ven 
into foamy cells by IL-10 and a source of lipids. #ese uni-
nfected lipid-rich cells abrogate the host innate and adaptive 
cellular defense mechanisms, and when infected, they become a 
niche favoring pathogen persistence. In the latter case, we infer 
that uninfected individuals su"ering from a lipid dysbalance 
may bear an enlarged pool of lipid-rich cells that potentially 
increase the susceptibility, persistence and/or progression of TB. 
In fact, diabetes and obesity have been associated with TB disease 
progression (47, 48), and even asymptomatic dyslipidemia was 
correlated to a reduced antimycobacterial activity (15).
In the past, most reports focused on assessing the impact 
of certain cytokines in the accumulation of lipid bodies in 
macrophages within the context of atherosclerosis; FM were 
proposed to cause the formation of atheroma (49). In fact, IL-1β 
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and TNF-α are known to impede neutral lipid turnover in THP-1 
cells loaded with lipoproteins (50), and these pro-in$ammatory 
cytokines can decrease the e%ux of lipids in J774 murine mac-
rophages (51). In addition, IL-10 was shown to regulate lipid 
metabolism in human macrophages loaded with acetylated 
and oxidized LDL by increasing both cholesterol uptake and 
e%ux resulting in a net increase in cholesterol content (52, 53). 
Considering that both pro- and anti-in$ammatory cytokines 
were associated to the accumulation of lipid bodies, we evalu-
ated in this study the e"ect of depleting several cytokines from 
TB-PE on the FM formation. In our hands, unlike the depletion 
of IL-10, the foamy phenotype induced by TB-PE was not altered 
by depletion of IL-1β, TNF-α, IL-6 or IFN-γ, pointing toward a 
speci&c role of IL-10 in promoting FM formation in the context 
of the pleural infection. Moreover, anti-in$ammatory cytokines 
such as IL-4 and IL-13 were shown to alter lipid metabolism 
in macrophages through the activation of the lipid-activated 
nuclear receptors PPARγ (54), which mediates accumulation of 
lipid bodies (55, 56). Yet, we dismiss a potential role for IL-4 in 
our model given that its level was undetectable in TB-PE samples 
(data not shown).
In summary, our present study provides insights into the 
mechanisms by which host factors can enhance FM formation 
in macrophages. #is knowledge may contribute to the identi-
&cation of host molecular pathways that could be modulated to 
the bene&t of the patient. Besides, the complementation of the 
conventional anti-TB therapy with host-directed therapies is 
desirable in order to achieve shorter treatment times, reduction 
in lung damage caused by the disease, and lower risk of relapse 
or reinfection. In this regard, a better understanding of the 
molecular mechanisms underlying host–pathogen interactions 
could provide a rational basis for the development of e"ective 
anti-TB therapeutics.
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FIGURE S1 | Interleukin-10 (IL-10) promotes lipid bodies’ accumulation in 
TB-PE-treated macrophages. (A) TB-PE were incubated with neutralizing 
antibodies for 1 h (4°C) for the depletion of IL-10, IL-6, IL-1β, or TNF-α, and then, 
Protein G Sepharose beads were added and incubated for 1 h (4°C). Finally, 
TB-PE was centrifuged at 12,000 × g to remove antibody-bead complexes.  
In the case of IFN-γ depletion, it was performed by incubating TB-PE for 2 h in 
sterile 96-well plates that had been coated with the capture antibody provided by 
the human IFN-γ ELISA Kit. In all cases, depletions were controlled by ELISA.  
(B) Human monocyte-derived macrophages were treated with TB-PE depleted 
or not of IL-10 for 24 h and then, cells were labeled with BODIPY 493/503 to 
visualize the lipid bodies by green #uorescence emission. The left panels are DIC 
images of the same !eld.
FIGURE S2 | Correlation between cholesterol levels and different cytokines 
present in TB-PE. Correlation analysis between the levels of IL-6, IL-1β, TNF-α, 
or IFN-γ and the cholesterol content found in individual preparations of TB-PE  
(n = 23–24).
FIGURE S3 | Signal transducer and activator of transcription 3 (STAT3) activation 
enhances lipid bodies accumulation by TB-PE. (A) Immunoblot images of 
p705-STAT3, STAT3, and β-actin (left panel); quanti!cation of p705-STAT3 vs 
STAT3 on macrophages treated or not with Static (20 µM) or cucurbitacin (100 
nM) for 2 h and then exposed or not to TB-PE for 24 h (right panel; n = 3).  
(B) Macrophages were treated or not with different concentrations of 
cucurbitacin for 2 h and then were exposed or not to TB-PE for 24 h. Lipid 
bodies’ content was assessed by Oil Red O (ORO) staining. The results are 
shown like the integrated density of ORO staining (n = 6) (*p ≤ 0.05).
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Tuberculosis is associated with expansion of a motile, 
permissive and immunomodulatory CD16+ monocyte 
population via the IL­10/STAT3 axis
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The human CD14+ monocyte  compartment  is  composed by  two  subsets based on CD16 expression. We previ­
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7%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SDWKRJHQSHUPLVVLYLW\DQGLPPXQRPRGXODWLRQ7KLVSURFHVVLVGHSHQGHQWRQ67$7DFWLYDWLRQDQGORVVRIIXQFWLRQ
H[SHULPHQWVSRLQWWRZDUGVDGHWULPHQWDOUROHLQKRVWGHIHQVHDJDLQVW7%,PSRUWDQWO\ZHSURYLGHDFULWLFDOFRUUHOD­
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,QWURGXFWLRQ
Tuberculosis (TB) is a severe chronic bacterial  infec­
tion  caused by Mycobacterium  tuberculosis  (Mtb).  In 
2013, TB claimed  the  life of nearly 1.5 million people, 
ranking this disease as the second leading cause of death 
from a single infectious agent (Global TB report, WHO, 
2014). While TB mortality is slowly declining each year, 
it is still unacceptably high given that most cases would 
be curable if better diagnostic tools and correct treatment 
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were  available  to  complement  existing  technologies. A 
PDMRUREVWDFOHLVWKHODFNRI7%VSHFL¿FDQGQRQVSHFL¿F
immune activation biomarker and bio­signature  tools  to 
HVWLPDWHGLVHDVHVHYHULW\IROORZGUXJWUHDWPHQWHI¿FDF\
allow prognosis of disease outcome (recovery or relapse) 
and  estimate  vaccine protection  [1,  2]. As  the basis  for 
maintaining  the  flow of  novel  biomarker  candidates  in 
the product pipeline, fundamental science is necessary to 
better characterize Mtb interaction with the human host. 
Innate  immunity plays  a  key  role  in  host  defense 
against Mtb. Among  the  immune  innate  cells  involved 
in this resistance, macrophages are primordial regulators 
of  the balance of  pro­  and  anti­inflammatory  immune 
response  in order  to ensure  the control of bacterial  rep­
lication and  limit  the extent of  tissue damage following 
pathogenic insult [3­5]. They perform these roles accord­
ing  to  their  high degree of  phenotypic  and  functional 
plasticity  in  response  to  environmental  clues within  tis­
VXHV DQGDUHFODVVL¿HGZLWKLQD VSHFWUXP UDQJLQJ IURP
SURLQÀDPPDWRU\ 0 WR DQWLLQÀDPPDWRU\ 0 DFWL­
vation programs  [6]. Remarkably, Mtb displays  a  great 
FDSDFLW\ WR LQÀXHQFH WKHGLIIHUHQWLDWLRQPDWXUDWLRQ DQG
activation of macrophages, resulting in an effective eva­
sion of  the  immune  response  and  increased persistence 
in  the host  (for  review,  see  [7­9]). Despite  the  signifi­
cant  progress  in  understanding macrophage  subversion 
by Mtb,  one  aspect  that  remains poorly  studied  is  how 
monocytes  contribute  to  the dynamic  alteration of  the 
macrophage compartment during ongoing Mtb infection. 
As monocytes are the precursors of macrophages during 
LQÀDPPDWLRQVXEVWDQWLDO LQVLJKWV LQWRKRVWGHIHQVHVDUH
likely to be gained by determining the role of these leu­
kocytes within the TB context. In particular, while there 
DUHLPSRUWDQWFOXHVFRPLQJIURPWKH]HEUD¿VKDQGPRXVH
models, the human context remains poorly explored [7, 9, 
10].
Human blood monocytes  are  broadly  segregated 
into  two major  subsets: CD14+CD16í(classical)  and 
CD14+CD16+  (non­classical) monocytes,  hereafter  des­
ignated  as CD16í  and CD16+,  respectively  [11,  12]. 
Notably, the CD16+ subset accounts for only 10% of the 
total monocyte population  in healthy donors, displaying 
a unique cell­surface marker expression and cytokine se­
cretion pattern in comparison with its CD16í counterpart 
[13, 14].  Indeed, upon  stimulation with  lipopolysaccha­
ride, CD16+ monocytes isolated from healthy donors se­
FUHWHKLJKHUDPRXQWVRISURLQÀDPPDWRU\IDFWRUVVXFKDV
WXPRUQHFURVLV IDFWRUDOSKD 71)Į LQWHUOHXNLQEHWD
,/DQG,/EXWORZDPRXQWRIWKHDQWLLQÀDPPDWRU\
mediator IL­10 [13, 15­17]. Other features distinguishing 
the CD16+ subset are higher antigen processing and pre­
sentation, pro­angiogenic behavior and motility [10]. The 
expansion of CD16+ monocytes  is well  documented  in 
different  types of  diseases, mainly deriving  from  infec­
WLRQRU LQÀDPPDWRU\FRQGLWLRQV>@)RU WKHVHUHDVRQV
CD16+PRQRF\WHVDUHXVXDOO\ UHIHUUHG WRDVSURLQÀDP­
matory monocytes.
Interestingly,  the human monocyte  compartment  is 
perturbed in TB patients, as illustrated by the expansion 
of CD16+ monocytes, which can account for up to 50% 
of the total monocyte population, and its correlation with 
the disease severity [18]. This unbalance in the monocyte 
population  is  also  associated with  a  higher  cell­surface 
expression for CD14, CD11b, toll­like receptor­2 (TLR2), 
TLR5, chemokine C­C motif  receptor­1 (CCR1), CCR2 
and CCR5,  as  compared with  that  of  healthy  individu­
als  [18]. Functional  characterization  in  vitro  shows  that 
monocytes  isolated  from TB patients  are  refractory  to 
HI¿FLHQWGHQGULWLFFHOO'&GLIIHUHQWLDWLRQDQGGH¿FLHQW
in  the  activation of T  lymphocytes,  as  compared with 
monocytes from healthy donors [19, 20]. The cause and 
consequence of  this  unbalance  are  still  relatively un­
known.  In addition,  it  remains  to be elucidated whether 
there  is  an  effect  on  the  ability  of monocytes  from TB 
patients  to differentiate  into macrophages  that are capa­
ble of controlling  the bacilllus’  intracellular growth and 
mount  an  effective  immune  response.  Indeed,  this  is  a 
critical  functional  aspect  to  assess,  along with  its  prog­
nostic  value,  in  order  to  determine whether  the unbal­
DQFHGPRQRF\WH SRSXODWLRQ LV EHQH¿FLDO RU GHWULPHQWDO
to host defense against TB, and whether this represents a 
potential bio­signature and target for treatment.
Here we describe  that,  in  the  context  of TB,  human 
monocytes  differentiating  towards  a macrophage pro­
gram  (referred here  to  as monocyte­macrophages)  are 
tilted  towards  an M2­like  activation program charac­
terized by  the CD16+CD163+MerTK+pSTAT3+ marker 
phenotype  and  functional  properties  such  as  high pro­
tease­dependent motility,  pathogen permissivity  and 
immunomodulatory  activity. The  establishment  of  this 
program  is mainly dependent  on  the  signal  transduc­
er  and  activator  of  transcription 3  (STAT3)­dependent 
signaling pathway,  and points  towards  a  detrimental 
role  in  host  defense  against TB.  Importantly,  our  study 
provides direct correlation of the abundance of CD16+C­
D163+MerTK+pSTAT3+ cells with TB disease severity in 
humans and non­human primates (NHPs), and proposes 
the presence of the soluble form of CD163 (sCD163) in 
sera as a potential biomarker to monitor disease progres­
VLRQDQGWUHDWPHQWHI¿FDF\
Results
The  secretome of Mtb­infected macrophages  favors  the 
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differentiation of  human monocytes  towards an M2­like 
activation program
0WELQIHFWLRQLVNQRZQWRVLJQL¿FDQWO\DOWHUPRQRF\WH
differentiation upon  recruitment  to  pulmonary  tissue  in 
mice, alluding to a bystander effect derived from infect­
ed resident cells [21]. As the secretome of Mtb­infected 
macrophages  inhibits  human monocyte  differentiation 
towards DC program  [22], we  investigated whether  it 
also  alters monocyte­to­macrophage differentiation. To 
this aim, we devised an  in vitro model whereby  freshly 
isolated CD14+ monocytes from healthy donors were dif­
ferentiated towards a macrophage program (M­CSF driv­
en)  in  the presence of  conditioned media  from Mtb­in­
fected human macrophages (cmMTB). As a control, we 
differentiated monocytes using a conditioned media from 
non­infected macrophages  (cmCTR). Unlike  treatment 
with  cmCTR, we observed  an  expansion of  the CD16+ 
population  in  the  cmMTB­treated monocytes  (Figure 
1A).  In  addition, we  assessed  their  activation program 
E\ÀRZF\WRPHWU\ LQ WHUPVRI0DQG0FHOOVXUIDFH
marker expression. Monocytes conditioned with cmMTB 
differentiated into cells displaying an equivalent or low­
Figure 1 The secretome of Mtb­infected macrophages  induces  the differentiation of CD16+ monocytes  towards an M2­like 
phenotype. Monocytes were  cultured with  conditioned media  from Mtb­infected  (cmMTB, black)  or  non­infected  (cmCTR, 
white) macrophages. (A) Flow cytometry gating strategy of a representative donor and the percentage of CD14+CD16+ cells. 
(B)9HUWLFDOVFDWWHUSORWVVKRZLQJ WKHPHGLDQÀXRUHVFHQW LQWHQVLW\ 0),RIFHOOVXUIDFHPDUNHUVGXULQJFP&75RUFP07%
treatment.  (C) 9HUWLFDO VFDWWHU SORWV VKRZLQJ WKH0), RI&'0HU7.RU&' LQ WKH&'+CD16í  (white  circles)  and 
CD14+CD16+ (black circles) cell populations during cmCTR or cmMTB treatment. *P P P (DFK
circle within vertical scatter plots represents a single donor.
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er  expression of M1 polarization markers  (i.e., CD86, 
HLA­DR, FCAR and Serpine1)  compared with  cells 
differentiated in the presence of cmCTR (Supplementary 
information, Figure S1A­S1B). By contrast,  the expres­
sion of markers  related  to M2 macrophage  activation, 
such  as CD16, CD163, MerTK, CD206, AMAC1 and 
CD200R1  [23­27], was upregulated  in  cmMTB­con­
ditioned  cells  (Figure 1B, Supplementary  information, 
Figure S1B). Similarly,  the  expression of CCR2 and 
CCR5 chemokine receptors was higher in the presence of 
cmMTB,  supporting  the  acquisition of  the M2 program 
(Supplementary information, Figure S1C) [28, 29]. More 
SUHFLVHO\WKHH[SUHVVLRQRI0PDUNHUVZDVVSHFL¿FDOO\
augmented within CD16+ population compared with  the 
CD16í counterpart, with a higher increase of CD163 and 
CD206 upon cmMTB treatment monocytes (Figure 1C). 
    These results indicate that soluble factors secreted by 
Mtb­infected macrophages exert bystander effect affect­
ing monocyte differentiation towards an M2­like activa­
tion program.
The monocyte activation towards CD16+CD163+MerTK+ 
phenotype  is  dependent  on  the  IL­10/STAT3  signaling 
pathway in the TB context
In the presence of M­CSF, IL­10 triggers macrophage 
M2 activation  that  promotes  tolerance mechanisms,  in­
FOXGLQJ WKH UHVROXWLRQRI LQÀDPPDWLRQDQG WLVVXH UHSDLU
[28, 30]. Moreover, this cytokine is not only increased in 
serum and pleural  effusion  from TB patients  compared 
with healthy donors  [31,  32],  but  also  in  the  lungs of 
Mtb­infected NHPs [33]. As IL­10 is secreted by Mtb­in­
fected human macrophages [34], we investigated wheth­
er  it  is  responsible  for  the Mtb­derived bystander effect 
observed in our in vitroPRGHO:H¿UVWH[DPLQHGZKHWK­
er human recombinant IL­10 (recIL­10), in combination 
with M­CSF, recapitulated the effect of the cmMTB. As 
expected,  the  expression of CD206 was not  influenced 
E\UHF,/ UDWKHUFRQ¿UPLQJ WKH UHJXODWLRQRI WKLV UH­
ceptor  by  IL­4/STAT6 axis  [35]. By  contrast,  recIL­10 
treatment on monocytes stimulated the expression of M2 
markers (i.e., CD16, CD163 and MerTK) compared with 
control  cells, whereas M1 markers were  significantly 
decreased  (Supplementary  information, Figure S2A). 
Moreover, when IL­10 was depleted from cmMTB using 
blocking antibodies (Supplementary information, Figure 
S2B), we observed  impairment  in  the  establishment  of 
the M2 marker  signature  (except  for CD206)  (Figure 
2A),  accompanied by  a  slight  increasing  tendency of 
M1 markers  (Supplementary  information, Figure S2C), 
indicating  that  this  cytokine  is  one of  the main  soluble 
factors present  in  the secretome of Mtb­infected macro­
phages  responsible  for  the  induction of M2­like mono­
cyte­macrophages.
The binding of IL­10 to its receptor leads to the subse­
quent activation of STAT3, whose role is essential for all 
known functions of IL­10 [36]. As shown in Figure 2B, 
short­term exposure of freshly isolated monocytes to cm­
MTB resulted in STAT3 phosphorylation on tyrosine 705, 
reflecting  its  activation. This  activation was dependent 
on the presence of IL­10 since incubation of monocytes 
ZLWK,/GHSOHWHGFP07%IDLOHGWRWULJJHUVLJQL¿FDQW
phosphorylation of STAT3  (Figure 2B). Next, we  as­
sessed whether STAT3 was crucial for the establishment 
of M2­like monocyte­macrophages, using a  siRNA­me­
diated gene  silencing method  [37],  or  pharmacological 
inhibition of STAT3 activation with either cucurbitacin I 
(CCB), which inhibits JAK2 (Janus kinase 2)­dependent 
phosphorylation of STAT3,  or STATTIC, which  targets 
the STAT3­SH2 domain  thereby preventing  its  associ­
ation with upstream kinases. Both  approaches  enabled 
a  nearly  complete  inhibition of STAT3 expression or 
phosphorylation in human monocyte­macrophages (Sup­
plementary information, Figure S3A­S3C). As expected, 
inhibition of STAT3  in  cmMTB­treated  cells  reversed 
the acquisition of the CD16+CD163+MerTK+ phenotype, 
while CD206 or M1 marker  expression  remained unaf­
fected  (Figure 2C and Supplementary  information, Fig­
ure S3D­S3F). 
Altogether,  the  secretome of Mtb­infected mac­
rophages  favors  the human monocyte  differentiation 
towards  an M2­like  activation program, which  is main­
ly  but  not  absolutely dependent  (as  best  indicated by 
CD206 expression) on the IL­10/STAT3 axis. 
The CD16+ monocyte expansion  is predisposed  towards 
an M2­like phenotype in patients with active TB
Results  obtained  through our  in  vitro  approach  in­
ferred  that  the  reported  imbalance  in  circulating mono­
cyte  subsets  in TB patients might  be  associated with  a 
predisposition  towards  a STAT3­driven M2­like pro­
gram. To  address  the physiological  relevance of  this 
issue, we analyzed in more detail the activation program 
of  the  circulating monocytes  in TB patients. We  col­
lected peripheral  blood  from healthy  subjects  (PB­HS), 
patients with  active  (PB­TB) or  confirmed  latent  (PB­
LTB) TB  (Supplementary  information, Table S1),  to 
evaluate the status of the CD14+ monocyte compartment. 
$VSUHYLRXVO\GHVFULEHG >@ZH FRQ¿UPHG WKHKLJKHU
proportion of CD16+ cells in PB­TB compared with PB­
HS, accounting for about 40% of the CD14+ monocytes 
(Figure 3A, Supplementary  information, Figure S4A). 
Strikingly, the expansion of CD16+ monocytes is non­ex­
istent in PB­LTB, indicating that the abundance of these 
cells  is  associated with  active TB  (Figure 3A, Supple­
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mentary  information, Figure S4B). While we  failed  to 
correlate the enhanced level of CD16 expression with the 
M2­like phenotype  characterized  in  our  in  vitro model 
(Supplementary information, Figure S4B), freshly isolat­
Figure 2 7KH,/67$7SDWKZD\GULYHVWKHSUHGLVSRVLWLRQRI&'+ monocytes towards an M2­like phenotype. (A) Vertical 
VFDWWHUSORWVVKRZLQJWKH0),RIFHOOVXUIDFHPDUNHUVLQPRQRF\WHVFXOWXUHGZLWK,/GHSOHWHGFP07%FP07%Į,/RU
the mock depletion control (cmMTBĮ,J*(B),PPXQREORWLPDJHVRIS<67$767$7DQGDFWLQXSSHUSDQHOTXDQWL¿­
FDWLRQRIS<67$7YHUVXV67$7RQPRQRF\WHVDIWHUKWUHDWPHQWZLWKFP&75FP07%FP07%Į,/RUFP07%Į,J*
(n  GRQRUVORZHUSDQHO(C)9HUWLFDOVFDWWHUSORWVVKRZLQJWKH0),RIFHOOVXUIDFHPDUNHUVLQPRQRF\WHVWUDQVIHFWHGZLWK
67$7VL67$7EODFNRUQRQWDUJHWLQJFRQWUROVL&75ZKLWHVL51$VDQGFRQGLWLRQHGZLWKFP&75RUFP07%P 
**P P (DFKFLUFOHZLWKLQYHUWLFDOVFDWWHUSORWVUHSUHVHQWVDVLQJOHGRQRU
ed monocytes from TB patients displayed higher level of 
phosphorylated STAT3 compared with their counterparts 
from healthy  subjects  (HS),  as measured by western 
EORWDQDO\VLV)LJXUH%8VLQJDÀRZF\WRPHWU\EDVHG
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approach, we  found  that CD14+CD16+ can be differen­
tiated  into  two  sub­populations  according  to  the phos­
phorylation status of STAT3 (CD14+CD16+pSTAT3í and 
Figure 3 The CD16+ monocyte expansion  is  predisposed  towards an M2­like phenotype  in  patients with  active TB.  (A) 
Vertical scatter plots showing the percentage of CD14+CD16+FHOOV LQWKHSHULSKHUDOEORRGRIKHDOWK\VXEMHFWV3%+67%
SDWLHQWV3%7%RUVXEMHFWVZLWKODWHQW7%3%/7%(B),PPXQREORWLPDJHVRIS<67$767$7DQGDFWLQOHIWDQG
TXDQWL¿FDWLRQRI S<67$7YHUVXV67$7 ULJKW RQPRQRF\WHV IURPKHDOWK\ VXEMHFWV +6RU7%SDWLHQWV 7% n  
donors). (C)9HUWLFDOVFDWWHUSORWVVKRZLQJWKH0),RIFHOOVXUIDFHPDUNHUVLQ+6RU7%PRQRF\WHGHULYHGPDFURSKDJHVGLI­
ferentiated in vitroIRUGD\V(D) $QDO\VLVRIVROXEOHIRUPRI&'V&'OHYHOLQVHUDRI7%SDWLHQWVDFFRUGLQJWRGLV­
HDVHVHYHULW\DVFRPSDUHGZLWK+6(E)9HUWLFDOVFDWWHUSORWVVKRZLQJWKHVHUXPOHYHORIV&'LQ7%SDWLHQWVEHIRUHDQG
12 months after start of treatment (TB­M12), as compared with contact donors. (F) ROC (receiver operating characteristic) 
FXUYHRIV&'FRQFHQWUDWLRQ LQ7%SDWLHQWVFRPSDUHGZLWK+6 (G)52&FXUYHRIV&'FRQFHQWUDWLRQ LQ7%SDWLHQWV
before versus after treatment (TB versus TB­M12). The red circle represents the optimal cut point. (H) 0RQRF\WHVIURP+6
ZHUHWUHDWHGZLWKSOHXUDOHIIXVLRQ3(IURP7%3(7%RUQRQ7%3(QRQ7%SDWLHQWVRUFXOWXUHPHGLXP5HSUHVHQWDWLYH
LPDJHVRIZHVWHUQEORWLOOXVWUDWLQJWKHH[SUHVVLRQRIS<67$767$7DQGDFWLQn  (I) Vertical scatter plots showing 
WKH0),RI&'&'RU0HU7.RQ&'+PRQRF\WHVSUHVHQWLQ3(7%RU3(QRQ7%IURPSDWLHQWVP P 
***P (DFKFLUFOHZLWKLQYHUWLFDOVFDWWHUSORWVUHSUHVHQWVDVLQJOHGRQRU$8&DUHDXQGHUWKHFXUYH
CD14+CD16+pSTAT3+). In TB patients, the percentage of 
CD14+CD16+pSTAT3+ LV VLJQL¿FDQWO\ LQFUHDVHG 
± 11.2%) compared with control donors (13.2% ± 6.1%, 
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P < 0.01, n = 6). Moreover, when differentiated in vitro 
with M­CSF, blood monocytes from TB patients exhibit­
ed a CD163hiMerTKhiHLA­DRloCD86lo macrophage phe­
notype  (Figure 3C, Supplementary  information, Figure 
S4C). Together, these results point out a predisposition of 
the human monocyte  compartment  towards  an M2­like 
program in the TB context.
We previously  reported  that  the expansion of periph­
eral CD16+ monocytes correlates with disease severity of 
TB patients  [18]. To  further  characterize  the  activation 
program of  this  expanded  cell  population, we  then  as­
sessed  the M2­like phenotype of  circulating monocytes 
isolated  from patients with different  clinical  parameters 
to  distinguish TB  severity  (Supplementary  information, 
Table S2). Unlike CD163, we observed that the cell­sur­
IDFHH[SUHVVLRQRI0HU7.LVVLJQL¿FDQWO\DXJPHQWHGLQ
the case of patients with an advanced degree of the dis­
ease and accentuated within the CD16+ monocyte subset 
(Supplementary  information, Figure S4D­S4E). Given 
that membrane­bound CD163 and MerTK receptors are 
VXEMHFWHG WR LQÀDPPDWLRQGULYHQ VKHGGLQJ > @ZH
hypothesized  that  chronic  infection with Mtb may  also 
lead to the shedding of  these receptors from the surface 
of  circulating monocytes,  and  thus  increase  the  expres­
sion of  soluble CD163  (sCD163)  and MerTK  (MerTK 
ectodomain:  sMer)  in  the  serum of TB patients. Aside 
from a single report describing the circulating sCD163 as 
a predictive value  for patient  survival  [40],  there  is vir­
tually no  information about  this  scavenger  receptor  and 
MerTK  in  the TB context. We  thus  evaluated  the  sera 
from pulmonary TB patients and revealed a progressive­
ly increasing trend in the levels of sCD163, particularly 
striking in cases with an advanced degree of the disease 
(Figure 3D). Next,  to  examine whether  the  soluble  ex­
pression of  this  receptor  is  related  to  the presence of 
bacilli, we measured  sCD163  serum concentration  in 
TB patients  before  and  after  treatment  (Supplementary 
information, Table S3). Noticeably,  the TB­induced  ex­
SUHVVLRQRIV&'LVGHFUHDVHGVLJQL¿FDQWO\DIWHUWUHDW­
ment (Figure 3E). This was further supported by receiver 
operating  characteristic  (ROC)  curve  analysis  showing 
the  relationship between  the  sensitivity  and  specificity 
at  any  cutoff  values  for  sCD163  (Figure 3F  and 3G). 
For TB patients  in  relation  to HS,  the  area under  the 
ROC curve (AUC) value for sCD163 was 0.78 (± 0.04) 
ZLWKDFRQ¿GHQFHLQWHUYDO&,RIWRP < 
0.0001), with an optimal cut point yielding a sensitivity 
RIDQG VSHFL¿FLW\RI )LJXUH))RU7%
patients,  before  treatment  in  relation  to  the  same  cases 
after 12­month  treatment (TB­M12),  the AUC value for 
sCD163 was 0.76 (± 0.07) with a CI of 0.61 to 0.90 (P < 
0.001), with an optimal cut point providing a sensitivity 
RIDQGVSHFL¿FLW\RI)LJXUH* ,Q WKHFDVH
for  sMer,  however, we  found no  evidence  supporting 
its  shedding  in TB  (Supplementary  information, Figure 
S4F­S4I). These results indicate that altered serum levels 
of  sCD163 might  be of  potential  use  as  a  non­invasive 
biomarker  for  pulmonary TB disease progression  and 
PRQLWRULQJRIWUHDWPHQWHI¿FDF\
To  further  explore  the  association between Mtb  in­
fection and  the  alteration of  the human monocyte  com­
partment, we obtained pleural  effusion  fluids  from TB 
patients  (PE­TB)  and other  non­TB­related  infectious 
diseases  (PE­nonTB; Supplementary  information, Table 
S1). As PE­TB is the most common form of extrapulmo­
QDU\7%ZHWHVWHGLWVFDSDFLW\WRLQÀXHQFHWKHDFWLYDWLRQ
program of  freshly  isolated monocytes  from HS,  and 
noticed that both PE­TB and PE­nonTB were able to in­
duce a rapid phosphorylation of STAT3 (Figure 3H). Im­
portantly, when assessing the CD14+ population isolated 
directly from PE­TB, we observed that these cells tend to 
display a higher acquisition of the CD16+CD163+MerTK+ 
phenotype  in  comparison with  their  counterparts  from 
PE­nonTB  (Figure 3I),  suggesting  that  an Mtb­derived 
PLFURHQYLURQPHQWLQÀXHQFHVWKHKXPDQPRQRF\WHFRP­
partment via STAT3.
The abundance of  the CD16+CD163+MerTK+pSTAT3+ 
cell  population  correlates with  pathology  severity  in 
non­human primate pulmonary TB
Pulmonary granuloma formation is a hallmark of TB, 
and  the  activation program of monocyte­macrophages 
is thought to play an important role in this process [41]. 
Therefore, we  further  investigated whether  the M2­like 
CD16+CD163+MerTK+ cell population is present in pul­
monary granulomas of Mtb­infected NHPs. The NHP tis­
sue samples were derived from BCG (Bacillus Calmette­
Guérin)  vaccinated  and unvaccinated Mtb­infected 
rhesus macaques,  exhibiting different  degrees  of  lung 
pathology  that was  in  general  inversely  correlated with 
time to end point (survival; Supplementary information, 
Figure S5A).  Immunohistochemical  analyses  revealed 
WKDWPDFURSKDJHLQ¿OWUDWLRQ&'+) increased according 
to  lung pathology  severity  (Figure 4A, Supplementary 
information, Figure S5B);  this  pattern was  also  accom­
panied by  increased CD163  expression  in  tuberculous 
granulomas  in NHPs  (Figure 4A, Supplementary  infor­
mation, Figure S5B)  [42]. Concomitantly, we observed 
an elevated expression of CD16 and MerTK in NHP tu­
berculous granulomas (Figure 4A, Supplementary infor­
mation, Figure S5B). Notably, the expression of CD163, 
CD16 and MerTK positively correlated with the severity 
of  lung pathology  (Figure 4B). Co­localization  analysis 
within CD163+ macrophages  revealed  that CD16  and 
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Figure 4 The abundance of the CD16+&'+0HU7.+S67$7+ cell population correlates with pathology severity in non­hu­
PDQSULPDWH1+3SXOPRQDU\7% (A) Representative immunohistochemical images demonstrate expression and distribution 
RI&'&'&'DQG0HU7.LQOXQJJUDQXORPDVIURPQRQYDFFLQDWHG0WELQIHFWHG1+3VH[KLELWLQJGLIIHUHQWVHYHULW\
RISXOPRQDU\7%1+3QXPEHUVUHIHUWR6XSSOHPHQWDU\LQIRUPDWLRQ7DEOH6(B) Correlation analysis between the number 
of CD16+&'+RU0HU7.+FHOOVLQOXQJWLVVXHDQGOXQJSDWKRORJ\VFRUHLQ%&*YDFFLQDWHGUHGFLUFOHVRUQRQYDFFLQDWHG
EODFNFLUFOHV0WELQIHFWHG1+3V(C, D) ,PPXQRKLVWRFKHPLVWU\ VWDLQLQJVRIOXQJELRSVLHVIURP1+3QLQWHUPHGLDWH (C) 
8SSHUSDQHOFRORFDOL]DWLRQRI&'JUHHQ$OH[DDQG&'UHG$OH[D LQ OXQJ WLVVXH ORZHUSDQHOFRORFDO­
L]DWLRQRI&'JUHHQ$OH[DDQG0HU7.UHG$OH[DLQOXQJWLVVXH:KLWHDUURZVLQGLFDWHGRXEOHSRVLWLYHFHOOV
WKDWDUHPDJQL¿HGLQDQGLQVHWVFDOHEDU µm). (D) 8SSHUSDQHOQXFOHDUORFDOL]DWLRQRI67$7JUHHQ$OH[DLQ
&'UHG$OH[DSRVLWLYHFHOOVLQOXQJWLVVXHORZHUSDQHOQXFOHDUORFDOL]DWLRQRI67$7JUHHQ$OH[DLQ&'UHG
$OH[DSRVLWLYHFHOOVLQOXQJWLVVXH:KLWHDUURZVLQGLFDWH&'RU&'SRVLWLYHFHOOVZLWK67$7WUDQVORFDWHGLQWKH
QXFOHXVVWDLQHGZLWK'$3,EOXHLQVHWVFDOHEDU µm).
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MerTK were  co­expressed  in  this  population  (Figure 
4C). Even  though phosphorylated STAT3 could not  be 
assessed  in  the NHP  samples  due  to  technical  reasons, 
we did observe  accumulation of STAT3  in  the nuclear 
area of CD163+  and CD16+  cell  populations,  indicating 
that  this  transcription  factor  is  activated  in  these  leuko­
cytes (Figure 4D).
Collectively, these results suggest that the environment 
created during pulmonary TB  is  capable  to modulating 
macrophage  activation  into  an M2­like program, which 
becomes accentuated according to disease severity.
The CD16+CD163+MerTK+pSTAT3+ monocyte­macro­
phages display an  efficient  ability  to migrate  in  dense 
matrices
To determine whether  the  expansion of  the M2­like 
monocyte­macrophages  is  beneficial  or  detrimental  to 
host defense against TB, we investigated functional con­
sequences of this activation program. Studies performed 
LQ]HEUD¿VKPRGHOVKRZHGWKDWWKHHQYLURQPHQWLQGXFHG
by mycobacterial infection stimulates the recruitment of 
highly motile macrophages in a matrix metalloproteases 
(MMP)­dependent manner, which  is  known  to  enhance 
the pathogenesis  [43,  44]. On  the basis  of  these obser­
vations, we  investigated whether  cmMTB  influences 
human monocyte­macrophages migration in different 3D 
environments that mimic tissues [45]. Cell migration was 
¿UVW DQDO\]HG LQ GHQVH0DWULJHO LQZKLFKSURWHDVHPH­
diated matrix  digestion  is mandatory  for macrophage 
LQ¿OWUDWLRQLQFRQWUDVWWRSURWHDVHLQGHSHQGHQWPLJUDWLRQ
LQSRURXV¿EULOODU FROODJHQ ,PDWULFHV >@ ,Q0DWULJHO
when  cmMTB was used  as  chemoattractant,  the migra­
tion of  human monocyte­macrophages  into  this matrix 
was enhanced and the distance covered by the cells was 
increased  (Figure 5A, Supplementary  information, Fig­
ure S6A). Similar  results were obtained using  another 
Figure 5 The CD16+&'+0HU7.+S67$7+ monocyte­macrophages display a strong ability  to migrate  in dense matrices. 
(A)+XPDQPRQRF\WHVZHUHVHHGHGRQWKHWRSRI¿EULOODUFROODJHQ,RU0DWULJHOPDWULFHVDQGDOORZHGWRPLJUDWHLQUHVSRQVH
WRFP&75ZKLWHRUFP07%EODFN4XDQWL¿FDWLRQRIWKHSHUFHQWDJHRIPLJUDWLQJFHOOVn  GRQRUV(B)(IIHFWRISURWHDVH
3LPL[PDWUL[PHWDOORSURWHDVH*05KRDVVRFLDWHGNLQDVH<LQKLELWRUVRU'062RQFHOOPLJUDWLRQLQ0DWULJHO
(n = 9 donors). (C) Representative scanning electron microscopy images showing the matrix remodeling activity of cells on 
Matrigel  (n  GRQRUVVFDOHEDU µm).  (D) 4XDQWL¿FDWLRQRIJHODWLQ]\PRJUDPJHOV IRU003OHIWDQG003ULJKW
activities (n > 4 donors). (E)0RQRF\WHVWUDQVIHFWHGZLWK60$57SRROWDUJHWLQJ67$7VL67$7RUQRQWDUJHWLQJFRQWUROVL5­
1$VVL&75ZHUHVHHGHGRQ0DWULJHODQGDOORZHGWRPLJUDWHLQUHVSRQVHWRFP07%n  GRQRUV(F)0RQRF\WHVIURP+6
ZHUHVHHGHGRQ0DWULJHODQGDOORZHGWRPLJUDWHLQUHVSRQVHWR3(7%3(QRQ7%RUFXOWXUHPHGLXPn  GRQRUV5HVXOWV
DUHH[SUHVVHGDVPHDQ6(0P 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dense matrix such as gelled collagen I, strengthening the 
use of  protease  activity  during  cmMTB­induced migra­
tion  (Supplementary  information, Figure S6B).  In  con­
WUDVWFHOOVLQ¿OWUDWHGWKHSRURXV¿EULOODUFROODJHQ,PDWUL[
efficiently  regardless  of  the provided  chemoattractant, 
cmMTB or cmCTR (Figure 5A). We showed in the past 
that macrophage 3D migration in dense matrices depends 
on both protease  activity  and  the  tyrosine kinase Hck, 
but  not  the ROCK kinase pathway  [37,  45­47].  In  line 
ZLWKWKHVHSUHYLRXV¿QGLQJVERWKDFRFNWDLORISURWHDVH
inhibitors  (Pimix) and  the broad­spectrum MMP inhibi­
tor GM6001 abrogated the cmMTB­enhanced migration 
into Matrigel  (Figure 5B). Moreover,  this  process was 
also partially  inhibited by  siRNA­mediated  silencing of 
Hck  in  these  cells  (Supplementary  information, Figure 
S6C). As expected,  the use of a ROCK kinase  inhibitor 
(Y27632) had no effect on the cmMTB­enhanced motili­
ty in Matrigel (Figure 5B). To further support the role of 
MMP  in  the monocyte­macrophage migration, we per­
formed scanning electron microscopy. Our observations 
revealed that in response to cmMTB, cells profoundly re­
modeled the matrix compared with those treated with the 
cmCTR or the MMP inhibitor (Figure 5C). Interestingly, 
while MMP1 and MMP9 activities were increased in the 
culture medium of cmMTB­treated cells (Figure 5D), the 
MMP2 activity was unchanged (Supplementary informa­
tion, Figure S6D), alluding to the selectivity of MMPs in 
cmMTB­enhanced motility. 
Next, we investigated which soluble factor in cmMTB 
LQGXFHVPRQRF\WH'PLJUDWLRQLQ0DWULJHO,Q]HEUD¿VK
and mouse models,  the  chemokine C­C motif  ligand­2 
(CCL2)­dependent  recruitment  of CCR2+ macrophages 
plays  a  critical  role  in  the mycobacterial  pathogenesis 
[44,  48]. Here we  found  that migration  in Matrigel  is 
mainly based on  chemoattraction mediated by  recom­
binant CCL5 but  not CCL2 or CCL4  (Supplementary 
information, Figure S6E). Despite  the  fact  that  the  ex­
pression of CCR2 and CCR5 was enhanced by cmMTB 
(Supplementary  information, Figure S1C),  and  that 
their  different  chemokine  ligands  are  strongly  secreted 
by Mtb­infected macrophages  [29, 34],  the depletion of 
&&/&&/DQG&&/ IURPFP07%GLGQRW VLJQL¿­
cantly  alter  their migration properties  (Supplementary 
information, Figure S6F). Since  the  activation program 
of macrophages modulates their 3D migration capacities 
[49], we hypothesized that  the enhanced cell motility in 
response to cmMTB might result from the acquisition of 
the M2­like phenotype. To  explore  this  possibility, we 
¿UVWFRQGLWLRQHGIUHVKO\LVRODWHGPRQRF\WHVZLWKFP&75
or  cmMTB,  and  then  tested  their migration  capacity  in 
0DWULJHOZLWKRXW D VSHFL¿F FKHPRDWWUDFWDQW&RPSDUHG
with  cmCTR­treated  cells,  those  treated with  cmMTB 
Figure 6 The CD16+&'+0HU7.+S67$7+ monocyte­mac­
rophages are associated with  a  permissive phenotype  to Mtb 
infection.  (A) Representative  confocal microscopy  images of 
CD16+ FHOOV UHG$OH[D LQ OXQJJUDQXORPDV IURP1+3
1LQIHFWHGE\0WEJUHHQ$OH[D:KLWHDUURZLQGLFDWHV
CD16+FHOOVFRQWDLQLQJ0WEEDFLOOLLQVHWVFDOHEDU µm). (B) 
Monocytes  conditioned with  cmCTR  (white  circles)  or  cmMTB 
EODFNFLUFOHVZHUHLQIHFWHGZLWK0WE2QGD\DQGGD\DIWHU
infection,  the  intracellular  growth of Mtb was  scored by  colo­
Q\IRUPLQJXQLW &)8DVVD\ (C) Monocytes  transfected with 
60$57SRROWDUJHWLQJ67$7VL67$7RUQRQWDUJHWLQJFRQWURO
VL51$VVL&75ZHUHFRQGLWLRQHGZLWKFP07%DQGWKHQLQIHFW­
HGZLWK0WE7KH&)8VFRULQJZDVPHDVXUHGRQGD\DQGGD\
DIWHULQIHFWLRQ5HVXOWVDUHH[SUHVVHGDVEHIRUHDQGDIWHUSORW
*P 
efficiently  infiltrated  and  remodeled Matrigel  (Supple­
mentary information, Figure S6G), indicating that acqui­
VLWLRQRI WKH0OLNHSKHQRW\SH LV VXI¿FLHQW WRHQKDQFH
3D migration  regardless  of  a  chemoattractant  gradient. 
Furthermore,  the Mtb­derived bystander  effect  can be 
mimicked when monocytes were  conditioned with  re­
cIL­10  (Supplementary  information, Figure S6H­S6I). 
Consistently, when STAT3 expression was  inhibited  in 
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these cells, or IL­10 was depleted from cmMTB, the pro­
tease­dependent migratory  capacity of  conditioned cells 
was  impaired  (Figure 5E, Supplementary  information, 
Figure S6I).
Since  the monocyte­macrophages  characterized by 
the CD16+CD163+MerTK+ signature are abundant in the 
7%SOHXUDOFDYLW\ZHDVVHVVHGZKHWKHU3(7%ÀXLGDF­
tivates the motility of these cells. For these experiments, 
ZHXVHGQRQ7%SOHXUDOÀXLG 3(QRQ7%DVDSRVLWLYH
control since it  is known to activate STAT3 and serve a 
chemoattractant  [50]. As  illustrated  in Figure 5F,  fresh­
ly  isolated monocytes  from healthy donors  displayed  a 
JUHDWHU FDSDFLW\ WR LQ¿OWUDWH0DWULJHOZKHQ3(7%DQG
PE­nonTB were used as chemoattractants.
Taken together, our analysis shows that the acquisition 
of CD16+CD163+MerTK+pSTAT3+  activation program 
via  the IL­10/STAT3 axis  triggers MMP­dependent mo­
tility  and allows human monocytes  to penetrate  and  re­
model dense tissue environments.
The CD16+CD163+MerTK+pSTAT3+ monocyte­macro­
phages are associated with a permissive phenotype  to 
Mtb infection
The migration of mononuclear phagocytes towards in­
fectious sites  is essential for effective control and clear­
ance of bacteria [51]. First, we observed that, among oth­
er  cell  types, CD16+  cells  in NHP  tuberculous granulo­
mas contained bacilli, implying that these leukocytes can 
be infected  in vivo  (Figure 6A). Since M2 macrophages 
are associated with pathogen permissivity [3], we evalu­
ated  the ability of monocytes conditioned with cmMTB 
or cmCTR, and then infected with Mtb, to control bacilli 
growth. CFU  scoring  at  four  hours  post  infection  (p.i.) 
revealed  that  there was no difference  in  the bacterial 
loads present in cmCTR­ and cmMTB­treated cells, sug­
gesting that soluble factors present in cmMTB do not af­
fect the recognition and uptake of the bacilli (Figure 6B). 
+RZHYHU FP07%WUHDWHG FHOOVZHUH VLJQL¿FDQWO\PRUH
permissive  to Mtb growth  than cmCTR­treated cells, as 
illustrated at day 5 p.i. (Figure 6B). Inhibition of STAT3 
by  siRNA­mediated gene  silencing  in  cmMTB­treated 
cells reversed their pathogen­permissive phenotype (Fig­
ure 6C, Supplementary information, Figure S7A). Simi­
lar results were obtained by an alternative approach using 
the pharmacological inhibition of STAT3 activation with 
STATTIC (Supplementary information, Figure S7B).
Collectively,  these  results  show  that  the CD16+C­
D163+MerTK+pSTAT3+  activation program acquisition 
renders human monocyte­macrophages more susceptible 
to intracellular bacterial growth.
The CD16+CD163+MerTK+pSTAT3+ monocyte­macro­
phages display immuno­modulatory properties
0PDFURSKDJHVSURJUDPPHGZLWK ,/7*)ȕRU
glucocorticoids  are  known as  “deactivators”  of  the  im­
mune response [28]. Among the features that distinguish 
these  cells  is  the  low production of  pro­inflammatory 
F\WRNLQHVHJ71)ĮDQG,/FRQWUDVWLQJZLWKKLJK
H[SUHVVLRQRI DQWLLQÀDPPDWRU\PHGLDWRUV HJ ,/
7*)ȕDQG*DV > @:H¿UVW DVVHVVHG WKH DELOLW\
of  cmMTB­conditioned  cells  to  engage production of 
LQÀDPPDWRU\VLJQDOVLQUHVSRQVHWRNLOOHG0WELQRUGHU
to  discriminate  the well­described  suppressive  effects 
using  live Mtb  [4]. Our  results  indicate  that,  compared 
with  cells  treated with  cmCTR,  those  conditioned with 
FP07%H[SUHVVHGOHVVSURLQÀDPPDWRU\JHQHVVXFKDV
TNF, IL12A and CCL1 (Supplementary information, Fig­
XUH6$7KHUHGXFHGVHFUHWLRQRI71)ĮZDVFRQ¿UPHG
in  the supernatant of cmMTB­treated cells (Supplemen­
tary  information, Figure S8B). Strikingly,  a weaker  ex­
pression of IL­10 was observed in contrast to the elevated 
level of GAS6 and PROS1,  in cells pretreated with cm­
MTB (Supplementary information, Figure S8A). Another 
feature that distinguishes deactivator macrophages is the 
poor ability to activate T cells [28]. To evaluate this, we 
¿UVW H[DPLQHG WKHSURJUDPPHGGHDWK OLJDQG 3'/
expression  relative  to  that  of CD86,  since  an  increased 
PD­L1/CD86 ratio in mononuclear phagocytes is report­
ed  to  inhibit T  cell  proliferation  and  interferon­gamma 
,)1ȖSURGXFWLRQ >@1RWLFHDEO\ZH IRXQG WKDW WKH
PD­L1/CD86 ratio was highly elevated in cmMTB­con­
ditioned  cells  compared with  cmCTR  treatment  (Figure 
7A, Supplementary  information, Figure S8C). Stimula­
tion with killed Mtb did not change this unbalanced ratio 
in cmMTB­conditioned cells (Figure 7A, Supplementary 
information, Figure S8C). Next, we measured the capac­
ity  of  cmMTB­conditioned monocyte­macrophages  to 
activate allogeneic human T cells, using peripheral blood 
lymphocytes  labeled with CFSE.  Importantly,  the  cm­
MTB­conditioned  cells  displayed  a  significantly  lower 
FDSDFLW\ WR VWLPXODWH7 FHOO SUROLIHUDWLRQ DQG ,)1ȖSUR­
duction in comparison with cmCTR­treated cells (Figure 
7A). While we only observed  a  tendency  towards  the 
reversion of  the unbalanced PD­L1/CD86  ratio  (Figure 
7B),  the  inhibition of STAT3 phosphorylation with  cu­
FXUELWDFLQ VLJQL¿FDQWO\ UHYHUWHG WKH FHOO VXUIDFH H[SUHV­
sion of PD­L1 in cmMTB­treated cells and their poor ca­
pacity to activate T cells (Figure 7B and Supplementary 
information, Figure S8D). To validate these observations 
in  vivo, we  examined whether monocyte­macrophages 
in TB patients  display  immunomodulatory properties. 
As  shown  in Figure 7C,  upon  stimulation with killed 
Mtb, monocytes from PB­TB displayed an elevated PD­
L1/CD86  ratio  compared with  those  from PB­HS.  In 
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addition, PB­TB monocytes exhibited a  lower ability  to 
LQGXFH7 FHOO SUROLIHUDWLRQ DQG WKHSURGXFWLRQRI ,)1Ȗ
in  allogeneic T  cells  compared with PB­HS monocytes 
(Figure 7C).
Taken together, these data demonstrate that the acqui­
sition of  the CD16+CD163+MerTK+pSTAT3+  activation 
program  is  characterized by  a  (i)  low  ratio  of  pro­/an­
WLLQÀDPPDWRU\ IDFWRUSURGXFWLRQ LLKLJK UDWLRRI3'
L1/CD86 co­stimulatory molecule  expression  and  (iii) 
poor capacity to activate T cells, which indicates a nega­
tive contribution to a dedicated host response against TB.
Discussion
TB mortality  is  unacceptably high given  that most 
deaths  are  preventable. The  identification of  new bio­
Figure 7 The CD16+&'+0HU7.+S67$7+ monocyte­macrophages display  immunomodulatory  properties.  (A­C) Mono­
F\WHVZHUHVWLPXODWHGZLWKNLOOHG0WERU3%6PRFN7RSSDQHOVYHUWLFDOVFDWWHUSORWVVKRZLQJWKHUDWLRRI0),REWDLQHGIRU
3'/DQG&'5HVXOWVDUHH[SUHVVHGDVPHDQ6(0%RWWRPSDQHOV DOORJHQHLFKXPDQ7 O\PSKRF\WHV ODEHOHGZLWK
&)6(ZHUHFRFXOWXUHGZLWKPRQRF\WHV%HIRUHDQGDIWHUSORWVVKRZLQJ7FHOOSUROLIHUDWLRQ LOOXVWUDWHGDV WKHSHUFHQWDJHRI
&)6(GLYLGLQJFHOOVOHIWDQGWKHSURGXFWLRQRI,)1ȖE\SUROLIHUDWLQJ7FHOOVTXDQWL¿HGE\(A­B)(/,6$LQFRFXOWXUHVXSHUQD­
tants or (C)ÀRZF\WRPHWU\ULJKW(A)FP&75RUFP07%FRQGLWLRQHGPRQRF\WHVZHUHVWLPXODWHGZLWK3)$NLOOHG0WERU3%6
(mock). (B)FP07%FRQGLWLRQLQJRIPRQRF\WHVZDVSHUIRUPHGLQWKHSUHVHQFHRIWKH67$7LQKLELWRUFXFXUELWDFLQ,&&%RU
'062DVFRQWURO&HOOVZHUHWKHQVWLPXODWHGZLWK3)$NLOOHG0WERUPRFN(C)0RQRF\WHVIURP+6RU7%SDWLHQWVZHUHVWLP­
ulated with irradiated Mtb or mock. *P P (DFKFLUFOHZLWKLQYHUWLFDOVFDWWHUSORWVUHSUHVHQWVDVLQJOHGRQRU
markers  that could reduce  the size and duration of clin­
ical  trials  of  new drug  candidates  and define  treatment 
efficacy,  disease  activity,  cure  and  relapse,  is  highly 
desirable  to  reduce  the  impact  of TB. Considering  that 
the monocyte compartment is perturbed in TB, we asked 
whether  this  shift  is  beneficial  or  detrimental  to  host 
defense  against TB,  and whether  this  could  represent  a 
target  for  treatment. We believe  that  this  study makes 
four major contributions to the interface between hypoth­
esis­driven basic  research  and  the  identification of  po­
tential  bio­signatures  and molecular markers  for  human 
disease (Figure 8). 
First, we present evidence for how human monocytes 
are predisposed in the context of TB towards an anti­in­
flammatory M2­like  (CD16+CD163+MerTK+pSTAT3+) 
macrophage activation program, a process that is mainly 
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dependent  on  the  IL­10/STAT3  signaling pathway. This 
phenotype can also be obtained in vitro using the secre­
tome of Mtb­infected macrophages. We provide  a  new 
set  of markers  to  characterize  this M2­like  activation 
program in  terms of hallmark cell­surface markers  (i.e., 
CD16+, CD163+  and MerTK+),  the  transcription  factor 
67$7 F\WRNLQH FRQWHQW HJ71)Įlow),  chemokines 
receptors  (i.e., CCR2high  and CCR5high),  co­stimulatory 
molecules  (i.e.,  PD­L1high  and CD86low)  and MMP  (i.e., 
MMP1high and MMP9high). Interestingly, we also detected 
CD206 expression as part of the described M2­like phe­
notype, which was independent of the IL­10/STAT3 axis. 
Since CD206 is known to be dependent of STAT6 signal­
ing  [53],  it  is probable  that alternative signals  (e.g.,  IL­
Figure 8 Model  illustrating how  the environment  induced by Mtb  infection predisposes human monocyte differentiation  to­
ZDUGVDQ0OLNHPDFURSKDJHDOWHULQJKRVWGHIHQVHGXULQJLQIHFWLRQ$OYHRODUPDFURSKDJHVDUHRQHRIWKH¿UVWOHXNRF\WHV
DEOH WR UHFRJQL]HDQGSKDJRF\WRVH0WEXSRQHQWU\ LQ WKH UHVSLUDWRU\ V\VWHP$W WKLV VLWH LQIHFWHGPDFURSKDJHV UHVKDSH
their microenvironment by secreting many soluble factors  including cytokines and chemokines, which for the most part are 
UHVSRQVLEOHIRUWKHOHXNRF\WHLQ¿OWUDWLRQGXULQJWKHHDUOLHVWVWDJHVRILQIHFWLRQ+RZHYHU0WEKDVWKHFDSDFLW\WRPRGXODWH
WKHPDFURSKDJHUHVSRQVHDQGWRLQGXFHWKHVHFUHWLRQRIDQWLLQÀDPPDWRU\F\WRNLQHVVXFKDV,/,/WLOWVWKURXJKDE\­
stander effect, monocytes towards an M2­like macrophage program (CD16+&'+0HU7.+S67$7+LQD67$7GHSHQGHQW
PDQQHU,QWKHEORRG&'DQG0HU7.UHFHSWRUVDUHFOHDYHGRIIDQGFRQFHQWUDWLRQRIWKHLUVROXEOHIRUPFRUUHODWHVSRVLWLYH­
ly with disease severity. The CD16+&'+0HU7.+S67$7+SKHQRW\SHDFTXLVLWLRQLVDFFRPSDQLHGE\DQHQKDQFHGSUR­
tease­dependent motility through matrix metalloprotease activity (e.g., MMP­1), which allows extracellular matrix remodeling, 
DQGK\SRWKHWLFDOO\WUDQVWLVVXODUPLJUDWLRQ7KLVSKHQRW\SHDFTXLVLWLRQDOVRUHQGHUVPRQRF\WHPDFURSKDJHVSHUPLVVLYHWR
0WELQWUDFHOOXODUJURZWKDQGLPPXQRPRGXODWRU\LQWHUPVRIWKHLUUHGXFHGDELOLW\WRVHFUHWHSURLQÀDPPDWRU\F\WRNLQHVHJ
ORZ71)ĮDQGDFWLYDWHWKH7KHOSHU7KUHVSRQVHYLDFRVWLPXODWRU\VLJQDOLQJHJKLJKUDWLR3'/&'&ROOHFWLYHO\
WKH0WEGHULYHGE\VWDQGHUDFWLYDWLRQRI67$7LQPRQRF\WHVSUHGLVSRVHVWKHLUGLIIHUHQWLDWLRQSURJUDPWRZDUGVDPDFURSKDJH
population  that ultimately shifts  the microenvironment  (e.g.,  tuberculous granulomas)  in  favor of microbial  resilience  in  the 
host.
 ,/DQG ,)1ĮZKLFKDUHSDUWRI WKH VHFUHWRPHRI
Mtb­infected macrophages,  are  partially  responsible  for 
the  establishment  of  this M2­like phenotype. Neverthe­
less,  in our  in vitro model,  the blocking of  IL­10  in  the 
0WEGHULYHGFRQGLWLRQHGPHGLDVHHPVWREHVXI¿FLHQWWR
impair STAT3 activation  and  the  establishment  of M2­
like phenotype. This is in line with the fact that IL­10 is 
considered to be an important clinical biomarker of dis­
ease progression  [54],  increased  levels  for  this cytokine 
are reported  in both  the blood [31, 55] and  in  the bron­
choalveolar lavage of active TB patients [56], and in the 
tuberculous granuloma context  in NHP model [57]. The 
fact that we observed elevated levels of activated STAT3 
in monocyte­macrophages in both TB patients and in the 
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NHP tuberculous granuloma context, suggests that over­
active production of IL­10 may be responsible. It remains 
to be seen whether activation of STAT3 by other signals, 
such as IL­6 or IL­27, generates a similar activation pro­
gram with critical consequences for TB pathogenesis and 
RWKHUFKURQLFLQÀDPPDWRU\GLVHDVHV
Second, mainly based on our  in  vitro  approach, we 
characterized key  functional  properties  for  the human 
CD16+CD163+MerTK+pSTAT3+ monocyte­macrophages. 
To begin, we provided evidence  that  these cells display 
an  enhanced  capacity  to migrate  through dense matri­
ces  in  an MMP­dependent manner  contrasting with our 
previous observations  that  3D migration  in  dense ma­
trices  rather  involves cathepsins  [45, 47, 58, 59]. While 
we  cannot  exclude  that  chemokines present  in  cmMTB 
could be involved in the migration capacity of CD16+C­
D163+MerTK+pSTAT3+ monocyte­macrophages, we 
showed  that STAT3­dependent  acquisition of  the M2­
like phenotype is essential for the enhanced motility and 
extracellular matrix  remodeling  activity  in  these  cells. 
This  process  is  accompanied by MMP1 and MMP9 
activity  that may  contribute  to  lung  tissue damage  and 
TB pathogenesis, as suggested by  the  formation of pro­
tease­mediated tunnels in 3D matrices [47, 60, 61], by a 
study demonstrating that MMP1 is increased during Mtb 
infection  and  is  responsible  for  lung  immunopathology 
[62], and by other reports evidencing the role of MMP9 
in  the  recruitment  of macrophages,  granuloma matura­
tion and bacterial dissemination [44]. This is an exciting 
finding given  that,  in  the  zebrafish  and mouse models, 
mycobacteria  infection  recruits  highly motile macro­
phages as a tool for bacterial dissemination [44, 48]. An­
other  functional  characteristic  described  in  this  study  is 
the permissive nature of CD16+CD163+MerTK+pSTAT3+ 
cells  to handle Mtb  intracellular growth. To our knowl­
HGJHRXUVWXG\LVWKH¿UVWWRGHPRQVWUDWHWKDWDEURJDWLRQ
of STAT3 in monocyte­macrophages restores the control 
of Mtb  intracellular  growth. Actually, STAT3 has been 
shown  to block phagolysosome fusion,  induction of au­
tophagy, and optimal release of nitric oxide and reactive 
oxygen  species  [63]. However,  the  regulation of  these 
microbicidal activities by STAT3 has yet to be explored 
for TB  [63]. This  is  in  line with  the  antagonistic  effect 
of IL­10 on microbicidal activities of Mtb­infected mac­
rophages, such as phagosome­lysosome fusion [63, 64], 
DQG ,)1ȖLQGXFHGSURGXFWLRQRI R[\JHQ DQGQLWURJHQ
species  [65]. Likewise, mice overexpressing  IL­10  spe­
FL¿FDOO\LQWKHPDFURSKDJHFRPSDUWPHQWSUHVHQWVXVFHS­
tibility  to Mtb  infection due  to macrophages displaying 
an  exaggerated M2­like  activation program associated 
with a high pulmonary bacterial load [66]. In parallel, we 
also demonstrate  that CD16+CD163+MerTK+pSTAT3+ 
monocyte­macrophages display  an  immunomodulatory 
IXQFWLRQDO FDSDFLW\%HVLGHV WKHGLPLQLVKHGSURLQÀDP­
matory  cytokine  response, CD16+CD163+MerTK+p­
STAT3+  cells  also display  a  high PD­L1  to CD86  ratio 
and tolerant capacity to control T cell activation. This is 
in accordance with different reports showing that STAT3 
LVDNH\DQWLLQÀDPPDWRU\PHGLDWRUWKDWLQKLELWVLPSRUW­
ant  pro­inflammatory processes  [36,  63]. For  instance, 
PLFHGH¿FLHQWIRUWKH,/UHFHSWRUD67$7DFWLYDWRU
H[KLELWHGDQXQFRQWUROOHGSURGXFWLRQRISURLQÀDPPDWR­
U\F\WRNLQHVHOHYDWHG OHYHOVRI ,)1ȖSURGXFLQJ7FHOOV
enhanced macrophage  effector  functions  and  reduced 
bacterial  loads,  in  response  to Mtb  infection. Yet,  these 
animals eventually succumb to uncontrolled immunopa­
thology [67]. In a reciprocal case, a mouse with targeted 
deletion  in  the myeloid compartment  for  the suppressor 
of  cytokine  signaling­3  (SOCS3), which  is  known  to 
inhibit STAT3,  showed  increased  susceptibility  to Mtb 
infection [68]. On the basis of these functional observa­
tions,  our  study provides  an original  biological  context 
to further understand at the molecular level how STAT3 
activity  grants  protease­dependent migration  capacity 
and  inhibits  antimycobacterial  effector mechanisms, 
consequently  opening up new venues  to  investigate 
how  it might  contribute  to  tissue  remodeling,  pathogen 
dissemination  and  immunomodulation. Beyond  the  im­
munomodulatory  capacity  (Figure 7C),  it  remains  to be 
shown whether  this  IL­10/STAT3­dependent  functional 
program  is  truly  established during  the  expansion of 
CD16+CD163+MerTK+pSTAT3+ monocyte­macrophages 
in patients with active TB.
The third major contribution from this study concerns 
the  critical  correlation of  the  abundance of CD16+C­
D163+MerTK+pSTAT3+ monocyte­macrophages with the 
severity of TB disease  in  the human and NHP contexts. 
Recent studies by Zizzo et al. [25, 69] suggested a strict 
correlation between systemic lupus erythematosus (SLE) 
disease severity and the activation of an M2­like macro­
phage  characterized by CD163  and MerTK expression 
during  the monocyte­to­macrophage differentiation. 
Expanding upon our previous observation that the mono­
cyte compartment becomes perturbed in TB patients [18], 
we now  report  that  the CD163+MerTK+pSTAT3+  sig­
nature  accompanies  the  expansion of  the CD16+ mono­
F\WHV$VWKHVHUHVXOWVFRQWUDVWZLWKWKHSURLQÀDPPDWRU\
phenotype of CD16+ monocytes  in  healthy donors  [13, 
15­17], we  infer  that  all CD16+ monocytes  are  not  cre­
ated in a similar manner, and thus the CD16 expression 
in monocyte­macrophages  cannot  be  extrapolated  to 
indicate  a  pro­  or  anti­inflammatory nature. Their  final 
differentiation program might result as a consequence of 
the microenvironment shaped in health and disease pro­
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gression contexts. In agreement with a recent description 
of CD163+ macrophages during the onset of tuberculous 
pleurisy  [70], we show that  this M2­like macrophage  is 
particularly  enriched within  the CD14+CD16+  cell  pop­
ulation  isolated  from  the pleural  cavity  of TB patients. 
Considering  that  the CD16+ population  expansion dis­
plays an M2­like phenotype in the pleural cavity from TB 
patients,  and  that TB pleural  effusion  activates STAT3 
phosphorylation  in monocytes  from healthy donors  and 
stimulates  their  protease­dependent migration, we  infer 
that the environmental signals within Mtb infection sites 
perpetuate the CD16+CD163+MerTK+pSTAT3+ activation 
program and possibly  also  serve  as  chemoattractant. At 
the tissue level, although there are key reports integrating 
the concept of macrophage activation within tuberculous 
granulomas  [41,  42],  to  our  knowledge  this  is  the  first 
study to identify the CD16+CD163+MerTK+ macrophage 
activation program along with  the co­localization of ac­
tivated STAT3. Beyond the detection of CD163, we now 
provide  a  novel marker  signature  composed of CD16, 
MerTK and activated STAT3, which could be helpful to 
identify  the  anti­inflammatory  and  immunomodulatory 
macrophage program  in  the progression of TB disease. 
Based on  the known  inhibitory  role  for  IL­10  in  the 
formation of  protective mature  granulomas during Mtb 
infection  [63,  71],  the presence of  these  cells may  rep­
resent a cellular indicator of granulomas that foment the 
expansion and dissemination of disease [41, 44]. Indeed, 
human CD16+CD163+MerTK+pSTAT3+ macrophages 
meet  the criteria  for  the formation of pathogenic granu­
ORPDVPDLQO\GHVFULEHGLQWKH]HEUD¿VKPRGHOVHFUHWLRQ
of MMPs involved in granuloma formation (i.e., MMP1 
and MMP9), high protease­dependent motility, pathogen 
permissiveness and immunomodulatory capacity to regu­
ODWHDSURLQÀDPPDWRU\HQYLURQPHQW>@)RUH[DPSOH
the monocyte  predisposition  towards M2­like macro­
phage program alters  protective granuloma  formation 
during Schistosoma mansoni infection, which indicates a 
general  process  contributing  to  granulomatous diseases 
[72]. On the basis of these observations, we propose that 
the unbalanced monocyte compartment  in TB is predis­
SRVHGWRGLIIHUHQWLDWHWRZDUGVWKHDQWLLQÀDPPDWRU\0
like macrophages  as  a  continuously  failed  attempt  by 
the host  to limit  immunopathology, whose abundance is 
directly related to the severity of TB disease, ultimately 
contributing to the establishment of chronic infection.
The  last major  contribution of  this  study  is  the  iden­
WL¿FDWLRQRI VROXEOH IRUPRI&' DV D SRWHQWLDO ELR­
marker  to monitor,  in combination with actual and next 
to be discovered biomarkers, TB disease progression and 
DQWL7%WUHDWPHQWHI¿FDF\8QOLNHWKH&'+CD16+ cell 
population found in the pleural cavity, we failed to detect 
CD163 as part of the cell­surface marker signature in cir­
culating monocytes  in TB patients. This was an intrigu­
ing observation  as  circulating monocytes  from TB pa­
tients still displayed high level of phosphorylated STAT3 
and immunomodulatory potential in terms of high PD­L1 
to CD86 expression  ratio along with a poor capacity  to 
activate  allogeneic T  cells. The detection of  sCD163  in 
TB patients reconciled these observations, as monocytes 
are the only circulating cell population known to express 
CD163 and MerTK [38, 73]. Indeed, the plasma level of 
these soluble receptors correlated with TB disease sever­
LW\LQSDWLHQWVDQGXSRQDQWL7%WUHDWPHQWLWVLJQL¿FDQW­
ly decreased  to  the plasma concentration  level obtained 
from contact  individuals. As  sCD163  shows optimal 
VHQVLWLYLW\DQGVSHFL¿FLW\DFFRUGLQJWRWKH52&DQDO\VLV
provided in the TB context, we thus propose this soluble 
receptor,  in combination with actual diagnosis tools and 
next to be discovered molecules, as a potential biomarker 
to  evaluate  disease progression  and predict  drug  treat­
ment outcome. In a second step, these results need to be 
FRQ¿UPHG LQ D ODUJHU FRKRUW RI LQGLYLGXDOV IURPGLIIHU­
ent genetic background.  Indeed,  there  is only one study 
that  correlated  the plasma  concentration of  sCD163  to 
WKHVXUYLYDORIYHUL¿HG7%SDWLHQWV>@+RZHYHUWKHUH
KDVEHHQQRFRQ¿UPDWLRQRIWKHVHUHVXOWVHYHUVLQFHDQG
more importantly, there is no actual evaluation available 
on  the  effect  of  anti­TB drugs on  sCD163  levels  until 
now.  Interestingly,  sCD163  is  considered  as  a  valuable 
marker of the activation of an M2­like monocyte­macro­
phage program and biomarkers of disease activity in SLE 
>@DOOXGLQJWRDFULWLFDOELRORJLFDOVLJQL¿FDQFHIRU
the presence of this soluble receptor as immune response 
biomarkers in TB disease. 
In  conclusion,  our  study provides  a  novel  cellular 
FRQWH[WDORQJZLWKLGHQWL¿FDWLRQRIPROHFXOHVDQGSDWK­
ways, which may  fuel  new  research venues  concerning 
monocyte­macrophages  in  the TB context. Newly  rec­
ommended guidelines  for  the nomenclature of  the mac­
rophage activation process are based on three principles: 
source of macrophages,  definition of  activators  and  a 
consensus collection of markers to describe macrophage 
activation [23]. On the basis of these guidelines, the hu­
man CD16+CD163+MerTK+pSTAT3+ activation program 
described  in  this study within  the TB context  is  reason­
ably  related  to  the proposed  “M(IL­10)” nomenclature. 
However, in a pathological context, multiple signals can 
activate STAT3­dependent  signaling pathways  (e.g.,  IL­
6, IL­23 and IL­27) [36, 63]. Consequently, it remains to 
be determined whether they activate STAT3 in a similar 
fashion  as  IL­10  to  specifically  establish  the TB­asso­
ciated CD16+CD163+MerTK+pSTAT3+ phenotype  and 
functional  profile  reported  in  this  study;  if  so,  the no­
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menclature “M(STAT3)” would be a way to subsume the 
phenotype and functions of cells belonging to STAT3­de­
pendent  activation program(s).  Interestingly,  global 
biomarker  studies  are  sometimes  criticized  as  being 
non­hypothesis driven [2]. We believe that the functional 
characterization of  this M(IL­10)­like program,  and  its 
critical in vivo assessment in TB patients and NHP tuber­
FXORXVJUDQXORPDV DGGV D VLJQL¿FDQW SDWKRORJLFDO FRQ­
text to the biomarker potential of sCD163. Finally, since 
immune impairment is usually observed in patients with 
chronic  infections,  and given  that  the STAT3 activity 
grants a  tolerance capacity  to  the myeloid compartment 
[36], we  estimate  that  short­term blockade of STAT3 
within  the monocyte­to­macrophage differentiation 
program has  the potential  to modulate mechanisms of 
disease tolerance and restore the antimicrobial immunity. 
STAT3  inhibitors,  currently  assessed  in  phase  I  clinical 
trials for their antitumor effects [74, 75], might be partic­
ularly useful in patients with TB meningitis, for example, 
who  fail  to  control mycobacterial  proliferation because 
of  intrinsic exacerbation of  immune suppression, and  in 
which dexamethasone  treatment  has  deleterious  effects 
[76].
0DWHULDOVDQG0HWKRGV
Human and NHP samples
Studies involving human samples from healthy donors and TB 
patients, and samples from NHPs were performed in accordance to 
guidelines approved by all indicated Ethical committees; see Sup­
plementary information, Data S1.
Preparation of  human monocytes  and monocyte­derived 
macrophages
Monocytes from healthy donors and from TB patients were iso­
lated by CD14 positive magnetic  labeling  and differentiated  into 
macrophages as previously described [18, 37, 45]; see Supplemen­
tary information, Data S1. 
Preparation of conditioned media and monocyte treatment
The cmMTB medium was prepared  from Mtb­infected mono­
cyte­derived macrophages at a multiplicity of  infection  (MOI) of 
three bacteria per cell, in RPMI 1640 (Gibco) containing 10% FBS 
(Sigma­Aldrich). The  cmCTR medium was obtained  from unin­
fected macrophages. After overnight  incubation at 37 °C, culture 
media were  collected,  sterilized by  filtration  and  aliquots were 
VWRUHG DWí &)RU FRQGLWLRQLQJ KXPDQ&'+  sorted mono­
cytes were allowed to adhere for 1 h on glass coverslips in the ab­
sence of serum and then cultured for 3 days with 50% dilution of 
cmMTB or cmCTR containing M­CSF (Peprotech, 10 ng/ml) and 
10% FBS. Cell surface expression of macrophage activation mark­
ers (Supplementary information, Table S4), and bacterial intracel­
lular growth, were measured using standard procedures detailed in 
Supplementary information, Data S1.
3D migration assays
3D migration  assays were performed  as  previously described 
>@%ULHÀ\¿EULOODUFROODJHQ,JHOOHGFROODJHQ,RU0DWULJHOZDV
polymerized in transwell inserts and used immediately. Cells were 
seeded on  top of matrices,  the  lower chamber of each  insert was 
¿OOHGZLWKDGLOXWLRQRIFP07%RUFP&75LQFRPSOHWHPH­
dium or with complete medium supplemented with recIL­10. Cell 
PLJUDWLRQLQWR¿EULOODUFROODJHQ,ZDVTXDQWL¿HGDIWHUKZKHUH­
as the migration in dense matrices (Matrigel or gelled collagen I) 
ZDVTXDQWL¿HG DIWHU K7KHSHUFHQWDJHRI FHOOPLJUDWLRQZDV
obtained as the ratio of cells within the matrix to the total number 
of counted cells as described [45].
$VVHVVPHQWRIWKHLQÀDPPDWRU\F\WRNLQHUHVSRQVHDQGDFWL­
vation of T cells
7RWDO51$VZHUHUHYHUVHWUDQVFULEHGDQGDPSOL¿HGDVGHWDLOHG
in Supplementary  information, Data S1. Primers  for  qPCR are 
listed in Supplementary information, Table S5. The mRNA content 
was normalized to the metastatic lymph node protein 51 (MLN51) 
P51$DQGTXDQWL¿HGXVLQJWKH¨¨&WPHWKRG6HFUHWHG71)ĮDQG
IL­10 were measured by ELISA. Activation of allogeneic T cells 
was evaluated in mixed lymphocyte reactions including cell prolif­
HUDWLRQE\ÀRZF\WRPHWU\DQGVHFUHWHG,)1ȖDQDO\VLVE\(/,6$RU
ÀRZF\WRPHWU\
Plasma biomarker measurements
Concentrations of  soluble  sCD163  and  sMer  (R&D system 
DuoSet) were  assessed  in  cryopreserved human  serum  samples 
PDLQWDLQHGDWí&DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQ
For sCD163 analysis, the serum was diluted at 1/10, and for sMer 
at 1/2, in PBS.
Statistical analyses
One­tailed paired or  unpaired  t­test was  applied on data  sets 
with  a  normal  distribution, whereas  one­tailed Mann­Whitney 
(unpaired test) or Wilcoxon (matched­paired test) tests were used 
otherwise. P ZDV FRQVLGHUHG VWDWLVWLFDOO\ VLJQL¿FDQW&RU­
relations were  evaluated using  the Pearson’s  test.  For  biomarker 
measurements, a ROC curve was generated. The AUC value and 
&,ZHUHFDOFXODWHGWRGHWHUPLQHWKHVSHFL¿FLW\DQGVHQVLWLY­
ity of TB infection. All statistical analyses were performed using 
GraphPad Prism 6.0 (GraphPad Software Inc., USA).
$FNQRZOHGJPHQWV
This work was  supported by  the CNRS,  the European Union 
(ERA­NET/ERASysBio grant TB­HOST­NET,  and FP7 grants 
HEALTH­F4­2011­282095­TARKINAID and 241745 NEWTB­
VAC),  the French National Research Agency (ANR grants 2010­
01301 MigreFlame and ANR­12­BSV3­0002 B­TB) and by Fon­
dation pour  la Recherche Médicale  (FRM, DEQ 20110421312). 
CL  (FDT 20130928326) and GL­V (SPF20110421334) acknowl­
edge support from FRM; AB acknowledges support from ANR­12­
BSV3­0002. FAWV acknowledges support from Aeras (Rockville, 
MD, USA) for  the NHP study. This work was also partially sup­
ported by the PICT 2012­0221 and PICT 2011­0572 grants given 
E\ WKH$JHQFLD1DFLRQDOGH3URPRFLyQ&LHQWt¿FD\7HFQROyJLFD
Argentina. 
5HIHUHQFHV
Claire Lastrucci et al.
1349
npg
www.cell­research.com | Cell Research
1   Wallis RS, Kim P, Cole S, et al. Tuberculosis biomarkers dis­
covery:  developments,  needs,  and  challenges. Lancet  Infect 
Dis 2013; 13:362­372.
2   Kaufmann SH, Parida SK. Tuberculosis  in Africa:  learning 
IURPSDWKRJHQHVLVIRUELRPDUNHULGHQWL¿FDWLRQCell Host Mi­
crobe 2008; 4:219­228.
3   Benoit M, Desnues B, Mege JL. Macrophage polarization in 
bacterial infections. J Immunol 2008; 181:3733­3739.
4   Lugo­Villarino G, Verollet C, Maridonneau­Parini  I, Ney­
rolles O. Macrophage polarization: convergence point target­
ed by mycobacterium  tuberculosis  and HIV. Front  Immunol 
2011; :43.
5   Flynn JL, Chan J, Lin PL. Macrophages and control of gran­
ulomatous  inflammation  in  tuberculosis. Mucosal  Immunol 
2011; 4:271­278.
6   Martinez FO, Gordon S. The M1 and M2 paradigm of mac­
rophage  activation:  time  for  reassessment. F1000prime Rep 
2014; 6:13.
7   Lugo­Villarino G, Neyrolles O. Manipulation of the mononu­
clear phagocyte system by Mycobacterium tuberculosis. Cold 
Spring Harb Perspect Med 2014; 4: a018549.
8   O’Garra A, Redford PS, McNab FW, et al. The  immune  re­
sponse in tuberculosis. Annu Rev Immunol 2013; 31:475­527.
9   Cambier CJ, Falkow S, Ramakrishnan L. Host  evasion  and 
exploitation  schemes of Mycobacterium  tuberculosis. Cell 
2014; :1497­1509.
10   Wong KL, Yeap WH, Tai JJ, et al. The three human monocyte 
subsets:  implications  for  health  and disease.  Immunol Res 
2012; :41­57.
11   Robbins CS, Swirski FK. The multiple roles of monocyte sub­
VHWVLQVWHDG\VWDWHDQGLQÀDPPDWLRQCell Mol Life Sci 2010; 
67:2685­2693.
12   Ziegler­Heitbrock L. The CD14+ CD16+ blood monocytes: 
WKHLUUROHLQLQIHFWLRQDQGLQÀDPPDWLRQJ Leukoc Biol 2007; 
81:584­592.
13   Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, 
Ziegler­Heitbrock HW. Differential  cytokine  expression  in 
human blood monocyte  subpopulations:  a  polymerase  chain 
reaction analysis. Blood 1996; 87:373­377.
14   Frankenberger M, Hofer TP, Marei A, et al7UDQVFULSWSUR¿O­
ing of CD16­positive monocytes  reveals  a unique molecular 
¿QJHUSULQWEur J Immunol 2012; :957­974.
 6]DÀDUVND$%DM.U]\ZRU]HND06LHGODU0 et  al. Antitu­
mor  response of CD14+/CD16+ monocyte  subpopulation. 
Exp Hematol 2004; :748­755.
16   Belge KU, Dayyani F, Horelt A, et al7KHSURLQÀDPPDWRU\
CD14+CD16+DR++ monocytes are a major source of TNF. J 
Immunol 2002; 168:3536­3542.
17   Aguilar­Ruiz SR, Torres­Aguilar H, Gonzalez­Dominguez E, 
et  al. Human CD16+ and CD16­ monocyte  subsets  display 
XQLTXHHIIHFWRUSURSHUWLHVLQLQÀDPPDWRU\FRQGLWLRQVin vivo. 
J Leukoc Biol 2011; :1119­1131.
18   Balboa L, Romero MM, Basile  JI, et al. Paradoxical  role of 
CD16+CCR2+CCR5+ monocytes  in  tuberculosis:  efficient 
APC  in pleural  effusion but  also mark disease  severity  in 
blood. J Leukoc Biol 2011; :69­75.
19   Balboa L, Romero MM, Laborde E, et al. Impaired dendritic 
cell differentiation of CD16­positive monocytes in tuberculo­
sis: role of p38 MAPK. Eur J Immunol 2013; 43:335­347.
20   Tung YC, Ou TT, Tsai WC. Defective Mycobacterium tuber­
culosis  antigen presentation by monocytes  from  tuberculosis 
patients. Int J Tuberc Lung Dis 2013; 17:1229­1234.
21   Skold M, Behar SM. Tuberculosis triggers a tissue­dependent 
program of  differentiation  and  acquisition of  effector  func­
tions by  circulating monocytes. J  Immunol  2008; 181:6349­
6360.
22   Remoli ME, Giacomini E, Petruccioli E, et  al. Bystander 
inhibition of dendritic  cell differentiation by Mycobacterium 
tuberculosis­induced IL­10. Immunol Cell Biol 2011; :437­
446.
23   Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation 
and polarization:  nomenclature  and  experimental  guidelines. 
Immunity 2014; 41:14­20.
24   Calzada­Wack JC, Frankenberger M, Ziegler­Heitbrock HW. 
Interleukin­10 drives  human monocytes  to CD16 positive 
macrophages. -,QÀDPP 1996; 46:78­85.
25  Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient 
clearance of  early  apoptotic  cells  by human macrophages 
requires M2c polarization and MerTK  induction. J  Immunol 
2012; :3508­3520.
26   Sironi M, Martinez FO, D’Ambrosio D, et  al. Differential 
regulation of  chemokine production by Fcgamma  receptor 
engagement  in human monocytes: association of CCL1 with 
a distinct  form of M2 monocyte activation (M2b, Type 2). J 
Leukoc Biol 2006; :342­349.
27   Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization pro­
¿OHVRIKXPDQ0&6)JHQHUDWHGPDFURSKDJHVDQGFRPSDUL­
son of M1­markers in classically activated macrophages from 
GM­CSF and M­CSF origin. Cell Immunol 2013; :51­61.
28   Mantovani A, Sica A, Sozzani S, et al. The chemokine system 
in diverse  forms of macrophage  activation  and polarization. 
Trends Immunol 2004; :677­686.
29   Verreck FA, de Boer T, Langenberg DM, van der Zanden L, 
2WWHQKRII7+3KHQRW\SLFDQGIXQFWLRQDOSUR¿OLQJRIKXPDQ
proinflammatory  type­1  and  anti­inflammatory  type­2 mac­
rophages in response to microbial antigens and IFN­gamma­ 
and CD40L­mediated  costimulation. J Leukoc Biol  2006; 
:285­293.
30   Verreck FA,  de Boer T, Langenberg DM,  et  al. Human 
IL­23­producing type 1 macrophages promote but IL­10­pro­
ducing type 2 macrophages subvert immunity to (myco)bacte­
ria. Proc Natl Acad Sci USA 2004; :4560­4565.
31   Olobo JO, Geletu M, Demissie A, et al. Circulating TNF­al­
pha, TGF­beta, and IL­10 in tuberculosis patients and healthy 
contacts. Scand J Immunol 2001; :85­91.
32   Liang L, Zhao YL, Yue J, et al. Interleukin­10 gene promoter 
SRO\PRUSKLVPV DQG WKHLU SURWHLQSURGXFWLRQ LQ SOHXUDOÀXLG
in patients with tuberculosis. FEMS Immunol Med Microbiol 
2011; :84­90.
33   Roodgar M, Lackner A, Kaushal D, et al. Expression  levels 
of 10 candidate genes in lung tissue of vaccinated and TB­in­
fected cynomolgus macaques. J Med Primatol 2013; :161­
164.
34   Wang C, Peyron P, Mestre O, et al. Innate immune response 
to Mycobacterium  tuberculosis Beijing  and other genotypes. 
PLoS One 2010; :e13594.
35   Szanto A, Balint BL, Nagy ZS, et  al.  STAT6  transcription 
factor is a facilitator of the nuclear receptor PPARgamma­reg­
1350
A unique CD16+ monocyte­macrophage expansion in tuberculosisnpg
Cell Research | Vol 25 No 12 | December 2015 
ulated gene  expression  in macrophages  and dendritic  cells. 
Immunity 2010; 33:699­712.
36   Lang R. Tuning of macrophage  responses by Stat3­inducing 
cytokines: molecular mechanisms and consequences in infec­
tion. Immunobiology 2005; :63­76.
37   Troegeler A, Lastrucci C, Duval C, et  al. An  efficient  siR­
NA­mediated gene  silencing  in  primary human monocytes, 
dendritic  cells  and macrophages.  Immunol Cell Biol  2014; 
:699­708.
38   Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage 
scavenger  receptor CD163.  Immunobiology  2005; :153­
160.
39   Zagorska A, Traves PG, Lew ED, Dransfield  I, Lemke G. 
'LYHUVL¿FDWLRQRI7$0UHFHSWRUW\URVLQHNLQDVHIXQFWLRQNat 
Immunol 2014; :920­928.
40   Knudsen TB, Gustafson P, Kronborg G, et al. Predictive value 
of soluble haemoglobin scavenger receptor CD163 serum lev­
HOVIRUVXUYLYDOLQYHUL¿HGWXEHUFXORVLVSDWLHQWVClin Microbi­
ol Infect 2005; 11:730­735.
41   Lugo­Villarino G, Hudrisier D, Benard A, Neyrolles O. 
Emerging trends in the formation and function of tuberculosis 
granulomas. Front Immunol 2012; 3:405.
42   Mattila  JT, Ojo OO, Kepka­Lenhart D, et  al. Microenviron­
ments  in  tuberculous granulomas  are  delineated by distinct 
populations of macrophage  subsets  and  expression of  nitric 
oxide  synthase  and  arginase  isoforms. J  Immunol  2013; 
:773­784.
43   Cambier CJ, Takaki KK, Larson RP, et al. Mycobacteria ma­
nipulate macrophage  recruitment  through coordinated use of 
membrane lipids. Nature 2014; :218­222.
44   Ramakrishnan L. Revisiting  the role of  the granuloma in  tu­
berculosis. Nat Rev Immunol 2012 :352­366.
45   Van Goethem E, Poincloux R, Gauffre F, Maridonneau­Parini 
I, Le Cabec V. Matrix architecture dictates three­dimensional 
migration modes of human macrophages: differential involve­
ment  of  proteases  and podosome­like  structures. J  Immunol 
2010 184:1049­1061.
46   Cougoule C, Le Cabec V, Poincloux R, et  al. Three­dimen­
sional migration of macrophages requires Hck for podosome 
organization and extracellular matrix proteolysis. Blood 2010; 
:1444­1452.
47   Maridonneau­Parini  I. Control of macrophage 3D migration: 
a  therapeutic  challenge  to  limit  tissue  infiltration.  Immunol 
Rev 2014; :216­231.
48   Antonelli LR, Gigliotti Rothfuchs A, Goncalves R, et al.  In­
tranasal Poly­IC  treatment  exacerbates  tuberculosis  in mice 
through  the pulmonary  recruitment  of  a  pathogen­permis­
sive monocyte/macrophage population. J Clin  Invest  2010; 
:1674­1682.
49   Cougoule C, Van Goethem E, Le Cabec V, et al. Blood  leu­
kocytes and macrophages of various phenotypes have distinct 
abilities  to  form podosomes  and  to migrate  in  3D environ­
ments. Eur J Cell Biol 2012; :938­949.
50   Yeh HH, Lai WW, Chen HH, Liu HS, Su WC. Autocrine IL­
6­induced Stat3 activation contributes  to  the pathogenesis of 
lung  adenocarcinoma and malignant  pleural  effusion. Onco­
gene 2006; :4300­4309.
51   Shi C, Pamer EG. Monocyte recruitment during infection and 
LQÀDPPDWLRQNat Rev Immunol 2011; 11:762­774.
52   Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD­1 
immunoinhibitory  receptor  by  a  novel B7  family member 
leads  to negative  regulation of  lymphocyte activation. J Exp 
Med 2000; :1027­1034.
53   Lawrence T, Natoli G. Transcriptional  regulation of macro­
phage polarization: enabling diversity with  identity. Nat Rev 
Immunol 2011; 11:750­761.
54   Jamil B, Shahid F, Hasan Z, et  al.  Interferon gamma/IL10 
UDWLRGH¿QHVWKHGLVHDVHVHYHULW\LQSXOPRQDU\DQGH[WUDSXO­
monary tuberculosis. Tuberculosis (Edinb) 2007; 87:279­287.
55   Verbon A, Juffermans N, Van Deventer SJ, et al. Serum con­
centrations of  cytokines  in  patients with  active  tuberculosis 
(TB)  and  after  treatment. Clin Exp  Immunol  1999; :110­
113.
56   Bonecini­Almeida MG, Ho JL, Boechat N, et al. Down­mod­
ulation of  lung  immune  responses  by  interleukin­10  and 
transforming growth  factor  beta  (TGF­beta)  and  analysis  of 
TGF­beta receptors I and II in active tuberculosis. Infect Im­
mun 2004; :2628­2634.
57   Souza­Lemos C, de­Campos SN, Teva A, Porrozzi R, Grimal­
di G Jr. In situ characterization of the granulomatous immune 
response with time in nonhealing lesional skin of Leishmania 
braziliensis­infected  rhesus macaques  (Macaca mulatta). Vet 
Immunol Immunopathol 2011; :147­155.
58   Wiesner C, Le­Cabec V, El Azzouzi K, Maridonneau­Parini 
I, Linder S. Podosomes  in space: macrophage migration and 
matrix  degradation  in  2D and 3D  settings. Cell Adh Migr 
2014; 8:179­191.
59   Jevnikar Z, Mirkovic B, Fonovic UP, et al. Three­dimensional 
invasion of macrophages  is mediated by  cysteine  cathepsins 
in protrusive podosomes. Eur J Immunol 2012; :3429­3441.
60   Van Goethem E, Guiet R, Balor S, et al. Macrophage podo­
somes go 3D. Eur J Cell Biol 2011; :224­236.
61   Guiet R, Van Goethem E, Cougoule C, et  al. The process 
of macrophage migration promotes matrix metalloprotein­
ase­independent  invasion by  tumor  cells. J  Immunol  2011; 
187:3806­3814.
62   Elkington P, Shiomi T, Breen R, et al. MMP­1 drives immu­
nopathology  in  human  tuberculosis  and  transgenic mice. J 
Clin Invest 2011; :1827­1833.
63   Rottenberg ME, Carow B. SOCS3 and STAT3, major control­
lers of the outcome of infection with Mycobacterium tubercu­
losis. Semin Immunol 2014; :518­532.
64   O’Leary S, O’Sullivan MP, Keane J. IL­10 blocks phagosome 
maturation  in mycobacterium  tuberculosis­infected human 
macrophages. Am J Respir Cell Mol Biol 2011; :172­180.
65   Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. 
Interleukin­10 and the interleukin­10 receptor. Annu Rev Im­
munol 2001; :683­765.
66   Schreiber T, Ehlers S, Heitmann L, et  al. Autocrine  IL­10 
induces hallmarks of  alternative  activation  in macrophages 
and suppresses antituberculosis effector mechanisms without 
compromising T  cell  immunity. J  Immunol  2009; 183:1301­
1312.
67   Holscher C, Holscher A, Ruckerl D, et al. The IL­27 receptor 
chain WSX­1 differentially  regulates  antibacterial  immunity 
and  survival  during  experimental  tuberculosis. J  Immunol 
2005; 174:3534­3544.
68   Carow B, Reuschl AK, Gavier­Widen D, et  al. Critical  and 
Claire Lastrucci et al.
1351
npg
www.cell­research.com | Cell Research
independent  role  for SOCS3  in  either myeloid or T  cells  in 
resistance to Mycobacterium tuberculosis. PLoS Pathog 2013; 
:e1003442.
69   Zizzo G, Guerrieri J, Dittman LM, Merri JT, Cohen PL. Cir­
FXODWLQJOHYHOVRIVROXEOH0(5LQOXSXVUHÀHFW0FDFWLYDWLRQ
of monocytes/macrophages,  autoantibody  specificities  and 
disease activity. Arthritis Res Ther 2013; :R212.
70   Tang Y, Hua SC, Qin GX, Xu LJ, Jiang YF. Different subsets 
of macrophages in patients with new onset tuberculous pleu­
ral effusion. PLoS One 2014; :e88343.
71   Cyktor JC, Carruthers B, Kominsky RA, et al. IL­10 inhibits 
PDWXUH¿EURWLF JUDQXORPD IRUPDWLRQGXULQJMycobacterium 
tuberculosis infection. J Immunol 2013; :2778­2790.
72   Girgis NM, Gundra UM, Ward LN, et  al. Ly6Chigh mono­
cytes become alternatively activated macrophages in schisto­
some granulomas with help  from CD4+ cells. PLoS Pathog 
2014; :e1004080.
73   Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp 
HS. Cloning  and mRNA expression  analysis  of  a  novel  hu­
man protooncogene, c­mer. Cell Growth Differ 1994; :647­
657.
74   Hayakawa F, Sugimoto K, Harada Y, et  al. A novel STAT 
inhibitor, OPB­31121,  has  a  significant  antitumor  effect  on 
leukemia with STAT­addictive oncokinases. Blood Cancer  J 
2013; 3:e166.
75   Iwamaru A, Szymanski S, Iwado E, et al. A novel inhibitor of 
the STAT3 pathway  induces  apoptosis  in malignant  glioma 
cells both in vitro and in vivo. Oncogene 2007; :2435­2444.
76   Tobin DM, Roca FJ, Oh SF, et  al. Host  genotype­specific 
WKHUDSLHV FDQRSWLPL]H WKH LQÀDPPDWRU\ UHVSRQVH WRP\FR­
bacterial infections. Cell 2012; 148:434­446.
(6XSSOHPHQWDU\ LQIRUPDWLRQ is  linked  to  the online version of 
the paper on the Cell Research website.)
Bone degradation machinery of osteoclasts: An
HIV-1 target that contributes to bone loss
Brigitte Raynaud-Messinaa,b,c,1, Lucie Bracqd,e,f,2, Maeva Duponta,b,c,g,2, Shanti Sourianta,b,c,2, Shariq M. Usmanih,i,
Amsha Proaga, Karine Pingrisa,b,c, Vanessa Soldanj, Christophe Thibaultk,l, Florence Capillam, Talal Al Saatim,
Isabelle Genneron,o, Pierre Jurdicp, Paul Jolicoeurq,r,s, Jean-Luc Davignonm,n, Thorsten R. Mempelh,i, Serge Benichoud,e,f,
Isabelle Maridonneau-Parinia,b,c,1,3, and Christel Vérolleta,b,c,1,3
aInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, Université Paul Sabatier, 31400 Toulouse Cedex 4, France;
bInternational Associated Laboratory, CNRS “Immuno-Metabolism-Macrophages-Tuberculosis/HIV” (1167), 31000 Toulouse, France; cInternational
Associated Laboratory, CNRS “Immuno-Metabolism-Macrophages-Tuberculosis/HIV” (1167), 1425 Buenos Aires, Argentina; dINSERM U1016, Institut Cochin,
75014 Paris, France; eCNRS UMR8104, Université Paris Descartes, 75006 Paris, France; fInstitut Pasteur Shanghai, Chinese Academy of Sciences, 200000
Shanghai, China; gInstitute of Experimental Medicine-Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina, National Academy of
Medicine, 1425 Buenos Aires, Argentina; hCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA 02129;
iHarvard Medical School, Boston, MA 02115; jMultiscale Electron Imaging Platform, 31062 Toulouse, France; kLaboratory for Analysis and Architecture of
Systems, CNRS, 31400 Toulouse, France; lInstitut National des Sciences Appliquées de Toulouse, Université de Toulouse, 31400 Toulouse, France; mINSERM,
Université Paul Sabatier, École Nationale Vétérinaire de Toulouse, Centre Régional d’Exploration Fonctionnelle et de Ressources Expérimentales, Service
d’Histopathologie, 31000 Toulouse Cedex 3, France; nCentre de Physiopathologie de Toulouse-Purpan, INSERM-CNRS UMR 1043, Université Paul Sabatier,
31062 Toulouse, France; oInstitut Fédératif de Biologie, Centre Hospitalier Universitaire Toulouse, 31059 Toulouse, France; pInstitut de Génomique
Fonctionnelle de Lyon, CNRS UMR3444, Université de Lyon, Ecole Normale Supérieure de Lyon, 69007 Lyon, France; qDivision of Experimental Medicine,
McGill University, Montreal, QC H3G 1A4, Canada; rDepartment of Microbiology and Immunology, University of Montreal, Montreal, QC H3T IJ4, Canada;
and sLaboratory of Molecular Biology, Clinical Research Institute of Montreal, Montreal, QC H2W 1R7, Canada
Edited by Stephen P. Goff, Columbia University Medical Center, New York, NY, and approved January 19, 2018 (received for review July 28, 2017)
Bone deficits are frequent in HIV-1–infected patients. We report
here that osteoclasts, the cells specialized in bone resorption, are
infected by HIV-1 in vivo in humanized mice and ex vivo in human
joint biopsies. In vitro, infection of human osteoclasts occurs at
different stages of osteoclastogenesis via cell-free viruses and,
more efficiently, by transfer from infected T cells. HIV-1 infection
markedly enhances adhesion and osteolytic activity of human os-
teoclasts by modifying the structure and function of the sealing
zone, the osteoclast-specific bone degradation machinery. Indeed,
the sealing zone is broader due to F-actin enrichment of its basal
units (i.e., the podosomes). The viral protein Nef is involved in all
HIV-1–induced effects partly through the activation of Src, a reg-
ulator of podosomes and of their assembly as a sealing zone.
Supporting these results, Nef-transgenic mice exhibit an increased
osteoclast density and bone defects, and osteoclasts derived from
these animals display high osteolytic activity. Altogether, our
study evidences osteoclasts as host cells for HIV-1 and their path-
ological contribution to bone disorders induced by this virus, in
part via Nef.
osteoclast | HIV-1 infection | bone loss | Nef | podosome
Reduced bone mineral density is a frequent complication ofHIV-1–infected patients and often progresses to osteopo-
rosis and high prevalence of fractures. A sixfold increased risk of
low bone mineral density is observed in HIV-1+ individuals com-
pared with the general population (1). The use of highly active
antiretroviral therapy (HAART) has significantly improved the
lifespan of patients, revealing these long-term effects of the in-
fection and the persistence of latent proviruses in reservoir cells (2).
Multiple factors can contribute to bone loss in infected patients.
HAART is one of these factors, especially during the first years of
therapy. In addition, there is evidence of bone deficit in nontreated
patients, showing that the virus alone alters bone homeostasis (3–6).
Bones undergo continual remodeling, which mainly relies on
the sequential actions of bone-resorbing osteoclasts (OC) and
bone-forming osteoblasts, under the control of osteocytes (7, 8).
In the case of aging or HIV-1 infection, this balance can be
disrupted in favor of bone loss. HIV-1–induced bone disorders
are associated with an increase of blood biomarkers for bone
resorption and minor changes in bone formation-specific mark-
ers, suggesting a major contribution of OC in this process (6, 9).
OC are multinucleated cells derived from the monocytic lineage,
which have the unique ability to resorb bone matrix. They terminally
differentiate by fusion from mononucleated precursors, including
blood-circulating monocytes and bone-resident precursors (10).
This process is regulated by macrophage colony-stimulating factor
(M-CSF) and the key osteoclastogenic cytokine, receptor activator
of NF-κB ligand (RANKL), mainly secreted by osteocytes but also by
osteoblasts and activated B and T cells (10, 11). Terminally differ-
entiated OC express high levels of the αvβ3 integrin adhesion re-
ceptor and enzymes involved in resorption including cathepsin K,
matrix metalloprotease 9 (MMP9), and tartrate-resistant acidic
phosphatase (TRAP). Bone attachment and resorption are mediated
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by an OC-specific structure called the sealing zone (SZ). It is com-
posed of a dense array of interconnected F-actin structures, the
podosomes. The SZ anchors the cells to the bone surface and creates
a confined resorption environment where protons and osteolytic
enzymes are secreted (11–14). Alteration in SZ formation and dy-
namics are linked to defective bone resorption, and ultimately to
bone disorders, as demonstrated by knocking out regulators or con-
stituents of the SZ (14–17).
To explain the increase in osteolytic activity associated to
HIV-1–induced bone loss, only a few mechanisms have been
proposed: disruption of the immune system (6, 18), increased
production of proinflammatory cytokines (19), and direct in-
fection of OC (20). Regarding the immune system, studies from
the HIV-1–transgenic rat model revealed that bone damage re-
sults, in part, from an altered production of regulatory factors of
osteoclastogenesis secreted by B cells (18). This modified cyto-
kine profile correlates with some bone mineral defects in non-
treated HIV-1–infected patients (6). Along with CD4+ T
lymphocytes, macrophages serve as primary target cells for HIV-
1 in vivo (21–23). Because OC share a common myeloid origin with
macrophages, the last proposed hypothesis is that OC are targets for
HIV-1, and their infection would then contribute to bone loss. In-
deed, it has recently been shown that HIV-1 may replicate in vitro
in human monocyte-derived OC and enhance their bone resorption
activity (20). However, the relevance of this observation has yet to
be provided in vivo, along with the corresponding cellular and viral
mechanisms involved in the bone resorption process.
Here, we report the occurrence of infected OC in bones of
HIV-1–infected humanized mice and in human synovial explants
exposed to HIV-1. We further demonstrate that the exacerbated
osteolytic activity of infected OC results from modified structure
and function of the SZ, correlates with Src activation, and is
dependent on the viral protein Nef.
Results
Infected OC Are Found in the Bones of HIV-1–Infected Humanized
Mice and in Human Synovial Explants Exposed to HIV-1. We first
investigated whether OC are infected in vivo. Because bone
marrow/liver/thymus (BLT) humanized mice infected with HIV-
1 reproduce most hallmarks of infection in humans (22, 24, 25),
we used these mice infected for 14–21 d (2 × 104–8 × 104 RNA
copies/mL in blood, n = 4) to examine the growth plate of femurs
and tibias, the OC-enriched zone. For each bone section (head
of femur or tibia from four mice), we quantified 85 ± 22 cells that
exhibit OC characteristics (multiple nuclei, TRAP activity, and
localization at the bone surface). Importantly, for each infected
animal, we identified by immunohistochemistry (IHC) one or
two OC positive for the viral protein p24, which is used as an
indicator of productive viral infection (Fig. 1A and Fig. S1).
Negative controls were included for each sample by omitting the
primary antibody.
We then assessed whether OC can be infected in human tissue
using synovial membrane explants, which contain fibroblasts,
macrophages, lymphocytes, dendritic cells, and OC, in an abundant
extracellular matrix (26). Fresh human synovial tissues were in-
cubated ex vivo with the HIV-1 macrophage R5-tropic ADA strain
and maintained in culture with osteoclastogenic cytokines to keep
resident OC and OC precursors alive throughout the experiment.
Fifteen days postinfection, OC were characterized by multiple
nuclei, TRAP-, and cathepsin K-positivity by IHC. Remarkably, we
observed that about 10% of these cells were positive for the viral
p24 (n = 5 synovial explants examined) (Fig. 1B).
Altogether, these data show that infection of OC occurs both
in vivo in humanized mice and ex vivo in human tissues.
Human OC Are Permissive to HIV-1 Infection by Cell-Free Viruses at
Different Stages of Differentiation. To examine the stage of dif-
ferentiation at which the cells become capable to be infected, we
turned to human OC derived from primary monocytes differ-
entiated in vitro in the presence of M-CSF and RANKL. The OC
differentiation process was assessed by measuring OC protein
level at different stages. While we observed a rapid increase of
TRAP and β3 integrin as soon as day 1, we noticed the acqui-
sition of cathepsin K (a late-stage differentiation marker) at day
6; the expression level for all these proteins increased until day
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Fig. 1. Tissue OC are infected with HIV-1 in vivo and ex vivo. (A) HIV-1 in-
fects OC in vivo in HIV-1–infected BLT-humanized mice. Two serial sections
(3-μm thick, 1 and 2) of the head of a tibia of HIV-1–BLT mice were stained
for TRAP activity (in purple, 1) and with a monoclonal antibody directed
toward human viral protein p24 (in brown, 2). Representative sections (n =
4 mice, two sections per mouse of tibia and femur heads). Arrowheads show
an infected OC. (Scale bar, 50 μm.) Enlarged frames, 2× zoom. (B) Human OC
are infected with HIV-1 in synovial explants. Pieces of a noninflammatory
human synovial tissue were cultured with M-CSF and RANKL and infected
with HIV-1 (ADA strain). Two weeks postinfection, histological analyses
[TRAP activity in purple (1), p24 (2) and cathepsin K (CtsK) (3) IHC in brown,
nuclei in blue] were performed on three serial sections (3-μm thick, 1–3).
Representative histological sections (n = 3 synovial tissues, four pieces per
tissue). (Scale bar, 100 μm.) Enlarged frames, 2.3× zoom.
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10, when cells presented characteristics of mature OC, including
high fusion index, high TRAP and MMP9 activities, and bone
degradation activity (Fig. S2 A–E). Of note, monocyte-derived
macrophages (MDM) from the same donors differentiated with
M-CSF (at day 10) only exhibited undetectable or low levels of
OC markers, low fusion index, and lacked osteolytic activity (Fig.
S2 B–E). Cells were infected in vitro with the HIV-1 R5 ADA
strain at day 0, 1, 6, or 10 of differentiation (Fig. 2A). The extent
of HIV-1 infection and replication was evaluated at day 10
postinfection by immunofluorescence (IF) analysis of p24 and
quantified by measuring the concentration of p24 released in the
supernatant. While monocytes (day 0) were poorly able to sus-
tain infection, cells became increasingly permissive to infection
along the differentiation process (Fig. 2 B and C, black bars); this
correlated with the increased expression of the CCR5 entry
coreceptor from day 1 (Fig. S2F). Moreover, we observed that
virus production was inhibited by pretreatment of OC with the
CCR5 antagonist Maraviroc, the reverse-transcriptase inhibitor
AZT, the integrase inhibitor Raltegravir, or the protease in-
hibitor Ritonavir (Fig. S2G), indicating that the p24 signal cor-
responds to productively infected cells. We noticed that MDM
and OC equally sustained infection (Fig. 2 B and C) (≥95%
donors supported infection, n = 29), which is consistent with
similar levels of CD4 and CCR5 receptors expressed during
differentiation (Fig. S2F) and at day 10 (20). Moreover, the viral
particles produced by infected OC or MDM had comparable
infectivity, as assessed using the TZM-bl reporter cell line (27 ±
5% of p24+ TZM-bl for OC-produced particles vs. 26 ± 7% for
MDM, n = 5), indicating that both cell types released infectious
virions. Importantly, HIV-1 did not affect OC viability, as cell
density was not altered even at day 20 postinfection (1,580 ±
276 nuclei/mm2 for noninfected OC vs. 1,560 ± 352 for infected
OC, n = 6 donors, ≥3,000 cells per condition). Finally, we ob-
served virus budding in OC and both mature and immature virus
particles accumulating in membrane-delineated intracellular
compartments by electron microscopy (Fig. 2D).
Collectively, these results show that HIV-1 infects and replicates
in OC and their precursors, without significant cytotoxic effect.
Human OC Are Preferentially Infected by Transmission from Infected
T Cells. HIV-1 spreads by infecting target cells either as cell-free
particles or more efficiently via cell-to-cell transmission, both in
vitro and in vivo (27–30). We thus examined whether mature OC
could be infected by contact with infected CD4+ T lymphocytes,
first using Jurkat T cells infected with the HIV-1 R5-tropic
NLAD8-VSVG strain (>50% of infected T cells, n = 8).
Briefly, after 6 h of contact with OC, Jurkat cells were washed
out (more than 99% of the T cells were eliminated) (Fig. S3A)
and OC were harvested either immediately (day 0) or 5 d later
(day 5) and stained for intracellular viral p24 by IF (Fig. 3 A and
B). We observed that 6-h contact (day 0) was sufficient for T cell-
to-OC virus transfer with about 15% of p24+ OC, while no de-
tectable infection was observed at this time point when OC were
cultured with cell-free virions produced by T cells. The differ-
ence was maintained at day 5. At this time point, the high rate of
infected OC could result from the initial infection by T cell-to-
OC transmission and from enhanced OC cell fusion. Noticeably,
virus transfer via infected T cells led to a productive infection of
OC as shown by the amount of p24 detected in the supernatant
at day 5 (Fig. 3C), which is higher than in the case of infection
with cell-free virions. Finally, we confirmed the efficient virus
transfer from infected T cells leading to productive infection of
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Fig. 2. HIV-1 infects human OC and their precursors in vitro. (A–C) OC are
infected by cell-free viruses at different stages of differentiation. (A) Ex-
perimental design of infection (ADA strain). (B and C) Kinetics of the per-
centage of p24+ cells (B, determined by IF) and of p24 release in the
supernatants (C, determined by ELISA) in cells maintained in M-CSF plus
RANKL (OC, black bars) or M-CSF alone (MDM, blue bars) from the same
donors are shown. Results are expressed as mean ± SEM (n = 3 donors and
5 donors for day 10). Day of i, day of infection. (D) Transmission electron
microscopy images of infected OC. Mature OC were infected with HIV-1 and
examined 10 d postinfection. Images of a budding virus (Left, red arrow-
head) and viruses contained in a cytoplasmic membrane compartment
(Right, black arrowheads show mature viruses). (Scale bar, 100 nm.) A Cell-free HIV-1Non infected T cells
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Fig. 3. HIV-1 is transmitted from infected T lymphocytes to OC. (A–C) OC
have been in contact for 6 h with noninfected Jurkat T lymphocytes (Left),
with HIV-1–infected T lymphocytes (Center), or with cell-free viral particles
produced by T cells during 6 h (Right); they were washed, then harvested
immediately (day 0) or 5 d later (day 5). (A) Representative mosaic of 3 ×
3 confocal fields of original magnification 20×, after staining for p24 (green),
F-actin (phalloidin-Texas red, red), and nuclei (DAPI, blue) at day 5. (Scale
bar, 50 μm.) (B and C) Quantifications (mean ± SD, n = 8 donors) of the
percentage of p24+ cells evaluated by IF (B) immediately (day 0) or 5 d (day 5)
postinfection and of p24 release in the supernatants determined by ELISA
after 5 d (day 5) (C). **P ≤ 0.01; ****P ≤ 0.0001.
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OC by using autologous infected T lymphocytes as virus donor
cells (Fig. S3 B and C).
These results show that OC are not only infected by cell-to-cell
transfer via infected T cells, but it is also more efficient than
infection by cell-free virions.
HIV-1 Infection Enhances OC Precursor Migration and OC Bone
Resorption Activity. In HIV-1 transgenic rats, severe bone loss
has been correlated to an increase in the number and size of OC
(18). This increase could reflect an enhanced recruitment of OC
precursors or a stimulated OC differentiation. We tested both
hypotheses. It is known that migration of OC precursors from
blood to bones requires proteases in vivo (31), and that defects in
the 3D protease-dependent mesenchymal migration of these
cells in vitro correlates with lower recruitment of OC to bones
(16). For these reasons, we assessed whether HIV-1 infection
alters OC precursor mesenchymal migration (32, 33). Human
OC precursors were infected at day 1 of differentiation, seeded
at day 2 on Matrigel, and migration was measured 48 h later (Fig.
4). Of note, OC precursors inside Matrigel exhibited the char-
acteristic elongated shape of the mesenchymal migration (32).
The percentage of migrating cells and the distance covered by
the cells were both significantly increased upon HIV-1 infection.
Next, to test whether HIV-1 infection affects OC differentia-
tion, we examined the consequences of infection on the extent of
OC fusion and bone resorption activity. HIV-1 infection signif-
icantly enhanced cell fusion, as measured by the fusion index and
the area covered by infected versus noninfected OC (Fig. 5A),
the percentage of TRAP+ multinucleated cells, and the number
of nuclei per multinucleated cell (Fig. S4 A and B). When cells
were treated with Maraviroc before infection, the fusion index
was reduced to a similar level to controls (Fig. S4C). Moreover,
to explore the effects of OC infection on bone resorption activity,
we characterized the morphology of the resorption lacunae. The
total bone resorption area increased upon HIV-1 infection (Fig.
5 B–D) and resorption pits displayed profound morphological
modifications (Fig. 5 B–F). Infected OC generated resorption
pits that appeared deeper (28 ± 1.2 μm vs. 17 ± 0.7 μm for
controls, ****P < 0.0001) (Fig. 5C) and less elongated (Fig. 5E)
than those of noninfected OC, which form resorption trails
reminiscent of “inchworm-like migration” (34). These modifi-
cations correlated with a significant up-regulation of the bone
volume resorbed per pit in the HIV-1 infection context (Fig. 5F).
Furthermore, we also found a significant increase in the con-
centration of the C-terminal telopeptide of type 1 collagen (CTX)
released in the supernatants and used as an additional marker of
bone resorption (Fig. 5G).
Osteolytic activity is mediated by acidic dissolution of the
minerals and enzymatic digestion of the organic components
(35). HIV-1 infection enhanced these two activities, as evidenced
by the increase in the capacity of OC to dissolve minerals (Fig.
5H) and release TRAP (Fig. 5I). No variation in protein ex-
pression and activity was noticed regarding secreted cathepsin K
and MMP9 (Fig. 5 J and K).
Finally, we examined OC attachment/detachment, a critical
factor for bone degradation (12), given that OC resorption partly
proceeds through a succession of migratory phases alternating
with bone resorption stationary phases (12, 36). When infected,
OC were more resistant to detachment induced by Accutase
treatment than noninfected counterparts (Fig. 5L). This in-
creased adhesion likely slows down OC motility on bone, which
should contribute to the modified morphology of resorption la-
cunae and to the higher bone degradation activity.
All in all, these results indicate that HIV-1 infection enhances
the 3D migration of OC precursors, which may favor recruitment
of OC to bones, as well as the adhesion and bone resorption
activity of mature OC.
HIV-1 Infection Alters the Architecture of the SZ and Activates Src
Kinase. Because the SZ has been related to adhesion and bone
degradation capacities of OC (11, 37), we characterized the ar-
chitecture of this structure in infected OC. We observed that in
OC seeded on bones, the number of cells harboring SZ was in-
creased (Fig. 6 A and B). This effect was not duplicated by in-
fection with Mycobacterium tuberculosis, Francisella novicida, or
Salmonella typhimurium (infection rates ≥50% for each bacteria,
percentage of cells harboring SZ: 18 ± 9 forM. tuberculosis, 22 ±
6 for F. novicida, 25 ± 4 for S. typhymurium vs. 25 ± 10 in
noninfected OC, mean ± SD, n = 4), suggesting that this pa-
rameter was not generally influenced by OC infection. In addi-
tion, the size of the SZ was increased (Fig. 6 A and C),
delineating an area corresponding to 25 ± 1% of the cell surface
of infected OC vs. 18 ± 2% in control cells (Fig. 6D). We also
noticed that the fluorescence intensity of F-actin was higher in
the SZ of infected cells (Fig. 6 A and E) and the F-actin core of
podosomes, the basal element of the SZ, was larger (Fig. 6 F and
G). The tyrosine kinase Src plays a key role in bone homeostasis
by controlling the formation and stability of the SZ and the rate
of actin turnover within OC podosomes (14, 16, 38). Conse-
quently, OC from Src−/− mice do not assemble functional SZ and
the mice exhibit a strong osteopetrotic phenotype (15). In-
terestingly, we showed that in the context of HIV-1–infected OC,
the activity of Src kinase family was enhanced as measured by
phosphorylation of the regulatory tyrosine (Fig. 6H).
These results show that the increase in bone adhesion and
resorption observed in infected OC is associated with larger and
more numerous SZ as well as higher Src kinase activity.
The Viral Factor Nef Is Involved in HIV-1–Induced Effects on OC Both in
Vitro and in Vivo. To better understand the viral mechanisms in-
volved in HIV-1–induced effects in OC, we focused on the viral
accessory factor Nef because it is known, among other functions,
to modulate F-actin organization and to stimulate both the ki-
nase activity of Src (39–44) and cell fusion (45). To this end, we
used wt HIV-1 and nef-deleted HIV-1 (δnefHIV-1) ADA strains
that present the same level of infectivity in macrophages (33, 45–
47) and in OC (Fig. S5A). Importantly, the viral particles pro-
duced by OC infected with the wt or mutant strains showed the
same level of infectivity (26 ± 7% of p24+ TZM-bl cells for the wt
strain vs. 22 ± 5% for δnefHIV-1, n = 4). As shown in Fig. 7A,
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the 3D mesenchymal migration of OC precursors infected with
δnefHIV-1 was similar to noninfected cells. In mature OC, Src
kinase phosphorylation, bone resorption activity, percentage of
cells with SZ, fusion index, and SZ area were reduced in δnefHIV-
1–infected OC in comparison with cells infected with the wt virus
(Fig. 7 B–F).
Next, we considered performing ectopic expression of Nef-
GFP in OC, but we encountered a technical limitation; only 5%
of Nef-expressing cells were obtained, precluding a rigorous
quantification of SZ size and bone resorption activity. None-
theless, when the transfected cells were plated on glass, we ob-
served a fraction of Nef-GFP localized at the SZ on bones and
that podosomes occupied a larger area than those of control cells
(Fig. 7 G and H), thus mimicking the results obtained with OC
infected with the wt virus (Fig. 6 F and G).
Next, we took advantage of transgenic (Tg) mice expressing Nef
under the regulatory sequence of the human CD4C gene to over-
come the transfection difficulty of human OC. The CD4C regulatory
element drives Nef expression in CD4+ T cells, macrophages, and
dendritic cells (48, 49), and also in OC (Fig. S5B). In fact, in the
absence of any available Nef antibody for IHC, we used CD4C/HIV-
1GFP Tg mice. We verified that the GFP was expressed in all OC,
indicating that CD4C drives the expression of ectopic genes in
OC (Fig. S5B). To characterize the effects of Nef expression in OC,
OC precursors were isolated from bone marrow of Nef-Tg and non-
Tg mice and differentiated ex vivo. While the fusion of OC fromNef-
Tg mice was not modified compared with OC derived from control
mice (Fig. 8A), the bone resorption (Fig. 8B) and the width of F-actin
staining in the SZ were enhanced (Fig. 8 C and D), indicating that
Nef expression is sufficient to increase the osteolytic activity of OC.
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Fig. 5. HIV-1 enhances OC fusion, osteolytic activity,
and adhesion of OC. (A) HIV-1 triggers OC fusion.
Ten days postinfection, cells were stained for p24
(green), F-actin (red), and nuclei (blue). Images from
a mosaic of 4 × 4 confocal fields of original magni-
fication 20×. (Scale bar, 150 μm.) The cell fusion in-
dex (nuclei number in multinucleated cells/total
nuclei number) and the surface percentage covered
by multinucleated cells (surface index) were mea-
sured for >3,000 cells in each condition, n = 6 donors.
Results are expressed as mean ± SEM. (B–G) HIV-
1 infection increases the bone resorption activity of
OC. Day 10-noninfected and HIV-1–infected OC were
seeded on cortical bone slides for 48 h. Then, OC
were removed, the supernatants collected, and the
bone slices stained with Toluidine blue to visualize
resorption pits in purple. Data were obtained from
six donors. (B) Representative brightfield images of
bone-resorption pits (purple). (Scale bar, 20 μm.)
(C) Representative confocal images of pits. Color
codes for the depth of resorption pits (color scale
bar). (Scale bar, 20 μm.) Quantification of the per-
centage of degradation area (D) and circularity (E)
from brightfield images and resorbed volume
(F) from confocal images are shown. In D, the deg-
radation area of noninfected OC, normalized to
100%, corresponded to 9% of the total area. (G) The
concentration of CTX in the supernatant was mea-
sured by ELISA and normalized to 100% for non-
infected cells (mean CTX concentration = 1,790 pg/mL),
n = 6 donors. (H–K) Effects of infection on mineral
dissolution and extracellular osteolytic enzymes. (H) Day
10-noninfected and HIV-1–infected OC were seeded on
crystalline inorganic calcium phosphate-coated multi-
wells. The cells were removed and the wells stained to
reveal demineralized area (black). (Scale bar, 50 μm.)
Graph shows the area covered by mineral dissolution
pits from 10 fields per condition and per donor, n =
3 donors. (I–K) The supernatants of noninfected and
HIV-1–infected OC seeded on glass were collected at
day 10. TRAP and CtsK expression levels (Western blot,
I and J) and MMP9 activity (zymography analysis, K)
were quantified. Protein loading has been controlled
by Coomassie blue staining, n = 4 donors. (L) HIV-1 in-
fection increases OC adhesive properties. Noninfected
and HIV-1–infected OC were removed at day 10 with
Accutase for 10 min and the percentage of remaining
adherent cells quantified by counting nuclei (adhesion
index). Graph represents average of five fields per
condition from n = 3 donors (NI, noninfected). *P ≤
0.05; **P ≤ 0.01; ***P ≤ 0.001, ****P ≤ 0.0001.
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Finally, we addressed the role of Nef on bone remodeling in
vivo. Nef-Tg mice exhibited bone defects as evidenced by abnormal
bone fragility during dissection and by an overall decrease in bone
density (Fig. S5C). In tibia growth plates of 7-wk-old female mice,
we observed a decrease of the bone area (trabecular surface) in
Nef-Tg mice compared with non-Tg mice (Fig. 8 E and F, gray),
and a disorganized hypertrophic chondrocyte zone (Fig. 8E, de-
lineated by the red line), which appeared thinner and irregular.
Moreover, a marked increase in TRAP+ signal was noticed (Fig. 8
E and F, purple), indicating that OC were larger and more nu-
merous in Nef-Tg mice compared with control littermates.
Altogether, these results support that the viral protein Nef is
sufficient to increase the osteolytic activity of OC and, thereby,
potentially contribute to bone loss in vivo.
Discussion
Bone defects resulting from HIV-1 infection have long been
described, but the causes remain poorly investigated (1). We
report that HIV-1 infects OC in vivo, ex vivo, and in vitro. In
infected OC, the structure and function of the SZ are modified,
affecting bone attachment and resorption. The viral protein Nef
is instrumental in these processes. Hence, OC are cell targets for
HIV-1, which is, to our knowledge, the only pathogen able to
manipulate the SZ.
Using HIV-1–infected BLT-humanized mice, we obtained
evidence of the presence of infected OC in bones. Infected OC
appear as a rare event, either due to the moderated viremia (we
worked shortly after infection) and low sensitivity of the IHC
detection, or to the fact that infected OC are poorly detected in
tissues similarly to infected macrophages (22, 50–54). OC can
also be infected ex vivo in fresh human synovial explants. Im-
portantly, OC infection in vivo and ex vivo was detected by IHC
of the viral p24, which is suggestive of viral replication. In vitro,
electron microscopy images of infected OC revealed that the
virus particles bud and accumulate in intracellular compart-
ments, suggestive of the virus-containing compartments de-
scribed in macrophages (55–57). The virus production by OC was
quantitatively similar to that of macrophages, a well-known HIV-
1 host cell (21, 22, 58). Infection of OC occurred at different
time points along the differentiation process, starting at day 1 in
OC precursors and correlating with CCR5 expression. This
suggests that circulating OC precursors, which encounter the
virus in blood, could become infected and migrate to bones,
where they terminally differentiate (59, 60) (Fig. 9). Whether
mature OC can be infected directly in bones is difficult to ex-
plore. Up to now, the presence of HIV-1 in bones has not been
documented. As recently shown for macrophages (61), direct
contact of OC with infected Jurkat or primary CD4+ T lym-
phocytes leads to virus transfer and productive infection of OC,
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which is clearly more efficient than infection by cell-free viruses.
This is likely to be the physio-pathological route to infect OC in
situ, which would be consistent with data showing that cell-to-cell
infection is critical for efficient viral spread in vitro and in vivo
(25, 29, 61–69). Altogether, these results show that OC are host
cells for HIV-1.
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Regarding the consequence of HIV-1 infection on OC func-
tion, along with this study, there is another report describing that
the bone resorption activity of infected OC is exacerbated (20).
Herein, we revealed potential mechanisms involved in enhanced
bone resorption that concern the structure and function of the
SZ, the cell structure instrumental for bone resorption. SZ are
larger in HIV-1–infected OC and, consequently, they can de-
grade larger bone areas. This is in line with the formation of
giant OC, which contain twice as more nuclei when they are
infected. This exacerbated bone degradation by HIV-1–infected
OC also resulted from an increased demineralization process
combined with an enhanced secretion of TRAP. The SZ is made
of densely connected podosomes, F-actin–rich cell structures
involved in cell adhesion, mechanosensing, and cell migration
(70). SZ assembly and patterning are under the control of Src
(14, 38). Interestingly, we report that the Src kinase activity was
activated in infected OC and that podosomes were enlarged, as
visualized by an increase of F-actin staining. In human macro-
phages, modifications of the F-actin content in individual
podosomes have been correlated with fluctuations of protrusion
forces exerted onto the extracellular matrix by these cell struc-
tures (71). In OC, these modified podosomes may promote more
efficient sealing to bone surface. Indeed, we observed stronger
adhesion for HIV-1–infected OC compared with noninfected
OC. Because the SZ is a barrier that limits the diffusion of acidic
and proteolytic molecules released in the resorption lacunae
(11–14), increased adhesion would likely enhance the efficiency
of containment and favor bone resorption (72). From these re-
sults, we propose that modification of several parameters of the
SZ (i.e., increased size, adhesion, and degradative activity)
contribute to the enhanced osteolytic activity and to the modi-
fications of the topography of resorption pits on infection (12,
36, 73). Pharmacological destabilization of the SZ would reduce
the impact of HIV-1 on bone degradation. Several ongoing
therapeutic strategies, including the inhibition of the SZ com-
ponent DOCK5 or cathepsin K activity, are being developed to
reduce osteoporotic syndromes while preserving OC viability and
differentiation, and thus bone homeostasis (17, 74, 75). We also
noticed that OC precursors displayed an enhanced ability to
migrate when infected with HIV-1. Interestingly, the efficiency
of OC precursor migration has been correlated to OC density in
bones (10, 16). Therefore, in addition to enhanced bone re-
sorption activity of infected OC, increased migration of OC
precursors should favor OC recruitment to bones, as depicted in
Fig. 9, contributing to bone disorders in infected patients.
Nef is a crucial determinant of viral pathogenesis and disease
progression. It is known to physically interact with several host
proteins to control their activity at the benefit of the virus.
Namely, it regulates intracellular protein trafficking (76), actin
cytoskeleton (41), cell–cell fusion (45), cell migration (33, 42, 77,
78), and the kinase activity of several members of the Src family
(40). In infected OC, all these effects could contribute to the
enhanced bone resorption activity that is observed in the present
study. In vitro experiments show that Nef, in part located at the
SZ, was necessary for all of the HIV-induced effects. The role of
Nef was also revealed in vivo in CD4C-Nef-Tg mice that exhibit
reduced bone density and an increase of the surface occupied by
OC-TRAP staining, suggesting an increase in recruitment and
differentiation of OC. Similarly, in HIV-1–Tg rats, a model in-
volving the global transgenic expression of a nonreplicative HIV-
1, reduced bone mass was reported, which correlated with a high
OC-TRAP staining (18). OC derived from the bone marrow of
CD4C-Nef-Tg mice resorbed more and exhibited wider SZ,
mimicking the results obtained with human OC infected with
HIV-1. Therefore, it is likely that OC participate in the bone
remodeling defects evidenced in Nef-Tg mice. Because these
mice express Nef in CD4+ cells, including T cells, macrophages,
OC, and dendritic cells, we propose that the observed bone de-
fects are due, at least in part, to OC expressing Nef in addition to
disrupted immune responses, which are known to participate in
bone homeostasis (6, 18, 48, 79). Although we do not exclude
potential contribution by other viral proteins (80, 81), our results
reveal Nef as an essential mediator of the HIV-1 effect on bones
(Fig. 9).
It remains to be shown how the virus benefits from manipu-
lating OC. Although OC are giant cells, they do not produce
more viral particles than macrophages and these virions exhibit
the same infectivity. In contrast with T cells, the cell viability of
infected OC is not affected and we can suspect that these in-
fected cells may survive for a long time in bones. Moreover, drug
delivery to bones is limited by the unique anatomical features of
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this tissue (82). Therefore, a putative advantage for the virus may
consist in the use of OC as viral reservoirs to hide and survive.
In conclusion, OC are host target cells for HIV-1 that become
more osteolytic as a consequence of larger and more degradative
SZ. We propose that infected OC participate in bone disorders
encountered in HIV-1–infected patients and may constitute a
reservoir for the virus. The viral protein Nef appears as a key
regulator of the bone resorption activity of OC infected by HIV-
1. In summary, this study provides a better understanding of the
underlying causes of bone loss following HIV-1 infection.
Materials and Methods
Materials and methods, cell culture and transfection, HIV-1 infection of BLT-
humanized mice, viral transfer from infected T cells to primary human OC,
cell-free infection of OC and macrophages, and histological analyses of mice
bones and of human synovial tissues, are described in SI Materials andMethods.
Additional materials and methods included flow cytometry analysis, immuno-
blotting, gel zymography, TRAP staining, IF and transmission electron micros-
copy analyses, 3D migration, adhesion and resorption assays, chemicals and
antibodies, and statistical analysis are also available in SI Materials andMethods.
Human monocytes were provided by Etablissement Français du Sang, Toulouse,
France, under contract 21/PLER/TOU/IPBS01/2013–0042. Experiments with CD4C/
HIV Nef mice were approved by the Institutional Animal Ethics committee
(Laboratory of Molecular Biology, Clinical Research Institute of Montreal,
Montreal, QC, Canada), and experiments with female BLT mice were per-
formed in accordance with guidelines and regulations implemented by the
Massachusetts General Hospital Institutional Animal Care and Use Committee.
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SI Materials and Methods
Chemicals and Antibodies.Human and mouse recombinant M-CSF
were purchased from Peprotech and human and mouse RANKL
from Miltenyi Biotec. Leukocyte acid phosphatase kit for TRAP
staining and DAPI were purchased from Sigma-Aldrich. Matrigel
(10–12 mg/mL) was from BD Biosciences. The following anti-
bodies were used: Rabbit anti–Phospho-Src (Tyr416) (Cell Sig-
naling Technology, Ozyme), rabbit antiintegrin β3 (Cell Signaling)
mouse monoclonal anticathepsin K (clone 3F9, ab37259; Abcam)
and anti-TRAP antibodies (sc-28204) (Santa Cruz Biotechnol-
ogies, TEBU-Bio), monoclonal antiactin (clone 20–33), anti–
β-tubulin (clone B-5-1-2), mouse antivinculin (clone hVin-1)
(Sigma-Aldrich), and mouse monoclonal anti-human p24 (clone
Kal-1) (Dako) or anti-Gag/p24-FITC monoclonal antibody clone
KC57-FITC (Beckman Coulter). Secondary biotin-conjugated
antibodies and avidin-biotin-perodydasecomplex were from Dako
and Vector laboratories (LTP) and fluorescent secondary anti-
bodies and Texas Red/Alexa Fluor 488-conjugated phalloidins
were obtained from Molecular probes (Invitrogen). Maraviroc
(Sigma-Aldrich) was used at 10 μM, 30 min before infection.
Ritonavir, Raltegravir, and AZT were obtained from the AIDS
Research and Reference Reagent Program, Division of AIDS,
National Institute of Allergy and Infectious Diseases, and were
also used at 10 μM, 30 min before infection.
Mice. The CD4C/HIV Nef (previously named CD4C/HIVMutG)
(1) and CD4C/HIVGFP Tg mice (2) have been described pre-
viously. Experiments were approved by the Institutional Animal
Ethics committee (Laboratory of Molecular Biology, Clinical
Research Institute of Montreal, Montreal, QC, Canada).
Female BLT mice were generated as previously described (3).
Briefly, NOD/SCID/γc−/− (NSG) mice 6–8 wk of age were con-
ditioned with sublethal (2 Gy) whole-body irradiation, and 1-mm3
fragments of human fetal thymus and liver (17–19 wk of gestational
age) (Advanced Bioscience Resources) were implanted under the
recipient kidney capsules bilaterally. Remaining fetal liver tissue was
used to isolate CD34 cells with anti-CD34 microbeads (Miltenyi
Biotec), which were then injected intravenously (1 × 105 to 5 × 105
cells per mouse) within 6 h.
Intravaginal HIV-1 infection. NSG-BLT humanized mice were sub-
cutaneously injected with 200 μg progesterone (Depo-Provera;
Pfizer) 5–7 days before intravaginal infection to synchronize
their estrus cycle. Before intravaginal inoculation, mice were
anesthetized with a mixture Ketamine and Xylazine and infected
with 10-μL viral inoculum containing 2 × 104 infectious units of
NL4-3 virus that was engineered to express V3 loop from a Bal
strain, thus conferring CCR5 tropism (4). The control group
received 10 μL of PBS intravaginally. Plasma viremia was mon-
itored weekly by collecting few drops of blood from facial vein
and basis by quantitating plasma viral loads by qPCR. All animal
experiments were performed in accordance with guidelines and
regulations implemented by the Massachusetts General Hospital
Institutional Animal Care and Use Committee.
Plasma viral loads.Viral RNA was isolated from ∼50 μL of plasma
using the QIAamp viral RNA kit (Qiagen). Quantitative reverse
transcription and PCR was performed using HIV-1 gag specific
primers 5′-AGTGGGGGGACATCAAGCAGCCATGCAAAT-
3′ and 5′-TGCTATGTCACTTCCCCTTGGTTCTCT-3′ by us-
ing single step QuantiFast SYBR Green RT-PCR Kit (Qiagen)
on Lightcycler 480-II (Roche). Plasma from uninfected BLT
mice was used to determine the background signal, as described
previously (4).
Cell Culture and Transfection. Human monocytes were isolated
from the blood of healthy donors and differentiated as hMDM, as
described previously (5). For differentiation to human OC,
monocytes were seeded on slides in 24-well plates at a density of
5 × 105 cells per well in Roswell Park Memorial Institute me-
dium (RPMI) supplemented with 10% FBS, M-CSF (50 ng/mL),
and RANKL (30 ng/mL). The medium was replaced every 3 days
with medium containingM-CSF (25 ng/mL) andRANKL (100 ng/mL).
hMDM and OC from the same donor were used from days 1–
6 of differentiation (OC precursors) or at day 10 of differen-
tiation (mature OC). For transient expression of Nef, we used a
Neon MP 5000 electroporation system (Invitrogen) in human
OC (parameters: 1,000 V, 40 ms, two pulses, and 1 μg of DNA
for 2 × 105 cells), as in ref. 6. The constructs encoding the GFP-
tagged Nef for expression of HIV-1NL4-3 Nef fused to GFP have
been described previously (6). Cells were used within 24 h (5%
transfection efficiency).
HEK293T, TZM-bl and Jurkat T cells were from S.B.’s lab-
oratory and were cultured as described previously (7).
Autologous human primary CD4+ T cells (from the same
donors as the one used for monocyte preparation) were purified
by negative selection (CD4+ T cell isolation kit, Miltenyi). CD4+
T cells were kept for 10–12 days in RPMI supplemented with
20% FBS and nterleukin-2 at 10 U/mL (IL-2; Miltenyi). The day
of infection, phytohemagglutinin-P at 5 μg/mL (PHA-P; Sigma)
was added to the medium.
Mouse OC were differentiated from bone marrow cells isolated
from long bones, as previously described (8). Briefly, nonadherent
cells were cultured in α-MEM supplemented with 30 ng/mL mouse
M-CSF (Miltenyi Biotec) for 48 h. Then, OC differentiation was
initiated in medium containing 100 ng/mL mouse RANKL (Mil-
tenyi Biotec) and 30 ng/mL M-CSF, at the density 1.5 × 105 cells
per well (six-well plate) or of 4 × 104 cells per well (96-well plate).
Media was changed and cytokines were replenished every 2 d. Cells
were maintained in culture for 4–6 d before analyses.
Cell-Free HIV-1 Infection of Macrophages and OC.Wt- and Δnef-HIV
ADA strains were produced in HEK293T cells as in ref. 6, and
the NLAD8-VSVG strain was produced by cotransfection with
the proviral plasmid in combination with pVSVG (from S.B.’s
laboratory). Amount of HIV-1 p24 in viral stocks was assessed by
an home-made ELISA (with NIH reagents, NIH AIDS Reagent
Program, Division of AIDS, National Institute of Allergy and
Infectious Diseases). HIV-1 infectious units were quantified by
reverse transcriptase assay (9, 10) and using TZM-bl cells, as
reported previously (6). Macrophages and OC were infected at
multiplicity of infection (MOI) 0.1 (corresponding to 0.7 ng of
p24 for 2 × 106 OC) with the macrophage-tropic HIV-1 isolate
ADA or Δnef-ADA, as described previously (11). Infectivity and
replication was assessed by measuring p24+ cells by immunos-
taining, p24 level in cell supernatants by our home-made ELISA,
and using TZM-bl indicator cells, as previously described (6, 12).
Viral Transfer to OC via Infected T Cells.To study the transfer of HIV-
1 from T cells to OC, Jurkat cells (J77 provided by S.B.), or human
primary CD4+ T cells were infected with the CCR5-tropic virus
(NLAD8) coexpressing VSV-G envelope glycoprotein, to allow
efficient infection independently of entry receptors. The cells were
infected for 24 h at a MOI of 0.5 (MOI 10 for primary T cells),
then washed and cultured for another 24 h. At this stage, T cell
infection rate was evaluated to at least 50% by flow cytometry.
After three PBS-washes to remove free-cell viral particles, infected
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T cells were cocultured 6 h with OC (ratio 2:1), as in ref. 7. Then,
T cells were eliminated by washing extensively (once with PBS,
once with PBS-10 mM EDTA and twice with PBS) and OC were
maintained in culture in presence of M-CSF (25 ng/mL) and
RANKL (100 ng/mL) for additional 5 days.
Bacterial Infection of OC. Human mature OC (day 10) seeded on
bones were infected with Salmonella typhimurium MOI 15 (as
described in ref. 13), Francisella novicida MOI 7 (as described in
ref. 14), or Mycobacterium tuberculosis MOI 6 (as described in
ref. 15). Twenty-four hours after infection, cells were fixed and
stained for F-actin and DAPI, as previously described (6, 16).
The percentage of cells forming SZ was quantified for four in-
dependent experiments (n = 4 donors); at least 200 cells were
analyzed per condition.
Flow Cytometry Analysis. Cells detached by Accutase (Gibco
Technology) were incubated for 30 min on ice with the following
antibodies and fixed in 4% paraformaldehyde before analysis:
Alexa Fluor 488 anti-human CD16, APC anti-human CD4, PE
anti-human CCR5, APC anti-human CD61 (β3 integrin) from
Biolegend (Ozyme). Data were acquired on BD LSR II (BD
Biosciences) and analyzed with Flow Jo software (TreeStar).
Immunoblotting. Cells were lysed and total proteins were sepa-
rated through SDS/PAGE, transferred and immunoblotted.
Quantification of immunoblot intensity for several donors was
performed using Image Lab (Bio-Rad). The quantification was
reported to tubulin or actin (used as a loading control). Systematic
Coommassie blue staining was performed to control the charges
of extracellular lysates.
Gelatin Zymography.OC cell-conditioned medium was analyzed for
MMP9 activity by gelatin substrate gel electrophoresis, as in ref. 17.
TRAP Staining and IF Microscopy. Cells were fixed with PFA 3.7%
and stained for TRAP (Sigma-Aldrich), according to the man-
ufacturer’s protocol. IF experiments in 2D (on glass coverslips or
on bone slices) were performed as described previously (6, 16).
Quantification of OC fusion index (total number of nuclei in
multinucleated cells divided by total number of nuclei × 100),
number of nuclei per multinucleated cells and surface index
(surface covered by multinucleated cells/total surface × 100)
were assessed by using a semiautomatic quantification with a
homemade ImageJ macro, allowing the study of more than
3,000 cells per condition in at least five independent donors. All
images were prepared with Adobe Photoshop software. The
number of cells with podosomes and SZ was quantified after
phalloidin staining. F-actin fluorescence intensity inside podo-
somes and inside SZ (three zones per SZ) was assessed using
ImageJ software. Slides were visualized with a Leica DM-RB
fluorescence microscope or on a FV1000 confocal microscope
(Olympus), and the associated software. Images were processed
with ImageJ and Adobe Photoshop software.
Resorption Assays. To assess bone resorption activity, mature OC
were detached using Accutase treatment (Gibco Technology,
ThermoFischer Scientific) 10 min, at 37 °C, and cultured on
bovine cortical bone slices (IDS Nordic Biosciences) for 48 h in
medium supplemented with M-CSF (25 ng/mL) and RANKL
(100 ng/mL). Following complete cell removal by immersion in
water and scraping, bone slices were stained with Toluidine blue
to detect resorption pits under a light microscope (Leica
DMIRB; Leica Microsystems). Circularity and the surface of
bone degradation areas were quantified manually with ImageJ
software. For quantification of the volume of bone degradation,
we imaged the resorption pits with a confocal microscope
(Olympus LEXT OLS 3100, 50×, z = 50 nm). Cross-linked CTX
concentrations were measured using betaCrosslaps assay (Im-
munodiagnostic System laboratory) in the culture medium of OC
grown on bone slices. To assess demineralization activity, OC
were differentiated in multiwell Osteologic Biocoat (Corning,
VWR), fixed, stained with the Von Kossa method, as described
previously (18), and quantified using ImageJ software.
Adhesion Assays.OC were differentiated on glass coverslips in 24-
well plates, incubated for 10 min at 37 °C in Accutase (Gibco
Technology) or in a nonenzymatic cell dissociation buffer (Gibco
Technology). Cells were washed with PBS, adherent cells were
fixed and nuclei were quantified after DAPI staining.
Three-Dimensional Migration Assays. For 3D migration assays with
OC precursors, experiments were performed as described pre-
viously (16) and quantified at 48 h. Briefly, pictures of cells were
taken automatically with a 10× objective at constant intervals
using the motorized stage of an inverted microscope (Leica
DMIRB; Leica Microsystems); cells were counted using ImageJ
software as described previously (19). The number of cells inside
the matrix (percent of migration measured after 48 h of migration)
and the distance of migration were quantified using ImageJ.
Histological Analysis of GFP-Tg, Nef-Tg, and HIV-1–Infected BLT Mice.
Femurs and tibia from adult mice were fixed in 10% buffered
formalin solution (Sigma-Aldrich), decalcified in EDTA, and
embedded in paraffin. Longitudinal serial sections of the median
portion of whole bone were stained for TRAP (Sigma-Aldrich)
according to the manufacturer’s protocols and counterstained
with Fast green or Hematoxylin Gill 3. Stained slides were dig-
itized using Panoramic 250 Flash digital microscope (P250 Flash;
3DHisTech). Whole-slides were scanned in brightfield scan
mode with a 40×/NA 0.8 Zeiss Plan-Apochromat dry objective,
and images were acquired with a two megapixels 3CCD color
camera (CIS Cam Ref#VCC-F52U25CL; CIS Americas). This
objective and camera combination yield a 0.22 μm per pixel
resolution in fluorescence scan mode, which corresponds, in
conventional microscopy, to 56× magnification at the highest
optical resolution. Panoramic Viewer software (RTM 1.15.0.53)
was used for viewing, analyzing, and quantification of the digital
slides. Cortical bone surface and TRAP+ cells were quantified.
Animal groups were composed of three mice. Mononucleated
and multinucleated TRAP+ cells were counted on a minimum of
four serial sections chosen among the most median part of four
different tibias for each genotype. For histological analysis of
GFP-Tg, sections (3 μm) were stained for TRAP activity (Sigma-
Aldrich), Hemalum/Eosin, or with a rabbit antibody directed
toward GFP (ab6556; Abcam, dilution 1/400, epitope retrieval:
citrate buffer pH 6, boiling micro-oven, 2 × 10 min).
For histological analysis of HIV-1–infected BLT mice, serial
sections were stained for TRAP activity (Sigma-Aldrich), Hemalum/
Eosin, or with a monoclonal antibody directed toward human
p24 (clone Kal-1, dilution 1/10, usual epitope retrieval: Tris-
EDTA buffer pH 9, 95 °C, 40 min). In addition to the com-
monly critical technical issues associated with performing IHC
on calcified bone tissue, we needed to overcome first, the high
background due to the presence of some endogenous mouse Ig
(to this end we used a blocking step, mouse-on-mouse kit; Vector
Laboratory, LTP) and second, the detachment of samples from the
slides due to the high temperature required for p24 antigen re-
trieval (adapted epitope retrieval: Tris-EDTA buffer pH 9, 70 °C,
5 h) (20, 21). Animal groups were composed of four viremic mice
and three noninfected mice. The total number of OC (TRAP+
cell along the bone) was quantified for each section (heads of
tibia and femur) and the number of double-positive p24+/TRAP+
was quantified in the corresponding section (n = 4 infected mice).
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Histological Analysis of Human Synovial Tissues. Synovial tissues
obtained from arthroplastic surgery of nonarthritic patients were
cut into blocks of around 1–2 mm3 and incubated on gel-foam
sponges (Pfizer) with M-CSF (50 ng/mL) alone or with M-CSF
(50 ng/mL) and RANKL (33 ng/mL). Explants were infected
with the macrophage-tropic HIV-1 isolate ADA for 24 h, washed
free of virus particles and maintained in culture for 21 d at 37 °C,
5% CO2 in α-MEM supplemented with 10% FBS. Medium was
replaced every 3 d with M-CSF (50 ng/mL) and RANKL (100 ng/
mL) as described previously (22). Tissues were then fixed in 10%
phosphate-buffered formalin and embedded in paraffin. Sections
(3 μm) were stained for TRAP activity (Sigma-Aldrich), Hema-
lum/Eosin, or with mouse monoclonal antibodies directed toward
p24 (clone Kal-1; Dako) and cathepsin K (clone 3F9, ab37259;
Abcam, dilution 1/600, epitope retrieval: EDTA buffer 1 mM
pH8, boiling 8 min).
Transmission Electron Microscopy. Mature OC (day 10 of differ-
entiation) were infected at a MOI 1 (corresponding to 7 ng of
p24 for 2 × 106 OC) with the HIV-1 ADA strain. Ten days
postinfection, cells were fixed 2 h at room temperature with
2.5% glutaraldehyde and 2% paraformaldehyde (EMS, Delta-
Microscopies) in 0.1 M phosphate buffer, pH 7.2 and postfixed
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were treated for 1 h with 1% aqueous uranyl acetate then
dehydrated in a graded ethanol series and embedded in Epon.
Sections were cut on a Leica Ultracut microtome and ultrathin
sections were mounted on 200 mesh onto Formvar carbon-
coated copper grids. Finally, thin sections were stained with
1% uranyl acetate and lead citrate and examined with a trans-
mission electron microscope (Jeol JEM-1400) at 80 kV. Images
were acquired using a digital camera (Gatan Orius) at 10,000×
and 15,000× magnification, respectively.
Statistical Analysis.One-tailed paired or unpaired t test was applied
on data sets with a normal distribution, whereas one-tailed Mann–
Whitney (unpaired test) or Wilcoxon (matched-pair test) tests were
used otherwise (Prism). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001,
****P ≤ 0.0001.
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BA
TRAP
p24 TRAP
Fig. S1. (A) OC identification in the head of tibia (or femur) of HIV-1–infected BLT-humanized mice. A representative section of the head of tibia of HIV-1–BLT
mice stained for TRAP activity (purple) (n = 4 mice, two sections per mouse of tibia and femur heads). Arrowheads show some OC. (Scale bar, 500 μm.)
(B) Example of an OC negative for p24 staining. Enlarged image (5× zoom) of the A (TRAP staining in purple, Left) and an adjacent section stained with a
monoclonal antibody directed toward p24 (brown, Right). The black arrowhead shows an OC positive for p24 and the white arrowhead shows an OC negative
for p24. (Scale bar, 250 μm.)
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Fig. S2. (A) Kinetics of OC differentiation. Whole-cell extracts of cells maintained in culture with the osteoclastogenic cytokines during 0, 1, 6, or 10 d were
blotted using antibodies against β3 integrin, TRAP, cathepsin K (CtsK), and tubulin (loading control). A representative blot out of three independent ex-
periments is shown. (B–E) Characteristics of OC compared with human MDM at day 10 of differentiation. MDM (purple) and OC (gray) from the same donors
(n = 6) were examined for fusion index by IF (B), cell-surface expression of β3-integrin by flow cytometry (expression in MDMwas used as reference), β3-integrin
(intracellular), and CtsK (extracellular) expression level by Western blot and MMP9 activity by zymography (C). (D) Representative brightfield images of TRAP
staining of MDM and OC seeded on glass at day 10. (Scale bar, 30 μm.) (E) Brightfield images of bone-resorption pits. MDM and OC were seeded on bovine
cortical bone slides for 48 h and bone resorption pits revealed with Toluidine blue. (Scale bar, 20 μm.) (F) CCR5 cell-surface expression in OC precursors at day 0,
1, 2, and 3 of differentiation. The kinetics of cell-surface CCR5 expression in monocytes maintained in M-CSF (purple) and M-CSF/RANKL (gray) from same
donors were determined by the median fluorescent intensity (MFI) (n = 5 donors). (G) Treatment with several drugs abolishes HIV-1 production by mature OC.
Mature (10 d-differentiated) OC were treated with 10 μM Maraviroc, AZT, Ritonavir, or Raltegravir 30 min before infection, and p24 release was measured by
ELISA 10 d postinfection (n = 4 donors). ***P ≤ 0.001, ****P ≤ 0.0001.
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Fig. S3. (A) Washes after coculture allow efficient elimination of T cells. NLAD8-VSVG–infected Jurkat cells were cocultured with human OC for 6 h, and four
washings (once with PBS, once with PBS-EDTA, and twice more with PBS) were performed (after washes) or not (before washes). Cells were then collected and
stained for CD3 (T cell marker, green) and nuclei (DAPI, blue) (Left). Quantification of the percentage of Jurkat cells (CD3+ cells out of total nuclei) is shown
(Right). (Scale bar, 20 μm.) (B and C) OC are efficiently infected through viral transmission from HIV-1–infected autologous T cells. Human mature OC have been
in contact for 6 h with infected autologous primary T lymphocytes (white bars) or with cell-free viral particles produced by T cells during 6 h (black bars). They
were washed and harvested immediately (day 0) or 5 d later (day 5). Quantification of the percentage of p24+ cells evaluated by IF at day 0 and 5 (B) and of
p24 release in the supernatants determined by ELISA at day 5 (C) (n = 3 donors).
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Fig. S4. (A and B) HIV-1 enhances OC differentiation. (A) Representative brightfield images of TRAP staining of noninfected OC (Left) or HIV-1-infected OC
(Right) at day 10 postinfection. (Scale bar, 30 μm.) (B) Quantification of the percentage of multinucleated cells (≥two nuclei) and of the number of nuclei
per multinucleated cells after confocal analysis as in Fig. 5A. (C) Maraviroc inhibits the increase of the fusion index induced by infection. Mature
(10 d-differentiated) OC were treated with Maraviroc 30 min before infection and the fusion index was determined 10 d postinfection (n = 5 donors). NI,
noninfected. **P ≤ 0.01; ***P ≤ 0.001, ****P ≤ 0.0001.
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Fig. S5. (A) Replication kinetics of infected OC with wt and Δnef HIV-1 ADA strains. Mature OC (10 d of differentiation) were infected with equivalent MOI of
wt and Δnef HIV-1 viruses. The supernatants of infected OC were collected at several days postinfection and p24 level was measured by ELISA. Replication
kinetics for one representative donor out of three donors. (B) CD4C regulatory elements drive the expression of GFP in OC. Two representative images of
histological analyses (GFP IHC in brown and TRAP activity in purple) were performed on two serial sections of tibia of CD4C/HIVGFP Tg-mice (3-μm thick).
Representative histological sections (n = 3 mice). Arrowheads show GFP+ OC (TRAP+) along bone. (Scale bar, 50 μm.) (C) Nef-Tg mice exhibit a low bone density
and bone microdamages. Representative bone radio-density of non-Tg (Left) and Nef-Tg (Right) mice. Arrowheads show bone microdamages in Nef-Tg mice.
(Scale bar, 0.5 cm.)
Raynaud-Messina et al. www.pnas.org/cgi/content/short/1713370115 8 of 8
